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SUMMARY OF THE THESIS:
In this thesis, immunological parameters in multiple sclerosis patients 
(MS) have been examined and techniques contributing to the study of 
these aspects have been developed. The epidemiology of MS suggests 
that both environmental and genetic factors contribute to the disease 
process. According to a widespread theory, an autoimmune reaction 
leading to demyelination could be induced, in genetically determined 
individuals, by an infectious agent (s) e.g a paramyxovirus or a 
retrovirus.
In the first part of the thesis, the oligoclonal immunoglobulin (Igs) in 
the CSF of MS patients in relation to the paramyxovirus SV5 were 
studied. This was to complement an initial observation made in the 
department that a significant proportion of cerebrospinal fluids 
(CSF) could have oligoclonal bands directly acting against antigens 
(Ags) of this virus.
In the second part of the thesis, techniques were developed for the 
analysis of proliferative capacity of peripheral lymphocytes of MS 
and control patients using possible MS autoantigens viz myelin and 
brain vessels. The humoral response against these Ags was also 
assessed by immunoblotting using MS, neurological and normal 
control patients.
In parallel and in the view to obtaining antigens for the
immunological studies, techniques for the purification and ,
characterisation of human brain vessels from post mortem brains 
were assessed and attempts to culture human brain endothelial cell 
lines were made.
I: STUDIES ON THE SIGNIFICANCE OF THE
PARAMYXOVIRUS SV5 IN MULTIPLE SCLEROSIS
(MS),
This was tested in a series of 23 MS patients from Aberdeen, Dundee 
and Edinburgh. Particular attention was paid to the handling and 
storage of the CSFs which were screened initially by immuno-
fluorescence. Only eight of these CSFs showed any reaction against 
SV5/PF2 antigens. Two of these (with the highest titres) were then 
analysed for oligoclonal bands in the presence and absence of 
purified SV5 antigens and they failed to show any difference in the 
pattern obtained. In other experiments the effect of ionic strength, 
phosphate content and pH on the relatively cathodic oligoclonal 
IgGs suggested that some of the absorptions noted may have been due 
to non immune reactions.
In parallel with the immunoprecipitation technique, utilising 
standardised systems, the limits and use of other cerebral fluid 
characterisation techniques viz imprint immunofixation and 
immunoblotting technique were studied. The immunoblotting 
technique was extremely difficult to control and that it was prone to 
non specific reaction. On the other hand, the imprint immunofixation 
technique was easier to control but again the technique showed a 
narrow window of specificity.
In the light of these relatively negative results and in the light of 
current theories of the MS process it was decided to look at a related 
aspect of the aetiopalhogenesis of MS which is the consideration of 
potential target autoantigens in the induction of MS.
II. STUDY OF POSSIBLE AUTOANTIGENS IN
MULTIPLE SCLEROSIS :
It was thus decided to concentrate on 2 possible autoantigens: the 
myelin sheath and the brain vessels and to look at 2 arms, cellular 
and humoral , of the immune response (IR).
Concerning the cellular aspect of the IR, as very few antigens apart 
from myelin basic protein have been fully tested and because these 
types of studies have been hampered by the limitation in obtaining 
pure preparation of putative autoantigens, it was decided to use the 
'nitrocellulose T cell assay ' which has the potential to avoid difficult 
purification of protein. The nitrocellulose T cell technique utilises 
separation of antigens by SDS-PAGE followed by blotting onto 
nitrocellulose paper (NCP). The appropriate polypeptide antigen
band can then be cut out, dissolved in DMSO and reprecipitated as 
microparticles of antigen-NCP which can be used as antigen in a 
standard proliferation T cell assay. When the system was 
standardised and tested successfully with different antigens 
(adenovirus proteins, tetanus toxin and mycobacteria), NCP 
particles with myelin and human brain vessels (purified from post 
mortem brains) were prepared and tested with PBL from 6 MS 
patients and 6 neurological control patients from Dundee and 
Edinburgh and 6 normal controls from the department. Some 
reactivity was observed in 3 MS and 3 neurological controls against 
diverse myelin proteins and also against vessels proteins. However 
the level of reactivity was low (stimulation index between 1.5-3.5) 
but the batch of AB + serum used for the proliferation assay gave 
high background which may have masked a significant proliferation 
against a critical autoantigen. Nevertheless, in the context of 
autoimmunity and MS, this approach has been described and used 
successfully with peripheral blood mononuclear cells and thus its 
potential with T cell clones generated from the CSF and even also 
from the brain lesions is obvious.
A prospective blind study was also undertook with the sera from 45 
MS, 47 neurological controls and 18 normal controls from the 
department using the 'western blotting' technique and myelin and 
brain vessels as antigens. There was no obvious difference in the 
pattern of reactivity between MS patients and other neurological 
controls. However there was a small proportion of individuals from 
both groups who possessed autoantibodies against either myelin or 
vessels which can be visualised by this technique. Among the normal 
control, only one reacted against a protein of the brain vessels (and 
not of the myelin).
Ill PURIFICATION AND CHARACTERISATION OF 
BRAIN VESSELS AND BRAIN ENDOTHELIAL CELLS.
Myelin purification is well described and its molecular composition 
and function have been well studied. Therefore effort was 
concentrated on the brain vessels where the purification technique is 
less well established.
There are a number of techniques which describe the purification of 
brain vessels from animal brains (rodent,canine and bovine) and 
from human post mortem brains. They are based on different 
principles which are often combined : 1/enzymatic digestion of the 
brain by 'collagenase, dispase', 2/ mechanical homogenisation of the 
brain, 3/separation of the components of the brain by different 
gradient systems e.g dextran, sucrose 4/filtration through nylon 
sieves of different mesh sizes, 5/use of glass beads to trap the vessels. 
These different procedures have been assessed on the basis of yield 
and purity using bovine brains obtained from the local 
slaughterhouse and then on samples of human post mortem brains. 
The technique which was found to be the most adequate was a series 
of homogeneisations followed by filtrations through sieves of 
different mesh sizes (between 210 and 110 p). The brain vessels are 
trapped on the sieve, collected and washed. The purity of the 
preparation is assessed by light microscopy and scanning electron 
microscopy . Characterisation of these purified brain vessels by 
known markers e.g Von Willebrand factor and gamma glutamyl 
transpeptidase was also undertook.
Culture a brain endothelial cell line in vitro were sought and for this 
reason positive and negative markers of brain endothelial cell lines 
were collected and different culture conditions were tested.Two 
attempts using brain samples collected at temporal lobectomy from 
patients suffering intractable epilepsy were unsuccessful (although 
glial cell lines were grown for growth factors source).
INTRODUCTION.
BACKGROUND.
Multiple sclerosis (MS) is a neurological disease which affects 
the central nervous system; the lesions are characterised by a 
perivascular inflammation leading to demyelination - the destruction 
of myelin sheaths around the axons of neurons [Charcot J.M.,
1868,a] [Adams C.W.M,1983]. MS affects mainly young adults (in 
their 3 or 4 & decades [Souberbielle B.E et al, 1990]) and as it is 
a chronic disease, generally marked by relapses and remissions, the 
cost to society and to the patient - socially and financially - is 
important. Moreover, there is still no treatment which has been 
shown to alter the long-term course of MS [McFarlin D.E., 1983].
The prevalence of MS is high in the north east of Scotland [Phadke 
J.G et al, 1987]; the highest prevalence of MS in the world has 
indeed been recorded in the Orkney islands and in the Aberdeen area 
[Editorials a) andb), 1981].
Although MS is not an hereditary disease, genetic factors play 
a major role in the disease process. The genetic predisposition seems 
to be polygenic [McFarlin D.E. et al,1989] [Oksenberg J.R. et al,
1990]. At least one disease gene is associated with the class EE region 
of the HLA system on chromosome 6: associations have been 
described with the class II alleles DR 2 [Batchelor J.R. et al, 1978] 
and DQwl [Heard R.N.S. et al, 1989] [Vartdal F. et al, 1989].
Another disease gene seems to be linked to Gm allotypes on 
chromosome 14 [Pandey J.R. et al, 1981] and associations with both 
chains of the T cell receptor genes have been reported [Seboun E. et 
al, 1989][Oksenberg J.R. et al, 1989].
"MS epidemics", migrant and homozygotic twin studies 
indicate that a genetic factor is not the sole element in the aetiology 
of MS [Acheson E.D., 1985][Compston D.A.S., 1986]. It thus 
appears that one or even multiple external factor(s) are involved in 
the initiation and in the continuation of the disease [MacDonald,
1986]. The theory that an infectious agent(s) [Cook S.D. et al, 1980] 
induces demyelination in genetically determined individuals, by the 
mediation of an immunological reaction which could be 
autoimmune, is widespread [Waksman B.H. et al, 1984].
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Many environmental agents have been implicated but 
infectious agents - particularly viruses - are on the top of the list and 
paramyxoviruses have been the focus of interest for a long time. 
Members of the department have pursued this line of research in 
London and then in St Andrews mainly on the SV5 virus - a member 
of the paramyxovirus family (see below)[Russell W.C.R., 1983] 
[Randall R.E.R. et al, 1989] and part of the work presented in this 
thesis is the continuation of this investigation.
Another important line of research in MS is based on the 
hypothesis that MS is due to an autoimmune attack [Waksman B.H. et 
al, 1984] and, as already mentioned, this hypothesis could be 
compatible with a possible viral etiology of MS. As MS is a 
demyelinating disease, myelin has been investigated as a possible 
target by many research groups in the world [Hafler D.A et al, 1989] 
especially the myelin basic protein which has been shown to induce 
experimental allergic encephalomyelitis (EAE) in animals [Ben-Nun 
A et al, 1981]. However, MS researchers are now also focussing 
their attention on the blood brain barrier (BBB), the microvessels 
which supply blood and nutrition to the brain and on the possibility 
that it may be the primary site of the MS process as the lesions of 
MS are strikingly perivascular (see below) [Adams C.W. M., 1989]. 
The second part of this thesis presents data related to both areas 
(autoimmunity and BBB).
MS is undoubtedly a very complex disorder. It is also a 
difficult disease to work on, mainly because of the inaccessibility of 
the site of the lesions (the central nervous system) in live patients. 
Despite this limitation, a mass of information about many aspects of 
MS has been collected during more than a century of research since 
the first descriptions of this frustrating but nevertheless fascinating 
disease [Charcot J.M., 1868,b][Critical digest, 1896][Compston 
D.A.S., 1988]. In order to clarify the aim of this thesis, brief 
reviews on the clinical symptoms of MS, the description of the MS 
lesions, the immunology of MS, the cerebrospinal fluid (CSF) in MS, 
the association of viruses with MS and the BBB and MS will follow 
in addition to a brief review of the immunological techniques used in 
this thesis.
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CLINICAL ASPECTS OF MS.
MS is characterised clinically by episodes of isolated 
neurological symptoms (spinal cord, optic nerve and brain). 
Although pleomorphic in its clinical presentation, the picture seems 
to be determined by the location of the MS lesions. Classic features 
include impaired vision, nystagmus, dysarthria, intention tremor, 
vertigo, ataxia, impaired position and vibratory senses, bladder 
dysfunction, weakness or tingling of a limb and alteration in 
emotional responses [Poskanzer D.C. et al,1981].
The course of the disease differs between individuals and there 
are no known prognostic factors. Broadly, in about 15% of cases MS 
is completely asymptomatically silent and only found at autopsy 
[MacKay R.P. et al, 1967] [Morariu M. et al, 1976]; in 15 % the 
course of MS is ’benign' (it does not interfere with the social life of 
the patients); in 55 % of cases patients are disabled by MS and in 
another 15% of cases patients MS is the cause of death. Among the 
patients who show signs of the disease about 90 % have a relapsing- 
remitting form (Charcot's type) and 10 % a progressive disease (the 
latter patients are usually older) [Compston D.A.S., Conference on 
Positive trends in multiple sclerosis research, Royal College of 
Physicians, 1991]. Optic neuritis is a frequent initial symptom (about 
40% of the cases) and about 60-75% of patients who have had an 
episode of optic neuritis will go on to develop other lesions of MS 
[Francis D.A. et al, 1987]. It is thus unclear if an isolated episode of 
optic neuritis can be considered as a subclass of MS or a different 
disease [Kinnunen E. et al, 1989]. Other rare clinical subsets of MS 
have been described and named e.g Neuromyelitis Optica (Devic's 
form) but as they do not correlate with a specific prognosis they are 
of limited value. One uncommon type worth mentioning is the acute 
form of the disease or Marburg's type where MS runs an acute or 
subacute course leading to death in weeks or months. The 
differential diagnosis in this situation is disseminated
encephalomyelitis.
It is not known what causes the symptoms in MS. Recent 
nuclear magnetic resonance (NMR) studies in patients suffering 
from MS have shown that multiple lesions can appear and disappear 
without any clinical consequences whereas other lesions, at the same 
time, can give rise to a clinical attack [Jacobs L., 1986] [Ormerod
I.E.C., 1986]. The location of the lesion is likely to be a major 
factor in the appearance of clinical symptoms but it is thought that 
the functional defect is due to the oedema around the inflammatory 
lesions and not due to the cellular reaction in the lesion. It is also 
now thought that chronic disability may be due to the axonal loss in 
old lesions [McDonald W.I, Conference on Positive trends in 
multiple sclerosis research, Royal College of Physicians , 1991] : 
new lesions are characterised by the sparing of axons but older 
lesions are marked by scarring due to gliosis which lead also to 
axonal loss (see below [Adams C.W.M., 1983]).
Because of its nature, history and clinical diversity, it is 
evident that MS is a difficult disease to diagnose and to assess in 
terms of progression. Moreover, a diagnosis of multiple sclerosis 
raises the uncertainty of disability and loss of independence in a 
patient. Although NMR, when available, greatly helps in making a 
diagnosis of MS, there is still no specific diagnostic test and thus the 
diagnosis remains clinical for most doctors. 'Definite MS' is 
characterised clinically by the presence of at least 2 separate lesions 
that have appeared at different times in the white matter of the 
central nervous system [McDonald W.I., 1989]. Other possible 
causes of neurological dysfunction need to be excluded e.g HTLV-1 
associated neuropathies [Toumier-Lasserve E. et al, 1987]. The 
diagnosis is much more difficult in a patient with a progressive, non­
remitting pattern [McDonald W.I., 1989].
It is essential that clinical guidelines are being followed and 
can be compared when clinical researchers select patients suffering 
from MS for scientific projects or for therapeutic trials. It is also 
important to restrict therapeutic trials and other research protocols 
to 'definite MS' cases. Nowadays, the accepted criteria for diagnosis 
are those of Poser et al [Poser C.M. et al, 1983] and one needs to 
emphasize that the diagnosis must only be made by a neurologist. 
Disability status scales have also been published [Kurtzke J.F., 1970].
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THE HISTOPATHOLOGY OF MS.
Describing the MS lesions, understanding their evolution and 
their histories and comparing their locations are crucial scientific 
activities which give an overall chronological picture of the MS 
process and which may guide MS researchers on the trail of the 
etiological factors of MS. They may also identify elements or stages 
of the MS lesions which could be targets for successful therapies 
even though these treatments are not directed to the cause of MS 
[Compston D.A.S., 1990]. As pointed out before, this scientific 
approach is hampered by the inaccessibility of the MS lesions in live 
patients. Post mortem tissue is the only source of lesions for 
histopathological studies and the MS lesions at post mortem are often 
old. As a brain biopsy on a live MS patient may be harmful, it is 
unethical to biopsy a patient for research purposes only : fresh 
demyelinating lesions have been reported near the needle tract after 
stereotactic destruction procedures for severe tremor in MS patients 
[Gonsette R. et al, 1966] [Riechert T. et al, 1975].
Location of the MS plaques.
MS lesions, or plaques, commonly involve the central white 
matter but some pathologists have reported their presence - 
sometimes in greater number- in the grey matter [Adams C.W.M., 
1983 and 1989] [Lumsden C.E., 1970]. Macroscopically, they 
measure between 1 to 40 mm and are pinkish when they are new 
whereas older lesions are grey [McFarlin D.E. et al, 1982]. MS 
lesions favour particular locations which are seen at post mortem but 
also with great accuracy by NMR: they are extremely frequent (in 
over 90 % of the cases) in the periventricular regions and around the 
aqueduct (especially near the lateral and the 4 th ventricles and less 
commonly around the 3 rd ventricle) [Adams C.W.M., 1983] 
[McDonald W.I., 1989]. They are also commonly found in the optic 
tracts and frequently in the cord, pons, mid brain and basal ganglia. 
Plaques are twice as common in the cervical area of the spinal cord 
as in the lower part of the cord [Oppenheimer D., 1978][Poser C.M., 
1986].
In 20 % of MS patients, a perivenular exudate is present 
around the retinal veins and this phenomenon is called periphlebitis 
retinae (see figure 4 in [Bates D., 1986]). Periphlebitis retinae seem
to occur principally with optic neuritis [Engell T.A. et al, 1984 and 
1986] [Lightman S. et al, 1987]. Breakdown of the BBB has been 
demonstrated within the periphlebitis lesions [Engell T. et al, 1986]. 
Periphlebitis retinae appears to be associated with active disease 
[Engell T.A, 1986]
Lymphocytic meningitis is another feature of the MS disorder 
which is little understood. It may manifest itself as perivenular 
meningeal infiltrate or as a more diffuse meningeal inflammation. It 
is associated with acute cases of MS although it is not present in all 
acute cases. The lymphocytes are predominantly located in the 
subarachnoid space, particularly in the depths of the sulci (the space 
between the 2 cerebral hemispheres) [Adams C.W.M., 1977], 
Perivascular situation of the MS plaques.
Microscopically, it has been recognised, since the first 
histopathological descriptions of MS lesions [Charcot J.M., 1868,a] 
[Critical digest, 1896], that the characteristic MS plaques are located 
around brain vessels and almost exclusively around venules and 
small veins [Adams C.W.M., 1983 and 1989] and particularly in 
acute cases of MS [Adams C.C.W. et al, 1989, b]. It has been shown 
by serial studies that some plaques can extend over a considerable 
distance along the course of a vein [Fog T., 1964 and 1965] and this 
is particularly common in the spinal cord [Lumsden C.E., 1970].
The lesions can also spread out along the course of a vein as 
’Dawson's fingers'. These latter lesions often occur in the 
periventricular regions (the periventricular lesions are thus related 
to the periventricular veins and not to the ventricular lining or 
ependyma) [Fog T.,1965] [Adams C.W.M, 1987]. With NMR it has 
been shown that the MS lesion seems to develop in a centrifugal 
fashion [Kermode A.G. et al, 1990, b]. In some cases, MS lesions are 
thought to be composed of multiple smaller lesions [Adams C.W.M., 
1989].
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Relapsing-remitting MS and primary 
progressive MS may be 2 different diseases.
Recent NMR findings have shown that the pathogenesis of 
primary progressive multiple sclerosis appears to be different from 
the relapsing-remitting form. Gadolinium-DTPA has been used to 
assess the permeability of the BBB in conjunction with the NMR 
technique : it is a liquid of contrast which does not normally cross 
the BBB but in MS when the BBB is disrupted, it is able to leak into 
the brain and the lesions show enhancement by NMR. The MS 
lesions in early stages of primary progressing MS do not 'enhance’ 
with Gadolinium-DTPA whereas they enhance in relapsing-remitting 
form of the disease [Thompson A.J. et al, 1989].
Histopathology of the ’active MS plaque'.
a)The different cell types in the MS plaque - some general 
considerations.
The brain is composed of different cell components (the brain 
cells themselves and the other cells). The actual brain cells are the 
neurons and the neuroglial cells (astrocytes, oligodendrocytes, 
microglial cells and ependymal cells); they all are of
neuroectodermal origin apart from the microglial cells. Microglial 
cells, of mesodermal origin, are endogenous phagocytic brain cells 
which are thought to have migrated (as macrophages?) from the 
cerebral circulation into the nervous system in response to neuronal 
death early during development and which do not express markers 
of haematogenous macrophages [Esiri M.M. et al, 1986] [Esiri M.M. 
et al, 1988]. Microglial cells will thus be considered with the 
macrophage-monocyte cells. Ependymal cells are the cells lining the 
ventricles of the brain and do not seem to be involved in the MS 
process.
Other cells which make-up the brain are the meningeal cells, 
the cells which form the brain blood vessels and the connective tissue 
cells and are all of mesodermal origin. They will be dealt with in the 
relevant sections.
The cellular infiltrate - mainly lymphocytic - which 
characterises the MS lesions is thought to be principally of
haematogenous origin and will be discussed separately. The blood 
vessels and endothelial cells will be discussed in the blood-brain 
barrier section.
b) Histopathological features of the MS lesion.
A schematic representation of a MS plaque is shown in fig. HISTO-1 
at the end of the histopathology section.
In an ’active MS plaque’ (relapsing-remitting form), there is a 
peripheral zone of active demyelination where the myelin is only 
partially degraded. These peripheral zones show some 
hypercellularity which is spread throughout the plaque in active 
lesions. The hypercellularity appears to be due to the response of 
brain cells (astrocytes, microglial cells and oligodendrocytes) to the 
MS insult: this has to be differentiated from the inflammatory 
infiltration. Sudanophilic or osmophilic myelin lipid breakdown 
products are visualised within the macrophages or the microglial 
cells which are actively taking up and digesting the myelin [Adams 
C.W.M., 1989].
Within the plaque there is an increase of proteolytic enzymes 
and a loss of lipids and proteins (MBP and myelin associated 
glycoprotein (MAG)) which make up the myelin [Adams C.W.M., 
1989]. Interestingly, MAG seems to be lost earlier and to a greater 
extend than other myelin proteins at the edge of the MS lesions 
[Itoyama Y. et al,1980][Moller J.R., 1987].
Other criteria of activity are the presence of oedema and 
fibrinous exudation [Adams C.W.M. et al, 1985] as well as IgG and 
complement deposition. Oedema is frequent and is probably the first 
event in the formation of a MS lesion [Kermode A.G. et al, 1990 a 
and b]. Fibrinous exudation and the other pathological features are 
however not always present in ’active MS plaques' [Adams C.W.M., 
1989]. Complement deposition (C9) appears to be restricted to the 
brain vessels on the lumen but predominantly on the parenchymal 
side [Compston D.A.S. et al, 1989]. C3 shows a more diffuse 
perivenular distribution [Adams C.M.W. et al, 1985]. Complement 
has also been demonstrated in neuroglia, at the edge of active plaques 
and in the subependymal region of MS brains [Esiri M.M., 1977 and 
1980] [Adams C.W.M. et al, 1987]. IgG deposition has been detected 
in plaques, in the perivenular infiltrate and is also visible in 
astrocytes and microglial cells at the edge of the plaques [Prineas J.
et al, 1976] [Esiri M.M., 1977 and 1980] [Adams C.W.M. et al,
1987].
All these features are the mark of an inflammatory reaction 
and could be associated with increased permeability of the blood- 
brain barrier within the 'active region'. However in the case of IgG 
production and complement activation, it has been shown that they 
also happen intrathecally [Walsh M.J. et al, 1983] [Compston D.A.S. 
et al, 1989].
c) The oligodendrocytes in the MS plaque.
Oligodendrocytes are the cells which produce and maintain the 
myelin in the central nervous system. The myelin sheaths which 
originate from a single oligodendrocyte enfold short sections (30 to 
50) of many neighbouring axons within the CNS [Peters A. et al, 
1970]. This contrasts with the situation in the peripheral nervous 
system (PNS) where the Schwann cell (the myelin forming cell of 
the PNS) is associated with one axon and produces only a single 
myelin segment [Gregson N.A., 1983]. In the CNS, between the 
axonal portions enveloped by the oligodendrocyte processes, bare 
axonal segments are found and are named nodes of Ranvier. The 
nodes of Ranvier are covered by the foot processes of type 2 
astrocytes [Compston D.A.S., 1990]. Type 2 astrocytes and 
oligodendrocytes are derived from a common precursor cell, the O- 
2A progenitor cell [Raff M.C. et al, 1983]. Markers for 
oligodendrocytes can be detected by antibodies against galactolipid, 
carbonic anhydrase and transferrin [Adams C.W.M, 1989].
Two contradictory phenomena have been observed in the 
'active MS' plaques. In some instances, the number of 
oligodendrocytes is very much decreased in the plaques and 
demyelination may thus result from this loss of myelin-producing 
cells. However it has also been observed that oligodendrocytes 
persist and even proliferate at the demyelinating edge of the plaque 
[Raine C.S. et al, 1981]. This phenomenon may be due to 
recruitment of new oligodendrocytes by the glial progenitor cells but 
also it may be the consequence of a non specific response to the 
inflammatory reaction. For instance it has been shown that 
interleukin 2 - the main cytokine secreted by activated lymphocytes - 
stimulates oligodendrocyte proliferation [Benveniste E.N. et al,
1986].
It is still disputed whether the oligodendrocyte loss in MS is 
primary or secondary. The hypothesis that the oligodendrocytes may 
be injured in MS by auto-antibodies [Abrawsky O. et al, 1977] has 
not been confirmed [Traugot U. et al, 1979] .
More recently Compston and his colleagues revived the 
interest in oligodendrocytes and MS as they showed with others that 
oligodendrocytes are particularly susceptible to the action of 
complement [Compston D.A.S., 1990]. It appears that activation of 
the classical pathway, in the absence of antibody, is sufficient to 
induce oligodendrocyte cytotoxicity [Wren D.R. et al, 1989] and this 
mechanism is enhanced in the presence of any anti-oligodendrocyte 
antibodies and macrophages [Scolding N.J. et al, 1989]. However, 
there is no consensus about the presence of complement on 
oligodendrocytes in the MS plaques and this may be due to the 
difficulty in detecting complement components with
immunocytochemical techniques [Gay D., Conference on Positive 
trends in multiple sclerosis research, Royal College of Physicians, 
1991].
d) The astrocytes in the MS plaques.
The astrocytes are the supporting framework for nerve and 
blood vessels in the brain. They are located throughout the CNS and 
are particularly concentrated immediately under the pia matter and 
under the ependyma. They act as transport channels for the 
conduction of water and electrolytes within the CNS. Their many 
cytoplasmic processes make contact with the node of Ranvier of the 
axons and with the brain blood vessels. Most of the brain specific 
properties of the brain vessels are induced and maintained by the 
astrocytes [Golstein G.W., 1988] [Janker R.C. et al, 1987]. They also 
produce and secrete soluble factors which influence the brain cells 
and the supporting cells. The astrocytes have been shown to possess 
phagocytic properties and can act in vitro as antigen presenting cells 
[Fontana A. et al, 1984]. Astrocyte markers are glial fibrillary acidic 
protein (GFAP) and others less specific like vimentin [Lagenaur 
C.F., 1984].
Astrocyte activation and proliferation is a common feature of 
the active MS plaques and it seems that it is the first CNS cell to 
display overt reactivity during the development of MS lesions. 
Astrocytes show overt reactivity well into the adjacent unaffected
parenchyma [Prineas J.W. et al, 1976]. Astroglial hypertrophy is not 
specific for MS as it is found in other conditions like viral infection, 
stroke, trauma and tumours [Raine C.S.,1988]. Immunoglobulins 
phagocytosed by the astrocytes in MS plaques is a common feature 
[Prineas J.W. et al, 1976]. Astrocytes are also known to participate 
in myelin phagocytosis [Raine C.S., 1988]. It is still a matter of 
contention whether astrocytes in the active MS lesions are class II 
MHC positive [Traugott U. et al, 1985] or not [Hayashi T., 1988]. In 
summary, it is still unclear if astrocytes have a primary role in the 
genesis of the lesions e.g as phagocyte cells or APC or if their 
behaviour seen in the MS plaques is only a secondary response to the 
insult generated by other factors.
The inflammatory cellular infiltrate in the 
active MS plaque.
The cellular inflammatory reaction is characterised by a 
perivenular lymphocytic infiltration and is composed mainly of T 
lymphocytes (CD4 and CD8 positive cells) but also of monocytes, 
macrophages, B cells and plasma cells. It ranges from a modest to a 
more severe infiltrate as seen in vasculitis e.g in polyarteritis nodosa 
(in acute viral disease such as polyomyelitis the cellular infiltrate 
may be quite modest) [Adams C.W.M., 1989]. Adams and 
colleagues have observed that in some MS lesions the lymphocytic 
infiltration was initially confined to the cerebral vessel wall alone 
and this may be a feature of very early MS lesions [Adams C.W.M. 
et al, 1985]. Lymphocytes then seem to accumulate in the Virchow- 
Robin space between the vessels and the brain interstitial side. The 
point of maximum immigration of lymphocytes into the perivascular 
space seems to be the venocapillary junction [Adams C.W.M., 1989].
The cellular infiltrate has been described in detail by many 
researchers but it is not always clear from the literature which 
patient groups were used as source of the analysed brain material 
(remitting-relapsing or progressive MS). A summary of these 
findings follows.
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a) The T cell component of the cellular infiltrate.
There is debate about the proportion of the T cell subsets 
(CD4+ versus CD8+ cells) in the ’active MS lesions’. 
Immunocytochemical studies on fresh MS plaques, on balance, have 
revealed that suppressor/cytotoxic T cells predominate over T helper 
cells [Boos J. et al, 1983] [Woodroofe M.N. et al, 1986] [Hauser S.L. 
et al, 1986] [Hofman F.M. et al, 1986] [McCallum K. et al, 1987] 
[Hayashi T. et al, 1988] . When the proportion of the T cell subsets 
was correlated with the appearance of activity of the different 
plaques, it appeared that the active phase of a lesion was 
characterised by an increased number of T helper cells and therefore 
it was concluded that T helper/inducer cells are necessary for plaque 
expansion. On the other hand, plaques which were static showed an 
increased number of CD8+ cells and therefore T 
cytotoxic/suppressor cells were thought to be associated with 
controlled lesions [McCallum K. et al, 1987] [Raine C.S. et al, 1988]. 
On the contrary, Woodroofe et al found that CD8+ cells were 
associated with widespread staining of class IMHC antigen in the MS 
lesion (a prerequisite for antigen presentation to class I restricted 
cytotoxic T cells) and thus concluded that these CD8+ cells may 
function as cytotoxic instead of suppressor cells [Woodroofe M.N. et 
al, 1986].
In the same way there is much debate on the proportion of 
activated T cells (e.g IL2 receptor positive cells) within the ’active 
plaque’: Woodroofe and colleague have observed a high proportion 
of activated T cells (10 to 40 % of total cells) [Woodroofe M.N. et 
al,1986] whereas Hayashi and colleagues found very few activated T 
cells in the MS plaques [Hayashi T. et al, 1988]. Secondly, it is not 
clear what is the proportion of T cells at the edge of the lesion and 
how many T cells can be seen in the outside proximity of the MS 
lesions : overall, T cells at the periphery are usually scanty and 
always outnumbered by those in the perivascular space but 
nevertheless they seem to peak at the plaque edge in comparison with 
the rest of the plaque [Adams C.W.M., 1989] [McCallum K. et al,
1987].
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b) The B cell component of the cellular infiltrate.
It appears that the T cells precedes the B cell in the 
inflammatory reaction [Raine C.S. et al, 1988]. Although B cells are 
not represented at the hypercellular plaque borders, they sometimes 
account for a high proportion of the cells in the cellular infiltrate of 
the perivascular cuff (up to 40% of the total cells) [Woodroofe M.N. 
et al, 1986]. It has also been suggested that B cells are ’trapped’ in 
the MS lesions and produce oligoclonal bands. Plasma cells are also 
seen in the cellular infiltrate and, in some cases, their proportion 
may be high (up to 10%) and may be a feature of more chronic 
lesions [Prineas J.W. et al, 1978]
c) The monocyte-macrophage component of the cellular 
infiltrate.
Macrophages/microglial cells are part of the hypercellularity 
seen in active MS lesions. Again there is no real consensus about the 
role played by the macrophages in the initiation of the MS lesions 
and their role in demyelination. Some have suggested that 
haematogenous macrophages (e.g acid esterase and phosphatase 
positive) enter the lesions early and constitute most of the 'foam 
cells' (the cells which actively phagocytose the myelin). They then 
lose some of their markers and become resident macrophages [Esiri 
M.M. et al, 1988]. In older lesions the foam cells lack most of the 
markers specific for haematogenous macrophages and thus it is not 
clear if these cells originate from the cerebral vasculature and then 
loose their specific markers or if they are mainly endogenous 
microglial cells.
While scattered lipid-laden microglia/macrophages can be 
found throughout the white matter and plaques in MS, in 'active 
plaques' they populate the areas of intense demyelination where they 
seem to 'pick up' (sometimes seen as 'myelin stripping') the myelin 
in the form of globules (myelinic bodies). In some cases they are 
seen in contact with the demyelinating edge of the plaque [Raine C.S. 
et al, 1988] [Adams C.M.W., 1989] and capping of IgG has been seen 
in macrophages in contact with the myelin [Prineas J.W. et al, 1981]. 
Nevertheless, it is still not clear if macrophages/microglial cells are 
primarily responsible for the demyelination or if they only exert a 
secondary scavenger response to the myelin destruction. 13
One feature which favours a direct role in demyelination is the 
immunoglobulin-capping of macrophages which has been described 
in some active lesions [Prineas J.W et al, 1981]. Macrophages and 
microglial cells could also act as antigen presenting cells: they have 
been shown to express a large amount of class II but also a small 
amount of class I MHC molecules in MS lesions [Hayashi T. et al,
1988] [Woodroofe M.N. et al, 1986].
The chronic MS lesion.
The plaque may continue to be active at its periphery with a 
modest lymphocytic infiltrate or occasional foam cells. The chronic 
lesion shows an abundance of astrocytes and spider cells which 
accounts for most of the scarring in 'old plaques'. In such cases, 
axon loss may be seen; this Wallerian degeneration is unidirectional 
as it spreads along the length of the neuron in contrast to the spread 
of the MS lesion which is centrifugal.
14
Figure H
ISTO
-1: Schem
atic representation of a M
S plaque.
Complement
depositionvessel
OEDEMA
lipid-laden
macrophages
NORMAL WHITE 
MATTEROligodendrocyte
regeneration astroglial
hypertrophy
THE BRAIN VESSELS IN MS.
General considerations: the BBB.
a) Definition and function of the BBB.
The demonstration by Paul Ehrlich that intravenously injected 
vital dyes did not stain the brain and the spinal cord but stained other 
organs, has given rise to the concept of a barrier between the blood 
and the brain [Ehrlich P.,1885]. The BBB is present in virtually all 
vertebrates but absent in the brains of invertebrates. Thus in 
evolutionary terms, the BBB parallels the myelin as myelin is 
lacking in the invertebrate nervous system [Pardridge W.M. et al, 
1986, b]. The main morphological feature of the BBB is the presence 
of high-resistance tight junctions (or occluding junctions) which seal 
the brain endothelial cells together into a continuous tube separating 
the blood from the brain tissue. The molecular description of these 
tight junctions of the BBB is virtually still lacking but it appears that 
the properties of the BBB are induced and maintained by the local 
environment and especially by the astrocytes [Stewart P.A. et al, 
1981] [Janzer R.C. etal, 1987] [Golstein G.W., 1988] [Pardridge 
W.M. et al, 1986].
In the human healthy brain, the BBB is omnipresent except for 
about half a dozen of small areas in the circumventricular organs 
such as the median eminence of the floor of the third ventricle, the 
area postrema surrounding the caudal tip of the fourth ventricle, and 
the choroid plexus : these regions are probably sites of local 
exchange between the blood and brain for peptides or other 
substances which may then have access to the cerebrospinal fluid 
(CSF) through the low-resistance tight junctions of the ependymal 
cells lining the surface of the ventricles. The BBB therefore is to be 
differentiated from the blood-CSF barrier in terms of structure and 
in terms of function. Moreover, the composition of the brain 
interstitial fluid and of the CSF are different.
The transport through the BBB is selective and regulates the 
entry of fluid, electrolytes, small molecules and proteins. It 
maintains the composition of the brain extracellular fluid which is 
very different from that of the blood plasma especially by keeping a 
low concentration of proteins in the brain interstitial fluid. The
transport through the BBB is governed mainly by the specific 
chemical characteristics of the penetrating substance rather than by 
its molecular size. On the BBB, specific membrane proteins (carrier 
proteins) involved in the transport of specific molecules have been 
described e.g for insulin [Pardridge W.M. et al, 1985, b] or for 
phenylalanine [Choi T.B. et al, 1986]. Conversely, the BBB is 
known to be highly impermeable to the centrally active 
neurotransmitters and thus prevents their loss to the blood plasma 
after their synthesis in the brain. However, the BBB is not totally 
impermeable to the plasma proteins as a minimal degree of leakage 
can be observed: this phenomenon may be due to a residual 
pinocytosis seen in the brain vessels although pinocytic vesicles are 
characteristically minimal in the brain endothelial cells [Pardridge 
W.M. et al, 1986, b] [Reese T.S et al, 1967].
b) Anatomical structure of the BBB.
For a complete understanding of the BBB, one first has to 
understand the organisation of the vascular tree. The blood is 
confined to a close circuit of vessels lined by a simple squamous 
epithelium, the endothelium. For the entire vasculature, an 
approximate number of 6.1013 endothelial cells is estimated and their 
solid mass should approximate 1 kg. It is now known that endothelial 
cells differ in their nature and their composition between different 
organs and also between different types of vessels within the same 
organ [Zetter B.R.,1981 and 1988] [Rupnick M.A. et al, 1987].
The vascular tree is made up of different types of vessels 
organised in series from the arterial to the venous system as follows: 
elastic arteries, muscular arteries, arterioles, capillaries, pericytic 
venules, muscular venules and small, medium and large-sized veins. 
Vessels larger than 100 pm in diameter are considered part of the 
macrovasculature whereas smaller vessel are part of the 
microvasculature. The microvasculature corresponds to the 
arterioles, capillaries and emerging venules as well as the 
arteriovenous anastomoses. Anatomically speaking, the BBB involves 
only the microvasculature and more specifically the capillaries and 
their emerging venules as it is only in these types of vessels that 
exchanges between blood and tissue occur. The vessels in the rest of 
the vasculature tree possess a continuous vessel wall which prevents 
significant exchanges [Simionescu N. et al, 1990].
Continuous capillaries are not only a feature of the CNS as 
they are also found in muscular tissue (skeletal, cardiac and smooth 
muscle) but also in the exocrine pancreas and the gonads [Palade 
G.E., 1961] [Simionescu N. et al, 1990]. The structure of the vessels 
is organised into three layers or ’tunics' : the intima , the media and 
the adventitia. In the brain capillaries, the intima consists of a single 
layer of thin endothelial cells and a basal lamina (basement 
membrane) in close contact with the pericytes. The endothelial cells 
are joined together by tight junctions. These occluding junctions 
display a different organisation from that seen in other epithelia 
[Simionescu N. et al, 1990]. The media is normally composed of 
muscular cells but it is virtually lacking in the brain capillaries. The 
adventitia consists of the brain connective and neural tissue which, in 
the brain, is tightly packed around the vessels. The passage of 
substances from the blood to the brain is further restrained by the 
foot processes of the astrocytes which are closely applied to the 
vessel wall and cover 70 % of its surface [Golstein G.W., 1988].
The postcapillary (pericytic) venules range from 10 to 50 pm 
in diameter and appear to have a comparable vessel wall as the 
transition between the capillaries and the venules occurs gradually. 
Immunologicaly, the post capillary venule is an important site for 
inflammation and allergic reactions and exhibits a high concentration 
of adhesion molecules [Raine C.S. et al, 1990]. Prineas has also 
described structures resembling lymphatics around the brain vessel 
especially in the Virchow-Robin space [Prineas J.W., 1979]. The 
Virchow-Robin space (VRS) has recently been reviewed by Esiri and 
Gay [Esiri M.M. et al, 1990]. The VRS is the space between the 
brain vessels and the cerebral matter. The VRS is now known to be 
an extension of the subpial space rather than of the subarachnoid 
space in man. The pia is made of a single layer of cells linked 
together by desmosome and gap junction. From the pia, the space 
extends as far as the capillaries. At this level the VRS is occluded by 
the glia limitans formed by the foot processes of the astrocytes.
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Endothelial cells (EC) and brain endothelial 
cells.
a)The endothelial cells and their characterisation.
Information on the biology of the EC has been amassed during 
the past decades because of the important role of these cells in the 
biology of the human body : they cover the lumen of blood vessels 
and lymphatics, they have an important role in homeostasis and in 
the permeability of blood vessels and mediate response to 
physiological and pathological stimuli by excreting soluble factors 
and expressing new molecules [Vane J.R. et al, 1990] [Dinh Xuan
A.T. et al, 1989]. It is nevertheless important to stress that the source 
of EC for most of these studies was the macrovasculature namely the 
vein of the umbilical cord because of the accessibility of this organ 
in live patients and because of the relative ease in culturing human 
umbilical vein endothelial cells (HUVEC) [Jaffe E. A., 1977]. It is 
mainly because of Folkman and his colleagues in the late seventies 
that culture of EC from the microvasculature became feasible 
[Folkman J. et al, 1979]. However, EC from the microvasculature of 
some organs are still very difficult to propagate in culture : there is 
no universal method as it appears that the optimal conditions of 
culture for these cells are different as a function of the organ of 
origin [Pearson J., 1990].
Typically, EC in culture are flat, thin, of cobblestone 
morphology with large round nuclei and are contact inhibited 
whereas cultured smooth-muscle cells and fibroblasts grow as 
overlapping spindle-shaped cells [Jaffe E.A., 1977], Some markers 
specific for EC are now available. The best known is von Willebrand 
factor (vWf) protein which is synthetised by EC and megakaryocytes 
and is found at low concentration in the plasma [Wagner D.D. et al, 
1982]. The confusion between vWf protein and factor VIII - in some 
cases, described as a specific marker for EC - arose as it was not 
possible to measure these 2 compounds separately as vWf was part of 
the so called 'factor VIII related antigen' [Jaffe E.A., 1977].
However factor VIII is not synthetised in EC but in the liver and not 
found in EC but in the plasma. Other less established and also less 
specific markers are used and can be measured by 
immunohistochemistry, when there is a monoclonal antibody 
available, or, by a biochemical assay. For example angiotensin­
converting enzyme (A.C.E) is considered as indicative of EC 
[Caldwell P.R.B. et al, 1976] [Auerbach R. et al, 1982] even if it is 
also found in alveolar macrophages, in certain epithelia, in brush 
cells of the gut, and in the proximal tubes of the kidneys [Zetter
B.R., 1981]. ACE activity often decreases in culture [Del Vecchio 
P.J. et al, 1981] as does vWf expression [Gerhart D.Z. et al, 1988] . 
A number of lectins have been shown to be specific for the EC; the 
best known being Ulex Europaeus Agglutinin I (UEA-I) in humans 
[Holthofer H. et al, 1982]. However, these lectins do not seem to be 
universal in all species e.g UEA-I does not bind canine EC whereas 
Ricinus communis agglutinin I (RCA-I) does [Gerhart D.Z. et al, 
1986]. EC express other molecules like the antigens recognised by 
the monoclonal antibodies PAL-E and EN4 which are also 
endothelial cell specific [Schlingemann R.O. et al, 1985 and 1991]. 
They (HUVEC) also express many immunological markers e.g 
ICAMI (CD54), CD29, CD34, CD 31, GP Hla, and OKM 5 
[Romano P. et al, 1989]. The antigens corresponding to CD 31 
(ENDO-CAM) is considered to be an endothelial marker but is also 
present on platelet as platelet GP Ila antigen and is also present on a 
number of other blood cells [Albeldo S.M. et al, 1990]. CD 34 has 
been shown to be expressed in dividing endothelial cells during 
angiogenesis, therefore expressed in the vasculature of a number of 
tumours [Schlingemann R.O. et al, 1990].
Other assays for the characterisation of EC have been 
described e.g the 'platelet adhesion test' that ascertains that EC have 
a nonthrombogenic surface [Wechezak H.R. et al, 1979] or the 
demonstration of the uptake and degradation of LDL by endothelial 
cells by the presence of acetylated low density lipoprotein [Voyta 
J.C. et al, 1984] although the latter test doesn't seem to be positive 
with EC from all origins [Rupnick M.A. et al, 1988]. By 
electromicroscopy, the specific endothelial organelles or Weibel- 
Palade bodies can be seen in human EC from the macro- and micro­
vasculature [Wagner D.D. et al, 1982] [Folkman J. et al, 1979]; they 
have been shown to contain vWf protein [Wagner D.D. et al, 1982].
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b)The brain endothelial cells.
EC from the brain microvasculature of some animals (mouse, 
cow, guinea-pig) have been maintained in culture by some groups 
[Bowman P.D. et al, 1983] [Audus K.L. et al, 1986] [Wilcox C.et al, 
1989]. However, reports of human brain EC culture have been rare 
[Gerhart D.Z. et al, 1987] [Vinters H.V. et al, 1987] and biological 
and molecular characterisation of these cells - other than their 
morphology and the description of expression of some markers - is 
still lacking.
Brain EC from all species express the specific endothelial 
markers (vWf, ACE) and sometimes show some brain specific 
properties. However, the main difficulty in the characterisation of 
brain EC in culture is that they appear to lose these brain and 
endothelial specificities rather quickly.
Brain specific characteristics of EC are likely to be related to 
the function of the BBB. For example gamma-glutamyl 
transpeptidase (y GTP) has been used as a marker for brain- and 
retinal-derived EC [Pardridge W.M. et al, 1986]. The enzyme is 
important in glutathione metabolism and amino acid transport: it 
catalyses transfer of the y - glutamyl residue of glutathione to amino 
acids. It is not limited to cerebral endothelium but seems to be 
present only in cells with active transport properties and polarity 
transport, such as biliary epithelia and renal tubular epithelial cells 
[Orlowski M. et al, 1974] [DeBault L.E. et al, 1980]. Another 
enzyme which is claimed to be specific for brain EC is alkaline 
phosphatase [Audus K.L. et al, 1986] but this enzyme is also present 
in other cells e.g HELA cells a cancer derived cell line from the 
cervix [W.C Russell, personal communication]. Monoclonal and 
polyclonal sera have been produced and seem to be specific for the 
brain EC but these sera are not universaly available: N. Stemberger 
and colleagues made a monoclonal antibody called anti-EBA which 
reacts with rat brain EC and is specific for a protein triplet of 
23,500, 25,000 and 30,000 Kd [Stemberger N.H. et al, 1987] (this 
monoclonal antibody is now commercially available). A polyclonal 
sera specific for a 46 Kd protein seems to be also specific for the 
BBB [Pardridge W.M. et al, 1986]. On the other hand, the antigen 
recognised by the monoclonal antibody Pal-E is absent from 
endothelium in sites with an intact BBB but is present in some brain
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tumors where the BBB is likely to be disrupted [Leenstra S. et al, 
1990].
With electronmicroscopy, some have demonstrated the 
presence of tight junctions between brain EC in culture and freeze 
fracture revealed a complex anastomosing network of 
intermembranous ridges [Bowman P.D., 1981]. Brain EC have 
characteristically very few pinocytic vesicles contrary to other 
sources of EC. They do not appear to contain Weibel-Palade bodies 
which are thought to be mainly a feature of the macrovasculature 
although Weibel-Palade bodies have been observed in EC from the 
microvasculature [Weibel E.R. et al, 1964] [Folkman J. et al, 1979].
Most of the immunological features demonstrated by animal 
brain EC have also been demonstrated with HUVEC or other types 
of EC (for a review see [Pober J.S., 1988]). Although normal brain 
EC do not express class II MHC molecules, the expression of this 
molecule is inducible by INF-y as is the expression of class I MHC 
[Male D.K. et al 1987], By immunohistochemistry it has been shown 
that brain EC also express a number of adhesion molecules [Raine
C.S. et al, 1990]. Both features are likely to be important in 
leukocytes and especially lymphocyte interactions. For example, 
adhesion of lymphocytes to cerebral EC is increased by INF- y, TNF 
and IL 1 [Hughes C.C. et al, 1988]. Moreover, both MHC and 
adhesion molecules are critical for antigen presenting capacity which 
has been demonstrated in rodent brain EC [Wilcox C.E. et al, 1989].
The brain pericyte and smooth muscle cell.
The vascular smooth muscle cell is the main cell of the 
subendothelial connective tissue in all vessels, except, in capillaries 
and pericytic venules, where this place is taken by the pericyte which 
is probably a variant of a smooth muscle cell.
Some groups have described the culture of smooth muscle 
cells from mice brain microvessels: these cells actively produced a - 
actin, a smooth-muscle-specific isoactin. However, the differentiation 
between brain smooth muscle cells and pericytes is not
straightforward [Moore S.A. et al, 1984] [Larson D.M. et al, 1987]. 
Nevertheless, they have shown that these smooth muscle cells can 
express class II MHC antigens vitro [Hart M.N. et al, 1987] and 22
that this MHC expression is inducible by INF- y [Fabry Z. et al, 
1990], These cells have been shown to act as antigen presenting cells 
and this antigen-presenting capacity is also enhanced by INF- y 
[Fabry Z, et al, 1990].
The immunological interest in smooth muscle cells is further 
bolstered by the demonstration of autoimmune vasculitis resulting 
from sensitisation of lymphocytes to smooth muscle cells [Hart M.N. 
et al, 1985].
Historical background of the brain vessels in 
relation to MS.
The importance of the brain vessels in the aetiopathogenesis of 
MS was recognised soon after the first clinical descriptions of MS. 
For example, the conclusion drawn from one of the first 
international symposia on MS almost a century ago was: ”... These 
changes are very suggestive that the disease is associated with 
vascular lesions, either in the nature of a partial or complete 
vascular obstruction (multiple thrombosis of minute vessels), or of a 
process allied to multiple embolism, or possibly the presence of 
some irritating agent in the circulation may stimulate the 
endothelium cells of the walls of the vessels, and give rise to 
extravasation of lymph cells, and perivascular changes at certain 
spots, and as a result patches of degeneration may follow ...” 
[Critical digest, 1896]. This interest in the brain vessels in MS 
seemed to have evaporated, about the time of Louis Pasteur, with the 
recognition that neuroparalytic accidents could arise after injection 
of rabies vaccine prepared from the spinal cord of rabbits. Then 
Rivers and colleagues induced acute encephalomyelitis in monkeys 
by nervous tissue immunisation [Rivers T.M. et al, 1935] and soon 
after, experimental allergic encephalomyelitis (EAE) was generated 
with the introduction of Freund adjuvant [Freund J. et al, 1947]. 
Most of the MS researchers focussed their interest on the myelin and 
on the autoimmune theory of MS; the brain vessels were forgotten, 
few tried to revive them but were mostly unnoticed [Putman T.J., 
1937]. As MS researchers were preoccupied with the viral theory of 
MS in the sixties and seventies, it is only recently that the brain 
vessels have regained the place they deserve alongside the myelin- 
autoimmune and viral theories of MS.
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Histopathological considerations of the brain 
vessels in relation to the MS lesions.
As already discussed, the MS lesions are strikingly 
perivascular, sometimes extending over a considerable distance along 
the course of a vein or sometimes as Dawson’s fingers. Cellular 
infiltrates or cuffings don't always arise in proximity to myelin as 
MS lesions are sometimes present in the grey matter and, as 
periphlebitis retinae, around the veins of the retina which is devoid 
of myelin. NMR studies with Gadolinium-DTPA show that in the 
relapsing-remitting form of the disease, disruption of the BBB is an 
early event and that the MS lesions develop in a centrifugal fashion. 
The disruption of the BBB appears to be reversible in serial NMR 
studies [Kermode A.G. et al, 1990] but is still present in established 
lesions: T. Broman demonstrated that perfusion of the brain with 
trypan blue shortly after death caused staining in the MS plaques 
[Broman T., 1947]. In addition, in some very early lesions the 
lymphocytic infiltrate is confined to the cerebral vessel wall and in 
the typical MS lesions the perivenular infiltrate seems to accumulate 
in the Virchow-Robin space.
What happens to the vessel wall in 'active 'MS plaque is less 
well documented. Signs of vessel wall damage has been observed in 
some cases. They range from 'recent perivenular haemorrhages', 
'venular thrombosis' and 'intramural fibrinoid deposition' in about 
2-5 % of cases to 'perivenular iron deposition' - sign of old 
hemorrhage - in about 30 % of cases [Adams C.W.M., 1989]. In 
chronic MS lesions, the prolonged effect of inflammatory or 
traumatic damage to the vessel leads to the collagenisation and 
marked scarring even to the extent of collagenous degeneration or 
hyalinisation of the vessel [Adams C.W.M., 1989] [Allen I., 1981].
Electronmicroscopical studies of the vessels in acute MS 
plaques has shown that the tight junctions appear closed but it is still 
possible that temporary opening and subsequent closure of the 
junctions may occur: '...the gate can open and close depending upon 
who knocks...'[Brown W.J., 1978]. The shape and number of the 
endothelial cell mitochondria are not modified by the presence of 
recent MS plaques but the number of pinocytic vesicles is markedly 
increased in the endothelial cells of the MS plaques [Brown W.J., 
1978]. The same findings have been observed in chronic EAE 
[Hawkins C.P. et al, 1990]. 24
Hypotheses: the involvement of the brain blood 
vessels in the aetiopathogenesis of MS.
Thrombosis has been linked with the pathogenesis of MS 
[Putman T.J., 1937] but it is now thought that it is a result rather 
than the cause of the plaque (for review see [Adams C.W.M., 1989]). 
In the same context, P. James suggested that the lesions of MS might 
be due to transient venous occlusion by fat embolism [James P.B., 
1982] and this would explain the possible effectiveness of hyperbaric 
oxygen treatment in MS. However, neither the fat embolism theory 
nor the effectiveness of hyperbaric oxygen treatment have been 
confirmed [Oppenheimer D.R., 1982] [Wiles C.M., 1986].
Trauma of the vessels has been put forward by C.M Poser as a 
possible trigger for MS lesions [Poser C.M., 1896]. He argued that 
fresh MS lesions have been observed near the needle tract after 
stereotactic procedures [Gonsette R. et al, 1966][Riechert T. et al, 
1968]. Also, the predominance of cervical lesions compared with the 
rest of the spinal cord may implicate mechanical stresses as a 
triggering factor for MS lesions : the lateral portion of the spinal 
cord close to the attachment of the denticulate ligaments were the 
most common sites of plaques in a study of MS spinal cords 
[Oppenheimer D., 1978]. However, trauma of the vessels is not 
sufficient for the genesis of MS: Poser compared MS to the 
experimental conditions designed by Clark and colleagues when they 
observed clustering of the EAE lesions (after immunization with 
spinal cord and Freund's adjuvant) around the previously made 
electrolytic lesions in the cerebral cortex and white matter of rabbits 
and guinea pigs [Clark G. et al, 1955] [Bogdanove L. et al, 1957]. 
However, Poser hypothesised that the cause of alteration of the brain 
vessels in MS patients may be due to factors other than trauma, for 
example it may also be generated by viral infection.
Other immunological hypotheses stem from the potential 
immunological functions of these cells. Post capillary venules are the 
sites of extravasation of lymphocytes in inflammatory lesions and 
thus can be compared to some extent with the high endothelial venule 
of the lymph nodes para-cortex [Kraal G. et al, 1987]. This function 
seems to arise in part because of the large density of adhesion 
molecules. In MS these adhesion molecules could be overexpressed 
due to a number of different mechanisms e.g viral 25
infection. On the other hand the lymphocytes in MS could be more 
’sticky’ because of their activation and expression of adhesion 
molecules [Springer T.A., 1990] and therefore adhere to the 
endothelial cells. Consequently, the lymphokines generated by 
lymphocyte activation could induce, in a paracrine fashion, enhanced 
expression of MHC and adhesion molecules on the surface of the 
endothelial cells [Pober J.S., 1988]. The same types of mechanisms 
for the extravasation of lymphocytes can also be put forward using 
monocytes and macrophages. It has also been proposed that EC may 
act as antigen-presenting cells for autoimmune antigens (e.g MBP) in 
MS. It has been shown that peroxidase-labelled MBP injected into the 
CSF of rabbits was presented at the level of the brain vessels after a 
period of time [Vass K. et al, 1984]. Cross and colleagues have 
proposed that a small number of antigen (MBP?) specific T cells 
could prime central nervous system endothelial cells which could 
then recruit inflammatory cells in a non specific manner [Cross A.H. 
et al, 1991]. During the antigen presentation, brain endothelial cells 
could become target for MBP specific cytotoxic T cells. This has 
been demonstrated in vitro with rat brain endothelial cells which are 
able to present MBP to MBP specific T cell lines and be lysed in the 
process [McCarron R.M., 1991][Risau W. et al, 1990].The possibility 
that after destruction of the myelin in optic neuritis some myelin is 
released into the circulation and then taken up by the EC of the 
retinal vessels could perhaps explain the occurrence of periphlebitis 
retinae in some MS patients; this possibility could also explain the 
lesions in the grey matter. Targetting the early events at the level of 
the blood-brain barrier could lead to rewarding therapeutic results 
in patients suffering from MS. Yednock and colleagues have shown 
that EAE can be prevented by treating the animal with an antibody 
against a4pi integrin which is an adhesion molecule expressed on 
lymphocytes and monocytes [Yednock T.A. et al, 1992].
Reactivation of a viral infection or a low-grade persistent 
infection of the brain EC in patients suffering from MS is also a 
very interesting possibility. This could interfere with cell synthesis 
or induce a local T or B cell response to the virus but also to the EC 
themselves [Ault K.A. et al, 1979] [Friedman H.M. et al, 1981]. 
Release of normally hidden antigens, opening up of the BBB as well 
as the expression of immunological molecules could amplify this 
immunological response. Moreover it has been shown that EC 
infection with some viruses increases local procoagulant activity 26
[Etingin O.R. et al, 1990], Very little work has been published on 
viral infection of brain EC: it has been noted that human brain EC 
are permissive for infection by human cytomegalovirus which 
occurs frequently in AIDS patients [Lathey J.L. et al, 1990].
The brain vessels could also be the target for an autoimmune 
attack without viral infection. Tsakuda and his colleagues have 
reported the induction of chronic EAE in guinea pigs and in 
monkeys by immunisation with cerebral endothelial cell membranes 
[Tsakuda N. et al, 1987 and 1988]. However, this study still needs to 
be reproduced by other independent research groups. Concerning 
the humoral arm of the immune response it has been reported that 
MS patients and patients suffering from HTLV1-associated 
myelopathy have autoantibodies to endothelial cells [Tanaka N. et al,
1987] [Tsakuda N. et al, 1989, a and b]. Complement induced 
toxicity of the brain vessels triggered by different factors e.g 
infection, can be induced with or without autoantibodies to EC. 
Compston and colleagues have reported the deposition of C9 (part of 
the membrane attack complex) on the brain vessels of MS plaques 
[Compston D.A.S. et al, 1989]. Involvement of autoantibodies to EC 
has been suggested as causal in some 'low grade vasculitis' e.g in 
connective tissue diseases [Rosenbaum J. et al, 1988] or in systemic 
lupus erythematosus [Vismara A. et al, 1988]
If injury of EC is causal in MS, demyelination could occur and 
be perpetuated non specifically by macrophages [Cuzner M.L. et al,
1988] , by complement [Scolding N.J. et al, 1989] or even by 
proteinase from the disrupted myelin sheaths [Chantry A. et al,
1988]. Moreover cytokines secreted by lymphocytes can also mediate 
demyelination [Owen S.J. et al, 1988].
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THE VIRAL THEORY IN MS.
Epidemiology.
Although genetic predisposition has been well established in 
the cause of MS, many features of the epidemiology of MS implicate 
one or multiple environmental agents [McDonald W.I., 1986] 
[Kurtzke J.F., 1980]. Among the possible environmental agents, 
viruses are on the top of the list; other factors which have been 
proposed as causal have been extensively reviewed by Acheson 
[Acheson E.D., 1985] and will not be discussed in the present 
review.
The increasing prevalence of MS with latitude in both the 
northern and southern hemispheres has led epidemiologists to believe 
that environmental factors may play a role in MS [Kurzkte J.F.,
1980] and that these environmental factors are influenced by latitude 
associated factors e.g the degree of sunlight exposure [Acheson E.D., 
1985]. This correlation with MS prevalence can be seen in New 
Zealand [Skegg D.C.G. et al, 1987], Australia [Hammond S.R. et al, 
1988] and the United States [Kurtzke J.F. et al, 1979]. Thus, J.F. 
Kurtzke divided the globe into almost parallel zones of high, 
medium and low risk following the lines of latitude [Kurtzke J.F., 
1980]. There are however many exceptions to this ‘latitude rule', for 
example the unexplained very high MS prevalence in the north of 
Switzerland (almost as high as in the north east of Scotland) 
[Compston D.A.S., 1989] and also the relatively high prevalence of 
MS in Sardinia [Granieri E. et al, 1983].
Epidemiologists have studied migrants from different risk 
zones and noticed that if one migrated before the age of puberty, one 
acquired the risk of the country of adoption whereas if one migrated 
after puberty one retained the risk of the country of origin. This was 
demonstrated both ways: from low risk to high risk areas [Alter M. 
et al, 1978] and also from high to low risk countries [Dean G. et al, 
1971] [Acheson E.D., 1985]; it was therefore concluded that the 
environmental agent(s) was likely to have been contracted around the 
time of puberty. More recently, it has been reported that children of 
migrants from the West Indies (a low risk country) to the West- 
Midlands (a high risk area) have the same risk (unlike their parents) 
of getting MS as the general population of the West-Midlands and 
thus it was concluded that the role played by environmental agents 28
may be even more important than the genetic predisposition [Elian 
M. et al, 1987].
Foci of MS have been reported in Scotland [Sheperd D.I,
1980] , in Scandinavia [Kurtzke J.F., 1974] [Kinnunen E., 1984], in 
the north of Switzerland [Compston D.A.S., 1989] and in Brittany, 
France [Gallou M. et al, 1983] to cite but a few examples. Small 
clusters of the disease has also been reported in small villages or 
areas for example in Mossyrock, Washington [Koch M J. et al,
1974], in Duxubury [Deacon W.E. et al, 1959], in Mansfield, in 
Massachusetts [Eastman R. et al, 1973] and in Nova Scotia [Murray 
T.J., 1976], in an Aberdeenshire valley [Sheperd D.I., 1980] and in 
Los Alamos, New Mexico, near the plant where the atomic bomb 
was developed during the second world war [Hoffman R.E. et al,
1981] . An interesting MS cluster was reported by Campbell and his 
colleagues: 4 of 7 main research workers on swayback, a 
demyelinating illness of sheep, developed MS like symptoms some 
months after completing this work [Campbell A.M.G. et al, 1947]. A 
diagnosis of MS was confirmed in some of the patients when the post 
mortem brains became available [Dean G. et al, 1985]. It appears 
also that in familial cases of MS, siblings concordant for the disease 
often develop the signs of MS during the same year even though they 
are of different ages [Waksman B., 1986]; these observations point 
again to common triggering agents.
The most interesting and the most commented report was the 
'MS epidemic' of the Faroes islands during and just after the second 
world war [Kurtzke J.F. et al, 1979]. From the beginning of this 
century to the second world war, the Faroes, a group of secluded 
islands, situated between the North of Scotland, Norway and Iceland 
had only one case of MS recorded. Compared to the neighbouring 
islands, the Shetlands and the Orkneys, and, also to Norway, the low 
prevalence of MS in the Faroes never fitted the 'latitude theory of 
MS'. However, 32 native and resident Faroeses developed MS 
during and after the war [Kurtzke J.F. et al, 1986]. At the beginning 
of 1940, British troops occupied the Faroes and stayed defending the 
islands until the end of the war [Kurtzke J.F. et al, 1986]. It was thus 
postulated that an environmental agent carried by or accompanying 
the British soldiers was introduced in the islands and caused this 'MS 
epidemic' [Cook S.D. et al, 1978] (see the paramyxovirus section). 
The same phenomenon seemed to have occurred in Iceland after the 
war [Kurtzke J.F. et al, 1980]. More recently, another 'MS epidemic' 29
was described in Key-West, a small island south of the Florida coast; 
this ’epidemic' did not correlate with the risk zones of MS as the 
Gulf of Mexico is a low risk area [Sheremata W.A. et al, 1985].
Although most of the epidemiological features of MS in 
favour of an external causal agent are interesting and reasonably 
convincing, it is fair to acknowledge, first, that the statistical tests 
used in some studies were stretched to the limit of significance (for 
example in the migrant studies), and, secondly, that some MS 
researchers have questioned the validity of some observations: Poser 
and colleagues had doubts about the 'Faroes epidemic' [Poser C.M et 
al, 1988, a and b] and others about the 'Key-West epidemic [Roman 
G.C. et al, 1987]. Also, some MS researchers gave a possible genetic 
explanation to some epidemiological features of MS: the relationship 
of MS prevalence to latitude could be explained by the distribution 
of white people of Nordic origin around the globe [Poser C.M.,
1987] [Ebers G.C. et al, 1986], and even in New-Zealand [Skegg 
D.C.G. et al, 1987] or in Great Britain [Swingler R.J. et al, 1986].
Nevertheless, it is paradoxically the genetic twin studies which 
give the strongest evidence of the involvement of environmental 
agents in MS. Only 30 % of identical twins are concordant for the 
disease; in other words, in 70 % of cases, an individual with exactly 
the same set of genes as a person suffering from MS, will never 
develop symptoms of MS [Ebers G.C et al, 1986]. However, in a 
further 10 % - still leaving 60 % - of these monozygotic pairs of 
twins, the unaffected twin shows signs of MS on NMR [Ebers G.C. et 
al, 1986]. Interestingly, a concordance study of paralytic polio in 
twins gave similar results to the MS twins studies (paralytic polio - 
concordance in monozygotic (MZ) twins: 35.7 %; in dizygotic (DZ) 
twins: 6 %. MS - concordance in MZ twins: 25.9 %; in DZ twins:
2.3 %) [Herndon C.N. et al, 1951] [Eldridge R., 1987]). This latter 
study suggests, again, that MS is caused by an environmental agent, 
probably viral and fairly ubiquitous in the general population, only 
in individuals with a specific genetic background.
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Human and animal demyelinating diseases 
caused by viral infections: general 
consideration.
Viral diseases leading to demyelination occur in humans and 
in animals and can also be induced in laboratory animals. Although 
some of the mechanisms leading to demyelination are not completely 
understood in most of these viral diseases, it is nevertheless clear that 
these mechanisms can be different between diseases and may also be 
multifactorial within the same disease. Nevertheless, some insight 
into demyelination caused by viruses has been gained by the study of 
these viral diseases. Some of the diseases have been modified in 
laboratory animals to resemble MS more closely and thus alongside 
the autoimmune experimental allergic encephalomyelitis (EAE) 
induced by myelin basic protein (MBP), these viral demyelinating 
illnesses are reasonable models for multiple sclerosis. Many more 
viruses can cause infection of the nervous system but do not lead to 
demyelination and thus they will not be discussed in this chapter.
Human demyelinating diseases caused by viral 
infections.
For a summary of the human demyelinating diseases caused by 
viral infection and their characteristics see Table la.
a) Progressive multifocal leukoencephalopathy (PML).
PML occurs in immunocompromised hosts (e.g patients with 
AIDS, leukemia or lymphoma), and is caused by the human 
papovavirus JC [Richardson E.P., 1988] [Padgett B.L., 1976] and 
had also been associated with SV 40 [Weiner L.P. et al, 1972]. 
Multifocal regions of demyelination can be seen in post mortem 
brains. They become confluent as the disease progresses. The 
oligodendrocytes are enlarged as well as the astrocytes [Brooks B.R. 
et al, 1984]. Large number of papovavirus particles can be visualized 
in the nuclei of oligodendrocytes by electron microscopy [zuRhein 
G.M., 1967] and virus can be detected occasionally in astrocytes but 
not in endothelial cells with in situ hybridization techniques 
[Aksamit A.J. et al, 1985].
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One possible explanation of the demyelination process in PML 
comes from the study of transgenic mice. Transgenic mice 
containing the JC early region, which codes for the T antigen, have 
been produced [Small J.A. et al, 1986]. These mice develop ’shaking' 
and the expression of the T antigen correlates with the severity of 
the ’shaking’. As the T antigen shares some homology with the C- 
terminal part of MBP, it appears to inhibit competitively the protein 
kinase phosphorylation of the C-terminal portion of MBP. This 
blocks the production of myelin and arrests the maturation of 
oligodendrocytes [Chan K-F.J. et al, 1986]. The T-antigen has been 
demonstrated in the nuclei of oligodendrocytes of patients with PML 
[Stoner G.L. et al, 1986] but is not detected in oligodendrocytes of 
patients with MS [Stoner G.L. et al, 1986].
b) Post infectious encephalomyelitis.
Post infectious encephalomyelitis (PIE) shows an obvious 
temporal relationship to some acute viral infections particularly 
measles, chickenpox, as well as smallpox vaccination. It can also be 
seen following unidentified upper respiratory febrile infections. 
Children are most commonly affected. PIE usually occurs a few days 
after the beginning of an acute infectious illness. Fever, headache, 
vomiting and increasing drowsiness may be accompagnied by focal 
or diffuse signs of brain or spinal cord disease. Death occurs in 
about 20 % of cases and although some patients suffer permanent 
neurological sequelae recovery can be complete [Matthews W.B., 
1985].
The virus is rarely isolated from the brain and the 
histopathology resembles acute EAE with demyelination and intense 
perivascular inflammation and thus it is thought that the disease is 
immune mediated and that the virus does not play a direct role in the 
pathogenesis. PIE due to measles has been studied extensively. CD4 
positive lymphocytes specific for MBP mediate demyelination, at 
least in part [Lisak R.P., 1977] [Johnson R.T. et al, 1984] [Hafler D. 
A. et al, 1987]. It is not understood why such pathogenic T cells 
arise after so many different viral infections. Some have suggested 
molecular mimicry between a common virus and MBP as possible 
trigger of autoimmunity [Jahnke U et al, 1985] [Weise M.J. et al, 
1988] [Souberbielle B.E. et al, 1991] . 33
c) HTLV-1.
The human T-cell leukemia/lymphoma virus (HTLV-1) is a 
retrovirus which causes adult T-cell leukemia (ATL) and T cell 
lymphoma [Yoshida M. et al, 1982] [Poiesz B.J. et al, 1980]. It has 
also been associated with tropical spastic paraparesis (TSP) [Vemant 
J.C. et al, 1987] [Cruickshank K. et al, 1989]. In Japan, a similar 
disease has been described and named HTLV-1 associated 
myelopathy (HAM) and seems to be the same disease despite some 
slight differences (see below) [Osame M. et al, 1987].
Clinically, TSP is characterised by a slowly progressive, 
symmetrical, predominantly upper motor neuron disorder where 
signs of spastic paraparesis are predominant. Thus TSP lacks 
remissions typical of MS and also sensory signs are minimal or 
absent - in HAM the sensory signs have been claimed to be more 
prominent than in TSP [Osame M. et al, 1987] [Vemant J.C. et al, 
1987]. Elevated serum antibodies to HTLV-1 are present in patients 
suffering from TSP compared to controls [Gessain A. et al, 1985]. 
High level of antibodies are detected in the patients' CSFs and are 
produced intrathecally with occasionally oligoclonal banding - the 
CSF disturbances appear to be more pronounced in HAM than in 
TSP [Toumier-Lasserve E. et al, 1987] [Osame M. et al, 1986]. 
Mononuclear cells with large multilobular nuclei in the CSF have 
also been described in HAM [Osame M. et al, 1986]. Histologically, 
demyelination and perivascular cuffing by lymphocytes of small 
vessels of the spinal cord are present. Macrophages as well as plasma 
cells are also seen in the lesions which are distributed in both white 
and grey matter. The extent of meningeal inflammation is much 
more important in TSP/HAM than in MS [Editorial, Lancet, 1988].
As in most (if not all) demyelinating diseases, host factors are 
very important in the disease (determining occurrence and also 
progression). The cause of demyelination in TSP/HAM is still 
unclear: it is not known if the vims has a direct effect on the 
oligodendrocytes and/or the myelin or if the demyelination is 
immune-mediated. For example it has been demonstrated in vitro 
that antibody directed cytotoxicity (against HTLV-1 infected cells) is 
much higher in symptomatic patients than in asymptomatic 
individuals [Dalgleish A.G. et al, 1988]. However,the prime suspect 
for initiating the disease is the HTLV-1 infected lymphocytes and it
is thought that HTLV-1 is not truly neurotropic [Dalgleish A.G., 
1991]. In the peripheral blood the main cell infected is the CD4+, 
CD45 RO+ T lymphocytes [Richardson J.H et al,1989,b]
d) Acquired immunodeficiency syndrome (AIDS).
HIV produces a variety of neurological conditions but there is 
still some confusion about the name(s) of the syndromes related to 
these conditions. Moreover, categorisation may be oversimplistic as 
seen below. It is generally accepted that the encephalopathy 
associated with psychiatric symptoms and with a persistent infection 
of the CNS by the HIV agent is described under the term "AIDS- 
dementia complex” but has also been named AIDS encephalopathy, 
AIDS-related-dementia and subacute encephalitis. However it is not 
yet clear that this clinical syndrome corresponds to a single 
aetiopathogenetic entity. Pathologically this syndrome is associated 
with different histopathological features: vacuolar myelopathy, 
multinucleated cell encephalitis, diffuse pallor of the white matter 
and aseptic meningitis (although the latter tends to be also associated 
with an earlier symptomatic infection of the CNS). Central nervous 
system (CNS) demyelination is a major feature of the first 2 
conditions [Shubin R.A. et al, 1989] whereas pallor of the white 
matter is related to astrocytic hyperactivity. These abnormalities are 
predominant in the subcortical structures of the brain and of the 
spinal cord [Price R.W. et al, 1988]. Other neurological syndromes 
seen in HIV patients are sensory polyneuropathy and dysimmune 
motor polyneuropathy as well as the infectious neurological 
complications associated with AIDS e.g PML or cytomegalovirus 
and cryptococcus infection of the brain.
Some authors have differentiated the 2 pathological conditions, 
vacuolar myelopathy and multinucleated cells subacute encephalitis 
on a clinical basis, although these conditions often coexist in the same 
patient. Vacuolar myelopathy is characterised by paraparesis, ataxia 
and incontinence [Petito C.K. et al, 1985] [Levy R.M. et al, 1985]. 
Pathological examination reveals demyelination predominantly in the 
lateral and posterior columns of the thoracic spinal cord and 
demyelination appears to result either from swelling within the 
layers of the myelin sheaths [Price R.W et al, 1988] or from 
intramyelin vacuoles resembling lipid-laden macrophages [Petito 
C.K. et al, 1985] [Asher D.M. et al, 1987]. It also appears that HIV is
not directly associated with the vacuolar myelopathy [Price R.W. et 
al, 1988]. Some have suggested that this condition resembles subacute 
combined degeneration of the spinal cord resulting from vitamin 
B12 deficiency but serum B12 levels are normal.
Multinucleated cells subacute encephalitis is characterised 
clinically by impaired memory and concentration with psychomotor 
slowing [Navia B.A. et al, 1986, a] and pathologically by 
abnormalities in the CNS white matter and subcortical structures; the 
spinal cord is generally less often affected. These abnormalities 
consist of white matter pallor, microglial nodules and perivascular 
and parenchymal macrophages, multinucleated giant cells, microglia 
and lymphocytes [Navia B.A. et al, 1986, b]. These infiltrates are 
often surrounded by focal rarefaction of the myelin (demyelination) 
but more commonly by oedema; loss of oligodendrocytes is not 
characteristic. HIV has been demonstrated in monocytes and 
multinucleated cells in the regions of demyelination but not in 
oligodendrocytes [Navia B.A et al, 1986, b].
Oligoclonal immunoglobulins are produced intrathecally in 
some patients suffering from AIDS-dementia complex but the 
specificity of these oligoclonal immunoglobulins is not fully known 
although some have related these oligoclonal bands to HIV proteins 
using the immunoblotting method but this result has to be confirmed 
by other CSF characterisation methods [Goswami K. et al, 1991] .
There is also an intrathecal synthesis of antibodies to HIV which has 
not been correlated to these oligoclonal bands. The virus can be 
isolated in the CSF. The cell types infected in the brain (in vivo) by 
HIV are still a matter of debate but it is generally accepted that the 
main cell involved in productive infection is the macrophage and the 
cells derived from the macrophage i.e microglial cells [Price R.W. et 
al, 1988] [Kennedy P.G.E. et al, 1989]. Multinucleated cells appear 
to be induced by cell fusion similar to the syncytial pathology 
described for HIV-1 infected CD4 positive cells in culture [Price 
R.W. et al, 1988]. It is not clear whether or not other cell types are 
infected in vivo i.e endothelial cells [Willey C.A. et al, 1986], 
astrocytes, oligodendrocytes and neurons [Gyorkey F. et al, 1987].
The occurrence and the progression of the AIDS- dementia 
syndrome appear to be influenced by host/genetic factors [Price 
R.W. et al, 1988] and immunosuppression overall appears to be 
associated with increasing neurological signs. The CNS signs may
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relate as much to the inflammatory changes and ’bystander effects’ as 
to the cytopathic effect of the virus itself. It is not known if the CNS 
disease is due to specific neurotropic HIV strains in a patient as it is 
well known that several isolates from a single patient may differ 
from each other [Saag M.S. et al, 1988] [Fisher A.G. et al, 1988].
The cause of the demyelination (as well as the other pathological 
signs) is not understood and as already described above the 
demyelination associated with vacuolar myelopathy is likely to be of 
different aetiopathogenesis to the demyelination occurring with 
multinucleated cells subacute encephalitis. However it is likely that in 
both cases soluble factors are responsible, at least in part, for the 
myelin attack. These (e.g cytokines or enzymes) could be secreted by 
infected cells (e.g macrophages), by the inflammatory cells (e.g T 
cells) or by activated cells in the vicinity of the lesions (e.g 
endothelial cells).
Viral demyelinating diseases in animals.
Most of the following diseases share interesting characteristics: 
they are biphasic with a stage of acute encephalitis followed by a 
stage of chronic demyelination. The virus is present in the brain of 
the animals, particularly in the white matter and the lesions are 
multifocal (for a summary of the different characteristics of the 
animal demyelinating diseases mentioned in the text, see Tables lb)
t
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a)Theiler’s murine encephalomyelitis virus.
Wild type Theiler's murine encephalomyelitis virus (TMEV), 
a picomavirus, usually produces an asymptomatic enteric infection 
in mice, and only rarely encephalomyelitis. One strain of TMEV, 
Daniel’s (DA), when injected intracerebrally, produces a biphasic 
neurologic disease in Swiss mice without significant neuronal 
necrosis [Lipton H.L., 1975]. Nine to twenty days after inoculation 
the mice develop encephalomyelitis and the survivors, one to five 
months later, develop a mild gait disturbance in conjunction with the 
occurrence of demyelination in areas of intense mononuclear 
inflammation. Mice strains vary in their degree of susceptibility to 
TMEV [Lipton H.L. et al, 1984] [Yamada M. et al, 1991] and it is 
the D region (MHC class I) which determines this [Rodriguez M. et 
al, 1986].
During the acute phase of the disease, TMEV can be found in 
neurons and oligodendrocytes but it is only present in 
oligodendrocytes cells during the late phase [Brahic M. et al, 1981] 
[Rodriguez M. et al, 1983] and virus can also be detected in 
macrophages [Yamada M. et al, 1991]. In nude mice, viral mRNA 
has been detected in brain endothelial cells [Zurbriggen A. et al, 
1988]. It appears that the demyelination is due to a delayed-type 
hypersensitivity (DTH) T cell response against persistently infected 
oligodendrocytes [Clatch R.J. et al, 1985], and attempts to 
demonstrate autoimmune demyelination by adoptive transfer of 
lymphocytes from diseased mice into genetically compatible mice 
that have not been infected with TMEV have failed [Bamabo R.L. et 
al, 1984]. However, as athymic nude mice infected with TMEV can 
develop demyelination, albeit to a lesser extend than the other mice, 
TMEV could in part cause demyelination by direct cytopathic effect 
on the oligodendrocytes or through humoral immune response. 
Molecular mimicry between components of oligodendrocytes and the 
Theiler’s virus has been implicated as a possible cause of myelin 
damage. Shared molecular structure has been demonstrated between 
the VP-1 glycoprotein of the virus and galactocerebrosides of the 
myelin [Yamada M. et al, 1990].
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b) JHM strain of mouse hepatitis virus.
JHM virus (JHMV), the neurotropic strain of mouse hepatitis 
virus, is a coronavirus which produces an acute, diffuse 
encephalomyelitis with patchy demyelination in mice and rat [Weiner 
L.P., 1973]. Lesions develop 5 to 7 days after intracerebral 
inoculation of the virus and inflammation and necrotic lesions are 
found in the white and grey matter. The degree of demyelination 
depends on the age and the strain of the animal [Stohlman S.A. et al, 
1978]. JHMV is present in the oligodendrocytes but there is 
apparently no anatomical relation between the inflammation and the 
demyelination, thus a direct effect of the virus seems to be 
responsible for the demyelination [Shubin R.A. et al, 1989],
After this acute episode, the animal can recover and go on to 
develop chronic recurrent demyelination [Stohlman S.A. et al, 1981]. 
Temperature sensitive mutants of JHMV cause chronic demyelination 
with minimal encephalitis [Knobler R.L. et al, 1982] and a clinical 
relapsing form of the disease [Wege H. et al, 1984]. In this situation, 
the immune system is likely to play a role in the demyelination as 
demyelination can be transferred from infected to naive rats by 
adoptive transfer of the lymphocytes, following in vitro stimulation 
with MBP [Wanatabe R. et al, 1983] [ter Meulen V.T., 1988]. The 
chronic demyelination may also be due to a persistent attenuated 
infection of oligodendrocytes [Erlich S.S. et al, 1987].
c) Canine distemper.
Canine distemper virus (CDV) is a paramyxovirus related to 
measles which produces acute or chronic demyelinating disease in 
dogs (as well as an associated respiratory infection) depending on the 
strain of the virus and on the age of the dog [Raine C.S., 1974] 
[Russell W.C., 1983], Demyelination can apparently occur in the 
absence of inflammatory cells: perivascular inflammation can be 
seen in infected brains in association with demyelination but more 
often in association with areas in which clearance of the virus has 
taken place. Thus, this inflammatory reaction may represent a 
secondary response to demyelination [Bollo E. et al, 1986]. 
Oligodendrocytes appear not to be infected by the virus [Zurbrigger 
A. et al, 1987] but it has been shown that other cells of the CNS are 
infected e.g astrocytes [Mutinelli F. et al, 1989] and it appears that 40
infection of the endothelial cells of the blood-brain barrier is an 
early event in the disease process [Axthelm M.K. et al, 1987]. 
However, the role of the humoral response is not clear in the 
demyelination process as antibodies could act upon CDV-infected 
oligodendrocytes and/or myelin, alone or in association with 
complement.
In mice a chronic neurological disease has also been 
established with a mouse-adapted strain of CDV. Lethality of the 
infection was found to be mouse-strain-dependent. However mice of 
resistant strains, notably the SJL strain, were able to survive the 
acute infection but after a period of clinical normality showed signs 
of subacute CNS disease with gait disturbances. Histopathological 
analysis of the brain and spinal cord revealed significant perivascular 
mononuclear infiltrate and meningitis. However, unlike CDV 
infection in the dog, demyelination was not seen [Lyons M.J. et al, 
1980]. Moreover, in the chronic phase of the mice infection, CDV 
was not detected in the brain unlike in the dog where CDV persists 
and retains the capacity to undergo complete replication [Summers 
B.A. et al, 1983]. CDV has also been studied in an hamster model 
and it is clear that different strains of the virus can produce very 
different disease syndromes [Cosby S.L. et al, 1981]
d) Measles virus (MV).
MV can produce a chronic relapsing myelitis in hamsters 
when injected intracerebrally in very young animals. The difference 
between this disease and the other animal viral demyelinating 
diseases is that there is no acute episode. The onset of the myelitis 
occurs 5 to 50 weeks after the inoculation. In most animals, 
pathological changes are confined to the spinal cord and are 
characterised by mononuclear infiltration with gliosis and 
widespread demyelination and necrosis. The virus cannot be detected 
by immunofluorescence in the brain of the hamster [Carrigan D.R., 
1980]. A chronic relapsing encephalomyelitis in hamsters which 
bears some similarity to MS has been described [Carrigan D.R., 
1987].
Liebert and ter Meulen have also developed a rat model 
system where the strain of the animal influences the course of the 
neurological disease [Liebert U.G. et al, 1987]. The same research 
group showed that in one strain of rat the persistent measles virus
infection resulted in the induction of a cell-mediated autoimmune 
response against myelin basic protein [Liebert U.G. et al, 1987, b]. 
ter Meulen and colleagues have used the neurotropic strain of 
measles CAM/RBH to induce a subacute encephalomyelitis with a 
20% success rate. In Lewis rat, the virus cannot be isolated although 
the antigens of the virus can be detected suggesting that the virus 
cannot be fully assembled. Cell mediated immunity against MBP is 
detectable and the encephalomyelitis is transferred to naive animals 
by lymphocytes from diseased animals. In the CSF, intrathecal 
production of anti-measles antibodies can be detected but there is no 
oligoclonal IgG [ter Meulen V.T., 1988]. Rats infected with this 
virus are prone to develop EAE when immunised with a non- 
encephalitogenic peptide of MBP suggesting again that regulation of 
the immune system has a important role to play in the demyelination 
in these measles-infected rats and the measles virus appears to act 
merely as a trigger for this autoimmune reaction [Liebert U.G. et al, 
1989].
e) Semliki Forest virus (SFV).
SFV is a non-human pathogenic alphavirus and produces 
demyelination in mice when inoculated intracerebrally [Chew-Lim 
M. et al, 1977]. Demyelination occurs in conjunction with an 
inflammatory infiltrate and is immune-mediated [Fazakerley J.K. et 
al, 1983]. It does not occur in immuno-incompetent mice or 
immunosuppressed mice despite the presence of the virus in the 
brains of these animals. Moreover, reconstitution of SFV-infected 
immuno-incompetent mice with normal spleens leads to 
demyelination [Fazakerley J.K. et al, 1987, a and b].
In the rat, it has been demonstrated that viral strains are 
critical: the neurovirulent strain L10 causes extensive neuronal 
damage whereas the avirulent strain A7/M9 induces infection of 
oligodendrocytes and demyelination which is likely to also be 
immune-mediated [Atkins G.J. et al, 1990].
f) Herpes simplex virus type 1 (HSV-1).
HSV-1 can produce meningitis and encephalitis in man. After 
oral-facial inoculation in mice, lesions of demyelination in 
association with an inflammatory mononuclear infiltrate in the 42
brainstem adjacent to the trigeminal root entry zone (TREZ) can be 
induced [Kastrukoff L. et al, 1989]. Multifocal demyelination of the 
CNS has been induced in mice with HSV-1 [Kastrukoff L. et al, 
1989]. This condition depends on the murine strain used e.g PL/J is 
the most susceptible strain. After lip inoculation with HSV-1, PL/J 
mice develop demyelination at the TREZ as in other susceptible 
strains of mice. However, in this strain of mice, lesions appear in 
other parts of the brain later. The demyelination is associated with 
mononuclear inflammation where macrophages are predominant.
The virus is not detected in the multifocal lesions unlike the unifocal 
lesions of the TREZ where HSV-1 is detected in neurons, astrocytes 
and oligodendrocytes [Kastrukoff L. et al, 1989] [Townsend J .J., 
1983].
The mechanisms mediating demyelination are still unclear but 
probably involve both the immune system and a direct cytocidal 
effect of the virus. [Townsend J.J. et al, 1979] [Kristensson K. et al, 
1982]. These mechanisms appear to be different between the unifocal 
and the multifocal disease.
g) Visna.
Visna is a lentivirus of the retrovirus family which produces 
pneumonia (the disease is called 'maedi' in Iceland ) and/or a chronic 
progressive, although occasionally relapsing-remitting, myelopathy 
in sheep (the disease is then called visna) [Weinshenker B. et al, 
1989]. Visna has some clinical and biological parallels to MS e.g age 
dependence, genetic determined resistance, and increased intrathecal 
IgG with oligoclonal bands in the CSF [Weinshenker B. et al, 1989]. 
Pathogenically, demyelination occurs in 2 phases in both the spinal 
cord and the brain: during the initial phase, demyelination is located 
in regions of inflammatory infiltrates with relatively little tissue 
necrosis, and during the later phase, demyelination occurs in 
conjunction with necrosis of both grey and white matter [Pertusson 
G., 1976].
The visna virus undergoes antigenic drift during the 
persistent type of infection in sheep [Narayan O., 1977] [Haase A.T., 
1986] [Clements J.E. et al, 1988]. It can be isolated from the CNS 
and the blood of affected animals. Then as the disease progresses, 
the virus appears to be confined to mononuclear cells (primarily to
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monocytes and macrophages and can be detected in the blood, CNS 
and CSF in these cells. This correlates with the period of intense 
humoral immune response [Cruickshank K. et al, 1989]. It appears 
that immunopathological mechanisms, especially soluble factors 
released by infected macrophages play a role in the genesis of 
demyelination [Shubin R.A., 1989] [Cruickshank K. et al, 1989] but 
perturbation of the function of oligodendrocytes mediated by a non 
productive infection of these cells by the visna virus has not been 
excluded as a possible cause of myelin damage.
h) Caprine arthritis encephalitis
Caprine arthritis encephalitis virus is also a retrovirus from 
the lentiviridae family. In young goat a progressive paraplegia 
occurs and pathologically the lesions are similar to those of visna . 
However the antibody response to this virus is absent in the affected 
animal unlike in cases of visna [Narayan O. et al, 1985] [Cruikshank 
K. et al, 1989].
Immune response against viruses in MS.
a) Humoral response.
Numerous surveys of antibody titers specific to viruses have 
been carried out in MS patients compared to controls [Cook S.D. et 
al, 1980]. Measles has been studied extensively after Adams and 
Imagawa first demonstrated that patients with MS when compared to 
controls had higher titers of serum antibodies specific to the measles 
virus [Adams J.M. et al, 1962]. This observation has been repeated 
many times in the serum and in the CSF, with different methods. 
Moreover the humoral immune response is directed against more 
than one measles protein [Norrby E., 1978]. The measles antibody 
titer elevation is modest - about 2 fold higher than in the controls. It 
appears also that in most cases measles virus antibodies are being 
produced intrathecally as alterations in serum/CSF measles antibody 
ratios have been found in a number of studies [Haire M., 1977] 
[Norrby E. et al, 1974] [Vandvik B. et al, 1975] [Salmi A.A., 1972]. 
However, no relationship has been found between measles titer and 
disease activity [Norrby E., 1978] [Haire M., 1977]. Interestingly, 44
the measles serum antibody titer of MS patients’ siblings without 
evidence of MS also tends to be higher than that of controls [Henson 
T.E. et al, 1970] [Ammitzboll T. et al, 1972] [Panelius M. et al, 
1973].
Other viral antibodies serum titers have been found elevated in 
MS populations compared to controls (although this is less consistent 
than for measles) for example with vaccinia, rubella, herpes simplex, 
mumps, canine distemper, Epstein-Barr virus, adenovirus [Cook 
S.D. et al, 1980] or HTLV- 1 (see below). Thus, it is thought that 
higher titers of serum antibodies to measles and to other viruses may 
reflect a non specific dysregulation of the immune system (either 
secondary or primary to the disease process).
In the CSF of MS patients intrathecal production of antibodies 
to viruses other than measles have been detected for example with 
vaccinia, herpes simplex, rubella, mumps and other viruses (for 
reviews see [Cook S.D., 1980] and [Walsh M.J. et al, 1983]). 
Furthermore, multiple viral antibodies may be detected in the CSF 
from the same patient and fluctuations in titers may occur [Salmi A. 
et al, 1983] [Amadottir T. et al, 1979]. Salmi and colleagues 
measured the intrathecal antibody synthesis to 16 different viruses in 
the CSF of 30 patients with MS and 29 neurological controls without 
demyelination. They found that, apart from 2 MS patients, all 
showed intrathecal synthesis against more than one virus (usually 
about 10 different viruses), and, only 3 controls had antiviral 
intrathecal synthesis but against only one virus. In the MS group the 
viruses that were over-represented were measles, rubella, 
parainfluenza 1 and 3, herpes zoster and mumps [Salmi A. et al, 
1983]. This multiple intrathecal anti viral response is interpreted as 
being the sign of a non specific stimulation of immunocompetent 
cells (B cells and plasma cells) trapped beyond the BBB in MS 
brains. In the same way, local synthesis of anti-measles and anti­
rubella antibodies has also been demonstrated in the synovium of a 
rheumatoid arthritis patient [Vandvik B. et al, 1977]
The antiviral response has never been convincingly related to 
the CSF oligoclonal IgGs which can be detected in over 90% of 
definite MS cases. For example a small proportion of the measles 
antibodies can be associated with oligoclonal banding but most of the 
anti-viral response is of polyclonal nature. Moreover measles 
antibodies account for a minor proportion of the total CSF IgGs 
[Vartdal F. et al, 1982]. Investigation of the CSF antibodies specific 45
to the paramyxovirus SV5 will be presented as part of the work in 
this thesis and background to this work is discussed subsequently in 
this chapter.
An IgM response (indicative of a primary response or of 
persistent infection) to measles as well as anti-mumps and anti­
varicella IgM can be detected in the CSF of patients suffering from 
MS [Chodi F. et al, 1987]. This was again interpreted as a sign of 
non specific intrathecal stimulation in MS brains.
In conclusion, the antibody specificity of the majority of the 
CSF IgGs produced intrathecally in patients suffering from MS has 
not been defined; a variable small fraction of these IgGs are found to 
be virus - specific. It is however possible that some CSF IgGs are 
directed against an unknown antigen involved in the cause of MS 
(viral or non-viral) even though most of the CSF IgGs are probably 
due to non specific intrathecal stimulation. On the other hand, it is 
possible that the cause of MS is different between patients and that 
one virus may induce MS in one individual, depending, for example, 
on the HLA status of this individual, whereas another virus may be 
the causative agent of MS in another person.
b) Cellular immune response.
The cellular immune response to viruses has been much more 
difficult to evaluate in MS patients and their controls than the 
humoral immune response. This may be due to the difficulty of 
purification of viruses and viral proteins for T cell assays but also 
due to the incomparability of the techniques used to measure such a 
response. The antiviral T cell response has been measured by 
multiple methods especially T cell proliferation assays (an indication 
of the T helper response), migration inhibition (more difficult to 
interpret) and cytotoxicity assays (an indication of the T cell 
cytotoxic response). Even skin tests (an indication of the delayed 
type hypersensitivity response) have been used. Numerous viruses 
have been tested - for example measles, mumps, parainfluenza virus, 
vaccinia, rubella, herpes simplex and cytomegalovirus (CMV) [Cook 
S.D. et al, 1980]. Overall, the results of the past decades are 
inconclusive as the reported T cell responses of MS patients when 
compared to controls have been greater, less or the same with most 
of the viruses tested.
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The techniques of cytotoxic lymphocyte (CTL) assays have 
recently improved with the recognition of HLA restriction. Target 
cells used in CTL assays are autologous (of the same HLA as the 
patient's CTL) whereas in the early days some of the cytotoxicity 
assays were done with heterologous target cells e.g HELA cells 
infected with measles. Jacobson and his colleagues have studied the 
CTL response to measles in patients with MS. First, they 
demonstrated that in the measles system a high proportion of CTL 
were HLA Class II restricted and were CD 4 + [Jacobson S. et al, 
1984 and 1989]. This was at odds with the concept that CTL must be 
Class I restricted. Other viral systems however also showed this 
predominance of class II restricted CTL response e.g herpex simplex 
virus [Schmid D.S., 1988]. Interestingly, it has also been 
demonstrated that some CTL clones specific for measles viral 
proteins were HLA DR 2 restricted in some MS patients [Richert 
J.R. et al, 1986] (HLA DR 2 allele being associated with multiple 
sclerosis predisposition [Compston D.A.S., 1986] and thus it was 
suggested that this anti-measles response may be relevant in the MS 
process). In addition, the generation of specific CTLs against 
multiple measles proteins was impaired in a number of selected MS 
patients [Dhib-Jalbut S., et al, 1989] and the authors suggested that 
this was due to a persistent infection of measles in MS patients. 
However, these observations were done on selected patients and thus 
need to be confirmed to be considered relevant to MS in general.
Natural killer (NK) cell activity in multiple sclerosis patients 
has been found to be decreased by a number of research groups 
[Benczur M. et al, 1980]. The explanation for this phenomenon is 
unknown. Some have suggested that it is a sign of a persistent viral 
infection.
Virus isolates in MS and transmissibility of the 
disease.
During the last 50 years, it has been claimed that a number of 
viruses have been isolated from multiple sclerosis patients or have 
been visualised by different techniques (by electron-microscopy (the 
virus itself), by 7 (the viral proteins) or by in situ hybridization (the 
viral genome)). In his review of viruses and multiple sclerosis T.J. 
Johnson listed the viruses which had been
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candidates : rabies [Margulis M.S. et al, 1946], herpes simplex 
[Gudnadottir M. et al, 1964], scrapie [Palsson P.A. et al, 1965] 
parainfluenza I [ter Meulen V. et al, 1972], measles [Field E.J.,
1972], MS associated agent of Carp [Carp R.L et al, 1972], 
coronavirus [Tanaka R. et al, 1976], bone marrow agent or SV5 
[Mitchell D.N. et al,1978], subacute myelo-optico-neuropathy 
(SMON)-like virus [Melnick J.L., 1982], simian cytomegalovirus 
(CMV) [Rorke L.B. et al, 1975] and tick bome encephalitis 
flavivirus [T.J. Johnson, 1985] (see also [Cook S.D. et al, 1980]). 
Retroviruses have now been added to this list (see below). No one 
has claimed that these viruses are causative but only that they are 
associated with MS. However, none of these observations has been 
reproduced by other independent research groups.
Using in situ hybridization techniques, Haase and his 
colleagues demonstrated that viruses (or at least part of their viral 
genomes) can reside in the CNS even in normal people and these 
viruses were also seen in MS brains e.g measles [Haase A.T. et al, 
1981 and 1984] or herpes simplex type I [Fraser N.W. et al, 1981]. 
Thus, description of viral genomic material in MS tissue has to be 
taken cautiously.
No one has been able to transmit a MS-like disease from MS 
tissue to an animal. However this does not mean that a virus is not 
involved in MS as it has already been seen above that strains, age and 
even routes of inoculation of viruses are critical factors in the 
induction of viral demyelinating diseases. Moreover, HIV for 
example does not induce AIDS in animals other than man, not even 
in monkeys which apparently have identical CD4 molecules 
(receptor of the HIV virus) to man [Wanatabe M. et al, 1991]. The 
reason for the lack of disease in the animal is a matter of debate 
[Dalgleish A.G., 1992]. In the same way, HIV does not induce a 
neurological disease in monkeys despite a persistent infection with 
prolonged viraemia [Fultz P.N. et al, 1986], Another point to 
consider is that the virus may have disappeared from the patients 
suffering from MS at the time of disease. Epidemiology of MS 
suggests that the environmental agent is contracted 10 to 20 years 
before the clinical onset of the disease [Rudge P. et al, 1991][Rudge 
P., 1991].
The question remains whether or not the agent(s) of multiple 
sclerosis is transmissible between humans. This question is extremely 
difficult to answer. For example, familial cases are well described 48
but it is difficult to dissociate the genetic factors from the 
environmental factors which are both likely to be shared or be 
transmitted between members of a same family. It appears that MS is 
not ’passed' between husband and wife [Acheson E.D., 1985] but it is 
thought that the environmental agent(s) is likely to act around 
puberty before marital age. Kurtzke and Hylldested have suggested 
that in the Faroes epidemic, there were in fact three waves of MS 
and that the second and third waves were due to the transmission of 
the external agents from affected but asymptomatic Faroes 
inhabitants to other unaffected islanders [Kurtzke J.F. et al, 1986]. In 
the Key-west epidemic, an usually high number of nurses has been 
found in the group of patients suffering from MS and was 
interpreted as a consequence of a possible transmission of the 'MS 
factor' from patients to nurses [Sheremata W.A. et al, 1985].
Apart from the agents isolated from tissue of patients with 
MS, numerous viruses other than members of the paramyxoviridae 
family have been postulated as being the cause of multiple sclerosis 
for example herpes virus [Koprowski H. et al, 1979] [Martin J.R. et 
al, 1988] [Bergstrom T et al, 1989], Epstein-Barr virus [Operskalski 
E.A. et al, 1989] or poliovirus [Poskanzer D.C. et al, 1963] . Some 
have also postulated that common viruses like measles and rubella 
may induce MS if they are contracted at a specific period in life for 
example around puberty [Sullivan C.B. et al, 1984] [Compston 
D.A.S. et al, 1986].
Before reviewing the relationship between paramyxoviruses 
(the subject of some of the work presented in this thesis), one family 
of viruses namely the retroviruses will be discussed in more detail as 
there has been a sustained interest in retroviruses in the context of 
MS during the past 10 years. Two human retroviral diseases which 
induce demyelination have been described - AIDS and TSP. Also, a 
number of animal retroviral diseases are associated with 
demyelination : visna and caprine arthritis encephalitis.
Retroviruses and MS.
In 1985 Koprowski and his colleagues implicated HTLV-1 
-like virus as an aetiologic agent in MS after they identified 
antibodies to the p24 protein of HTLV-1 in the CSF of patients from 
Key West and Sweden. They also found HTLV-1 nucleotide 
sequences in the leukocytes derived from interleukin 2 expanded
lymphocytes from 4 out of 8 MS CSF samples using the polymerase 
chain reaction (PCR) technique. The hybridization stringency 
conditions were, however, low [Koprowski H. et al, 1985]. In 
addition one group in Japan reported the detection of antibodies to 
HTLV-1 in a quarter of patients with MS [Ohta M. et al, 1986]. 
However, subsequent studies looking at the prevalence of anti- 
HTLV-1 antibodies or at the presence of genomic material from 
HTLV-1 in the lymphocytes, monocytes or brains of MS patients 
were unsuccessful [Hauser S.L. et al, 1986] [Karpas A. et al, 1986] 
[DeRossi A. et al, 1986] [Gessain A. et al, 1986] [Rice G.P.A. et al, 
1986] [Kuroda Y. et al, 1987] [Swingler R.J. et al, 1987] [Bimbaum 
G. et al, 1988] [Bangham C. et al,1989] [Richardson J.H. et al, 1989] 
suggesting that the original positive result may have been related to 
contamination during PCR processing.
Nevertheless, retroviruses as well as paramyxoviruses (see 
below), are still interesting possible aetiological candidates in MS. 
They are characterised by a long period of incubation or latency as 
epidemiological studies of MS suggest for the causal agent.
Moreover, latency can be broken by immunological stimuli which 
are known to be present in MS patients. It has been hypothesised tiiat 
a still unknown retrovirus could be the cause of MS, and, that this 
agent will be detected when the right conditions of culture or for 
example in situ hybridisation can be found [Weinshenker B. et al, 
1989] [Perron H. et al, 1989 and 1991]. It is worth remembering that 
a retrovirus was first incriminated as the cause of AIDS after the 
demonstration that 30 % of patients with AIDS had antibody reactive 
to cells infected with HTLVI in immunofluorescence assays 
[Weinshenker B et al, 1989] [Gallo R.C. et al, 1985].
Since Koprowski and colleagues’ report, there have been a 
number of scientific communications that indicate that retroviruses 
may be present in MS tissue. For example, Kam-Hansen and 
colleagues have described a cytopathic effect and the detection of 
reverse transcriptase activity in the culture of blood mononuclear 
cells of some patients with MS [Kam-Hansen S. et al, 1989]. Others 
have detected retroviral genomic material in post-mortem MS brains 
[Reddy E.P et al, 1989] or in mononuclear cells of some patients 
with MS e.g sequences homologous to the pl9 gag protein 
[Sandberg- Wolhein M. et al, 1988] or sequences related to the pol 
proteins [Greenberg S.J. et al, 1989]. The conclusions of all these 
observations was that a retrovirus different but related to HTLV I
may be associated with some MS cases. More recently, Perron and 
his colleagues claim that they have isolated a retrovirus from the 
CSF of one MS patient [Perron H. et al, 1989]. This retrovirus is not 
a known retrovirus. The CSFs of 2 other MS patients had also 
antibodies again this virus whereas 2 normal controls did not show 
any reactivity [Perron H. et al, 1991]. The same group has also 
reported the presence of antibodies to fragments of retroviral 
reverse transcriptase in a higher proportion in the sera of patients 
with multiple sclerosis compared to neurological controls.
Comparing the reactions of the positive sera against other proteins of 
known human retroviruses, they concluded that the reaction 
observed may have been due to cross reaction against an unknown 
retrovirus which is likely to be related to the lentivirus family 
[Perron H. et al, 1991,b]. Other groups have also recently visualised 
retrovirus-like particles in MS lymphocyte cultures [Haar S. et al, 
1991]. However, it is not clear if these retroviruses are endogenous 
and merely innocent bystanders. Endogenous retroviral DNA is 
widespread in humans and animals [Larsson E. et al, 1989]. For 
example, retrovirus-like particles have been observed budding from 
normal placental trophoblasts [Johnson P.M et al, 1990].
Paramyxoviridae and MS.
The viruses of the Paramyxoviridae family have a special 
place in the long history of viruses implicated in MS. Some of these 
viruses (MV, CDV and SV5) have been implicated in neurological 
diseases in both man and animals. As SV5 is particularly relevant to 
this thesis, a special section of this chapter will be devoted to it.
The paramyxoviridae family is subdivided into 3 genera: 1. 
the morbilliviruses e.g measles virus (MV), canine distemper virus 
(CDV), 2. the pneumoviruses e.g respiratory syncitial virus (RSV)) 
and 3. the paramyxoviruses proper e.g mumps, parainfluenza viruses 
(PFV) and simian virus 5 (SV5). The viruses of this family have a 
single strand of negative sense RNA (the genomic viral RNA has to 
be transcribed in order to act as messenger RNA) and at least 6 
virus-coded polypeptides [Russell W.C., 1983]. Some of these viruses 
can establish persistent infections in vitro and in vivo [Randall
R.E.R. et al, 1990]. One other important property of these viruses is 
that they are enveloped viruses and are released from the infected 
cells by ’budding’. Before viral ’budding’, viral membrane proteins
are inserted in the plasma membrane of the host cell. It appears that 
host membrane proteins are displaced and viral proteins agglomerate 
into patches. The nucleocapsid binds to specific viral protein signals 
on the membrane viral proteins and the virus extrudes from the cell. 
In the process host lipids and glycolipids are incorporated into the 
viral membrane. However, host proteins are not included in the viral 
membrane [Roizman B., 1990] [Kingsbury D.W., 1990] .
a) Measles.
MV has already been covered in the preceding sections of this 
chapter. Briefly, animal models of demyelinating diseases caused by 
measles have been described. Patients suffering from MS have 
higher titers of antibodies to MV in their serum and CSF than 
normal controls. The cytotoxic T cell response to MV appears to be 
defective in some MS patients and thus it was proposed some MS 
patients may harbour a persistent MV infection.
MV or MV-like particles have been detected in the jejunum of 
some MS patients and not in their controls [Pertschuk L.P. et al, 
1976] [Prasad I. et al, 1977] [Ebina T et al, 1979]. These 
observations were however not confirmed [Woyciechowska J.L. et 
al, 1977] [Kingston D. et al, 1977] [Fraser K.B. et al, 1977] but no 
recent work has been done in this domain with molecular biological 
techniques. MV genomic material has been detected in some post­
mortem brains of MS patients (but also in normal controls) by the in 
situ hybridization technique [Haase A.T. et al, 1984]. However, 
Cosby and colleagues claim that they were able to detect MV 
genomic material only in MS brains and not in the control brains 
[Cosby S.L. et al, 1989],
In more general terms, Alford and colleagues also 
hypothesised that measles and other common viruses may share some 
amino acid sequence in common with the myelin proteins (MBP 
[Jahnke U. et al, 1985] and proteolipid protein (PLP) [Shaw S.Y. et 
al, 1986]) and this molecular "mimicry" may induce an autoimmune 
response to myelin in some individuals. They also hypothesised that 
measles vaccination should in this case lead to a decrease in 
prevalence of MS in the near future [Alvord E.C et al, 1987]. In the 
same way, Randall and Russell commenting on the T cell 
crossreactivity among the paramyxoviridae, for example between 2 
unrelated members of the family such as mumps and RSV [Ziola B. 
et al, 1988], suggested that infections with different paramyxoviruses 52
may induced cross reactive T lymphocytes which may also cross 
react with components of the brain [Randall R.E.R. et al, 1990]. A 
yet unknown virus of the paramyxoviridae responsible for MS could 
in the same way cross react with other members of the family and 
induce some of the changes seen in MS patients with MV and with 
the other related viruses.
b) Canine distemper virus (CDV).
CDV is a virus closely related antigenically to MV [Imagawa 
D.T. et al, I960]. CDV is a canine virus which can induce 
demyelination, and, in laboratory animals, it can lead to a chronic 
relapsing demyelinating illness (see the section on viral 
demyelinating diseases in animal in this chapter). CDV was first 
implicated in MS after Cook and his colleagues observed the 
occurrence of multiple sclerosis in 3 members of a family 2 or 3 
years after the family pet dog suffered from an acute encephalopathy 
which was thought to have been caused by CDV. They then found in 
a case control epidemiological study that individuals suffering from 
MS had more indoor exposure contact with dogs or cats than the 
control population [Cook S.D. et al, 1977]. During the same period, 
W. Chan, analysing the geographical distribution of MS and the 
increase incidence of the disease in families, postulated that MS may 
be caused by a canine vector, perhaps transmitted by an agent in 
urine [Chan W.W.C., 1977].
The Faroe epidemic gave more impetus to this possible 
association of CDV with MS when Cook and his colleagues 
discovered that a large proportion of dogs in the islands succumbed 
to a CDV-like disease and particularly to the more virulent, 
neurologically associated form known as "hard pad”. They 
correlated this CDV-like epidemic to the introduction into the islands 
of guard dogs by the British troops [Cook S.D. et al, 1978] [Russell 
W.C., 1983]. The same relationship with CDV and MS was 
postulated by Cook et al in other 'MS epidemics' as in Iceland [Cook
S.D. et al,1980, b] or in Key-West [Cook S.D. et al, 1987].
The relationship between CDV and MS is however far from 
demonstrated. For example, many epidemiological studies have not 
found the association between pet contact and multiple sclerosis 
sufferers [Read D. et al, 1980] [Cook S.D et al, 1985] . However, it 
is important to stress that biases (positive or negative) may be 
introduced in these retrospective studies and a significant difference 53
may be missed [Cook S.D et al, 1985] [Souberbielle B.E. et al, 1990]. 
There has been some reports of elevation of antibodies to CDV in 
MS patients [Cook S.D. et al, 1979] [Hughes R.C. et al, 1980] 
[Madden D.L. et al, 1981] [Appel M.J. et al, 1981] but other studies 
have found no difference [Poskanzer D.C. et al, 1980] [Amadottir
T., 1980] (see [Russell W.C., 1983] and [Cook S.D. et al, 1980] for 
reviews). The difficulty again in the serological studies is to 
dissociate the antibody response to MV and to CDV as these 2 
viruses cross react extensively [Roberts J.A., 1965] [Russell W.C., 
1983]. Finally, Cosby and colleagues failed to detect CDV genomic 
material in MS post mortem brains by in situ hybridization [Cosby 
S.L. et al, 1989].
In conclusion, despite some interesting epidemiological data 
between CDV and MS, there is no biological demonstration that 
CDV is a causative agent of MS. However, it is still possible that 
most of epidemiological features of MS related to CDV are in fact 
due to a yet unknown canine virus. In this connection SV5 is an 
interesting candidate.
c) Simian virus 5 (SV5).
SV5 is a paramyxovirus closely related to but different from 
parainfluenza 2 (PF-2) and to a lesser extent to mumps [Randall 
R.E.R. et al, 1988, a]. SV5 is capable of producing persistent 
infections in vitro and in vivo [Randall R.E.R et al, 1990]. It was 
first isolated in monkey but seems to be able to infect across species 
as it has been isolated in dogs and cats and can be used 
experimentally to infect mice and hamsters [Randall et all, 1988, b 
and 1990]. It appears that SV5 only causes mild upper respiratory 
symptoms in animals. It has also been suggested that SV5 may cause 
widespread inapparent infections in humans [Hsiung G.D., 1972] 
[Randall R.E.R. et al, 1987]. Nevertheless and despite its name, 
epidemiologically SV5 is considered to be a canine virus.
In 1978, Mitchell and colleagues reported the isolation of SV5 
from the bone marrow aspirates of multiple sclerosis patients 
[Mitchell D.N. et al, 1978]. This finding was complicated by the later 
discovery of mycoplasma contamination in some of the original 
isolates and the possibility was raised that the isolates were the result 
of adventitious contamination during the isolation procedures 
[Mitchell D.N. et al, 1979], Later on, SV5 was detected by 
immunofluorescence technique in bone marrows from 60 % of 54
patients with MS but also in 30 % of controls and thus it was 
concluded that SV5 was not a contaminant in the original report 
[Goswami K.K. et al, 1983 and 1984]. Interestingly, immuno­
fluorescence studies indicated that cross-reacting antigens between an 
antigen present in rat myelin and the major surface glycoprotein of 
SV5 may exist [Rastogi S.C. et al, 1979] [Goswami K.K. et al, 1985]. 
In the next series of experiments, Goswami et al showed that some 
MS’ CSFs appeared to contain a significant proportion of oligoclonal 
antibodies against SV5 [Goswami K.K.et al, 1987]. To do so, CSFs 
from MS patients were incubated with purified SV5 or with purified 
MV and then centrifuged to pellet possible immune complexes. CSF 
supernatants were then compared by isoelectrofocusing before and 
after viral absorption. In CSFs of some MS patients, the majority of 
the oligoclonal pattern disappeared after viral absorption. This was 
not observed with MV or with the CSFs of the neurological controls 
tested. It was therefore concluded that, in some MS patients, most of 
the oligoclonal response was directed again SV5 [Goswami K.K.A. et 
al, 1987].
Conclusions on how viruses could be 
responsible for MS.
There are numerous proposed ways in which a virus could 
induce demyelination and some of these mechanisms have been 
elucidated by the study of viral induced demyelination in animals 
(see the corresponding sections).
Direct effect of the virus.
A virus can be cytopathic to oligodendrocytes and therefore 
induce demyelination by death of the myelin-producing and 
maintaining cell or by interfering with the normal metabolism of the 
myelin-producing cell (as it appears to be the case in progressive 
multifocal leukoencephalopathy). In this case a secondary 
inflammatory reaction may occur in response to this destruction as a 
scavenger effect.
55
Bystander effect due to viral infection .
On the other hand the inflammatory reaction may be 
responsible for the demyelination when an immunological response 
is triggered against viral antigens expressed during a persistent 
infection (as possibly in the case of Theiler’s virus encephalitis). The 
destruction of the oligodendrocytes is, in this case, a bystander effect 
of the immune response to viral infected oligodendrocytes/myelin. 
This destruction could occur and be perpetuated non specifically for 
example by macrophages [Cuzner M.L. et al, 1988]. Antigenic 
modulation at the level of oligodendrocytes due to an antibody 
response against some viral antigens could induce a persistent 
infection without an overt inflammatory reaction and changes in 
antiviral titers influence the relapse in case of relapsing remitting 
demyelinating disease [Fujinami R.S. et al, 1984] [Randall R.E.R. et 
al,1990].
Bystander effects can be promoted by soluble factors released 
during a normal anti-viral immune reaction and these soluble factors
e.g cytokines released by lymphocytes and macrophages or enzymes 
released by macrophages could have a deleterious effect on the 
myelin. Such soluble factors toxic to myelin have already been 
described e.g complement [Scolding N.J. et al, 1989] , proteinase 
from disrupted myelin sheaths [Chantry A. et al, 1988] or cytokines 
secreted by lymphocytes [Owen S.J. et al, 1988].
Autoimmunity as a bystander effect of viral infection.
The other possibility is that the demyelination is due to an 
autoimmune response triggered by a viral infection. In this case the 
virus need not be present in the brain. An autoimmune response is an 
immune reaction orchestrated by components of the immune system 
towards a component(s) of the body - e.g the myelin or the cell 
producing the myelin. The autoimmune response could be triggered 
by tissue damage due to viral infection (the viral damage is not the 
direct cause of demyelination but only a trigger).
a. Release of hidden antigens.
This autoimmune reaction could for example be triggered by a 
release of sequestrated autoantigen normally hidden from the 
immune system e.g myelin basic protein (MBP) is normally not 
exposed in the mature myelin sheath in contrast to proteolipid 
protein (PLP) which is normally exposed [Norton W.T., 1984]. 56
b. Presentation of autoantigen through increased expression of HLA 
molecules.
Along the same line of thought, it has been hypothesised that 
tissues threatened by viral infection increase their level of HLA 
molecule expression through the action of interferon or other 
cytokines [Dalgleish A.G. et al, 1987]. This facilitates presentation of 
viral peptides but may inadvertently raise presentation of tissue 
specific peptides (MBP or other brain specific antigens) to levels that 
activate previously quiescent autoreactive T cells [Parham P, 1991]. 
This hypothesis follows on a more general hypothesis for tissue 
specific autoimmunity, according to which T cells directed against 
tissue-specific peptides presented by aberrantly expressed HLA 
molecules are the cause of autoimmune disease [Bottazo G.F. et al, 
1983 and 1986] [Hanafusa T et al, 1983] [Londei M. et al, 1984]. 
Autoreactive T cells have been demonstrated in normal people e.g 
against MBP [Martin R. et al, 1990] or against acetylcholine receptor 
[Sommer N. et al, 1991] and it is thought that they escape the normal 
negative selection (deletion) because these antigens may not be 
presented, in the thymus, during foetal life.
c. Insertion of a viral component into a host component.
Retroviruses produce latent infection in infected cells.
Insertion of the viral genome into the genome of the cell is mostly 
random. The possibility that only part of the viral genome insert into 
the genome of the cell exists. This could induce transcription of a 
single viral protein during transcription of cellular proteins and 
expression of the viral protein alongside the cellular proteins. Some 
of the superantigens (see below) already characterised e.g the Mis 
system may have arise from this mechanisms. Such viral proteins 
could induce an autoimmune reaction if not tolerised.
d. The 'superantigen’ hypothesis.
Superantigens induce proliferation, deletion or anergy of 
certain T cell subsets through interaction of the superantigen with 
specific V|3 segments of the corresponding T cell receptors [Acha- 
Orbea H. et al, 1991]. It has been hypothesised that among the 
potential T lymphocytes stimulated, there may be lymphocytes 
specific for myelin component especially MBP [Rudge P., 1991].
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e. Incorporation of a host component into a viral component.
Another interesting possibility is the triggering of an 
autoimmune reaction by the incorporation of host antigens into viral 
envelopes during viral release by ’budding' i.e any virus with a viral 
envelope e.g retroviruses or paramyxoviruses. This incorporation of 
cellular components e.g glycolipids into viruses has been proposed as 
a possible cause of natural tolerance breaking leading to autoimmune 
reaction. Viruses could then act as helper-carrier for the glycolipids 
which are considered as haptens [Webb H.E. et al, 1984] [Dalgleish 
A.G. et al,1987].
f. 'Molecular mimicry'.
The autoimmune reaction could also arise by 'molecular 
mimicry' - in other words as a result of molecular structures shared 
by host components and viral gene products [Fujinami R.C., 1988] 
[Srinivasappa J. et al, 1986], In this case, the infectious agent does 
not need to be present in the brain or even in the body when 
neurological symptoms occur. Indeed, an autoimmune reaction due 
to molecular mimicry by an initial viral infection could be kept 
under control by suppression mechanisms orchestrated by the 
immune system ('tolerated'). The breaking of tolerance could then 
happen by a non specific phenomenon for example another viral 
infection. Thus, Sibley and colleagues have shown that MS patients 
have more viral infections before their attacks than a control 
population [Sibley W.A. et al, 1985]. So far, molecular mimicry 
between viruses and host components has been demonstrated mainly 
with intermediate filaments (intermediate filaments are a large part 
of the host structure). For example, Fujinami and colleagues have 
demonstrated cross-reactivity with different antibodies between 
herpes and measles virus proteins and human intermediate filaments 
[Fujinami R.S. et al,1983] [Dales S.et al, 1983] [Nigg E.A. et al,
1982].
Fujinami and Oldstone immunised rabbits with a peptide of 
hepatitis B virus polymerase which shares some homology with an 
encephalitogenic site of myelin basic protein. Consequently, the 
rabbits developed neuropathological signs resembling experimental 
allergic encephalomyelitis; an antibody response and a T cell 
proliferation were demonstrated against both the myelin and the 
hepatitis B virus polymerase [Fujinami R.S. et al, 1985].
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Molecular mimicry can be determined by computer analysis of 
the primary sequence of the proteins of interest [Jahnke U. et al, 
1985] [Shaw S-Yet al, 1986] [Weise M.J. et al, 1988] [Souberbielle et 
al, 1991]. However, it is likely that proteins with different primary 
structures could also induce molecular mimicry if their three 
dimensional structure are similar as Rudensky and colleagues eluted 
proteins from a mice MHC molecule and found different peptide . 
sequence bound to this MHC molecule [Rudensky A.Y. et al, 1991]. 
In addition flanking regions of an antigenic site may influence its 
presentation [Eisenlhor L.C. et al, 1992] and thus flanking regions 
may be an additional important factor in molecular mimicry.
Some have also proposed that 'molecular mimicry' could arise 
between host antigens and idiotypes of antibodies specific for viral 
antigens. Idiotypes are antigens of the variable regions of antibodies 
and it is thought that some of these idiotypes are the internal image 
of the antigen specific for the antibody. It has been hypothesised that 
the immune system is thus possibly regulated through this network 
of idiotypes [Jeme N.K., 1974]. Thus a response against an idiotype 
(anti-idiotype) could react against the antigen [Plotz P.H., 1983]. For 
example it has been demonstrated that a monoclonal antibody raised 
against an antibody specific for the reovirus 3 haemaglutinin reacts 
also with normal lymphoid and other normal cells [Nepom J.T. et al, 
1982]. Cooke and colleagues have proposed that T cell specific for 
idiotype on antibodies specific for an environmental antigen could 
recognise an autoantigen through molecular mimicry between the 
idiotype and the autoantigen (T- inducer bypass) [Roitt I.M., 1984] 
and it is one of the theories which deals with the disruption of the 
complex regulation of the immune system (see below).
It has also been hypothesised that autoimmunity could arise 
through non specific polyclonal activation of B cells after viral 
infections. Some of the antibodies produced could be directed to 
autoantigens. The classic example given is Epstein Barr virus 
infection which induce polyclonal activation of B cells [Roitt I.M., 
1984].
g. Disruption of the immune system regulation.
The immune system appears to be a closely regulated network 
of effector and suppressor cells and it has been proposed that 
autoimmunity results from a disruption of this regulatory system 
[Hafler D.A. et al, 1991]. For example, destruction of a subtype of 59
lymphocyte (e.g some specific suppressor cells) after viral infection 
could in turn trigger an autoimmune response towards a host 
component. On the other hand, stimulation of autoaggressive cells 
could also follow viral infection through non specific activation of 
certain T cells or stimulation of T cell at a paracrine level. Brod and 
colleagues demonstrated that activated T cells expressing high 
surface density of adhesion molecules were able to trigger 
neighbouring resting T cells to proliferate via these adhesion 
pathways. In the same way, this non specific T cells stimulation 
could arise thus after viral infection [Brod S.A. et al, 1990].
In the context of MS, all the possibilities developed above concerning 
infections of the myelin and/or the oligodendrocyte (or autoimmune 
reaction towards one of these biological structures) as a system 
could, in theory, also be applied to the brain vessels .
THE CEREBROSPINAL FLUID (CSF) AND 
MULTIPLE SCLEROSIS.
The CSF is of importance in multiple sclerosis for 2 reasons. 
The first is that oligoclonal intrathecal production of IgG can be 
demonstrated in over 90 % of patients with definite MS. The second 
reason is that the CNS is bathed by the CSF and thus the CSF may 
reflect more closely than the blood the changes that occur in the CNS 
in MS patients.
General considerations.
a) Circulation of the CSF.
The CSF is derived from the plasma and 70% is produced at 
the blood-CSF barrier of the choroid plexus. The remaining 30% is 
derived from the capillary bed and meninges (18%) or from 
metabolic water production (12%) [Leibowitz S. et al, 1983]. The 
CSF has a volume of about 140 ml and is secreted at the rate of 0.35 
ml/min, which means that the entire volume is replaced 3 to 4 times 
a day.
The CSF leaves the ventricular system and enters the cistema 
of the subarachnoidal space which envelopes the spinal and the 60
cortical regions of the brain. The CSF then leaves the subarachnoidal 
spaces through the arachnoid villi into the venous system (The CSF 
is secreted by the arterial system and leaves through the venous 
system). With increasing distance from the ventricles there is an 
increasing concentration of the total protein between blood and CSF 
via the BBB and extracellular fluid. In summary, the transport 
systems between the brain compartments are multiple: one goes from 
the blood to the extracellular fluid (ECF) of the brain and can go 
back to the blood. Alternatively, the transport could be blood-brain- 
ventricle-CSF or blood-brain-subarachnoidal spaces-CSF. Another 
transport system is blood-meningeal vessels and then CSF. 
Additionally, CSF can be moved around via the lymphatics of the 
head and neck [Esiri M.M. et al, 1990].
Additionally, the local production of proteins from the cells in 
the brain has to be considered as a source of increased protein 
concentration in extracellular fluid and subsequently in CSF.
b)The composition of the CSF in patients with MS and in 
normals.
The CSF in MS patients as in the normal situation is crystal 
clear and of normal pressure [Walsh M.J. et al, 1983]. The total 
leukocyte count is normally (< 5 leukocytes per mm3). 60% of
MS patients, it is <5, in 95 % of all MS patients <15 and <20 in 99.7 
% and rarely exceeds 50. The average leukocytes count in all MS 
patients (in remission and in relapse) is 5.6. As the duration of MS 
increases, the total leukocytes count becomes more normal [Walsh 
M.J. et al, 1983]. The differential distribution of CSF leukocytes is 
normal in MS patients [Tourtellotte W.W., 1970][Walsh M.J. et al,
1983]. As an example, the average count in 20 normal individuals 
and 106 patients with multiple sclerosis measured by Tourtelotte is 
presented per ml (Normal/MS patients respectively): large 
lymphocytes 900/2520, small lymphocytes 900/3000, monocytes 
120/300, polymorphonuclear 10/12, eosinophils 2/6, plasma cells 
3/24. Although some studies have reported a correlation between 
pleocytosis and presence of a relapse of clinical activity, this was not 
observed by other neurological studies [Walsh M.J. et al,
1983][Tourtelotte W.W.C. 1970],
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The total protein concentration in normal CSF is 55 mg/dl. 
The total protein in MS CSF is < 55 mg/dl in 77% of patients, < 89 
in 95 % and <108 in 99.7 %. In the same way, the CSF albumin 
concentration is normal (<32 mg/dl) in 77% of MS patients, < 53 
mg/dl in 95 % of patients and <65 mg/dl in 99.7 % of patients.
The concentration of IgG in the CSF is normally 10-40 
mg/liter. In about 85 % of MS patients, the IgG/total protein is 
abnormal >0.15. The IgGs are intrathecally synthesized and the 
commonly used index for measuring intra-BBB IgG synthesis is the 
Link/Tibbling IgG index : (IgGCsf/IgGs) divided by (AlbCsf/Albs); a 
value exceeding 0.7 is considered abnormal and a sign of intra-BBB 
IgG synthesis. In about 90% of MS patients this value is abnormal 
[Link H. et al, 1977] [Hershey L.A. et al, 1980].
The rate of synthesis of the IgG per day has been evaluated by 
radioisotope methods (see [Walsh M J. et al, 1983]). The average 
production was 29 mg/day in 127 patients suffering from MS. It was 
higher in the more acute cases and tended to increase with age, 
duration of disease, number of relapses and with elevated CSF 
leukocyte counts. The IgG production decreased with ACTH or 
prednisone treatment [Tourtelotte W.W. et al, 1978],
The interesting feature of the CSF of MS patients is the 
presence of an oligoclonal pattern of the immunoglobulins G.
Oligoclonal bands and MS.
a) Definition and description.
The IgGs, in more than 90 % of patients with definite MS, show a 
qualitative abnormality as demonstrated by electrophoretic 
techniques [Lowental A.M et al, I960]. The so called oligoclonal 
bands are of restricted heterogeneity and the banding resembles that 
found in a serum after repeated immunization [Osterland C.K. et al, 
1966]. The oligoclonal bands are cathodic in location [Siden A., 
1980] and means that the isoelectric point (Pi) of these oligoclonal 
ranges from 6 to 9 in general. The banding pattern is unique for 
each MS patient and it is remarkably constant even if patients are 
studied over 5 or 10 years or are in relapse [Hershey L.A. et al, 
1980] [Livrea P. et al, 1981]. A small number of MS patients appear 
never to develop oligoclonal banding throughout the course of their 
diseases despite having autopsy-proved disease : this correlates with 
the relative or absolute absence of plasma cells in plaques [Ebers 62
G.C. et al, 1983]. The oligoclonal bands are known to be IgG. IgG 
oligoclonal bands are reduced but not eradicated by ACTH and/or 
steroids but the same pattern remains. This diminution is correlated 
with the decrease of IgG production (see above).
Mattson and colleagues eluted the IgGs of different plaques 
from the brain of a MS patient after autopsy and also from the brain 
of a patient who had died from subacute sclerosing panencephalitis 
(SSPE). They observed that unlike SSPE the pattern of oligoclonal 
banding produced was different between plaques although some of 
the oligoclonal bands were shared between different plaques. They 
concluded that the production of oligoclonal IgG may be due to the 
non-specific stimulation of B cells trapped in the CNS (leading to 
this heterogeneity of oligoclonal pattern between plaques) but that 
the oligoclonal bands shared between plaques may be specific for an 
antigen critical for the pathogenesis of MS [Mattson D.H. et al, 
1980].
In addition to this restricted heterogeneity, in the CSF of MS 
patients there is an altered kappa/lambda light chain ratio (about 50 
% of MS patients have a predominance of light chains of the kappa 
type which cannot be demonstrated in their serum) [Link H. et al, 
1970][DeCarli C. 1987] and a relative IgG subclass restriction with 
predominance of IgG 1 subclass [Vandvik B. et al, 1976].
b) Other immunoglobulins in the CSF.
IgM immunoglobulins are elevated in the CSF of 40-50 % of 
multiple sclerosis patients [Williams A.C. et al, 1978]. Chiodi and 
colleagues have showed that in some MS patients a small proportion 
of these IgMs is directed against viral proteins (mumps, measles or 
varicella) [Chiodi F et al, 1987]. IgM is usually not visualised in 
polyacrylamide gels because of restrictive pore size for large 
molecules. A discrete band corresponding to IgMs is sometimes seen 
in MS CSF on agarose-gel electrophoresis.
IgAs are elevated in a small proportion of patients with MS 
(<10 %). It does not appear however that IgAs show an oligoclonal 
pattern [Link H. et al, 1979]. Very little is known about the other 
classes of immunoglobulins.
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c) Other diseases show CSF oligoclonal pattern.
Other diseases show an increase of intra-BBB IgG synthesis 
and also oligoclonal banding. Ebers and colleagues classified these 
conditions into 2 groups. The first consists of a variety of disorders 
in which there is a local immune response in the nervous system in 
the CNS. These disorders include meningitis, encephalitis, 
paraneoplastic syndromes, neurosyphilis, polyneuropathy. The 
second group consists of a variety of disorders in which there is no 
obvious cause for oligoclonal bands. The most common of these 
disorders is stroke and oligoclonal banding can also been found in 
association with psychosis, headache, brain tumors etc, [Ebers G.C.,
1984]. More recently, oligoclonal immunoglobulins have been 
described in the CSFs of patients suffering from tropical spastic 
paraparesis and ’AIDS dementia complex' (see chapter on viruses 
and multiple sclerosis)
d) Techniques used to visualise oligoclonal bands.
Oligoclonal bands can be detected by electrophoresis and 
isoelectric focusing. At first CSF had to be concentrated for 
visualisation. The best method which does not appear to lead to a 
drastic loss of CSF proteins is by the use of the collodion bag method 
of Kaplan and Johnstone [Kaplan A. et al, 1966]. With the use of 
silver stains or immunological methods, the CSF oligoclonal banding 
can now be visualised with unconcentrated CSF.
Three methods for visualisation of oligoclonal bands are 
described in this study : isoelectric focusing (IEF) techniques on 
polyacrylamide gel combined with silver staining, the 
immunoprinting method (IPP) and the immunofixation method (IF). 
Only the last method requires concentration of the CSF.
e) Specificity of the oligoclonal IgG in MS.
A very small proportion of the oligoclonal IgGs is specific for 
viral proteins (see section on viruses and MS). However, the 
specificity of most of the oligoclonal IgGs is unknown. It is thought 
that at least some part of this oligoclonal response is due to non 
specific stimulation of plasma cells trapped in the CNS. However,
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some researchers still feel that a relevant specificity is present 
somewhere in the oligoclonal response so commonly present in MS.
Other components studied in the CSF in 
relation to MS.
In the CSF of MS patients, Morgan and his colleagues have 
described the significant consumption of the terminal component of 
complement (C9) [Morgan B.P. et al, 1984]. They also described the 
presence of membrane attack complexes of complement in the CSF 
of some MS patients [Scolding N.J. et al, 1989]. However, some 
other groups have not repeated the finding related to consumption of 
C9 finding only minor consumption of C9 [Halawa I. et al, 1990].
Other immunological parameters have been detected in the 
CSF of MS patients but their relevance to the MS process is still 
unknown. Schuller and colleagues detected the presence of anti-DNA 
and anti-RNA in about a third of the patients tested [Schuller E. et al, 
1978]. Others have detected antismooth muscle antibodies in a very 
small proportion of patients with MS [Vandvik B. et al, 1977]. Anti 
myelin protein antibodies can be detected in the CSF of some MS 
patients but it may be that these antibodies are the sign of myelin 
breakdown or at most only partly responsible for this breakdown 
[Baig S. et al, 1991][Ichioka T. et al, 1988].
More recently Zanetta and colleagues observed that 47 out of 
51 patients with multiple sclerosis had antibodies specific to a 
mannose-binding protein, the cerebellar soluble lectin (CSL). Only 
30 out of 188 neurological controls showed a positive reaction and 
14 out of the 30 controls positive for anti-CSL were over 60 year of 
age, an age-group not representative of multiple sclerosis [Zanetta 
J.P. et al, 1990]. This observation needs to be repeated to evaluate 
the potential diagnostic, but also aetiopathogenic relevance of CSL in 
MS.
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IMMUNOLOGY OF MULTIPLE SCLEROSIS
Evidence of immunological involvement in MS is given by the 
histopathology of the lesions (see section on the histopathology of 
MS). Moreover, there are signs that the immune system is perturbed 
as for example the occurrence of oligoclonal IgGs in the CSF of MS 
patients (see section on CSF and MS) and quantitative and functional 
changes have been described in the peripheral system. 
Epidemiologically MS is associated with some alleles of the HLA 
class II (DQwl in the north east of Scotland). Class II genes are also 
called immune response genes as they influence the immunological 
response to each individual making an individual's immune response 
unique in relation to all antigens that she or he may encounter. 
Association with certain HLA alleles is found with all the diseases 
which are thought to be autoimmune [Roitt I., 1984]. In addition, 
immunosuppressive agents such as corticosteroids [Milligan N.M. et 
al, 1987] can diminish the clinical symptoms of the disease although 
they are inefficient upon the long term course of the disease.
It is however not evident that all the immunological features seen in 
the disease are related to the aetiopathogenesis of the disease or if 
they are mainly consequences of the MS lesions.
One important theory of MS is that the disease is autoimmune 
in origin perhaps triggered by a viral infection. The autoimmune 
theory is supported by experimental allergic encephalomyelitis 
(EAE), an induced animal disease considered a model for MS. EAE 
is induced in genetically specific animals by the injection of myelin 
basic protein (MBP) or proteolipid protein (PLP) (both proteins of 
the myelin) with Freund's adjuvant. As in MS, the importance of the 
BBB has been recognised in EAE (see below). A great deal of work 
has been done with MBP in humans but the evidence to implicate this 
protein in the etiopathogenesis of MS is slim. In this chapter, a brief 
review on the current knowledge and theory of the immunology of 
MS will be presented.
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Peripheral blood and CSF immune 
abnormalities in MS.
The rational behind studying the immune system in MS is to 
understand the cellular and soluble factors that may initiate, mediate 
but also regulate the disease process. The autoantigen(s) is not known 
in MS and therefore the immunological studies in MS are limited to 
non antigen-specific assays.
A number of immune abnormalities have been observed in the 
peripheral blood of patients with MS. However, due to the difficulty 
in longitudinal studies, some of the findings are still questioned. 
Moreover, it appears that these abnormalities tend to be more 
pronounced in chronic progressive MS, and, from the literature, it is 
sometimes difficult to know what type of disease has been included 
in a study. The same abnormalities may happen in relapsing patients 
but studies of this group are complicated by imprecision in judging 
disease activity by clinical criteria alone. Moreover the correlation 
between clinical manifestations of the disease and the underlying 
pathological activity are poor. Using NMR, many silent lesions can 
be identified that often do not correspond with any clinical signs 
[Ormerod I.E.C. et al, 1987][Oger J. et al, 1987].
Some of the cellular abnormalities are interpreted as a 
decrease in suppression and immunoregulation [Hafler D.A. et al, 
1989] [Freedman M.S. et al, 1988]. In the peripheral blood, there is a 
decreased mitogen or autologous mixed lymphocyte reaction 
(AMLR) in patients with progressive disease [Antel J.P. et al,
1978][Hafler D.A. et al, 1985][Hirsch R.L., 1986][Baxevanis C.N. et 
al, 1987][Chofflon M et al, 1988]. A reduced suppression activity has 
also been correlated with formation of new lesions visualised by 
NMR in relapsing-remitting patients [Oger J. et al, 1987]. The 
suppression-induction function has been associated with a subset of 
CD4+ T cells harbouring CD45R+ molecules (recognised e.g by the 
2H4 mAb) whereas the helper-inducer function has been associated 
with a mutually exclusive CD4+ subset harbouring CD 29+ 
molecules (recognised e.g by the 4B4 mAb). On the other hand the 
suppressor-effector function is attributed to the CD8+ population 
although reports of CD4+ and non-T cell suppressors exist 
[Freedman M.S. et al, 1988]. In progressive and in relapsing- 
remitting disease, a decrease of the CD4+CD45+ subset (suppressor-
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inducer) has been observed [Rose L.M. et al, 1988] [Morimoto C. et 
al, 1987].
Other cellular abnormalities may be related to the consequence 
of the decrease in suppression and account for a state of T-cell- 
activation. Peripheral T cells from relapsing and progressive patients 
express 'activation' antigens (e.g CDw26, VLA-1, IL2 receptor) 
when compared with non-MS controls [Noronha A. et al, 1980] 
[Hafler D.A. et al, 1985 b and c] [Kerman R.H. et al, 1988].
In the CSF, similar changes can be detected. There is an over­
representation of CD4+ cells compared to the blood [Cashman N. et 
al, 1982]. There is also an increased number of CD4+ CDw29+ and 
decreased number of CD4+ CD45R+ T cells [Chofflon M.M. et al, 
1989]. The number of activated T cells is also high [Noronha A. et 
al, 1980] [Bellamy A.S. et al, 1985]. In progressive patients, it 
appears that the T cells are oligoclonal in nature. Moreover, 
oligoclonal T cells are also present in the blood and these oligoclonal 
T cells share the same T cell receptor Vb usage with their 
counterpart in the CSF. However, it appears that each MS patient is 
unique as TCR Vp usage of the oligoclonal T cells is not identical 
between patients [Lee S.J. et al, 1991].
In the brain, the changes are again similar with an increased 
number of CD4+ CDw29+ and decreased number of CD4+ CD45+
T cells [Sobel R.A. et al, 1988], increased activated T cells (IL2 
receptor positive) and activated macrophages [Traugot U. et al,
1983] and presence of Class II on astrocytes [Hofman F.M. et al, 
1986]. All the ingredients to fuel an inflammatory immune response 
are present. Moreover cytokines are detected in plaque areas 
[Hofman F.M. et al, 1986] for example TNF [Hofman F.M. et al, 
1989] [Selmaj K. et al, 1991]. The consensus on CD8+ T cells is that 
they tend to predominate at the edge of the plaques [Sobel R.A. et al, 
1988]. However it is not clear whether these CD8+ T cells are 
cytotoxic T cells expanding the edges of the plaques or if they are 
suppressor T cells preventing the centrifugal expansion of the 
plaque.
Along with the cellular changes detected in the MS brain, 
there is the characteristic production of oligoclonal IgG, the 
significance of which is still unknown (see the CSF section).
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Studies on a possible autoantigen in MS.
a) Antigens of the myelin.
The molecular structure of myelin has been studied 
extensively during the last decades. Lipids constitute 70-80% of the 
mass of the myelin. The distinguishing feature of myelin lipids is the 
high content of the galactosphingolipids, cerebroside and sulfatide 
[Norton W.T., 1984]. Glycosphingolipids are known to be lipid 
haptens and specific antibodies can also be raised against 
cerebrosides and sulfatide. It appears that myelin cerebroside is a 
specific marker of CNS oligodendrocytes [Raff M.C. et al, 1978].
The major proteins of myelin are myelin basic protein (MBP) 
(in human myelin, there are at least 2 basic proteins, a 18,500 kd and 
a 21,500 kd proteins), proteolipid protein (PLP) (25 kd) and the 
Wolfgram proteins group (between 42,000 and 50,000 kd) [Cruz 
T.F. et al, 1985]. The lower molecular weight protein of this group 
has been shown to be identical to the myelin 23' cyclic nucleotide 3’ 
phosphodiesterase [Drumond R.J. et al, 1980]. Another protein of 
myelin is myelin associated glycoprotein (MAG) of molecular 
weight 100,000 kd for the native glycosylated protein [Slazer J.L.et 
al, 1987]. Other proteins of myelin are known to have enzymatic 
activity and at least 20 enzymes have been described in myelin; some 
appear to be myelin specific.
b) T cell autoantigens.
Many attempts have been made to define the primary target(s) 
within the CNS for a possible autoimmune reaction. Attention has 
been focussed on MBP since EAE can be induced by MBP.
Moreover as MBP-specific T cell clones are sufficient to transfer 
EAE in rodents and because of the T cell predominance in MS 
lesions, the T cell response against different myelin antigens has been 
extensively studied in MS. Also, as it is known that the T cell 
immune response is 'restricted' by MHC molecules and because there 
is a genetic association with some HLA class II alleles and MS 
(particularly HLA DR2 and HLA DQwl), it is thought that the T cell 
arm of the immune response is central in the aetiopathogenesis of 
MS.
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The type of assays for assessing the T cell immune response 
are limited for technical and ethical reasons. For example, skin 
testing (a good indicator of the delayed type hypersensitivity (DTH) 
in vivo ) is unethical with myelin antigens in MS patients
Peripheral blood mononuclear cells (PBMC) from patients 
with MS at various stages of the disease and from control subjects 
have been studied for reactivity to CNS extracts and to MBP [Lisak 
R.P.B. et al, 1974, 1978 andl984] [Rocklin R.E. et al, 1971] [Hughes 
R.I. et al, 1979] [Colby-Germinaro S.P. et al, 1977 a and b] [Johnson 
D. et al, 1986]. However, most studies have been done using MBP 
and not with myelin extracts. Indeed, in the literature there are very 
few studies which have looked at the T cell response against whole 
myelin [Rocklin R.E. et al, 1971] [Lisak R.P.B. et al, 1978] 
[Brockman R.W et a, 1970] [Barfeld H. et al, 1970] and those that 
have been done were carried out 20 years ago when the T cell 
proliferation assay (or lymphoblastic assay) protocol (the proportion 
of lymphoblasts was counted on a slide after incubation with the 
antigen) was different from the usual protocol nowadays (the 
incorporation of ^H thymidine in PBMC is counted after incubation 
with antigen). From all these studies, no conclusive T cell-antigen (s) 
has been found. Some patients show a definite T cell reactivity 
against some myelin antigens e.g MBP, but it is not clear whether 
this immune response induces the myelin breakdown or whether it is 
secondary to it. Moreover the majority of studies described some 
reactivity in normals and neurological controls. T cells which are 
specific for MBP have been cloned from the peripheral blood 
lymphocytes and from the CSF of MS patients but T cell- clones with 
identical specificity have been obtained from normal or neurological 
controls [Bums J. et al, 1983 and 1986] and proliferation have been 
obtained in normal individuals with peripheral blood lymphocytes 
incubated with MBP, PLP or MAG [Johnson D. et al, 1986].
Other sources of lymphocytes apart from the peripheral blood 
and the CSF can be used to study the T cell reactivity in MS patients. 
For example, the study of cloned T lymphocytes from MS lesions or 
from local lymph nodes may be more rewarding. Due to logistic and 
technical problems, there is only one study published in the literature 
which reports the successful cloning of T cells from MS lesions. 
Hafler and his colleagues cloned T lymphocytes from 2 MS plaques 
of a post mortem brain from a 62 year old man who had MS for 34 
years and who was in progressive phase of his disease when he died. 70
They had previously isolated autologous antigen presenting cells (for 
the T cell cloning procedure and the T cell proliferation assay) 
before the death of this patient (D. Hafler, personal communication). 
They derived 57 clones which were tested for their reactivity to 
MBP and PLP. None of the clones proliferated with MBP or PLP 
although these T cell clones proliferated with the mitogen PHA 
[Hafler D.A. et al, 1987].
From the above discussion it is clear that the source of the T 
cell for T cell reactivity studies may be critical and other studies 
similar to the one Hafler and his colleagues have performed are 
needed. Indeed, the origin of the possible autoreactive T cells has 
been debated [Hafler D.A. et al, 1989] [Calder V. et al, 1989] since it 
is not clear if they are initially activated in the blood and then cross 
the blood-brain barrier or if they originate within the brain.
c) Fine specificity of MBP- specific T cells in patients 
with MS.
It has been recognised that specific T cell sites of MBP are 
responsible for the induction of EAE in animal. These T-cell sites 
correspond to short peptides and they are different in genetically 
distinct animals [Alvord E.C., 1985]. In human, the same restricted 
antigenicity is observed with MBP. Despite the lack of evidence, the 
major immunological MS research groups in the world are working 
on the premise that MBP is one of the autoantigens of MS. Thus the 
T cell sites of MBP have been defined fairly extensively [Martin R. 
et al, 1991]. Indeed a MBP peptide (MBP85-105) appears to be 
worth considering since it has been shown that this peptide is 
recognised by cytotoxic T cells or T helper cells restricted by Class 
II DR alleles associated with multiple sclerosis [Richert J. et al, 1989] 
[Ota et al, 1990]. Shared T cell receptor VP usage (VP 17) to this 
immunodominant region of myelin basic protein was demonstrated 
among individuals with specific T cells to this peptide 
[Wucherpfennig K.W. et al, 1990]. This peptide shares homology 
with a number of viral proteins especially a protein P3-A from 
Coxsackie virus [Souberbielle B.E. et al, 1991]
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d) B cell autoantigens.
The studies performed on MS patients in relation to a possible 
antibody response to myelin components are similarly inconclusive. 
There is no evidence that pathogenic antibodies directed against a 
component of the brain are prevalent in MS patients. Brain extracts, 
oligodendrocytes, myelin lipids and glycolipids as well as myelin 
proteins have been tested in different humoral assays but to no avail 
[Lisak R.P. et al, 1984], Inconclusive results have been published on 
the level of antibodies to MBP found in the CSF of patients with MS. 
Some researchers were not able to detect such antibody [Chou C-H J. 
et al, 1983] whereas others have detected low level antibodies to 
MBP which were part of the oligoclonal IgG production [Cruz M. et 
al, 1987].
There have been also reports of in vitro bioelectric blocking 
activity in the serum of patients with MS but the nature of the 
soluble factor involved in this process and its specificity has not been 
defined [Seil F.J. et al, 1976]. This bioelectric blocking factor(s) was 
claimed to block evoked electric activity in cerebral neocortex 
cultures. This factor(s) was never properly related to an antibody 
response and no further work was carried out on this matter.
Immune complexes have also been demonstrated in the CSF of 
some MS patients and some of the specificity of these immune 
complexes has been related to lipids [Lund G.A. et al, 1983], 
galactocerebroside, GM4 gangliosides and other brain antigens 
[Friedman J. et al, 1987].
e) Autoimmunity to brain vessels in MS.
Tsakuda and his colleagues have claimed that there is a 
humoral response against brain vessels in MS (the reader should 
refer to the BBB section of the introduction). No work have so far 
been done on a possible T cell response against the brain vessels in 
patients with MS and this is partly due to technical limitations.
Undoubtedly, the brain vessels could play a role in the 
aetiopathogenesis of MS but the precise mechanism is still to be 
defined (see BBB section) and may not be related to an autoimmune 
reaction to the brain vessels. For example, it is interesting that 
whereas EAE can be induced by the subcutaneous injection of MBP- 
reactive T cells, injection of these cells directly into the brain does 
not induce the disease. Thus, this model suggests that T-cell 72
migration across the endothelium is critical for the initiation of an 
inflammatory reaction in the CNS [Hafler D.A. et al, 1989].
Study of experimental autoimmune encephalo­
myelitis (EAE) and possible therapeutic 
intervention in MS.
Finding the autoantigen(s) in MS is an important goal as it has 
important therapeutic implications. Indeed, different 
immunotherapeutic protocols have been explored with the animal 
model EAE where the autoantigen is known and well defined. Some 
of these immunotherapeutic protocols do prevent the disease and are 
based on the knowledge of the autoantigens (see below). Others show 
some promising activity and based on non-specific immunotherapy 
e.g anti-TNF antibody can prevent EAE [Ruddle N.H. et al, 1990].
It is likely that a combination of specific (based upon the knowledge 
of the autoantigen) and non specific immunotherapies may be helpful 
in the treatment of MS which appears to be a more complex disease 
than the well defined disease EAE.
Different specific immunotherapies have been successfully 
tried in EAE. Animals have been vaccinated with inactivated 
autoreactive T cell clones or fragments of the T cell receptors 
derived from such clones. This approach has been claimed to be 
successful [Ben-nun A. et al, 1981] [Vanderbark A.A. et al, 1989] 
[Howell M.D. et al, 1989]. More recently, vaccination with TCR- 
derived peptide expressed on the T cells responsible for the disease 
has been shown to promote recovery from established EAE [Offner 
H. etal, 1991].
The use of specific monoclonal antibodies to critical 
determinants involved in the disease process has been another 
approach in order to prevent EAE. It has been shown that in H-2U 
mice, T helper cells recognising the peptide 1 to 9 of MBP are 
sufficient to induce EAE. These T helper cells share a common TCR 
Vp gene segment - VP 8.2 . A monoclonal antibody specific for this 
subset of TCR injected into the animal prior to challenge with MBP 
has been shown to prevent the onset of the disease [Acha-Orbea H. et 
al, 1988] [Urban J.L. et al, 1988]. More recently Aharoni and 
colleagues were able to prevent the onset of EAE by injecting a 
monoclonal antibody specific for the MBP-Ia complex [Aharoni R. 
et al, 1991]. 73
A third approach using specific immunotherapy for the 
treatment of EAE is based on the use of 'inhibiting peptides'. The 
peptide MBPi-9 is restricted by I-Au in PL/J mice. Analogues of 
MBP 1-9 have been developed which bind to I-Au more effectively 
than the native MBPi-9. Coimmunisation with the analogue peptides 
at the time of disease induction significantly reduced the incidence of 
clinical disease [Wraith D.C. et al, 1989]. More recently, 
immunization with an encephalitogenic MBP peptide (1-11) with a 
single amino acid change at position 4 confers the capacity to prevent 
rather than induce EAE. A similar mechanism may account for the 
prevention or reduction in severity of EAE and chronic EAE after 
oral immunisation with myelin in animals. Another explanation is 
that oral immunisation can induce active suppression [Stephen H. et 
al, 1990].
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CONCLUDING NOTES ON MULTIPLE 
SCLEROSIS.
In conclusion, multiple sclerosis is a difficult disease to 
diagnose as there is still no definitive laboratory or other test. Due to 
its relap sing-remitting course in most patients and due to the site of 
the disease, the brain , clinical research is difficult to undertake.
The epidemiology of the disease suggest that both 
environmental and genetic factors contribute to the disease process. 
The genetic predisposition seems to be polygenic with most of the 
associations described so far related to genes involved with the 
immune response. One theory suggests that an environmental 
factor(s) probably viral in nature induces, in genetically determined 
individuals, an immunological reaction which could be autoimmune 
in character.
Histopathological and immunological studies shows that there 
is a disregulation of the immune system in MS patients and that all 
the signs of a local, inflammatory reaction are present in the brain 
of MS patients. Moreover there is the production of the oligoclonal 
IgGs which are so characteristic of MS patients although not specific 
for this disease. The hallmark of the disease is the destruction of the 
myelin and thus a lot of effort has been spent in studying the possible 
immune response towards myelin antigens.
Since the lesions are perivascular, it is not unreasonable to 
suggest that the blood-brain barrier may be of some significance in 
the aetiopathogenesis of MS. However little data is available on this 
topic perhaps due to the difficulty in obtaining human brain 
endothelia and to the lack of an appropriate human brain endothelia 
cell line.
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BACKGROUND TO THIS THESIS.
Studies over a number of years carried out at Mill Hill, 
London, and then at St Andrews (mostly by Dr. Kamal Goswami) 
have sought to ascertain if the paramyxovirus SV5 plays any role in 
the aetiology of some cases of MS.
These investigations were initiated after isolations of SV5 
virus from MS bone marrows. Later on it was also shown that a 
third of the MS patients tested had antibodies specific for SV5 in 
their sera. The interest in SV5 and MS was further stimulated when 
it was observed that an epitope on the major surface glycoprotein of 
the virus cross reacted with an antigen present in myelin when tested 
with the immuno-fluorescence technique on cross sections of rat 
brain (see introduction on viruses and MS, the paramyxovirus 
section).
The next series of experiments (mostly done by Dr Goswami) 
analysed the oligoclonal antibodies present in the CSFs of MS 
patients on the basis that if SV5 played a role in the disease then it 
seemed likely that antibodies against the virus may compose a 
significant proportion of this oligoclonal response. The CSFs were 
screened by immunofluorescence techniques which indicated that 40­
50% of the MS CSFs had antibodies to either SV5 or PF-2. The 
immunofluorescence technique cannot distinguish between PF-2 and 
SV 5 because of cross reactions between these two viruses. Further 
characterisation of the CSF antibodies was made by using techniques 
which could distinguish between SV5 and PF-2 e.g by radioimmune 
precipitation (on the basis that the major surface glycoprotein, HN, 
of PF-2 and SV5 does not cross react [Goswami KK. et al, 1987]). 
This demonstrated that a significant proportion of the CSFs showing 
positive IF results contained antibodies against SV5. The most 
significant finding was that by using an immunoabsorption technique 
some of these CSFs had oligoclonal bands which were absorbed by 
preincubation with purified virus SV5 and even in one case with the 
purified virus SV5 HN glycoprotein. Moreover, I searched possible 
homologies between the known SV5 proteins and the National 
Biomedical Research Foundation protein sequence database using the 
FASTA program [Pearson W. et al, 1988] in the University of 
Wisconsin Genetics computer group package [Devereux J. et al,
1984] maintained at the Daresbury laboratory and also used the PSQ 
program from this package to compare the known myelin proteins
and the SV5 proteins. A high score was recorded when the SV5 HN 
protein was compared to myelin associated glycoprotein (MAG) 
[Salzer J.L. et al, 1987] corresponding to a 20 amino acids stretch. 
The homology between MAG and SV5 HN is shown in figure 
IntroB-1.
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Figure IntroB-1: Homology between myelin associated 
glycoprotein (MAG) and the HN protein of SV5. The solid lines 
represent identical amino acids between the 2 proteins and dashed 
lines represent structural homology between amino acids.
It was then decided that similar experiments should be 
repeated by independent researchers because of the potential 
significance for MS of these observations. Professor Erling Norrby 
and Dr Bodvar Vandvik (Norway) and Dr Brendan McLean (from 
the Institute of Neurology, Queen Square, London) were asked to 
carry out confirmatory tests. However, the techniques used in 
Norway and in London were different from the techniques in use at 
St Andrews.
The Scandinavian group used the 'imprint immunofixation' 
method which had been originally developed by them. The method 
depends on the ability of the oligoclonal bands displayed (after 
concentration of the CSF) by isoelectric focussing on polyacrylamide 
gels to be transferred sequentially to agarose gels containing 
different virus antigens. The antibodies which attach are then 
detected by 125 I labelled anti-human IgGs. The virus antigens are 
generally crude extracts of infected cells and controls are derived 
from extracts of uninfected cells (see Material and Methods and 
Results section). They studied 30 CSFs of MS patients and found 
that 7 had antibodies against SV5 and that these antibodies were
intrathecally synthetised (by comparison to the serum with the 
immunoprinting method). Most of these 7 patients showed 
intrathecal synthesis against other virus antigens. However, no 
correlation was observed between the patterns of the intrathecal 
SV5-IgG bands and the total IgG oligoclonal bands and it was 
concluded that SV5 intrathecal synthesis was not a major component 
of the total oligoclonal population. Further analyses also suggested 
that the bands noted were resulting from cross reacting antibodies to 
the other related paramyxoviruses PF-2 and mumps.
The second study was carried out by Dr B. McLean at St 
Andrews. The technique, immunoblotting , was used with CSFs 
brought from the London area. Unconcentrated CSFs were separated 
by isoelectric focusing on agarose gels and then blotted onto 
nitrocellulose coated with antigens. This method limited the 
possibility of denaturing the antigens but suffered from the lack of 
internal controls (see below). The basic results indicated that out of 
14 MS CSFs, four were positive for the SV5 virus preparation, two 
of these showing an oligoclonal pattern. Three of the ten controls 
were also positive, one showing oligoclonal bands. On testing with 
purified SV5 HN only one of the MS showed a positive oligoclonal 
response whereas four of the controls did (one extra). Test with PF- 
2 showed equally diverse results, two of the MS CSFs and three 
controls reacting. Some MS and control CSFs also reacted well with 
Sendai virus (a mouse virus and presumed negative control). It was 
therefore a matter of contention whether or not these results could 
be explained by possible cross reactivity between related viruses e.g 
a possible cross reactivity between Sendai virus and PF-1 or PF-3 
but another possibility was that the technique suffered from the lack 
of specificity.
The first aim of the work presented in this thesis was to test 
new CSFs of MS patients with the immunoabsorption technique. 
Secondly, results obtained by ourselves and the other 2 groups 
stimulated the need for an independent assessment of the 3 techniques 
used (imprint immuno-fixation, immunoblotting and 
immunoabsorption).
This study also relates to our supposition that viruses may play 
an aetiological role in the disease process. We therefore hypothesised 
that MS is an autoimmune disease induced by viral infection (see 
Introduction - Viruses and MS). It would therefore be critical to 
define autoantigen(s) concerned as a route to uncovering the nature 78
of the virus (or viruses) involved. Most of the studies carried out to 
date on the nature of the MS autoantigen have focussed on myelin, 
but more particularly on the study of only one protein, myelin basic 
protein (MBP) (see Introduction - Immunology of multiple 
sclerosis). However, the role played by the blood-brain barrier (see 
the blood-brain barrier section) or by other components of myelin in 
the aetiopathogenesis of MS have not been pursued to any great 
extent principally because of a limitation in the techniques available 
to study them. There is thus a need for a technique which will permit 
one to test the immunological response to many different antigens 
from the brain. Studies on the BBB have also been limited by the 
lack of a human brain endothelial cell line. It will also be apparent 
that other aspects of blood-brain permeability could gain from the 
availability of a human brain endothelial cell in culture e.g very little 
is known about viral infections of the blood brain barrier.
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MATERIAL AND METHODS.
MMl: POLYACRYLAMIDE ISOELECTRIC FOCUSING OF 
CSF.
Reference [Schipper H.I. et al, 1984].
Material - Isoelectrofocusing(IEF) Ampholine PAG gel-plates (pi 
interval 3.5- 9.5)(Pharmacia), stored at + 4°C.
- IEF gel apparatus (LKB) with a cold water cooling 
system
- Power pack (LKB Multiphor n, electrophoresis unit) 
connected to the IEF apparatus.
- Paper applicators for the samples (LKB or Whatman)
- Buffer applicator papers (LKB or Whatman).
- Anode buffer : 0.1 M H2SO4.
- Cathode buffer: 1 M NaOH.
- Very fine forceps.
Method.
- The water cooling system was switched on.
- Kerosene was applied over the apparatus flat bed.
- The IEF gel was cut to the desired dimensions and applied 
to the apparatus bed (bubbles were avoided).
- Anode, cathode blotting paper applicators and samples 
paper applicators were placed on the gel.
- Anode and cathode buffers were applied on their 
respective applicators.
- 10 pi of each test sample was applied on its applicator.
- The gel was run at a constant current of 35 mA until it 
reached 1000 volts and then set at a constant voltage of 
1000 volts for 105 minutes. (35 mA was adequate for the 
entire gel of 20 cm long; half a gel was run at 15 mA).
- The samples paper applicators were removed from the 
gel after 20 minutes of electrophoresis (the electrophoresis 
was switched off and on during this process).
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MM2: SILVER STAINING OF IEF GEL OR SDS PAGE 
GELS.
a/ Material - silver staining kit from BIO RAD:
1. Oxidiser (xlO strength stock solution) : 20 ml of the 
stock solution was mixed with 180 mis of deionized 
distilled water. The oxidiser working solution was 
prepared the day the staining was to be done.
2. Silver reagent (xlO strength solution): 20 mis of the 
stock solution was mixed with 180 mis of deionised 
distilled water prepared on the same day that staining was 
carried out.
3. Developer: the 32 g of the stock powder solution were 
dissolved in a litre of deionized distilled water (the solution 
could be kept for at least a month at room temperature).
- deionized distilled water (DDW)
- glass dishes (at least two) to contain the gel for stain.
- ampholytes removal solution A (ARS-A):
30 %(v/v) methanol, 10% (v/v) trichloroacetic acid, 3.5 % 
(v/v) sulphosalicyclic acid.
- ampholytes removal solution B (ARS-B): 30 % (v/v) 
methanol, 12 % trichloroacetic acid.
- fixative A (F-A): 40 % (v/v) methanol, 10 % (v/v) acetic 
acid.
- fixative B (F-B): 10 %(v/v) ethanol, 5 %(v/v) acetic acid.
- storage solution (SS): 5 % (v/v) acetic acid.
- ’rocker’
b/ Method: The duration of incubation with the different solutions 
depended on the width of the gel. All the experiments used 0.75 mm 
gels (IEF or SDS PAGE) and thus the duration quoted below was for 
gels of 0.5-1 mm width.
The method described is for IEF gels.
-The gel was transferred into deionized distilled water- 
cleaned glass dishes. Cleaned dishes were used for each 
step of the silver staining technique.
-The gel was incubated with the different solutions as 
follows.
- ARS-A: 1 hour
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- ARS-B: 2 hours (the solution was changed every 40
minutes).
*- F-B: 15 minutes incubation.
- F-B: 15 minutes incubation.
- Oxidiser: 5 minutes.
- DDW: 5 minutes.
- DDW: 5 minutes.
- DDW: 5 minutes.
- Silver reagent: 20 minutes.
- Developer: the gel was developed until the solution turned 
yellow or a 'smokey' precipitate appeared. The developer 
was poured off and fresh developer added. The gel was 
incubated in developer until optimum development was 
obtained (the developer was changed every 5 minutes or 
when it became cloudy).
- The reaction was stopped with SS
- The gel was photographed, or, stored in the SS solution, 
in a sealed bag.
The silver staining protocol of SDS-PAGE gels was different as it was 
not necessary to remove ampholytes before the silver staining. The 
protocol begins with a 30 minutes incubation in F-A solution and then is 
similar to the IEF gel silver staining from the asterisk step marked (*) 
(above).
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MM3: IMMUNOPRECIPITATION OF CSF.
(see figure MM3-1 for an outline of the technique).
a/ Material: - polypropylene centrifuge tubes for TL 100 centrifuge 
(Beckman).
- TL 100 ultracentrifuge (Beckman).
- purified virus preparation.
b/ Method: - The virus suspension was adjusted to give a protein 
content of 1-5 mg/ml.
- The CSF samples were centrifuged at 350,000 g for 2 
hours in the Beckman TL-100 at + 4°C .
- Each aliquot (95 pi) of the CSF supernatant was incubated 
with 5 pi of the virus preparation (or with PBS for the 
negative control) and after mixing, left overnight at + 4°C 
for absorption.
- the CSF-antigen mixtures were then centrifuged at 
350,000 g for 2 hours.
- About 70 pi of the supernatant was removed and then 
subjected to IEF and silver staining.
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Figure MM3-1: Outline of the immunoprecipitation of CSF for 
characterisation of possible antigen specific oligoclonal bands.
84
MM4: IMMUNOBLOTTING METHOD ON AGAROSE GEL.
This technique has been described by Moyle S. and colleagues 
[Moyle S. et al, 1984]. 
a/ Material:
1. Casting of the gel:
- casting frame (247mm x 13,6 mm x 3 mm) (see figure 
MM4-1).
- glass plate and bull-dog clips.
- IEF agarose (Pharmacia)
- glycerol.
- D-sorbitol.
- thermometer.
- ampholytes solutions (Pharmacia), kept at + 4°C
1. PI 3-10
2. P.I 8-10.5
- Gel- Bond film (agarose gel support medium), ICN 
Biomedical Ltd, thickness 0.1 mm, width 127 mm.
- syringe, needles and swabs.
- 10 ml pipettes.
- level spirit.
2. Isoelectrophoresis
- isoelectrofocusing system (see acrylamide IEF section).
- sample applicator (LKB or Pharmacia).
- cathode and anode buffer (see acrylamide IEF).
- tissue paper
- glass plate + weight
- blotting paper ( Whatman 3 MM)
- nitrocellulose paper (Sartorius GmbpH D3400 Gottingen, 
Germany,Nitro-cellulose 200x200 ref: 054217; 0.2 pm 
pore size).
3. immunoblotting visualisation
- Blocking solution: 1 % (w/v) bovine serum albumin 
(BSA), 1 % (w/y) gelatin in PBS.
- 'First antibody' for example for human CSF: [goat] anti­
human IgG Fc receptor specific ( Atlantic Ab).
- 'Second antibody' : [Rabbit] anti-goat total 
immunoglobulins peroxidase linked (Dako)
- Tween 20
- 3-amino-9-ethylcarbazole (Sigma) 85
- 0.02 M (H.C1) acetate buffer, pH 5.1, freshly prepared.
- Hydrogen peroxide (H2O2), kept at + 4°C.
- 'rocker' at 37 °C.
- air dryer.
b/ Method.
1. Casting of the agarose gel:
- The gel was made by mixing 27 ml of 10 % (v/v) 
glycerol in deionised distilled water and 0.3 g of agarose 
IEF and 3.6 g of D-sorbitol.
The mixture was dissolved by boiling and then kept in 
closed glass bottle where the gel set.
- The glass plate with the Gel-Bond and the casting frame 
fixed to the glass plates by bull-dog clip were warmed and 
then placed on a horizontal surface. The horizontal level of 
the plate was checked using a level spirit.
- The gel was warmed to 70 °C and 2ml of ampholyte (3­
10, PI) solution and 0.5 ml of (8-10.5) ampholyte solution 
were added with a syringe and a needle.
- The gel was casted inside the casting frame. A pipette was 
used to spread the gel evenly. The gel set quickly and was 
kept in a moist atmosphere for some days.
2. Isoelectrophoresis of the agarose gel: 2 methods are 
described which only differ in the type of NTP sheet used. 
When the pattern of the CSF oligoclonal bands was 
required, a standard NTP sheet was used in order to 
transfer the CSF immunoglobulins. If the assay attempted 
to localise virus-specific- oligoclonal bands, then the NTP 
sheet was covered with the purified virus preparation. (See 
figure MM4-2 for the outline of the method)
- The apparati were identical as those for the 
polyacrylamide method but the method differed somewhat.
- The cooling water system was switched on
- The bed of the apparatus was swabbed with alcohol.
- The gel was placed on the bed apparatus and the edges of 
the gels were trimmed with a scalpel (about 0.5 cm).
- A sheet of dry nitrocellulose paper, long enough to cover 
the gel, was placed on the gel and then taken off quickly 
and kept in distilled water for further use.
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- The cathode and anode applicators were placed and 
soaked in their respective buffers.
- The samples were applied to the gel with the help of the 
sample applicator.
- Tissue papers were placed on both side of the gel, outside 
the anode and cathode applicators.
- The gel was run at 1500V, 150 mA (power 20). At the 
beginning of the run, the voltage was about 500 V.
- The sample applicator was removed after 40 minutes and 
the electrophoresis was continued for another 50 minutes 
(total time 1 hour 30 minutes).
- When the run was completed, the nitrocellulose sheet that 
had been in distilled water was applied for 10 seconds to 
the gel and then discarded.
- A second nitrocellulose paper, soaked in distilled water 
was applied to the gel and then covered by 10 blotting 
papers (Whatman 3 MM).
* If specific- virus oligoclonal bands were sought, the NTP 
was covered with a purified preparation of the virus (see 
below).
- A glass plate was placed on the top of the blotting papers 
and a weight was placed on the glass plate.
- The incubation period was 20 minutes.
3. immunoblotting visualisation :
- The NTP was blocked in blocking solution for 1 hour 30 
minutes.
- The excess was washed away and the 'first antibody' was 
incubated for 1 hour with the NTP on a 'rocker' at 37 °C 
(for a 10x20 cm sheet, 50 pi of 'first antibody' in the 
minimum volume of 0.1 % (w/v) BSA-PBS.
- the NTP sheet was washed 3 times in PBS
- The 'second antibody' (peroxidase-linked) was incubated 
with the NTP in the same conditions as the 'first antibody'.
- The NTP was washed 4 times in 0.5 % (v/v) Tween 20- 
PBS and twice in distilled water.
- The reaction was visualised with:
10 mg of 3-amino-9- ethylcarbazole diluted in 6 ml 
of methanol and mixed with 44 ml of 0.02 M acetate 
buffer. Just before the development, 50 pi of H2O2 were 
added. The reaction was stopped with distilled water. 87
- The NTP sheet was air dried (this improved the contrast 
of the bands).
4, *For antigen blotting e.g a virus preparation, the NTP 
sheet was prepared as follow:
- The NTP sheet was wet in PBS and then soaked with 
antigen for 2 hours at room temperature or overnight at + 
40C.
10 ng (10-80 ng) of proteins / cm2 of NTP for unpurified 
antigen were required. The antigen preparation was 
diluted in the minimum volume of PBS.
- The NTP was incubated in blocking solution for 1 hour 
and 30 minutes.
- The excess of the blocking solution was washed away.
- The NTP was then applied to the agarose gel (see end of 
section 2.).
4
11.5cm
22.6cm
--------—__________ y
Top
Figure MM4-1: Casting frame for the preparation of the agarose gel 
for the CSF immunoblotting method.
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Figure MM4-2: Outline of the immunoblotting method for 
characterisation of CSF oligoclonal bands.
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MM5:IMPRINT IMMUNO-FIXATION (IIF) METHOD.
The IIF method has been described by H J. Nordal and colleagues 
[Nordal H J. et al, 1978] as well as the preparation of virus antigens for 
the nF [Vartdal F et al, 1979].
a/ Material:- all materials used in the polyacrylamide isoelectric 
focusing
- barbital buffer: 86 ml of 0.1 M sodium barbital were 
mixed with 13.8 mis of 0.1 N HC1 for a pH of 8.6
- IEF agarose (Pharmacia).
- antigen preparation: prepared from a SV5 or PF2 
infected VERO cell culture.
- ’first antibody’: Rabbit anti-human (or mouse ) antibody. 
-1251 linked to Protein A (Amersham)
- washing solution: 0.5 % (v/v) NP 40 in PBS.
- 10 ml pipette
- glass plate and casting frame.
- gel drier.
- rocker.
b/ Method: As in the immunoblotting method, 2 types of gels were 
prepared. If oligoclonal bands had to be visualised on the gel, the gel 
was purely made of agarose in barbital buffer. If specific-virus 
oligoclonal bands had to be visualised, the virus was incorporated into 
the gel.
1. Preparation of agarose gel (with or without antigen):
- SV5 or PF 2 cell pack antigens were prepared from 
infected VERO cell cultures (see section MM8).
- The infected cells were suspended in PBS to 10 %(v/v) 
and sonicated for 30 seconds on ice.
- The infected cell suspension was clarified by 
centrifugation (1000 g for 5 minutes).
- Control antigens were prepared from non infected 
VERO cells in the same way.
- The gel was made by mixing 1.5 % (w/v) agarose in 
barbital buffer and the mixture was allowed to set.
- Antigen (virus)-containing gel was prepared by heating 
the agarose gel (1.5 % (w/v) agarose in barbital buffer) to
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56 °C. 100 pi of the antigen preparation was added per 10 
mis of gel.
- The mixture (gel with antigen or alone) was layered (0.8 
mm) with a 10 ml pipette onto an alcohol cleaned glass 
plate (8x8 cm) already covered (’primed') with a layer
of gel and allowed to set. Once the gel was set, its edges 
were trimmed.
2. Isoelectrofocusing & imprint immuno-fixation
- Immediately after IEF of the CSF on polyacrylamide gel 
(see section MM1), the gel plates containing virus were 
placed (gel facing downwards) in a horizontal position in 
direct contact with the electrophoresis gel. (a small volume 
of de-aerated buffer was layered between the gels to 
prevent trapping of air bubbles.
- Immunodiffusion (gel to gel overlay) was carried out in a 
moist chamber for 5 minutes at room temperature.
- The 2 gels were separated by a gentle sliding movement 
after a brief submersion in barbital buffer.
- The antigen containing gel plate was repeatedly washed in 
PBS and pressed under filter paper.
- ’First antibody' was incubated with the gel (1 in 500 
dilution in 0.2 % BSA-PBS) for one hour at room 
temperature on a 'rocker'.
- The gel plate was washed in PBS 3 times.
- It was then incubated with 1251 linked to Protein A for 1 
hour on a rocker.
- The gel plate was washed with 0.5 % NP 40 in PBS, 
followed by a final wash in distilled water. The gel plate 
was pressed under filter paper and the gel was dried.
- The gel was then exposed to a X ray film at - 70 °C 
overnight.
- the X ray film was then developed.
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MM6: PREPARATION OF VIRUS INFECTED CELLS AND 
IMMUNOFLUORESCENCE SLIDES.
The method will be described for VERO (Monkey kidney cells) cells 
and SV5.
a/ Material- stock of VERO cells.
-75 cm3 ’Cel-cult’ culture flask.
- G-MEM medium (Gibco).
- newborn calf serum (NBCS).
-PBS
- fixative buffer: 5 % (v/v) formaldehyde
2 % (w/v) sucrose 
in PBS.
- permeabilisation buffer: 0.5 % (v/v) NP 40
10 % (w/y) sucrose 
in 1 % NBCS- PBS.
- 5% CO2 incubator.
- trypsin-EDTA solution:
0.05% trypsin, 0.02 % EDTA, in PBS, pH 7.3, 
filter-sterilised and kept at -20 °C.
- 12-well immunofluorescence slides (Hendley-Essex Ltd)
- coverslips (Arnold R. Ltd, London)
- square petri-dishes (Sterilin).
- sterile Pasteur pipette.
- Class II hood.
- haemocytometer slide.
b/ Method: l.Trypsinisation of the VERO cells
- Stock of VERO cells: cultured in G-MEM medium 
supplemented with 10 % NBCS, in 75 cm3 ’Cel-cult' 
culture plastic petri dishes.
- Under sterile conditions, the cells were washed twice with 
5 ml of trypsin-EDTA solution. Approximately, 2 mis of 
trypsin-EDTA solution was left on the cells. The flask was 
then incubated at 37 °C for 2-3 minutes. When most of the 
cells were seen to have been trypsinised optimally (the cells 
were of circular shape, attached loosely to the surface of 
the plastic flask), the flask was agitated gently and warm 10 
% NBCS medium was added to the flask.
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- The cells were counted and resuspended to a
concentration of 2.10^ per ml.
2. Preparation of the infected immunofluorescence slides.
-Autoclaved 12-well Micropore immunofluorescence 
slides were transferred under sterile conditions in square 
petri dishes (3 immunofluorescence slides per square petri 
dish). The top left comer of each slide was labelled.
- 70 pi of the cells suspension containing 2.105cells/ml was 
transferred to each well of the immunofluorescence slide.
- The slides were incubated overnight at 37 °C, in 5% CO2
atmosphere.
- When the cells had reached confluence (after 24 hours) 
the medium was removed with a Pasteur pipette connected 
to a vacuum line.
- 70 p.1 of 1/20 dilution of the virus seed in 2 % NBCS G- 
MEM was added in each well. NB: virus manipulation was 
done in predetermined controlled areas.
- The slides were incubated for 1-2 hours at 37 °C, in 5% 
CO2 atmosphere. 30 mis of 2 % NBCS G-MEM were then 
added to each square petri dish.
- The slides were incubated for 24 hours at 37 °C, in 5% 
CO2 atmosphere. This incubation time was optimal for 
immunofluorescence: plaques of viral infection cohabited 
with area of cells not infected with the virus thus providing 
an internal negative control. Uninfected slides were also 
prepared as negative control.
3. Fixation, penetration and storage of immunofluorescence
slides.
- Slides were washed in 1 % NBCS-PBS twice,
- Incubated for 10 minutes in fixative buffer, and washed 
once in 1 % NBCS-PBS.
- They were then incubated with the permeabilisation 
buffer for 5 minutes, and washed one to three times with 
1% NBCS-PBS.
- The slides were stored in 1 % NBCS-PBS + azide 
(0.01%) at + 4 °C for weeks.
93
MM7: INDIRECT IMMUNOFLUORESCENCE TECHNIQUE, 
a/ Material- Positive and negative antigen slides; the method will be
described for VERO cells infected with SV5.
- 'First antibody': a monoclonal anti-SV5 antibody made in 
mice or a polyclonal antibody made in rabbit or a human 
serum.
- 'Second antibody’ depended on the species of the first 
antibody. The second antibody used in the experiments was 
'conjugated' to fluorescein.
- VERO cell stock grown in 75 cm3 culture flask.
- 'Rocker' at 37 °C.
- syringe with filter holder and filter (e.g Millipore, cat
GSWP01300, type GS, pore 0.22p)
- Bench centrifuge with 1.5 ml Eppendorfs tubes.
- 1 % NBCS-PBS.
- forceps and tissues.
- Citifluor® anti fading agent (University College,
London).
b/Method: 1. Preabsorption of the 'conjugate' (second antibody): the 
'second antibody 'was absorbed with the cell line that was 
used for the preparation of the infected slides. This reduced 
the non specific background which could have occurred 
with some conjugated antibodies. When the 'second 
antibody' was 'absorbed' the optimum dilution had to be 
determined with positive controls.
- VERO cells in a 75 cm3 culture flask were fixed and 
permeabilised as described in section MM6 of "Preparation 
of virus infected cells immunofluorescence slides" and then 
washed 3 times with 1 % NBCS-PBS.
- Residual PBS was removed with a Pasteur pipette.
- 3 mis of the 'second antibody’ solution diluted 1/100 in 
PBS was incubated with the VERO cells in the flask.
- The flask was rocked gently at 37 °C for 1 hour.
- The 'conjugate' solution was aspirated from the flask and 
transferred into Eppendorf tubes which were then 
centrifuged at 12,000g for 2 minutes (in order to remove 
the cell debris from the conjugate solution). 94
- The conjugate solution was filtered through a 0.22 pm 
pore filter and kept at +4 °C for some weeks.
2. Indirect immunofluorescence procedure:
- Immunofluorecence slides (infected and uninfected) were 
washed once with 1 % NBCS-PBS.
- The slide without cells as well as the edges of the slide 
and the spaces between every wells were dried carefully 
with the comer of a tightly folded tissue.
- 10 pi of required dilutions of the first antibodies were 
placed in their respective wells in accordance with a 
predetermined pattern.
- The slides were placed in moist square petri dishes and 
incubated for 30 minutes to 1 hour at room temperature.
- The slides were then washed once with PBS quickly but 
gently and then 3 times with 1 % NBCS-PBS (5 minutes 
each time).
- The slides were then dried as previously described with a 
tissue paper.
- 10 pi of the appropriate dilution (and species) of second 
antibody (ies) were then incubated in their respective wells. 
At least one well was needed with no ’first’ or ’second 
antibody' and was therefore incubated with 1 % NBCS- 
PBS. The incubation time was 30 minutes to one hour at 
room temperature, in the dark.
- The slides were then washed 3 times with 1 % NBCS- 
PBS.
- the slides were dried as described before with a tissue and 
10 pi of Citifluor was applied between the wells, in the 
middle of the 2 rows. The coverslips were gently applied 
to the slides.
- The slides were visualised using the fluorescence 
microscope.
3. DAPI stain (Russell W.C et al, 1975).
-The first antibody incubation step is replaced by an 
incubation with 10 pg/ml of DAPI in PBS and the second 
antibody incubation step is omitted.
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MM8:TISSUE CULTURE AND VIRUS PREPARATION.
a/ Material- VERO cells
- virus seed : 106 pfu/ml (pfu (plaque forming unit))
- roller bottles and 'Hot* room.
- G-MEM medium (Gibco)
- Ultracentrifuge (Beckman)
- 30 % sucrose in PBS.
- new bom calf serum (NBCS)
b/ Method - VERO cells were grown in 75 cm3 cell culture flask and 
then expanded in 'roller’ bottles in G-MEM with 10 % 
NBCS.
- At confluence, the cells were washed with G-MEM 
without calf serum and then infected with 1/20 virus seed 
in G-MEM without calf serum.
- Cells were grown, without calf serum, for 30-35 hours at 
370 c.
- The supernatant was then collected and centrifuged at low 
speed in order to clear cell debris (5000 g).
- The supernatant was centrifuged over a 30 % sucrose 
gradient in PBS at 24 000 rpm (110,000 g) with a SW 28 
rotor on a Beckman centrifuge.
- The pellet was collected and suspended in PBS as the 
purified virus preparation.
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MM9:SDS PAGE ELECTROPHORESIS.
a/ Material: - 'antigen' sample
- sonicator (MSE probe)
- SDS PAGE marker (BCL)
- minigel rack (LKB)
- power pack (LKB, Multiphor II electrophoresis unit)
- minigel plates, spacers(0.75 mm), combs(0.75 mm) and
bull-dog clips (all from LKB).
- Hamilton pipette.
- electrode buffer:
30 g TRIS.
144 g Glycine.
50 mis of20%(w/v) SDS. 
deionised H2O to 10 liters.
- chemicals for separating and stacker gels :
10 % (w/v) SDS
Bis-acrylamide (50:0.235) solution for separator gel: 
50g of acrylamide + 0.235 g of MM- 
methylbisacrylamide
dissolved in up to 100 mis of distilled water
Bis-acrylamide (50:1.33) solution for stacker gel:
50 g of acrylamide + 1.33 g of MM- 
methylbisacrylamide
dissolved in up to 100 mis of distilled water.
1 M Tris buffer pH 8.6 
1 M Tris buffer pH 7 
TEMED
ammonium persulphate (10 mg/ml of deionised H2O) 
freshly made the same day.
- separating gel (for a 15.2 %(w/v) acrylamide gel) 
standard large size gel (for a minigel the quantity are 
divided by 3)
0.3 ml of 10 % (w/v) SDS.
9.5 ml of Bis-acrylamide (50:0.235)
11.2 ml of 1 M tris buffer pH 8.6.
6 ml of deionized H2O.
30 pi of TEMED.
3 ml of ammonium persulphate
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- stacker gel (for a minigel the quantity can be divided by 
5).
0.1 ml of 10 % (w/v) SDS 
1 ml of Bis-acrylamide (50:1.33)
1.25 ml of 1 M Tris buffer pH 7.
6.65 ml of distilled water.
10 gl of TEMED.
1 ml of ammonium persulphate.
- disruption mixture (x4 strengh) :
lml of 20% (w/v) SDS.
1 ml of 1 M Tris buffer pH 7 
1 ml of 8- mercaptoethanol 
1 ml of 50% (v/v) glycerol in H2O 
+ bromophenol blue (until desired colour obtained)
- stain solution:
20 % (v/v) acetic acid 
20 % (v/v) methanol
- destain solution:
10 % (v/v) acetic acid 
20 % (v/v) methanol
- 3 MM Whatman paper, cling film
- gel dryer.
b/ Method: 1. Preparation of the SDS PAGE gel:
- The glass plates, comb and spacers were thoroughly 
cleaned with detergent and distilled water.
-The glass plates were cleaned with 70 % (v/v) alcohol, 
polished with tissue and then the gel plates and spacers 
were assembled together. They were then taped with 
yellow waterproof electrophoresis tape in order to avoid 
leakage. The assembled gel plates were fixed in a vertical 
position with bull-dog clips.
- The separator gel solutions were mixed together in a glass 
vacuum flask, the flask was air-vacuumed and the contents 
pipetted between the 2 plates with a Pasteur pipette until the 
correct level was reached.
- Distilled water or isobutanol was added to the top of the 
gel in order to provide a straight line at the top of the 
separator gel. The gel was allowed to set (a sample of the
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mixed separator gel solution was kept in a container to 
checked when the gel was set).
- The distilled water or the isobutanol was poured off 
completely and the stacking gel solutions were mixed 
together and pipetted over the separator gel.
- the comb was inserted into the liquid stacking gel between 
the two plates and the stacking gel was allowed to set (a 
sample was kept in a small bottle to confirm that the 
stacker had set).
2. Electrophoresis:
- The bottom tank was filled with electrode buffer.
- The gel apparatus was connected to the power pack
- For a minigel, the gel was run at 40 V until the line 
reached the separator gel and then at 120 V to the bottom 
of the separator gel.
- At the end of the electrophoresis, the plates were 
separated and the bottom left-hand comer of the gel was 
cut out to mark the side of the first track. The gel was 
carefully transferred either
1. to the semi dry blotter apparatus (see section western 
blotting MM 10) or
2. placed in stain for 1 to 2 hours on a 'rocker'.
- The gel was then destained with multiple changes of the 
destain solution, placed on a blotting paper and covered 
with cling film, and dried in a gel dryer under vacuum..
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MM10:WESTERN-BLOTTING PROTOCOL.
a/ Material:- SDS PAGE gel (see section MM9)
- semi dry blotter (Novablot 2117-250 LKB, 
electrophoresis transfer kit)
- power pack (LKB Multiphor II, electrophoresis unit)
- forceps, scalpel, ruler and gloves.
- Whatman blotting paper M3.
- nitrocellulose paper: Schueller and Scleicher, 0.2pm pore 
size.
- anode buffer 1: 0.3 M Tris (for 500 ml, 18. 171 gr of
Tris)
20 % (v/v) methanol 
pH 10.4
- anode buffer 2: 0.025 M Tris (for 500 mis, 1.515 gr)
20 % (v/v) methanol 
pH 10.4
- cathode buffer:0.025 M tris
20 % (v/v) methanol
40 mM 6-amino-n-hexanoic acid (for 500 ml, 
2.642 gr) pH 9.4
- Marvel®
- ’first antibody'
- 'second antibody'
-NP 40
- Naphthalene black stain solution.
0.01 % (w/v) naphthalene black powder
20 % (v/v) acetic acid
20 % (v/v) methanol in water.
- Destain solution.
20 % (v/v) acetic acid
20 % (v/v) methanol in water
- 3',3'-Diaminobenzidine (DAB tetrahydrochloride):
- 50 mM Tris (pH 7.6).
- 30 % (v/v) H2O2 (H2O2 supplied as a 30 % solution 
(BDH) and kept at +4 °C)
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b/ Method: 1. Electroblotting transfer of proteins from SDS PAGE gel 
to NTP.
- The SDS PAGE was run (see SDS PAGE section MM9) 
with the different antigen preparations to be tested, or, 
with one antigen with a one-tooth-comb.
- At the end of the electrophoresis, the semi dry blotter was 
cleaned thoroughly with distilled water.
- 6 Whatman blotting papers were soaked with anode 1 
buffer and applied to the anodic plate of the blotter (excess 
of buffer was avoided). The Whatman paper was 0.5 cm 
larger on each side than the NTP sheet.
- In the same way, 3 Whatman papers were soaked with 
anode 2 buffer.
- The nitrocellulose paper was cut out (the NTP was 
handled carefully with scalpel and forceps) of the 
appropriate size (the NTP was 0.5 cm larger on each side 
than the SDS PAGE).
- The NTP sheet was placed on the top of the Whatman 
papers and was humidified by absorption of the anode 2 
buffer from the top Whatman paper.
- The SDS PAGE plates were separated carefully and the 
gel normally adhered to one plate. The gel was covered 
with a dry Whatman paper.The Whatman paper was then 
humidified by absorption over the cathode buffer (the gel 
was not in contact with the cathode buffer).
- The gel, with the Whatman paper on top, was placed over 
the NTP - the bottom left of the SDS-PAGE gel in contact 
with the bottom left of the NTP sheet.
- A 10 ml pipette was rolled over the top Whatman paper 
(to minimise bubbles) and 8 more Whatman papers, 
soaked in cathode buffer, were placed over the top 
Whatman paper.
- The electrotransfer was carried out at 0.8 mA/cm^ (of 
the Whatman paper) for 1 hour at room temperature.
- At the end of the electroblotting, the SDS PAGE was 
stained with coomassie blue to verify that proteins had been 
transferred. If the antigen transfer preparation was a single 
antigen preparation (loaded with a one tooth comb) the 
sides of the NTP paper were also stained in naphthalene 
black solution (1 minute in naphthalene stain, 1 minute in 01
SDS-PAGE destain and 1 minute in water before drying 
between 2 blotting papers) in order to locate exactly the 
location of the transferred proteins (for an example see 
figure R8-1 in Results section: the western blotting study). 
2. ’Western* blotting visualisation.
- The NTP sheet was ’blocked’ for 2 hours in 10 % (w/v) 
Marvel in PBS on a ’rocker’ at room temperature.
- The NTP was washed briefly in PBS.
- It was then incubated with the appropriate dilution of the 
'first antibody’ in 5 % (w/v) Marvel in PBS (e.g 1/1000 for 
a test serum). The incubation was for 2 hours or overnight 
at room temperature on a ’rocker'.
- The NTP was then washed
10 minutes in PBS
2 x 10 minutes in 0.05 % (v/v) NP 40 in PBS 
10 minutes in PBS.
- The next stages of the protocol were done in a dark 
container.
- The 'second antibody' (peroxidase conjugate) was 
incubated with the NTP for one hour at room 
temperature.
- The NTP was then washed
10 minutes in PBS
2 x 10 minutes in 0.05 % (v/v) NP 40 in PBS 
10 minutes in PBS.
- The visualisation of the reaction was done with DAB:
6 mg of DAB was dissolved in 10 mis of 50 mM Tris 
(pH 7.6) and filtered through Whatman 1 paper.
Just before development, 10 |il of 30 % (v/v) H2O2 was 
added. The blot was developed on a 'rocker', at room 
temperature, in a dark container. The reaction was stopped 
with PBS [Harlow E. et al,1988].
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MM10’: DOT BLOT FOR PROTEIN CONCENTRATION.
a/ material - Bovine serum albumin (BSA):
lmg/ml in PBS + 0.01 % azide, kept at + 4° C.
- Nitrocellulose paper: Schueller and Scleicher, 0.2pm pore 
size.
- Naphthalene black stain solution.
0.01 % (w/v) Naphthalene black powder
20 % (v/v) acetic acid
20 % (v/v) methanol in water.
- Destain solution.
20 % (v/v) acetic acid
20 % (v/v) methanol in water
- 96 Microtiter plate.
b/ Method
A microtiter plate is labelled in order to allocate one row of this 
microtiter plate to each protein solution to be tested. The first row is 
allocated to the standard solution (BSA). Ten pi of PBS are pipetted 
into each necessary well. Ten pi of the standard solution of BSA 
(lmg/ml) are pipetted into the first well of the microtiter plate and 
double dilutions of this standard solution are made along the first row 
of the microtiter plate. Then the solutions to be tested are processed 
similarly, each solutions requiring a row. Two pi from each well are 
then spotted on a nitrocellulose paper so as to compare the different 
protein solutions (each solutions requiring a line commencing with the 
more diluted dilution of the solution). The different dilutions of the 
protein solutions are allowed to absorbed unto the nitrocellulose paper 
for 1 minute. The nitrocellulose paper is then stained for one minute in 
the stain solution destained for 1 minute in the destain solution and 
washed for 1 minute in water. The nitrocellulose paper is then dried 
between 2 blotting papers and the concentrations of each protein 
solutions calculated by comparing the known concentration of the 
standard solution (BSA= lmg/ml, 2 pg of BSA correspond to the first 
spot)
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MM11: T CELL PROLIFERATION ASSAY.
a/ material- sterile plastic universal.
- heparin preservative-free (Leo Ltd, 1 million unit/ml).
- venepuncture material (butterflies, micropore tape, 
scissors, swabs, tourniquet and labelled universal containers 
with heparin).
- sterile Pasteur pipette.
- sterile 10 ml centrifuge tubes (white cap, V bottom).
- a set of multidispensing pipettes (Gilson pipettes)
- sterile tips for Gilson pipettes
- electric multidosage pipette.
- test tube holders (one for universal and one for 10 mis 
tubes)
- Class H hood with 10 mis sterile pipette and automatic 
dispensing pipette system.
- Ficoll- Hypaque® (Pharmacia), sterile.
- Hank’s medium, pH 7.4, sterile, for diluting the blood and 
washing the mononuclear cells.
- swing-out centrifuge for 10 ml and universal tubes
- glutamine solution (x 100): 29.2 mg/ml of double distilled 
water filtered and sterilised.
The solution was aliquoted and stored at - 20 °C 
The final concentration (x 1) was 2 mM
- Penicillin / streptomycin solution (x 100):
The final concentration (xl) was 5 UI/ ml of 
penicillin and 75 pg/ml of streptomycin.
e.g in the laboratory the Penicillin/streptomycin 
solution was prepared as follows:
In 400 ml of sterile deionized distilled water 
Crystapen (1 million UI/ vial) 2 vials 
Streptomycin (lg/vial): 3 vials
The solution was aliquoted and stored at - 20 °C
- hepes solution (x 100): 292 mg/10 ml of deionized 
distilled water
buffered to pH 7.4 , 
filtered, sterilised.
The solution was kept at + 4 °C
The final concentration (x 1) was 10 mM
- B-mercaptoethanol solution (B-MCE): (x 100 solution) 04
B-MCE (Sigma) special cell culture grade, was 
kept at + 4 °C aliquoted e.g 100 pi aliquots. An 
aliquot was used only once.
5 pi of B-MCE were added to 15 ml of PBS 
The solution was filtered, sterilised and kept 
at + 4 °C for 3 weeks.
- T cell medium: filtered sterilised.
for 20 mis
RPMI 1640 (Gibco) 19.2 mis
glutamine solution (xlOO) 200 pi
Penicillin/Streptomycin (xlOO) 200 pi 
Hepes (xlOO) 200 pi
B-MCE solution 200 pi
- Trypan blue solution:
Solution A: 0.2 % (w/v) + azide 
Solution B: 4.25% (w/v) + azide.
1/2 working concentration: 2 volumes of solution A 
+ 0.5 volume of solution B. Add 10 pi of the cells 
solution for counting to the same 10 pi volume of 
trypan blue solution.
- sterile 96 wells plates (U bottom) with sterile lids.
- sterile Eppendorf tubes for dilution of antigens and 
mitogens.
- Eppendorf racks
- antigen preparation : diluted in T cell medium.
- mitogen preparation : diluted in T cell medium.
- 3h thymidine(methyl-3H), (Amersham) , 1 m Curie/ml.
- cell harvester with vacuum pump on line (Bacon, 
Tunbridge)
- glass fiber paper (Ilacon).
- scintiUation fluid : home-made for 4 liters
2666 ml xylene (kept in cold room)
1333 ml triton xlOO
0.48 g POPOP (1.4 Di-2-5 phenyloxazoly-Benzene) 
24 g PPO (2.5 -Diphenyloxazole)
- scintillation vials and pico-vial
- forceps and scalpels for radioactive work.
- B counter A300 Canberra Packard liquid scintiBation 
fluid.
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b/ Method: (see figure MM11-1 for outline of the technique)
- Peripheral blood was collected by venepuncture in a 
sterile plastic universal with preservative-free heparin (20 
units/ml of blood) and used within 4 hours.
- The blood was mixed with the heparin and left for at least 
30 minutes at room temperature and then diluted 1 in 2 
with warm (18-22 °C) Hank’s medium. The method 
described was for 10 mis of blood, diluted 1 in 2 to obtain 
a Hank's-blood mixture of 20 mis and overlaid on the
: in each labelled 10 ml centrifuge tube, 3 ml of ficoll- 
hypaque was overlaid with 7 mis of blood. Thus 3x10 mis 
centrifuge tubes were required.
- The tubes were centrifuged at 800 g for 20 minutes (18­
22 °C) (the centrifuge rotor was slowly accelerated and 
decelerated).
-Mononuclear cells were recovered at the interface with a 
sterile Pasteur pipette. The upper plasma layer was not 
removed before recovering the mononuclear band. The 
mononuclear cells were collected from the periphery and 
cross sectional area of the centrifuge tube. From each of 
the 3 tubes, they were transferred into 3 respective new 10 
ml tubes.
- Mononuclear cells were washed with warm Hank's 
solution at 800 g for 10 minutes. After centrifugation, the 
supernatant was discarded and the pellet of cells was 
resuspended gently and the contents of the 3 tubes 
transferred to 2 tubes (one tube was discarded).
- The cells were washed a second time with warm Hank's 
solution, at 400 g for 10 minutes and again the pellet was 
resuspended gently and pooled in one tube.
- After another washing with Hank's solution at 400 g for
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Figure MM11-1: Outline of the T cell proliferation assay
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10 minutes, the cells were resuspended in one ml of T cell 
medium containing 10 % of sterile serum (for human 
studies, the serum was AB+ from human source or FCS).
- The cells were then counted with the Trypan blue solution 
and only live mononuclear cells were taken into account 
(normally more than 90% of the mononuclear cells were 
viable).
- The cells were resuspended to a final concentration of 
2.105 per 100 jliI (2.10^ per ml) in 10 % AB + T cell 
medium.
- 100 pi of the cell suspension was added to predetermined 
wells of a 96 well plate.
- 100 pi of antigen/mitogen or medium dilutions were 
added to each well, in triplicate for each test sample, in 
accordance with a preorganised pattern (for an example see 
figure MM 11-2)
-The 96 well plate was then incubated at 37 °C in a 5 % 
CO2 atmosphere for 3-7 days.
- 0.5 p Ci thymidine was pulsed into each test well 18 
hours before the harvesting: the thymidine was diluted 
in T cell medium in 20 pi of T cell medium per well.
-After 18 hours, the cells were harvested onto glass fiber 
paper.
- Each glass fiber paper was placed into a plastic pico vial 
which was itself placed into a glass vial scintillation fluid. 5 
mis of scintillation fluid was added to each pico vial.
- The vials were then counted in a B counter and the results 
analysed.
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Figure MM11-2: T cell proliferation assay pattern of the 96 well 
plate used for the ’NTP and T cell proliferation 
assay. All test samples were done in triplicate.
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MM12: NITROCELLULOSE T CELL TECHNIQUE
PRQ-T.Q.C-Q.L,
a/ Material (in chronological order as used)
- Antigen (Ag) preparation: the concentration of proteins 
was necessary for the calculation of the protein load on the 
gel. The loading concentration was determined as a 
function of the protein concentration of the Ag preparation 
and of the number of proteins in the antigen preparation 
(e.g mycobacteria preparation was a very heterogeneous 
antigen preparation in comparison with purified tetanus 
toxin).
- disruption buffer for SDS PAGE (see section SDS 
PAGE, MM9).
- solutions for the gel casting ( see section SDS PAGE).
- spacers and comb (0.75 mm wide) cut for this 
experiment.
- gel apparatus (minigel LKB®).This technique was carried 
out using a minigel and therefore all the data and 
calculations will be standardised for this type of gel.
- power pack for SDS PAGE and for the electroblotting 
(see corresponding sections).
- nitrocellulose paper (NTP): (Shueller and Sleich, porosity 
0.2 pm).
- semi-dry electroblotter apparatus (Novablot® 2117-250 
LKB electrophoretic transfer kit)-with material for 
blotting: Filter papers, anodes (1 and 2) and cathode buffer 
and NTP (see Western Blotting section MM10).
- ruler and pencil.
- sterile scalpels (at least 2 or 3)
- sterile forceps (at least 2 pairs)
- naphthalene black solution, with destain, water and filter 
paper to dry stained NTP.(see Western Blotting section 
MM10)
- polystyrene board with needles to dry the nitrocellulose 
paper for blotting experiments.
- sterile square dishes for tissue culture
- vacuum line with clean Pasteur pipette.
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- fridge or cold room (if possible near the cell culture lab) 
where a minifuge for Eppendorfs tubes (MSE 
microcentrifuge at 10,000 g) was placed and where NTP 
sheets pined over the polystyrene board were dried.
- Class II hood with at least two power points available.
- Glass vials with lids(Clear neutral glass vials Adelphi® 
Tubes, Haywards Heath, with 15.5 mm white screw caps).
- Magnetic fleas: one magnetic flea was placed inside each 
glass vial (magnetic followers for oxygen electrode Rank 
Bros Ltd, Cambridge). The glass vials with the magnetic 
fleas were autoclaved.
- sterile Pasteur pipettes.
- DMSO : 100ml bottle (BDH), kept at + 4° C, lid tightly 
closed.
- a set of multidispensing pipettes e.g Gilson pipettes.
- test tube vortexer (whirlmixer).
- peristaltic pump (Minipuls 2, Anachem)
- silicone plastic tube to fit the peristaltic pump:
The 2 ends were wrapped in foil and the entire tube then 
autoclaved in a plastic beaker covered with foil.
- a stand, small enough to fit inside the hood, to hold the 
silicone tube.
- magnetic stirrer with plug
- filter-sterilised 0.05 M carbonate buffer Ph 9.6 in plastic 
universal. The recipe of the carbonate buffer was as 
follows [Hudson L. et al, 1989]:
Stock A: 0.2 M anhydrous sodium carbonate, Na2CO3 
2.12 g/100 mis
Stock B: 0.2 M sodium hydrogen carbonate 
1.68 g/100 mis
For pH 9.6, 13 mis of solution A and 37 mis of solution B 
were added to 150 mis of distilled water and then the pH 
was checked.
After dilution of 1/4 a solution of 0.05 M was obtained.
- autoclave tape.
- Eppendorfs 2 sorts: 1) 400 pi for aliquots (the number 
needed was calculated in function of the number of bands ; 
in general, 10 aliquots/bands were sufficient)
2) 1.5 mis for washing
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Both types of Eppendorfs were autoclaved.
- Eppendorf racks (2 or 3 depending on the number of 
aliquots)
- RPMI 1640 for washing.
- minifuge(s) (12 Eppendorfs were centrifuged at the same 
time)
- test tube support with teeth (Endicott Seymour, Ann 
Arbor, Michigan, U.S.A.)
- T cell medium with penicillin /streptomycin, hepes pH 7.4 
, glutamine and P-mercaptoethanol (if used in the T cell 
medium), cell culture grade e.g from Sigma (see section 
MM-11).
2. METHOD
2 techniques were used - the spotting technique and the western blotting 
techniques. These 2 techniques differed only in the way the antigen(s) 
was applied to the NTP but both techniques were the same after this 
stage. In the protocol below, the sign * marks the stage at which the 2 
techniques begin to be identical and remain so until the end of the 
procedure.
A/ SPOTTING TECHNIQUE:
- Antigen preparation: protein content was calculated by 
the dot blot technique ( with albumin solution of lmg/ml as 
standard) .
- A piece of NTP sheet (4 x 4 cm ) was prepared.
- Rectangles of 20 mm2 (5x4 mm) were drawn using a 
fine pencil and a ruler on the NTP. The number of these 
rectangles depended on the number of antigen-NTP 
particles required.
See figure MM12-1
Rectangles were labelled for the corresponding antigen.
At least one square was needed for the negative control: 
e.g PBS spotted on NTP / buffer of the antigen preparation 
without antigen spotted on NTP.
112
Negative
Figure MM12-1: Spotting 'nitrocellulose technique'. Rectangles 
corresponding to the different antigens to be prepared are drawn on 
nitrocellulose paper.
- The NTP was then soaked (only one side) with PBS to 
humidify . The NTP was taken out of the PBS when its 
colour had changed (thus the NTP was not be completely 
covered with PBS).
- The NTP was then dried in order to dispose of the excess 
PBS.
- 10 gg of antigen were spotted on each rectangle. If the 
concentration of the Ag preparation was not very high, 
great care was taken to avoid spillage over the boundaries 
of the rectangle; for example a 20 mm2 rectangle received 
easily 5 to 10 gl corresponding to an Ag preparation of a 
concentration of 2 to 1 mg /ml of proteins respectively. 
Below 1 mg/ml, the volume of Ag preparation required to 
achieve 10 gg per rectangle was too great to avoid 
spillage. In this case the Ag was spotted over a period of 
time to allow absorption of the Ag solution by the NTP.
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- The NTP was dried at + 4° C using a polystyrene board 
with needles:
see figure MM12-2.
NTP soaked with PBS
NTP sheet fixed on polystyrene board 
with needles and dried in air
Figure MM12-2: The nitrocellulose paper where antigen have been 
spotted is dried on a polystyrene board.
- When the NTP was completely dry, the NTP was placed 
on a sterile square petri dish in a hood flow cabinet.
- Each rectangle was then processed separately, starting 
with the negative control. Each rectangle was cut out and 
then cut into small pieces of 1 to 2 mm square using sterile 
forceps and scalpels.
-*** AT THIS STAGE THE 2 TECHNIQUES (SPOTTING AND
BLOTTING BECOME IDENTICAL)
-The pieces were transferred with the tip of a sterile 
Pasteur pipette into a labelled (DMSO can erase marker
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ink) sterile glass vial, which contained a sterile magnetic 
flea.
see figure MM12-3.
Figure MM12-3: The pieces of nitrocellulose are transferred into 
sterile glass vials.
- All rectangles were processed in the same way and 
transferred into their corresponding labelled glass vials.
- 500 pi of DMSO were added (the quantity of DMSO 
depended on the quantity of NTP in the vial- see the section 
results)
- the vials were closed with sterile lids.
- the NTP pieces dissolved in the DMSO and a colourless 
liquid was left.
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When the pieces had disappeared, the DMSO was stirred 
for 30 seconds to 1 minute with a magnetic stirrer. A 
constant slow speed was maintained.
- the glass vials were left at room temperature for one hour 
and were stirred every 15-20 minutes.
- after this incubation period, sterile condition were strictly 
adhered to (the DMSO kills most, if not all germs and 
therefore after this stage the preparation was considered 
sterile).
- under the flow cabinet, the peristaltic pump was fitted 
with the autoclaved siliconised plastic tube hanging from 
the stand (care was taken to keep the 2 ends of the tube 
sterile as they hung)
- One end of the tube was submerged in the filtered 
sterilised carbonate buffer contained in a sterile plastic 
universal beaker.
The plastic universal was taped inside a small beaker to 
avoid accidental spillage.
- The glass vial was taped at the middle of the magnetic 
stirrer.
- The magnetic stirrer was set at a fast speed ; this speed 
was kept constant for each vial and between vials in order 
to standardise the method.
- The carbonate buffer was then added to the vial at a speed 
of 0.8 ml/minute through the silicone tube using the 
peristaltic pump.
see figure MM 12-4
- 750 pi were added if the original volume of DMSO was 
500. For an original volume of 250 pi, 500 pi of carbonate 
buffer were sufficient.
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Magnetic stirrer 
at high speed
Figure MM12-4: System for dispensing the carbonate buffer into the 
vials containing the pieces of nitrocellulose.
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- Small particles of NTP precipitated and the liquid in the 
vial became cloudy.
- The liquid containing the NTP particles was transferred 
with a sterile Pasteur into a sterile labelled 1.5 ml 
Eppendorf.
- The Eppendorf was centrifuged at 10,000 g for 10 
minutes
- The NTP particles formed a pellet at the bottom of the 
Eppendorf tube. The colourless supernatant was sucked up 
carefully using a sterile Pasteur pipette connected to the 
vacuum line.
- 50 jil of RPMI was then added to the Eppendorf tube.
- The closed Eppendorf tube was then "run to, missing the 
fro" 5-10 times over the teeth of the test tube support. This 
helped to resuspend the particles in the RPMI.
- 1 ml of RPMI was then added and centrifugation, 
washing, resuspension were repeated 3 times but, unlike the 
first centrifugation, the next centrifugations were done at 
+ 4° C.
- After the last washing, the particles were resuspended in 
complete T cell medium instead of RPMI.
- Normally 20 mm2 NTP was resuspended in 1 ml of 
complete T cell medium and aliquoted in 50 ml aliquots.
- The aliquots were stored at - 70° C and could be kept for 
months.
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B/ THE BLOTTING TECHNIQUE.
The Ag in this technique was run on a SDS PAGE gel and then blotted 
onto NTP by electroblotting with a semi dry blotter. In this protocol, 
the details relevant to the NTP T cell technique only will be described.
- A comb was cut out as a function of the template of the 
experiment.Usually, 3 tracks for Ag were needed as well as 
the tracks for the marker.
1. one track for the negative control: disruption mixture 
alone
2. one track for the Ag to be tested
3. one track for an Ag known to produced a positive 
response in an available control (in our case tetanus toxin 
or adenovirus).
The tracks corresponding to the Ag measured 12 mm in 
width.
The tracks corresponding to the marker measured 3 mm 
only.
Figure MM12-5: Template of the comb used for loading the antigens 
on the SDS-PAGE gel
- The loading concentration varied with the antigen 
preparation and the number of proteins bands recognised 
on a gel. Normally the loaded amount of protein for a
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single band was between 1.5-3 p,g, for a 12 mm minigel 
track (see figure MM 12-6).
- The gel was run (see SDS PAGE section MM9) 
and transferred onto NTP by electroblotting (see 
electroblotting section MM 10)
- During the preparation of the electroblotting, specific 
precautions and preparations were followed:
1. When the 2 gel plates were separated after 
electrophoresis, the SDS page gel was normally stuck to 
one of the plates. A dry sheet of Whatman paper was then 
applied to the gel.
2. The tracks of the SDS PAGE gel were located on both 
sides - top end and bottom end - of the gel. This was 
straightforward with the top end as the indentation of the 
comb was still visible in the stacking part of the SDS PAGE 
gel. At the bottom end, the boundaries of the tracks were 
guessed by projection from the top end of the tracks. A 
transparent ruler was used on the assumption that the tracks 
ran perpendicular to the gel.
3. When the limits of the tracks were established, holes in 
the Whatman sheet were made, with a small needle, 
corresponding to the 4 comers of the track.
4. The Whatman paper was then soaked in cathodic 
electroblotting buffer (the SDS PAGE must not be in 
contact with this buffer) and then the Whatman paper with 
the SDS PAGE gel was applied to the NTP.
5. The holes, already made in the Whatman paper, were 
used as a guide to mark the peripheries of each track on the 
NTP sheet. Again a small needle was used for this.
6. The end of the electroblotting procedure was similar to 
standard electroblotting method.
- After transfer, the NTP was carefully cut to give vertical 
lanes measuring 6 mm of width spanning the track of the 
sample. The NTP on both sides - which were labelled - was 
then stained (3 mm each side of the lane) in order to locate 
the proteins of interest.
See figure MM 12-6
- 2 mm bands were then cut out from the 6 mm width lane. 
Each bands corresponded to a region of the track to be 
tested as a 'specific antigen’. 120
- Each band was then processed in a similar fashion to the 
rectangles of the spotting technique. The quantity of DMSO 
necessary to produce an optimum precipitation at the end 
of the procedure, was 250 p.1 for each 12 mm2 band. 
However, a mock experiment was run to determine this 
quantity (see the spotting technique result section).
12 3 4
Figure MM12-6: Blot of Tetanus Toxin (TT) used for the 
preparation of nitrocellulose particles (NCP) coated with TT. TT 
was transferred on nitrocellulose (Ntcp) from an SDS minigel. A 
comb measuring 12 mm in width was used to load the proteins on 
the gel. The Ntcp was then carefully cut to have vertical lanes 
measuring 6 mm of width spanning the track of the sample. The 
Ntcp on both sides was then stained (3 mm each side of the lane) 
in order to locate the proteins of interest. Lane 1 corresponds to 
the track where 3 p.g of TT were loaded, lane 2 had 1.5 pg of TT 
loaded. Lane 3 corresponds to the stained molecular weight 
marker. Lane 4, where only loading buffer was run, was used for 
the preparation of the negative control.
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MM13: STATISTICS USED FOR THE WESTERN 
BLOTTING CLINICAL STUDY AND THE T CELL 
PROLIFERATION ASSAY.
Western blotting clinical study.
Three groups of individuals were compared (patients suffering 
from MS, neurological controls and normal controls) (see section MM- 
for details).
a. .Mean concentration of serum IgG (+/- standard deviation (SD) =
V Lx2 - (Zx)2/n where n is the number of individuals in each group ) 
n-1
were calculated for each groups for comparison.
b. The number of individuals with autoantibodies against human brain 
vessels were recorded and the percentage calculated. These results were 
compared between the 3 groups of individuals using a Chi square test. 
Yates' correction for continuity was applied when any cell in the 
calculation contained a value less than 10 [Swinscow T.D.V., 1976].
T cell proliferation studies.
Stimulation was measured in triplicate for each test sample and the 
count per minute (c.p.m) as well as the disintegration per minute 
(d.p.m.= c.p.m x coefficient of efficiency of the machine for the test) 
were recorded.
Results were calculated as :
1. Mean d.p.m +/- standard error with the corresponding 95% 
confidence interval.
1. Stimulation indices (SI) which was the mean d.p.m of the test with 
stimulant / mean d.p.m of test in T cell medium for a classical T cell 
assay and was the mean d.p.m of the test with stimulant on 
nitrocellulose paper particles (NCP) / mean d.p.m. of the test with 
MOCK-NCP (NCP without antigen ) for the NTP T cell assay (see 
section MM-12 for more detail).
122
MM14:M¥ELIN PREPARATION:
The myelin preparation method was based on a protocol devised by Dr 
S. Gillepsie (University of Stirling) [Gillepsie C.S. et al, 1989]:
a/ material:
- Transport medium: sterile Hank's medium pH 7.4 
with 250 mM sucrose,
10 mM Hepes, pH 7.4 
3mM DTT
- 0.25 M sucrose solution: sterile 
with 10 mM hepes, pH 7.4
3 mM DTT.
- 0.85 M sucrose solution: sterile 
with 10 mM Hepes
3 mM DTT.
- Osmotic shock solution: sterile 
deionised water
with 3 mM DTT.
- Storage solution: sterile 
osmotic shock solution 
with leupeptin 0.5 jxg/ml,
EDTA 37 jLtg/ml, 
pepstatin lgg/ml 
aprotinin l(ig/ml
- sterile scalpels and forceps.
- sterile petri dishes.
- ultracentrifuge at + 4 0 C (Beckman).
- 2 x 50 mis centrifuge tubes, sterile.
- rotating homogeniser.
b/ protocol:
- The brain sample was transported in cold transport 
medium and keeping all manipulations sterile washed 2 or 
3 times with transport medium (the meninges, if present, 
were removed).
- The sample was weighed and then placed, in a sterile petri 
dish, in ice cold 0.85 M sucrose solution to make a 
homogenate of 5 % weight/volume of solution (this
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proportion gave the optimum result). The total volume 
necessary for each preparation was 30 mis.
- The brain was cut into small pieces with a scalpel and a 
forceps and homogenised with a rotating homogeniser.
- The homogenate was split up into two 50 mis centrifuge 
tubes and overlaid with the 0.25 M sucrose solution.
- The tubes were centrifuged at 70 000 g for 90 minutes at 
+ 4°C.
- Myelin was recovered at the interface between the 0.25 M 
sucrose solution and the 0.85 M solution was collected and 
subjected to an osmotic shock by resuspension in 10 
volumes in osmotic shock solution and then centrifuged for 
30 minutes at 23 000 g, at + 4°C.
-The pellet was then subjected to 2 more osmotic shocks.
- The pellet was then frozen at - 70 0 C in storage solution 
until further analysis.
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MM15 BRAIN VESSELS PREPARATION.
The technique presented below is a modification of the method 
described by Brendel et al [Brendel K. et al, 1974]. Different 
modification of this technique as well as other techniques of purification 
of brain vessels were investigated and found to be less successful, 
a/ Material:
- transport medium: Hank's medium
with 15 mM glucose
10 mM hepes (pH 7.4)
pH adjusted to 7.4 with 1 M NaOH solution
autoclaved
- purification medium: transport medium
with 5 Ul/ml of sterile heparin (Leo Ltd)
Penicillin/ streptomycin filtered 100 X solution 
Fungizone sterile 100 X solution (Gibco)
-PBS
- scalpels and forceps
- petri dishes
- Pasteur pipettes.
- large and small ice polystyrene boxes.
- stand for different mesh sieves with their respective
holders.
- mesh sieves (John Staniar & Co, Manchester)
2 types of sieves are needed: - 210 pm nylon mesh sieve 
-150 pm nylon mesh sieve
- holders for the sieves: home-made holders were the most 
practical, for example the bottom of a plastic beaker 
(beakers of different sizes and circumferences 
provided the range needed) were cut in order to obtain 
tubes where a mesh sieve can be taped at one end - the 
system served as a cylindric filter (see figure MMl5-2 for 
representation). The holders with the sieves were 
autoclaved in foil at 10 p.s.i.
- beakers for collection of the filtrates through the sieves.
- rotating homogeniser
- homogeniser pestle piston and corresponding glass tubes 
2 types were needed: one loose pestle piston of around 350 
pm of aperture and one tight pestle piston of around 200 
pm of aperture. 25
- glass universals
- plastic universal tubes for centrifugation (V bottom).
- inverted microscope and light microscope.
- Eppendorf tubes for storage
Cut out base 
of beaker
Nylon mesh sieve 
attached over base 
of beaker with 
autoclave tape
Tape
Sieve
Figure MM15-2: Representation of the holders for the sieves.
b/Method :See Figure MM 15 >1 for general overview of the method. 
All procedures were carried out in sterile and cold 
conditions.
- The post mortem brain sample was transported to the 
laboratory in ice cold transport medium and washed in a 
petri dish with cold PBS, 3 times.
- The meninges and the surface vessels were stripped off 
the brain sample and discarded.
- The brain sample (about 10 grammes) was placed in cold 
purification medium and cut into small pieces of about 2 
mm3.
- The pieces were then homogenised in cold purification 
medium with 20 up-and-down strokes of the loose pestle 
piston. The first homogenate was homogenised a second
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HOMOGENISATION 
20 strokes/100g 
300 pm clearance
Post mortem 
brain sample 2mm3 pieces
o Q O
Filtration through 
a 210pm mesh sieve
HOMOGENISATION 
20 strokes/100g 
200 pm clearance
Collection of the 
trapped vessels
Filtration through a 
150 pm mesh sieve
Collection of the 
trapped vessels
Centrifugation 
10 mins. 1000g
VISUALISATION 
Inverted microscope 
cytocentrifuge slide 
G transpeptidase 
Factor 8 SDS Page 
Polyclonal antisera
Storage
Figure MM15-1: Overview of the brain vessel purification method.
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time with 20 up-and-down strokes of the tight piston pestle 
at 100 circles/minute.
-The homogenate was then filtered through the 210 pm 
mesh sieve (see Figure MM15-3). The filtrate was kept, 
homogenised again and filtered - if diluted with the 
purification medium - through a 150 pm mesh sieve. 
However, the principal source of purified brain vessels was 
from the trapped material on the 210 pm sieve mesh. The 
material was collected with a Pasteur pipette and medium 
and then homogenised with 20 up-and-down strokes of the 
tight pestle piston at 100 circles/minute.
- This homogenate was filtered through a 150 pm sieve.
- The trapped brain vessels were collected on the sieve.
- The yield and purity of the preparation were checked by 
light microscopy.
- The vessels were processed as desired. For antigen 
studies, the vessels were centrifuged for 10 minutes at 
lOOOg and the pellet stored at - 70 °C.
HOMOGENISATION FILTRATION
Figure MM15-3: Homogenisation and filtration of the brain sample.
MM16:HUMAN BRAIN ENDOTHELIAL CELL CULTURE. 
The culture of human brain endothelial cells was attempted. The
optimal method of growing such a cell line is described below and 
discussed in the Result and Discussion sections. This method is derived 
from published work by groups who have claimed to have succeeded in 
growing human brain endothelial cell lines [Vinters H.V. et al, 1987] 
[Gerhart D.Z., 1988] and from review on the culture of microvascular 
endothelium [Pearson J.D., 1990].
a/ Material: - scalpels, forceps, petri dishes, Pasteur pipettes.
- all the material described in the Section on brain vessel 
preparation (MM 15).
- astrocyte conditioned medium from U 138 astrocyte 
medium [Clapham P.R. et al, 1989] or GO-C-CM 
conditioned medium [Frame M.C. et al, 1984](European 
cell culture collection) or from normal astrocytes grown in 
culture could provide the source of growth factor (see 
section astrocyte culture).
- Endothelial Cell Growth Factor (E.C.G.F.) (Sigma)
Stock solution is 3 mg/ml in water or medium and can be 
stored at - 20 °C.
- selenium/transferrin/insulin media supplement (Sigma) 
stock (25pg/25 mg/25mg, respectively) is stored desiccated 
at -20°C. The stock is diluted with 5ml distilled water 
(DDW) then with 45 ml DDW. It is left for 1 hour at room 
temperature. The 50 mis can be diluted to a final 
concentration (5pg/ml, 5 pg/ml,5ng/ml respectively) into 5 
liters of medium. After reconstitution, it should be stored 
at + 4 °C.
- human brain endothelial cell culture medium:
10 % foetal calf serum (heat inactivated) or human serum 
10 % new bom calf serum (heat inactivated)
20 mM Hepes 
Glutamine 4 mM 
Selenium/T ransferrin/Insulin 
Heparin 2 IU/ml or 20-40 pg/ml 
ECGF 20 pg/ml 
40 % ACM.
in Iscove/F12 Ham’s medium (Gibco)
- collagenase (Sigma). 129
- 25 cm^ and 75cm3 cell culture flasks.
b/ Method:- The brain sample was obtained from a temporal
lobectomy and transported to the laboratory in cold sterile 
Hank's buffer, pH 7.4 with Penicillin /Streptomycin and 10 
% NBCS.
- The brain was washed 3 times in PBS. The pia matter and 
the associated vessels were removed with a forceps and the 
grey and white matter of the brain sample was placed in 
'vessels purification medium' (see section on vessels 
purification).
- The purification of the vessels was done exactly as 
described in the section "Brain vessels preparation".
- When the vessels were collected from the 150 pm mesh 
sieve , they were centrifuged at 500 g, 5 minutes) and 
resuspended in 1ml of warm Ml99 medium containing 1 
mg/ml of sterile collagenase solution.
- The vessels were incubated at 37 °C in collagenase 
solution for 5 to 15 minutes. The vessels were visualised by 
microscopy.
- At the end of the incubation the vessels were resuspended 
in Ml99 with 10 % NBCS and centrifuged at 500 g for 5 
minutes.
- The vessels were resuspended in human brain endothelial 
cell culture medium and seeded, if possible, 5-10 
fragments into a fibronectin coated cell culture petri 
dishes.
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MM17: UMBILICAL CORD ENDOTHELIAL CELL 
CULTURE.
This technique was provided by Dr Jeremy Pearson (Clinical Research 
Center, Harrow).
a/ Material: - cannulation: sterile Luer female to Luer male adaptors, 
product n° 700/180/700; distributor HR Howell.The 
adaptors were scored with a hot needle, in the middle all 
around their periphery. This helped to fix the ends of the 
cord to the adaptor with a string (see figure MM17-1).
String
Figure MM17-1: Representation of the adaptor for cannulation of the 
umbilical cord vein
- Hank’s buffer + bicarbonate (pH 7.4) 
-PBS
- scalpels, scissors and forceps.
- paper towel, and cling film
- crocodile clips.
- syringes
- collagenase (Sigma)
- culture medium: Medium 199 (Gibco )
10 % new bom calf serum (NBCS)
10 % foetal calf serum (FCS)
10 mM Hepes
2 mM Glutamine
Penicillin / streptomycin / Fungizone 
4 UI/ ml of Heparin
20 |ig/ml of endothelial growth supplement(ECGF). 
ECFG is optional for the first passage.
- 25 cm3 and 75cm3 cell culture flasks
- 0.2 % (w/y) gelatin (Sigma) in PBS, kept at +4 ^C.
- conical centrifuge tube (Falcon).
b/Method: - The umbilical cord was collected in a sterile container 
from the maternity ward (cords less than 36 hours old can 
be used). The cord must be kept in Hank's buffer at + 4 °C.
- In the laboratory, a board platform covered with foil was 
placed inside a cell culture hood and the preparation of the 
cell culture was carried out on this board.
- The 2 ends of the cord were cut in order to trim the 
extremities of the cord. All areas with clamp marks were 
cut off.
- The 2 ends of the cords were cannulated with the adaptors 
through the umbilical vein. To do so, all fibrous processes 
around the 2 extremities of the umbilical vein were 
dissected out. The adaptors were then securely fixed to the 
cord with a string which was guided along the scored line 
(see figure MM17-2).
- The umbilical vein was flushed with warm PBS or Hank's 
buffer (about 20 mis). All the clots were expelled (when 
only one end of the cord was cannulated). All leaks were 
stopped with sterile crocodile clips (see figure MM17-2). 
The 2 ends-cannulations were connected to 2x10 mis 
syringes.
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Board covered with foil
Figure MM17-2: Representation of the umbilical cord vein with the 2 
cannulated ends connected to the syringes.
- The buffer was then expelled from the cord
-10 mis of 0.5 mg/collagenase in warm medium 199 + 
bicarbonate without serum was added with a syringe inside 
the umbilical vein.
- The cord was wrapped in cling film and left in the 
incubator at 37 °C. The incubation time was between 5 to 7 
minutes (longer increased the contamination with smooth 
muscle cells).
- The cord was flushed and the contents collected in a 
conical centrifuge tube. 10 to 20 mis of Hank’s buffer were 
added to the cord and flushed again 3 or 4 times by moving 
up and down the piston of the 2 syringes. Then the Hank’s 
buffer was added to the centrifuge tube.
- The tube was centrifuged at 250 g for 10 minutes.
- The pellet was washed once with Hank's buffer, 
centrifuged at 250 g for 10 minutes.
- The pellet was then resuspended in culture medium and 
incubated in a 25 cm3 cell culture flask which may have 133
been previously coated with 0.2% gelatin. The content of 
one cord were grown in one 25 cm3 cell culture flask
- Coating of the cell culture flask with gelatin (optional): 
0.2% gelatin was prepared in sterile PBS and incubated in 
the cell culture flask for 30 minutes at 37 ^C.
The cell culture flask was then washed twice in PBS.
The gelatin coated flask could be stored about a week at + 
4°C. Just before culture, the flask was washed twice with 
warmed PBS.
- When the endothelial cells had reached confluence they 
were passed with trypsin-EDTA, washed once in Hank's 
buffer and split 1 in 3.
134
MM18: CULTURE OF HUMAN ASTROCYTE.
Reference: Bama and colleagues [Bama BP, 1985].
a/ Material- transport medium:
RPMI 1640 
10 % NBCS
Penicillin / streptomycin
- astrocyte cell culture medium:
RPMI 1640 
10 % FCS 
2 mM glutamine 
Penicillin / streptomycin.
b/ Method - The brain sample was collected at neurosurgery (glial 
tumor removal or operation for vascular tumor or 
temporal lobectomy for intractable epilepsy).
- The sample was transported in cold transport medium to 
the laboratory and placed in a petri dish.
- The brain sample was washed 3 times in PBS, the pia 
matter and the associated vessels are removed with a 
forceps.
- The brain sample was placed in astrocyte cell culture 
medium, minced and then flushed with a syringe through a 
small gauge needle.
- The pieces were cultured in astrocyte cell culture medium 
until some cells were seeded at the bottom of the tissue 
culture dish.
- The floating elements were then discarded and the cells 
were allowed to reached confluence
- They were split (1 in 2) with trypsin-EDTA after one 
wash (centrifugation 800g 10 minutes).
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MM 19 : Y -GLUTAMYL TRANSPEPTIDASE ASSAY.
This method has been described by L.E. DeBault and P.A.
Cancilla [DeBault L.E et al, 1980]
a/ Material: - cytocentrifuge slides
- cytocentrifuge
- Pasteur pipette, forceps.
- antigen preparation with negative control available
- acetone
- substrate-acceptor-indicator solution:
0.5 mM g-glutamyl-4-methoxy-b-naphthylamine 
20 mM glycylglycine (Koch-light).
0.05 % (w/v) Fast Blue BB (Koch-light).
0.25 % (v/v)dimethyl sulfoxide, 
in 25 mM PO4 buffer saline (pH 7.4)
- chelator: CuSO4; 0.1 M in 25 mM PO4 buffer saline (pH 
7.4) .
b/Method: - Cytocentrifuge slides of the test sample with its negative 
control are prepared e.g for brain vessels a centrifugation 
of 100 g for 5 minutes is adequate.
- The slides were air dried overnight at +4 °C.
- The preparations were fixed with cold acetone for 10 
minutes, then rinsed twice with distilled water.
- They were then incubated with the substrate-acceptor- 
indicator solution for 90 minutes at 37 °C. The 
cytocentrifuge preparation, on the slide was covered by the 
solution; generally 500 jlxI of the solution was sufficient.
- After the incubation, the chelator was added for 1 to 2 
minutes; this incubation time was checked by inverted 
microscopy.
- The reaction was stopped with distilled water.
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MM20: SCANNING ELECTRON MICROSCOPY (SEM) OF 
THE BRAIN VESSELS PREPARATON.
Purified vessels in chilled Hanks buffer solution with heparin and 
antibiotics were centrifuged at lOOOg for 10 minutes. After change of 
medium by gentle aspiration the vessels were incubated at 4 °C in 4% 
glutaraldehyde in phosphate buffer saline overnight. Immediately 
before preparation of the vessels for SEM, the vessels were dehydrated 
through increasing concentration of alcohol in PBS : 30 minutes at 
50% , 15 minutes at 75%, 15 minutes at 95%, and twice for 15 minutes 
in absolute alcohol (between each incubation the purified vessels were 
allowed to sediment and the alcohol solution sucked off). The purified 
vessels were then allowed to sediment on circular 10 mm 
microcoverslips (Horwell A.R. Ltd). The preparation was then put into 
a Samdri critical point dryer with alcohol replaced with liquid CO2 and 
dried. It was then fixed with tape on a stup and placed in a EMSCOPE 
sputter water where it was covered in 10 nanometers of gold and 
viewed in a JEOL JSM 35 CF scanning electronmicroscope.
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MM21: TRANSMISSION ELECTRONMICROSCOPY OF THE 
MYELIN PREPARATION.
Myelin was prefixed overnight in 2.5% (v/v) glutaraldehyde in PBS at 
+ 4°C and then postfixed in 2 ml of 1 % (w/v) osmium tetroxide in PBS 
for 1 hour at room temperature. The myelin was centrifuged at lOOOg 
for 10 minutes and after removal of the osmium tetroxide, the myelin 
was rinsed in PBS, dehydrated using ascending acetone concentrations 
(50 %, 70%, 90% and 100% (v/v)) for 15 minutes corresponding to 
each concentration and then fixed overnight in 50% (v/v) araldite 
(Taab) in 100% acetone on a rotary mixer at room temperature. The 
araldite-acetone was then replaced with 100% araldite from which all 
the air had been previously been removed under vacuum and aliquots of 
the preparation were placed in conical beam capsules (Agar Aids) with 
the myelin at the base. The resin was then polymerised at 600°C for 24 
hours after which thin section of approximately 40 nm were cut using a 
Huxley ultramicrotome and collected on copper grids (Emscope, 300 
nm).
Grids were stained for 5 minutes in Reynolds lead citrate, washed in 
distilled water for 30 seconds and counterstained in 2 % (w/v) aqueous 
uranyl acetate. The sections were visualised using a Phillips electron 
microscope (Model EM 301).
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MM22: CLINICAL STUDY USING THE WESTERN 
BLOTTING ASSAY AND MYELIN AND HUMAN BRAIN 
VESSELS AS ANTIGENS:
a/ The human brain vessels antigen preparation
Human brain vessels were prepared from a single brain <36 hours 
after death (see section MM 15). The vessels were assessed by light 
microscopy, electron microscopy (see section MM-20), presence of von 
Willebrand factor by indirect immunofluorescence (see section MM7) 
and y- glutamyl transpeptidase (7G.Tr.Pase) as described in section 
MM 19 and in result section R4.
b/ Human myelin antigen preparation.
Myelin was prepared from a single post mortem brain < 36 hours after 
death but different from the brain used for the preparation of the 
human brain vessels. The characterisation and assessment of the 
preparation are described in sections MM 14 and MM21 and in result 
section R3.
c/ Selection of the MS and the neurological patients and 
normal controls for the clinical studies.
MS patients and neurological controls were selected by the neurologists 
and their clinical and biochemical data recorded. The assay was carried 
out in a blind fashion. When the code was broken, the diagnoses were 
as follow: MS 45 , epilepsy 20, Parkinson's disease 2, myasthenia 
gravis 2, migraine/headache 5, stroke 2, neuropathy (1 diabetic) 2, 
unexplained syncope 2; 1 each of: vertigo, carpal tunnel syndrome, 
hyperventilation, anoxic brain damage, vasculitis, pineal tumor, cervical 
spondylitis, prolapsed disc, polymyositis, hysteria, cramp, motor 
neurone disease. Eighteen normal sera from laboratory personnel 
(department of Biochemistry and Microbiology , St Andrews 
University) were also tested. The mean age of the MS group was 45 
years (range 27-67), the neurological controls 45 years (range 16-84) 
and the normal controls 28 years (range 22-60). Table MM22-1 
summarizes the characteristics of the patients and controls selected for 
the 'western blotting' clinical study.
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Number age (range)
MS 45 45(27-67)
Normal controls 18 28 (22-60)
Neurological
controls
47 45 (16-84)
Epilepsy 20
Parkinson's disease 2
Myasthenia gravis 2
Migraine/headache 5
Stroke 2
Neuropathy 2
Unexplained syncope 2
Vertigo 1
Carpal tunnel syndrome 1
Hyperventilation 1
anoxic brain damage 1
vasculitis 1
pineal tumor 1
cervical spondylitis 1
prolapsed disc 1
polymyositis 1
hysteria 1
cramp 1
motor neurone disease 1
Table MM22-1: Characteristics of the patients and controls selected 
for the western blotting clinical study.
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d/ Western blotting assay for the clinical study.
-IgG level was determined for each patient by an immunodotblot 
technique [Randall R.E.R et al, 1984] using standard controls (ICL 
scientific) and thus the assay was standardised for the amount of IgG 
(see Results section R1 for an example).
- Myelin and vessels were denatured in electrophoresis buffer 
(containing SDS and P-mercaptoethanol), heated at 75°C for 5 minutes 
and run on SDS-PAGE gel (15 % acrylamide) on a single line made by 
a one tooth comb. Molecular weight standard markers (BRL, Bethesda 
Research Laboratory) were run in parallel in order to characterise the 
vessel proteins (see figure R3-1 for detail of the molecular weight 
marker). The proteins were then blotted onto nitrocellulose paper for 1 
hour at 0.8 mA/mm^ using a semidry blotter (LKB). After blotting, the 
nitrocellulose paper where the antigens had been transferred was cut 
into 20 vertical and parallel strips and the strips on both sides were 
stained with naphthalene Black in order to locate the pattern of the 
antigen (the myelin or the human brain vessels).
-Each strip was incubated with the aliquoted serum (each serum dilution 
contained 120 pg of IgG per strip in 400 pi of 1% Marvel/PBS; this 
corresponded to dilutions ranging from 1/25 to 1/60 for the tested sera) 
for 1 hour, washed and then incubated with the second antibody viz an 
anti - human - polyvalent immunoglobulins linked to horse radish 
peroxidase (1/50 in 400 pi of 1% Marvel/PBS) (Sigma). The reaction 
was visualised by diaminobenzidine as described in section MM 10.
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MM23: CLINICAL STUDY USING THE
"NITROCELLULOSE T CELL ASSAY’ WITH MYELIN AND 
HUMAN BRAIN VESSELS AS ANTIGENS.
a/ Preparation of the antigen preparations (myelin and
vessels) for the 'nitrocellulose T cell assay’.
-The same myelin and vessel preparations used for the western blotting 
clinical study were used for the 'nitrocellulose T cell' assay.
- Eleven different types of myelin antigen nitrocellulose particles and 
seventeen different types of human brain vessel nitrocellulose particles 
were prepared as described in section MM 12, part B. The protein bands 
selected from the myelin preparation spanned most of the myelin 
preparation corresponding to the molecular weight region between 15 
to 200 kd and particular attention was taken to include the region 
corresponding to the myelin basic proteins region (18 to 22 kd) - band
1 , the proteolipid protein region ( 25kd) - band 2 [Cruz T.F. et al,
1985] .The proteins bands selected on the human brain vessels 
preparation spanned the whole preparation corresponding to the 
molecular weight region between 10 to around 120 Kd (see figure 
MM23-1).
b/ Selection of the MS patients, neurological controls and 
normal controls for the T cell assay.
-MS patients and neurological controls were selected by the neurologists 
and their clinical and biochemical data recorded. The T cell 
proliferation assay (section MM11) was carried out in a blind fashion.
- When the code was broken, the diagnoses were as follow. Six MS 
patients, 4 patients suffering from epilepsy, one patient suffering from 
diabetes and one suffering from brain damage.
- Six normal controls were also tested and were selected from the 
laboratory personnel. They were not selected in a blind fashion unlike 
the neurological patients.
c/ 'Nitrocellulose T cell' assay for the clinical study.
-The assay was carried out in a blind fashion and only one pair of 
patients (one MS, one neurological control) was tested at each run.
The six normal controls were tested independently thereafter.
- For each patient medium alone, PHA, NCP-blank (NCP with blotted 
denaturing buffer alone, 11 different myelin protein-NCP and 17
“1 d. 9different vessel protein NCP were tested. For the last 3 pairs of patients
myelin spotted on NC and electrophoresis buffer-disrupted vessels 
spotted on NC were also included. NCPs were incubated for 7 days 
with 2x10^ mononuclear cells/200 pi well. Each well was pulsed with 
0.5pCi 3H thymidine for the last 16 hours and then harvested and 
counted.
Figure MM23-1: Blots of brain vessels (A) and
myelin (B) samples used for the preparation of the nine 
myelin protein-NCPs and the eleven vessel protein-NCPs.
A/ lane 1: stained molecular weight marker; lane 2: brain 
vessels (3 mm are stained both sides of the track which has 
been used for the preparation of the NCPs) - the 
corresponding bands are located on the right side of the track. 
B/ lane 1: loading buffer alone (for the preparation of the 
MOCK-NCPs); lane 2: stained molecular weight marker; lane 
3: adenovirus type 2; lane 4: myelin preparation - 9 bands 
were prepared and are located on the right hand side of the 
track.
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RESULTS
PARAMYXOVIRUS SV5 RELATED CSF STUDIES.
Twenty three CSFs from patients suffering possible or definite 
multiple sclerosis were supplied by the neurologists in Aberdeen, 
Dundee and Edinburgh. Great care was taken in the transport of 
these CSFs which were collected in sterile glass containers. On 
arrival at the laboratory, they were aliquoted, labelled and stored at 
-70°C until testing. The CSFs were not frozen and thawed more than 
once before analysis.
The immunoglobulin concentration was measured in the CSFs 
by immunodotblot [Randall RE et al, 1985]. Figure Rl-1 shows an 
example of this screening procedure where a known control (from 
ICL) was used. Table 1, column 2, provides the data for the 23 
CSFs. The CSFs were then screened for the presence of oligoclonal 
bands using the isoelectrofocusing (IEF) technique and silver 
staining (see Materials and Methods and reference [Goswami K.K.A. 
et al, 1987]). An example of the silver staining of IEF gels is shown 
in fig. Rl-2a and Rl-2b with some of the CSFs tested. The column 3 
of table 1 summarises the data for the 23 CSFs.
Concerning the virological investigation, the CSFs were first 
screened by indirect immunofluorescence using SV5 infected VERO 
cells. Positive and negative control monoclonal antibodies were 
readily available in the department [Randall R.E and Young D.F., 
1988] and only optimally infected slides were used for this screening 
procedure. Figure Rl- 3a shows a positive reaction with a CSF from 
an MS patient and figure Rl-3b shows a negative reaction. The 
results are given in column 4 of table 1. CSFs positive for the 
presence of antibodies to SV5/PF2 were then titrated by the same 
method using doubling dilutions of the CSFs starting with undiluted 
sample. The slides were always read by 2 examiners (BES and 
WCR) in a blind fashion. Two CSFs showed reasonable levels of 
antibodies to SV5 (i.e titration > 1/400) and were thus selected for 
further studies. They were first titrated for PF2 antibodies and 
measles antibodies. Table 2 summarises the data of this study.
The absorption experiments were then carried out on these 
two CSFs. The principle of the method, described in detail in the 
Methods section, is based on the fact that immune complexes (the 
antigen being the whole virus) can be pelleted after high speed
ANALYSIS OF CSF’S FROM THE EAST 
OF SCOTLAND
1
CODE
2
IgG C/S
3
OLIGO. BANDS
4
SV5/PF2
SOURCE OF CSF KK 6/12 +/-
TH 18/12 + ++
EM 10/10 + Mi
CG 14/8 + ++
ABERDEEN MO 10/8 + -HG 12/12 +/“ -
OM 14/12 + -AD 12/10 + -
McR 10/12 - +
BK 12/8 +
AB 14/12 + -
BD 16/10 +/- -AN 10/12 + ■1
EG 8/10 + + ,SP 12/12 + +
JG 12/14 + +
SC 10/8 +
JL 14/14 + +
DUNDEE WN 14/8 + -PB 8/10 +
EG 10/8 +
DB 14/12 + +EDINBURGH DH 10/12
19/23 8/23
Table 1: List of the 23 CSFs tested using the immunoabsorption 
technique.
Column 2: level of IgG (C= in the CSF (mg/dl); S= serum (mg/ml)). 
Column 3 : presence of oligoclonal bands after isoelectrofocusing 
and silver staining.
Column 4: presence of antibodies to SV5/PF2 by indirect 
immunofluorescence.
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Figure Rl-1: Immunodotblot of CSF and sera from MS 
patients with an anti-human immunoglobulin linked to 
peroxidase .Two pi of the different samples and their 
corresponding double dilutions were spotted on the 
nitrocellulose paper from bottom to the top of the 
picture. Lanes 1 and 11: double dilutions of the IgG 
standard starting at 12 mg/dl. Lanes 2 to 10: double 
dilutions of the CSF (C) or serum (S) of 5 different 
patients (lane 2: TH (C); lane 3: KK (S); lane 4: KK (C); 
lane 5: JL (S); lane 6: JL (C); lane 7: DB (S); lane 8: DB 
(C); lane 9: CG (S); lane 10: CG (C). The CSFs started 
neat and the sera were diluted 1/100 prior to the test. 
The estimated levels of IgGs are recorded in table 1 
column 2.
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Rl-2a
Figure Rl-2a and 2b: Silver staining of CSFs tested after 
isoelectrofocusing with some showing oligoclonal bands (see table 1 
for the list of the patients). Rl-2a/ lane 1: DB; lane 2: EG; lane 3: 
CG; lane 4: KK; lane 5: DH; lane 6: EM. Rl-2b/ lane 1: EM; lane 2: 
DH; lane 3: JG; lane 4: SP; lane 5: PB; lane 6: WM; lane 7: McRa; 
lane 8: HG; lane 9: OM. 147
Figure Rl-3a: CSF positive for SV5/PF2 antibodies by indirect 
immunofluorescence on SV5 infected VERO cells, (magnification x 
400).
Figure Rl-3b: CSF negative for SV5/PF2 antibodies by indirect 
immunofluorescence on SV5 infected VERO cells (magnification x 
400).
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ANALYSIS OF THE SELECTED CSFS I
ABERDEEN TH
CG
McR SV5 
EC SV5 
SP SV5 
JG SV5
SV5 = 1/400
PF2 = 1/200
MEASLES = 1/200
SV5 = 1/400
PF2 = 1/200
MEASLES = 1/200
= 1/15 
= 1/15 
= 1/15 
= 1/15
SV5 =1/50
SV5 = 1/50
Absorption
with
SV5
_ FLU 
PBS
negative results
DUNDEE JL
EDINBURGH DB
Table 2: Antiviral titers (anti-SV5, PF2 and anti measles) of the 
selected CSFs which were positive for antibodies to SV5/PF2 by 
indirect immunofluorescence (see table 1).
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centrifugation in contrast to free antibodies which are retained in the 
supernatant. If purified virus is mixed with CSFs containing 
antibodies to this same virus, immune complexes will result from 
the specific reaction of these antibodies to this virus. Because in this 
system, there is an excess of antigen, it is likely that, if these 
antibodies are part of the CSF oligoclonal IgGs, oligoclonal bands 
corresponding to these antivirus antibodies will not be present in the 
supernatant of the CSF centrifuged after its incubation with the 
virus. The technique used to compare the possible difference was the 
silver staining IEF pattern of the supernatants of different aliquots of 
a CSF, each incubated with a specific purified virus or with a 
negative control mixture e.g PBS.
This approach was used with the 2 selected CSFs named CG 
and TH. A preparation of influenza virus (a gift from the National 
Institute for Medical Research (NIMR)) was used as a negative 
control. The SV5 virus was prepared in the department (BES and B. 
Precious), the purity of the preparation being checked by SDS 
PAGE (figure Rl-4). The respective concentration of the virus 
preparation was measured by dot-blot assay and the concentration of 
each virus each in the absorption assay was therefore standardised (1 
mg/ml of virus). Five aliquots of each CSF were processed: one 
aliquot was incubated with purified influenza virus, one with 
purified SV5 virus , one with PBS, one was not mixed with anything 
but left overnight at +4 °C and the last CSF aliquot kept at - 70° C 
overnight. Figures Rl-5a and Rl-5b show the silver staining IEF 
pattern of the 5 aliquots of CSF CG and CSF TH after 
centrifugation. It was clear that the patterns of both CSFs were 
slightly different between the aliquots but it was not related to the 
virus itself. For example in Figure Rl-5a the patterns between 
aliquots did not differ greatly apart from the last track which 
corresponded to the CSF alone incubated at +4° C overnight. In 
Figure Rl-5b, however, the oligoclonal bands have almost 
disappeared from CSF-TH which was incubated with PBS (track3) 
or with influenza (track 4). Figure Rl-6 shows another negative 
absorption experiment (TH repeated, EM and JL CSFs)
Different factors could have induced this effect. As previously 
established in the department, the technique appeared to be 
reproducible and little difference was seen between different tracks 
of the same sample especially when they were silver stained in 
parallel (Dr K. Goswami, personal communication). It is noticeable 150
Figure Rl-4: SDS-PAGE minigel of the purified SV5 preparation 
used for the immunoabsorption experiments. Five pis were loaded 
on the gel as shown on the photograph. The proteins of the virus are 
named on the right side of the track.
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Figure Rl-5a: Immunoabsorption with the CSF CG (see table 1 
and 2). From left to right track 1: incubated with purified influenza 
virus overnight. Track 2: incubated overnight- nothing added. Track 
3: incubated with SV5 overnight. Track 4: incubated with PBS 
overnight. Track 5: not incubated overnight- nothing added.
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Figure Rl-5b: Immunoabsorption with the CSF TH (see table 1 
and 2). From left to right; track 1: not incubated overnight; track 2: 
incubated overnight with SV5; track 4 incubated overnight with 
influenza virus; track 5: incubated overnight.
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Figure Rl-6: Immunoabsorption experiments with 3 different 
CSFs from patients with MS (JL, TH, EM). JL’s CSF and TH’s CSF 
are CSFs with antibodies specific for SV5 (see table 1) EM's is a 
CSF with no antibodies specific for SV5 (see table 1). Tracks 
1,2,8,9,10: CSF from JL- track 1 and 10 incubated with PBS; track 2 
and 8 incubated with measles virus; track 9 incubated with 
SV5.Tracks 3 and 4: CSF from TH - track 3 incubated with SV5; 
track 4 incubated with PBS.Tracks 5, 6,7 : CSF from EM - track 5 
incubated with measles virus; track 6 incubated with SV5; track 7 
incubated with PBS.
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that in the IEF of the TH and CG aliquots the tracks which were on 
the edges were better stained than the other tracks. This is not the 
case with other IEF gels of CSFs and thus the position of the tracks 
was not a likely explanation for the discrepancy seen between the 
aliquots of TH. It was then hypothesised that the ionic strength, 
phosphate content or pH of the CSF mixed with different mixtures of 
virus or PBS may have influenced the properties of the relatively 
cathodic oligoclonal IgGs. It is therefore possible that non-immune 
reactions e.g absorption or precipitation may have been the cause of 
the original observations [Goswami K.K.A. et al, 1987] indicating 
that a large proportion of oligoclonal bands in CSFs of some MS 
patients were reacting to the virus SV5.
To test this hypothesis the following experiment was set up: 
aliquots (95 Jill) of a CSF from a patient (EM) were incubated with 
5 pi of phosphate buffer solutions (phosphate 50 mM in 0.1 M NaCl) 
of different pH (trackl, pH 6; track 2, pH 7; track 3, pH 8). Another 
aliquot was incubated with phosphate buffer of pH 7 but with high 
salt content (0.25 M NaCl)(track 4). The last track (number 5) 
corresponded to the CSF alone. The aliquots were centrifuged as 
previously described and their supernatants run in IEF and silver 
stained. The result of this experiment is shown in figure Rl-7. The 
staining of the oligoclonal bands in the supernatant run on track 4 
was less than in the other tracks. Track 5 was the aliquot which had 
not been diluted and the pattern was not different from track 1, 2 or 
3. This correlated with previous observations made in the 
department that the dilution effect due the addition of 5 pi of buffer 
to the 95 pi of CSF was not responsible for the difference of staining 
seen between aliquots which had been incubated with a virus 
preparation or PBS and a CSF aliquot which has not been diluted. 
The overall conclusion of this experiment was that the high salt 
content of aliquot 4 may have induced a precipitation of some 
oligoclonal bands.
To corroborate this conclusion, another experiment was 
designed: aliquots of CSF-EM were incubated overnight with virus, 
PBS or on its own. They were then centrifuged and the pellet of each 
of these aliquots was dissolved in denaturing mixture (see Methods 
section, SDS-PAGE electrophoresis) and a sample run on a SDS 
PAGE minigel which was then silver stained. The gel is shown in 
Figure Rl-8. Track 1 was pellet of aliquot not diluted, track 2, 3 and 
4 corresponded to aliquots incubated with influenza virus , SV5 1 55
1 2 3 4 5 6
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Figure Rl-7: Isoelectrofocusing of the CSF EM after changing pH 
and salt content. From left to right track 1,2,3 : phosphate buffer 50 
mM in 0.1 M NaCl, track 1: pH 6, track 2: pH 7, track 3: pH 8. 
Track 4: pH 7 in phosphate buffer 50 mM in 0,25 NaCl. Track 5: 
CSF incubated overnight. Track 6: CSF not incubated overnight.
Figure Rl-8: SDS-PAGE minigel of the pellets after centrifugation 
of the CSF EM incubated overnight with: track 1 CSF alone, track 2 
incubated with influenza virus, track 3 incubated with SV5, track 4 
incubated with PBS. Heavy (H) and light (L) chains from 
immunoglobulins are marked.
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virus or PBS respectively. The conclusion of this experiment was 
that the immunoglobulins (heavy and light chain on an SDS gel) 
appeared in the pellet when the CSF was incubated with virus (track 
2 and 3) but they were also precipitated, especially the heavy chain, 
when the CSF was incubated with PBS. This effect was not seen with 
the undiluted CSF aliquot.
In conclusion it was suggested from the above experiments 
that changes in ionic strength, phosphate content and pH may have 
been responsible for some of the differences observed in the original 
observation even though phosphate buffer and control antigens were 
run in parallel at that time.
ASSESSMENT OF THE TECHNIQUES USED IN THE
STUDIES OF THE POSSIBLE INVOLVEMENT OF SV5
IN MS; THE IMMUNOABSORPTION, IMMUNO­
PRINTING AND THE IMMUNOBLOTTING OF CSF.
The aim of this investigation was to compare these 3 
techniques which were used by different research groups in the study 
of the possible involvement of SV5 in MS. The immunoabsorption 
technique was currently in use in the Department at St Andrews, the 
imprint immuno-fixation method was used by Dr Vandvick in 
Norway and the immunoblotting method was used by Dr McLean in 
London (see the Discussion section).
The imprint immuno-fixation method depends on the ability of 
the oligoclonal bands displayed after concentration of the CSF and 
isoelectrofocusing on polyacrylamide gels to be transferred 
sequentially to agarose gels containing different virus antigens (virus 
specific antibodies) or to agarose gel without anything (detection of 
oligoclonal pattern). The antibodies which attach are then detected 
by 125 i labelled anti-human IgG. The virus antigens are generally 
crude extracts of infected cells and controls are derived from 
extracts of uninfected cells (see Material and Methods section).
The principle of the immunoblotting technique is only slightly 
different: unconcentrated CSFs are separated by isoelectrofocusing 
agarose gels and then blotted onto nitrocellulose coated with or 
without antigens (to detect virus specific antibodies or to assess the 
oligoclonal pattern respectively) (see also Material and Methods).
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The principle of the third method, the immunoabsorption 
technique, has been described in the previous section and also in the 
Materials and Methods section. The interpretation of the results is 
based on the disappearance of bands corresponding to oligoclonal 
IgG which have been absorbed by a specific antigen. These bands are 
visualised after isoelectrofocusing by silver staining. The sensitivity 
of the technique therefore depends greatly on the sensitivity of the 
silver staining methods for CSF oligoclonal IgG.
Two parameters were assessed: the specificity and the 
sensitivity of these 3 methods. To achieve this aim, a defined system 
was chosen: monoclonal antibodies specific for parainfluenza 2 and 
SV5 virus were available in the Department. Monoclonal antibodies 
161 and 173/2 (specific for SV5) and monoclonal 77/4 (specific for 
PF2) are protein A binding-monoclonal antibodies [Randall R.E. et 
al, 1987] and thus were purified using a protein A column. Figure 
R2-1 shows the monoclonal antibodies characterised by SDS PAGE 
after purification. The protein content of the purified preparation of 
monoclonal antibodies were then measured by dot blot (see Method 
section MM10').
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Figure R2-1: SDS-PAGE of the viruses and of the monoclonal 
antibodies, after purification on protein A column, used to assess the 
different CSF techniques described in section R2, stained with 
coomassie blue. From left to right, tracks 1 and 2 show the viral 
preparation used: track 1, influenza virus, track 2, SV5 virus. 
Monoclonal antibody 161 (track 3) is specific for SV5, 173/2 (track 
4) is specific for SV5, 77/4 (track 6) is specific for PF2. Track 5 
shows a purified preparation of human immunoglobulins (not used 
for the work presented in this thesis). 158
a) Sensitivity of the techniques:
1. Silver staining method:
Different concentrations (0.5, 0.1, 0.05, 0.025, 0.0125 mg/ml) 
of the monoclonal antibody 173/2 were examined using an 
isoelectrofocusing gels and the gel was silver stained. Figure R2-2 
shows the resulting silver stained gel indicating that the sensitivity of 
the method was 0.05 mg/ml using a 10 |xl sample.
Figure R2-2: Silver staining on electrofocusing polyacrylamide gel 
of different concentrations of 10 gl samples (from track 1 to track 5: 
0.5, 0.1, 0.05, 0.025, 0.0125 mg/ml) of the monoclonal antibody 
173/2.
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2. Imprint-immunofixation method:
Different concentrations of the monoclonal antibodies 77/4 (2,
1, 0.5 mg/ml) were examined on an isoelectrofocusing gel alongside 
the 2 mg/ml dilution of the monoclonal antibody 173/2 (The 
monoclonal 77/4 is specific for the parainfluenza virus PF2 and 
173/2 is specific for SV5 and does not cross react with PF2 [Randall 
R.E., 1987]). After isoelectrofocusing of these 2 monoclonal 
antibodies, the gel was put in contact with the agarose gel which 
contained PF2 virus infected VERO cells for 5 minutes. The agarose 
gel was then incubated with Iodine 125 labelled protein A. Figure 
R2-3a shows the separating gels after transfer and Figure R2-3b 
shows the transfer pattern onto PF-2 -containing agarose gel. The 
sensitivity of the technique appears to be 1 mg/ml with the 
monoclonal antibody 77/4 (anti PF-2). However, the specificity of 
the technique is questionable as 173/2 (not specific for PF-2) also 
transferred at the concentration of 2mg/ml. No lower concentrations 
of 173/2 were included.
Figure R2-3a: Sensitivity and specificity of the imprint immuno­
fixation method. Isoelectrofocused agarose gel stained with 
coomassie blue after transfer by the immunoprinting method of 
different concentrations of the monoclonal antibody 77/4 (track 1 to 
3: 2, 1, 0.5 mg/ml loaded on the gel) and 2 mg/ml dilution of the 
monoclonal antibody 173/2. 160
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Figure R2-3b: Sensitivity and specificity of the imprint immuno­
fixation method: PF2-containing agarose gel used for the transfer of 
the monoclonal antibodies isoelectrofocused in figure R2-3a is 
shown. This gel was overlaid on the gel shown in figure R2-3a and 
the monoclonal antibodies allowed to transfer between the 2 gels.
The transferred monoclonal antibodies were visualised by protein A 
labelled with iodine 125 (see material and methods).
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3. Immunoblotting method.
a/ Sensitivity for non specific transfer of antibody:
This technique is used to detect the presence of oligoclonal
IgGs in clinical samples. Two alternatives are available: the IgGs are 
either transferred on uncoated nitrocellulose paper and the 
transferred IgGs are then detected by an anti IgG and then by the 
second antibody conjugated to peroxidase. The second possibility is 
that the first antibody (the anti IgG) is coated on to the 
nitrocellulose paper before the transfer of the IgGs. Different 
concentrations (0.5, 0.1, 0.02, 0.025, 0.0125, 0.0063, 0.0031 mg/ml) 
of the monoclonal antibody 173/4 were thus transferred either to 
uncoated nitrocellulose paper (figure R2-4a) or to anti-mouse IgG 
coated nitrocellulose paper (figure R2-4b). In both cases, the 
sensitivity is < 0.003 mg/ml with perhaps a better pattern at the 
lower concentration for the anti-mouse coated IgG nitrocellulose 
paper.
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Fig R2-4a Fig R2-4b
Figure R2-4: Sensitivity of the immunoblotting method . Different 
concentrations (from right to left: 0.5 (lane 1), 0.1 (lane 2), 0.02 
(lane 3), 0.025 (lane 4), 0.0125 (lane 5), 0.0063 (lane 6) , 0.0031 
(lane 7) mg/ml) of the monoclonal antibody 173/4 (specific for SV5) 
were transferred to nitrocellulose paper which was
R2-4a: uncoated
R2-4b: coated with an anti mouse IgG.
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b/ Sensitivity for detection of virus specific antibody.
In this experiment, the nitrocellulose paper was coated with
SV5 infected cells. Different concentrations (0.5, 0.05, 0.02, 0.01, 
0.005 mg/ml) of the monoclonal antibody 173/2 were transferred to 
this SV5 coated membrane. The transferred monoclonal antibody 
was then visualised by an anti-mouse IgG linked to horse radish 
peroxidase. Figure R2-5 (section A) indicates the result of the 
experiment and the sensitivity of the technique indicates 0.005 mg/ml 
similar to that for the non specific transfer of IgG.
abcde abcde abcde
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Figure R2-5: Section A: Sensitivity of the immunoblotting method 
with virus coated nitrocellulose paper. The nitrocellulose paper was 
coated with SV5 infected cells. Different concentrations (0.5(a), 
0.05(b), 0.02(c), 0.01(d), 0.005(e) mg/ml) of the monoclonal antibody 
173/2 (specific for SV5) were transferred to this SV5 coated 
nitrocellulose paper. The concentrations are decreasing from right to 
left. The transferred monoclonal antibody was then visualised by an 
anti-mouse IgG linked to peroxidase
Section B and C: Specificity of the immunoblotting 
method. Different dilutions (from right to left) of the monoclonal 
antibody 161, specific for SV5 (0.25(a), 0.05(b), 0.02(c), 0.01(d), 
0.005(e)) [B] and different concentrations of the monoclonal antibody 
77/4, specific for PF2, (l(a), 0.5(b), 0.25(c), 0.05(d), 0.02(e) mg/ml) 
[C] were transferred onto SV5 infected cells coated nitrocellulose 
paper after isoelectrofocusing and then visualised by an anti mouse 
IgG labelled with peroxidase.
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b) The specificity of the techniques:
1. The immunoabsorption technique.
The experiments which assessed specificity of this technique
have been described in the section Rl (CSF studies in relation to the 
paramyxovirus SV5).
2. The imprint immuno-fixation method.
This technique was not explored much further. One 
experiment was carried out however to assess if the overlay contact 
time of the 2 gels influenced specificity. Monoclonal 173/2 and 77/4 
were run at the concentration of 1 mg/ml. the gel to gel contact time 
was 30 seconds, 2 min, and 5 minutes. It appears that at 30 seconds, 
the technique is specific whereas when the contact time is longer non 
specific reactions occur.
3. The immunoblotting technique.
In the first experiment, different dilutions of 3 monoclonal 
antibodies were isoelectrofocused in parallel: 173/2 (0.25, 0.05,
0.02, 0.01, 0.005 mg/ml) a monoclonal antibody specific for SV5, 
161 (0.25, 0.05, 0.02, 0.01, 0.005 mg/ml) a monoclonal antibody 
specific for SV5 and 77/4 (1, 0.5, 0.25, 0.05, 0.02 mg/ml) a 
monoclonal antibody specific for PF-2. The gel was then overlaid 
with nitrocellulose coated with SV5 infected cells. Figure R2-5 
(section C) shows the result of this experiment indicating that at 1 
mg/ml the monoclonal antibody 77/4 is apparently transferred and 
detected thus the specificity of the technique is called into question at 
this concentration.
In the next experiment, other antigens were tested in a similar 
way with different monoclonal antibodies. Three types of antigen 
coated nitrocellulose papers were tested viz SV5 coated 
nitrocellulose paper, measles virus (Mv) coated nitrocellulose paper 
and adenovirus (Ad) coated nitrocellulose paper (see Material and 
Methods section); the SV5 purification has been described in the 
previous section (see Figure Rl-4); the adenovirus was purified by 
Ian Leith in the laboratory and the measles virus was purified by 
Bernie Precious in the laboratory. Four different monoclonal 
antibodies were run at the same concentration (0.02 mg/ml): 
173/2(SV5 specific), 161 (SV5 specific) [Randall R.E. et al, 1987] , 164
B 10 (Mv specific) [Russell W.C. et al, 1983] and 13G4G9 (Ad 
specific against the fiber type 2) [Russell W.C., personal 
communication]. Figure R2-6 shows the result of this experiment. 
On the SV5 coated nitrocellulose paper, 173/2, 161 and BIO were 
transferred and detected, on the Mv coated nitrocellulose paper the 
four monoclonal antibodies were transferred, and, on the 
adenovirus coated nitrocellulose paper only the 13G4G9 (Ad 
specific) was transferred. Therefore, in this experiment, at the 
concentration tested and with the monoclonal antibodies tested, only 
the adenovirus system was specific.
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Figure R2-6: Specificity of the immunoblotting technique. Three 
types of antigen coated nitrocellulose paper were tested viz SV5 
coated nitrocellulose paper (Ntcp) [A], measles virus (Mv) coated 
Ntcp [B] and adenovirus Ntcp [C]. Four different monoclonal 
antibodies were run at the same concentration (0.02 mg/ml). From 
left to right: BIO (Mv specific), 13G4G9 (adenovirus specific), 161 
(SV5 specific) and 173/2 (SV5 specific).
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A similar result, was obtained a second time with a SV5 coated 
nitrocellulose paper when BIO (Mv specific), 77/4 (a PF-2 specific 
monoclonal antibody) and 173/4 (SV5 specific) were tested. All 3 
monoclonal antibodies reacted with the SV5 coated nitrocellulose 
paper. BIO and 173/2 were transferred onto the nitrocellulose paper 
coated with SV5 infected cells. The Mv - coated nitrocellulose paper 
was more difficult to interpret but BIO and 173/2 appeared to have 
transferred.
ABC
Figure R2-7: Specificity of the immunoblotting technique. Monoclonal 
antibodies BIO (Mv specific) [1] , 77/4 (adenovirus specific) [2] and 173/2 
(SV5 specific) [3] were transferred on SV5 coated nitrocellulose paper 
[A], on SV5 infected cells coated nitrocellulose paper [B] and on measles 
coated nitrocellulose paper [C]. 166
SUMMARY AND CONCLUSION OF Rl AND R2 SECTIONS:
Oligoclonal IgGs specific for SV5 were not found in the series of 25 
multiple sclerosis patients tested using the immunoprecipitation technique. 
Consequently, a series of experiments assessed this technique in an 
attempt to explain a previous report of SV5 specific oligoclonal IgGs 
detected in the CSF of MS patients. It was found that the modulation of 
ionic strength, phosphate content and pH of the buffer used in the 
immunoprecipitation assay could lead to non immunological precipitation 
of the relatively cathodic oligoclonal IgGs and thus to false positive 
results in some cases. This result stimulated an assessment of two other 
CSF techniques (immunoblotting and imprint-immunofixation) which had 
also been used for looking at the presence of SV5 specific antibodies in 
multiple sclerosis CSFs. The immunoblotting technique was extremely 
difficult to control and was prone to non specific reaction. On the other 
hand, the imprint-immunofixation technique was easier to control but 
again the technique showed a narrow window of specificity.
In view of these relatively negative results and in the light of current 
theories of the MS process it was decided to look at a related aspect 
of the aetiopathogenesis of MS i.e potential target autoantigens in the 
induction of MS following a widespread theory that a possible 
autoimmune reaction leading to demyelination could be induced, in 
MS patients, by an infectious agent. In accordance with the 
histopathological features of multiple sclerosis, the possible 
autoantigens which were considered at the time of this study were 
human myelin and human brain vessels. In order to test this 
hypothesis techniques were developed to purify and characterise , 
antigens for the cellular and humoral immunological studies. The 
next 3 sections describe the purification and characterisation of 
human brain myelin, the purification and characterisation of brain 
vessels and the attempts to establish a human brain endothelial cell 
line in culture.
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PURIFICATION OF MYELIN FROM HUMAN BRAINS:
Myelin was prepared from a single post mortem brain less 
than 36 hours after death. The brain was provided by the courtesy of 
Dr J. Anderson (Department of Pathology, Ninewells Hospital, 
Dundee).
The sucrose gradient method for the preparation of myelin is 
described in detail in Material and Methods. The yield of the 
preparation was very satisfactory: from a brain sample of 1.5 gm, 7 
mis of myelin preparation were obtained with a protein 
concentration of 1.5 mg/ml as measured by dot-blot.
The polypeptide pattern of the preparation on SDS PAGE (15 
% acrylamide) was in agreement with the published pattern of 
myelin [Wray W.T. et al, 1981] (see Figure R3-1). The purity of the 
preparation was then checked by transmission electronmicroscopy 
with the help of J. Mackie (Department of Biology and Preclinical 
medicine, St Andrews University).
1 2
Figure R3-1: SDS PAGE (15% acrylamide) of the myelin
preparation (track 1) and of the molecular weight 
marker (track 2) (from the bottom: 14 kd, 18 kd, 
29 kd, 43 kd, 68 kd, 97 kd, 200 kd). 168
Multiple sections were examined and it was concluded that the 
preparation was substantially of myelin. Figure R3-2, R3-3, R3-4 
show increasing magnification of the preparation.
Furthermore, the preparation was recognised using the 
Western Blotting technique by a rabbit polyclonal antisera to rat- 
myelin prepared by Dr E Blair (Department of Biochemistry, Leeds 
University); this antisera cross reacted with human myelin and 
recognised most of the proteins of the myelin sheath (E. Blair, 
personal communication, unpublished data); see Figure R8-2.
Figure R3-2: Transmission electronmicroscopy of the myelin 
preparation at low magnification (x 4200).
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Figure R3-3: Transmission electronmicroscopy of the myelin 
preparation at medium magnification (x 25 000).
Figure R3-4: Transmission electronmicroscopy of the myelin 
preparation at high magnification (x 200 000).
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PURIFICATION OF BRAIN VESSELS FROM BOVINE
AND HUMAN BRAINS:
There are a number of techniques which describe the 
purification of brain vessels from animal brains (rodent, canine and 
bovine) and from human post mortem brains. They are based on 
different principles which are often combined : 1) enzymatic 
digestion of the brain by 'dispase', 2) mechanical homogenisation of 
the brain, 3) separation of the components of the brain by different 
gradient systems e.g. dextran, sucrose or percoll, 4) filtration 
through nylon sieves of different mesh sizes, 5) use of glass beads to 
trap the vessels (see the Discussion section for references). These 
different procedures were assessed on the basis of yield and purity 
using bovine brains obtained from the local slaughterhouse and then 
on samples of human post mortem brains. The post mortem samples 
were provided by pathologists from Edinburgh (Dr Lessell, Dr 
MacIntyre and Dr Bell) and from Dundee (Dr Anderson).
Comparison between the methods was done solely with an 
inverted microscope; photographic facilities were not available with 
this system and only description and characterisation of the brain 
vessels purified by the method of choice will be shown. When the 
other methods were assessed in the department, some techniques (the 
use of glass beads and the use of dextran and percoll gradient after 
dispase digestion ) were found totally unsuccessful and others (e.g 
the use of sucrose gradients after homogenisation) were found to be 
of limited success. The outline of these unsuccessful methods are 
presented in figure R4-1. One protocol was found to give very 
satisfactory results and thus the exploration of the other techniques 
was abandoned
This successful brain vessel purification method was the 
combination of 2 techniques : homogenisation of the brain followed 
by filtration through nylon sieves of different mesh sizes (described 
in detail in Materials and Methods). It gave reproducible results with 
bovine brain and human samples. At the end of the 2 cycles of 
homogenisation and filtration, the purity of the brain vessel 
preparation was checked by inverted microscopy and if it was not 
satisfactory, an additional cycle of homogenisation followed by 
filtration through another 150 pm nylon mesh sieve was found to 
improve the purity of the preparation but at the cost of the yield. It 
was also found that it was possible to increase greatly the proportion 
of the small vessels (less than 12 pm of diameter) in the preparation 171
Brain sample
trough 
210 m sieve
5800g , 10 1500g, 15' 
1000 g 10'
gradient 
5800g 15'
rehomogenisation filtration 
trough 120 m 
sieve
filtration 
through 
150 m sieve
sucrose 
gradient 
58 OOOOg
Filtration 
trough 120 m
sieve
incubation
with
glass beads
collagenase
dispase
10-12 hours
Percoll 
gradient 
10', lOOOg
u
Result 
see text
washing 500g
Result
very few vessels
Result
very few vessels
v
Result
Unsuccessful: 
no vessels
Figure R4-1: outline of the protocols of the experiments set up to 
investigate the purification of brain vessels.
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when the preparation was filtered through a 150 pm nylon mesh 
sieve and when the filtrate was then collected over a 40 pm nylon 
mesh sieve. This modification of the protocol was not utilised in this 
thesis but its potential is evident for the study of the structure and the 
composition of vessels of different sizes.
When the preparation was judged to be satisfactory, the vessels 
were collected and the purity of the preparation was assessed by light 
microscopy on a cytocentrifuged sample stained with toluidine blue. 
The preparations normally contained more than 95% of brain 
vessels. Figure R4-2 shows such a preparation of bovine brain 
vessels (400 pi were cytocentrifuged; about 10 mis of the same 
preparation were obtained from 10 grammes of brain). Vessels of 
different sizes, branched and unbranched, were present i.e capillaries 
and small venules as well as small arterioles. Figure R4-3 shows, at 
higher magnification, some of the small vessels stained with toluidine 
blue and the nuclei of the endothelial cells or the pericytes are very 
well delineated. The position of the nuclei seemed to rotate about one 
third of a turn along the course of the vessels. Other figures 
illustrate some of the scanning electronmicroscopical features of 
fixed brain vessels from a human post mortem brain 5 days after 
death : figures R4-4 and R4-5, capillaries; fig R4-6 lumen of the 
vessel and nucleus (arrow) of a pericyte, fig R4-7 shows the 
extracellular matrix of a small brain arteriole.
The vessels were characterised by the presence of vW factor 
(antibody from Dako) using immunofluorescence and a penetration 
buffer during incubation of the antibody with the vessels in order to 
allow this antibody to reach intracellular antigens (Fig R4-8). They 
also showed reactivity for gamma glutamyl transpeptidase (see 
method section) which is an enzyme apparently specific for brain 
endothelial cells (Fig R4-9a) [DeBault L.E., 1980]. HELA cells were 
used as a negative control for gamma glutamyl transpeptidase (Fig 
R4-9b). The SDS-PAGE pattern of the human brain vessels (Fig R4- 
10) was compared to the pattern published by one other group 
[Pardridge W.M. et al, 1985] and it was similar. Some of the 
proteins of brain vessels are already been characterised to some 
extent e.g the low molecular weight proteins are mainly histones 
[Pardridge W.M. et al, 1989] and it appears that a 46 kd protein is a 
blood-brain barrier (BBB) specific protein [Pardridge W.M. et al, 
1986] (see discussion for a more complete review).
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Figure R4-2: Cytocentrifuged preparation of bovine brain vessels 
stained with toluidine blue (x 100).
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Figure R4-3: Nuclei of the endothelial cells and of the pericytes of 
purified brain vessels stained with toluidine blue 
(x 400).
Figure R4-8: Human brain vessels positive for von Willebrand 
factor after treatment with penetration buffer (x 450).
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Figure R4-4: Scanning electronmicroscopy of human brain
capillaries isolated from a post mortem brain (x 450) 
(bar =100 pm).
Figure R4-5: Scanning electronmicroscopy of human brain
capillaries isolated from a post mortem brain (x 900) 
(bar= 10 pm). 176
Figure R4-6: Lumen of one of the human brain vessels and nucleus 
(arrow) of a putative pericyte (x 15000).
Figure R4-7: Extracellular matrix of a small human brain arteriole 
(x 2800).
Figure R4-9a: Human brain vessel positive for y-glutamyl 
transpeptidase (x 600).
Figure R4-9b: HELA cells negative for y-glutamyl transpeptidase 
(x 600).
1 2
Figure R4-10: SDS-PAGE of the human brain vessels preparation 
(track 1). A molecular weight marker is run in parallel in track 2. 
The corresponding molecular weights of the protein markers are 
(from the bottom): 14 kd, 18 kd, 29 kd, 43 kd, 68 kd, 97 kd, 200 kd.
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ATTEMPTS TO ESTABLISH HUMAN BRAIN
ENDOTHELIAL CELLS IN CULTURE :
Attempts at the establishment of rat or human brain 
endothelial cell lines were unsuccessful. It was hoped that these cell 
lines would be available for the T cell and the ’western blotting' 
studies (see corresponding sections). This approach was not explored 
further and purified brain vessels were used as antigens in the 
clinical studies and because these clinical studies had a tight schedule, 
there was not enough time or immediate purpose to explore further 
the growth of brain endothelial cell lines.
A. Culture of astrocyte cell lines
It has been demonstrated that most of the brain-specific 
properties of the endothelial cells in the brain (e.g the possession of 
tight junctions and an enzyme system like gamma-glutamyl 
transpeptidase (y-GTPase)) are induced by the local environment 
[Golstein G.W., 1988] especially by the astrocyte cells [Janzer R.C. 
et al, 1987]. Secondly, it is well known that the brain specific 
properties of endothelial cells can be lost after a few passages in 
culture [Gerhart D.Z. et al, 1988] and that brain endothelial cells can 
regain some of their brain specific characteristics when they are co­
cultured with astrocytes or astrocyte-conditioned medium [Tao- 
Cheng J.H. et al, 1987] [Arthur F.E. et al, 1987] [Debault L.E. et al, 
1980]. It was therefore anticipated that it would be easier to culture 
a human brain endothelial cell line if this cell line was cultured in 
astrocyte-conditioned medium. Thus the first goal was to grow 
human astrocyte cells in culture.
Two brain samples were available during this time, one was 
from a resection for a brain aneurysm (the sample, kindly provided 
by Mr Varma, was macroscopically normal) and the second came 
from resection of a high grade glioma grade III (kindly provided by 
Mr Wittle). The protocol for growing astrocyte cells was the 
method described by Bama and colleagues [Bama B.P. et al, 1985]: 
the cells were cultured on a petri dish after mincing the brain sample 
(see Method section). In both cases, cells grew and were confluent 
after 7 to 10 days and were passaged at least 20 times. One culture 
was named N.GLIA and came from the normal biopsy and the other 
was named GLIO and came from the glioma sample. In the 
meantime, antibodies specific for the glial lineage cell - Glial 180
Fibrillary Antigen Protein (GFAP) - were obtained (one rabbit 
polyclonal anti-GFAP from Dako and one monoclonal anti-GFAP 
from Sera Lab). Cells that had been passaged at least 3 times were 
aliquoted and frozen in liquid nitrogen. With a DAPI stain (see 
Materials and Methods, section MM7), none of the 2 cell lines 
appeared to be infected with mycoplasma (see figure R5-1) but they 
were also 100 % negative for GFAP (see figure R5-2). The 2 cell 
lines (GLIO and N.GLIA) were tested for other markers and were 
both positive for an anti- factor VIII/vW - an endothelial specific 
marker - provided by the Scottish Antibody Production Unit 
(SAPU). Figure R5-3 shows GLIO cells positive for SAPU anti­
factor VIII/vW. At higher magnification perinuclear granules 
positive for the marker were also visible (figure R5-4). This 
appearance was possibly due to Weibel-Palade bodies which are 
thought to be storage and/or processing organelles for the von 
Willebrand (vW) protein [Wagner D.D. et al, 1982]. However the 
culture morphology was not that of an endothelial cell line which has 
a typical cobblestone morphology at confluence. Figure R5-5 shows 
that GLIO cells produced long appendages as with glial type cell line 
and when subconfluent the culture had a ’* hill and valley”- like 
morphology more in keeping with a smooth muscle cell line (see 
Figure R5-4). The SAPU-anti factor VIII/vW marker was also 
positive on VERO cells and it therefore appears that the SAPU 
polyclonal anti-factor VIII/vW can cross react with unknown 
cellular proteins non specific for the endothelial cell lineage (Dr 
Peters; BTS, Edinburgh, personal communication). A monoclonal 
antibody Eswf/2, which is specific for von Willebrand factor was 
also utilised (kindly provided by Dr Peters) and it was found that 
GLIO and N.GLIA did not express this specific marker.
In conclusion, the 2 cell lines (GLIO and N.GLIA), which were 
thought to be astrocytic cell lines, did not express GFAP. They did 
not express vW factor specific for the endothelial cell lineage, and in 
culture they had a moiphology which could be related to the 
astrocyte lineage or to smooth muscle lineage. At the time, there was 
no reliable specific marker for smooth muscle cells.
As an alternative to 'home-made' astrocyte cells, 2 cell lines of 
the astrocytic lineage were obtained from external sources. The first 
cell line, kindly provided by Professor Weiss (ICR, London) , was U 
138 and had been shown to be susceptible to HIV despite its lack of 181
Figure R5-1: Absence of mycoplasma contamination of cell line 
GLIO as visualised by DAPI stain (magnification x 800) (N.GLIA 
cell line did not show any infection by mycoplasma either).
Figure R5-2: GLIO cell line negative for GFAP. Some cells are 
mitotic (—>) (N.GLIA was also negative for GFAP (magnification 
x 400). 182
Figure R5-3: GLIO cell line positive for VIII/vW antigen by 
immunofluorescence using the SAPU antibody (magnification x 
600).
Figure R5-4: Perinuclear granules visible with the SAPU anti­
factor VIII/vW in the GLIO cell line (magnification x 1200).
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Figure R5-5: Long appendages of GLIO cell line stained with the 
SAPU anti factor VIII/vW (magnification x 600)
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expression of the CD4 receptor [Clapham P.R., 1989]. The second 
cell line, G-CCM ,was obtained from the European Cell Culture 
Organisation and was originally produced by I. Fresney’s group in 
Glasgow [Frame M.C. et al, 1984]. Both cell lines were originally 
said to express 100 % GFAP. However, when tested in our 
laboratory, only 10 % of the cells expressed this marker. Again, this 
phenomenon of limited expression of GFAP by astrocyte cells has 
been reported [Frame M.C. et al, 1984]. Figure R5-6 and R5-7 show 
the GFAP reactivity with G-CCM cells and U-138 respectively. 
Conditioned culture media from these 2 cell lines were collected, 
centrifuged to eliminate cell debris and stored at - 20 0 C for further 
use.
R5-6a R5-6b
Figure R5-6a : G-CCM cell line stained with anti-GFAP (Dako). 
R5-6b : U 138 cell line stained with anti- GFAP (Dako).
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B. Human umbilical cord endothelial cells.
As already discussed, characterisation of any brain cell line in 
culture is hampered by the fact that the cell line can stop expressing 
markers specific for the lineage of origin . This is well documented 
with both types of cell lines dealt with in this chapter - endothelial 
and glial cell lineage. It was therefore important to establish well 
characterised endothelial cell lines which are known to express 
consistently endothelial lineage markers in order to assess the 
different antibody markers available and possibly to use this 
characterised cell line as standard. The astrocyte cell lines have 
already been described above.
A well established source of endothelial cells is the umbilical 
cord and with advice from Dr Jeremy Pearson (Clinical Research 
Center, Harrow) a method for culturing human umbilical vein 
endothelial cells (HUVEC) was devised (see Material and Methods 
Section). Umbilical cords were obtained from consenting patients in 
the maternity hospital at Kirkcaldy.
The culture of HUVEC was successful, and during this time 
multiple markers specific for the endothelial lineage were collected 
from different sources and tested on HUVEC and on negative 
control cell lines (HELA and VERO cells). Table R5-1 gives a list of 
all the markers tested and the results observed on known cell lines.
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Table R5-1: List of specific markers tested on HUVEC and other 
known cell lines using the immunofluorescence method .
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C. Growing human brain endothelial cells in culture
The frequency of these experiments was greatly influenced by 
the availability of normal human brain samples from the 
neurosurgery departments. The only source of such a sample for a 
human brain endothelial cell line was temporal lobes obtained at 
lobectomy for intractable temporal lobe epilepsy. This type of 
neurosurgery is not frequent (roughly 40 cases a year in Great 
Britain) and 2 such samples were available during the time course of 
this thesis).
The optimal method for growing human brain endothelial cell 
lines in culture is described in detail in the Material and Methods 
section. However some parts of this method needed to be refined and 
changed. The overall principle of the method was to purify brain 
vessels from a brain sample taken at surgery and to treat the vessels 
with collagenase in order to break parts of the structure of the 
vessels so that endothelial cells migrated outside these vessels. The 
vessels in culture should stick to the culture petri-dish and then 
endothelial cells should migrate from these vessels and form a 
confluent monolayer which can be trypsinised and expanded.
The first human brain sample was processed and purified 
brain vessels were seeded on culture petri dishes without treatment 
with collagenase. After a week of culture, the purified vessels were 
floating but none of the vessels had adhered to the culture plate. It 
was then thought that the collagenase treatment would make the 
vessels more sticky as the extracellular matrix -site of protein 
involved with adhesion processes - was likely to be exposed by the 
collagenase treatment. Just before obtaining the second human brain 
sample, the collagenase treatment was standardised with purified rat 
brain vessels. The brain vessels were purified, treated with 
collagenase for different lengths of time and a change in the 
structure of the vessels visualised by inverted microscopy. During 
the first minutes of treatment with collagenase, the structure of the 
vessels did not change. However after 5 minutes the architecture of 
the vessels opened up and the cell nuclei (from pericytes or 
endothelial cells) protruded to a greater extent than in the intact 
structure. After about 10 minutes at 37 °C (1 mg/ml of collagenase) 
the vessels disintegrated. It was thus concluded that a collagenase 
treatment of 7 minutes was optimal. Unfortunately , despite the 
collagenase treatment the rat vessels did not stick to the culture petri 188
dish. The human brain sample arrived before the method with the 
rat vessels was further refined. The only modification that was 
introduced for the second human brain sample was that the culture 
petri dishes were coated with gelatin as an attachment factor 
(fibronectin or other attachment factors were not available in the 
department at the time) as it had been reported that the presence of 
attachment factors on the culture dishes was an important factor 
[Shivers R.R. et al, 1988]. However, the collagenase treated vessels 
did not stick to the petri dish even after 5 days in culture.
It is clear from the present limited experience of growing human 
brain endothelial cell lines in culture and from the small number of 
published papers that no simple method will work and that multiple 
factors are critical for the success of such methods [Pearson J., 1990].
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INTRODUCTION OF THE T CELL PROLIFERATION 
STUDIES:
After preparation, the antigens - human brain vessels and human 
myelin - were used in a T cell proliferation and a humoral assay to 
assess immune response from multiple sclerosis patients and controls 
to support the 'autoimmune theory' of multiple sclerosis. A T cell 
response in MS patients has been sought in response to very few 
myelin antigens apart from myelin basic protein and it is therefore 
pertinent to attempt to investigate the possible immune response 
against other myelin antigens as well as the antigens of the blood 
brain barrier. It was thus decided to separate the proteins of both 
myelin and brain vessels and to test each of these proteins in the T 
cell assay. In order to do so, it was decided to use the 'nitrocellulose 
T cell assay ' which has the potential to avoid difficult purification 
of proteins . The nitrocellulose T cell technique utilises separation of 
antigens by SDS-PAGE followed by blotting onto nitrocellulose 
paper (NCP). The appropriate polypeptide antigen band can then be 
cut out, dissolved in DMSO and reprecipitated as microparticles of 
antigen-NCP which can be used as antigen in a standard proliferation 
T cell assay.
In the following chapter standardisation of the 'NTP T cell’ assay is 
described.
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R6: T CELL PROLIFERATION STUDIES:
Abbreviations used in this section (see text) :
NTP T cell assay : 'nitrocellulose T cell' assay.
NCP : nitrocellulose particles.
Ntcp : nitrocellulose paper.
Ag-NCP : Antigen-NCP.
Neg (Ag)-NCP : Negative control NCP with irrelevant antigen. 
Mock-NCP : Buffer alone-NCP.
PBMCs : peripheral blood mononuclear cells.
FCS: Foetal calf serum 
PHA : Phytohemagglutinin
PPD : Purified protein derivative (from Mycobacterium
tuberculosis).
Standardisation of the ’NTP T cell assay*.
The first aim of the T cell study was to standardise and 
optimise the 'nitrocellulose T cell' assay (’NTP T cell' assay). First, 
the conditions of a standard T cell proliferation assay were assessed 
in order to compare them with those of a 'NTP T cell' assay. Both 
techniques were standardised on the same basis that each test sample 
was incubated in triplicate with 2.10^ peripheral blood mononuclear 
cells (PBMCs) /well in a final volume of 200 pi/ well. The PBMCs 
were cultured for a variable period of time (3 days -5 days with 
mitogens and 5 to 7 days with soluble antigens or antigen-NCP (Ag- 
NCP)) and pulsed with 0.5 pCi of 3h thymidine per well for the last 
16 hours of culture. For practical reasons of availability and also of 
continuity for the comparisons, the PBMCs of one individual (BES) 
were used as standard in the first instance.
In relation to a standard T cell proliferation assay, mitogenic 
stimulation was assessed with phytohemagglutinin (PHA) and 
antigenic stimulation was assessed with different antigens (purified 
protein derivative (PPD), M. tuberculosis, tetanus toxoid, tetanus 
toxin, adenovirus, influenza virus). These antigens were chosen and 
tested for different reasons. Some were available in the department 
(adenovirus). This antigen preparation as well as influenza were 
taken as good examples of viral antigens likely to be recognised by 
normal PBMCs. The other antigens were gifts and were known to be 
good 'recall' antigens for T cell proliferation assay e.g tetanus toxin 
or PPD.
However these antigens were only available in the department 
over a period of time (either because they were gifts or because they 
had to be prepared). This delay in obtaining a battery of antigens 
made the assessment of the 'NTP T cell' assay more difficult and 
longer to undertake than was expected. A chronological summary of 
this investigation is presented below.
For each set of experiments, appropriate negative controls 
were prepared depending on the antigen tested and the T cell 
proliferation assay used (classical T cell assay or 'NTP T cell' assay). 
Concerning the 'NTP T cell' assay, a simple nomenclature will be 
followed in order to describe the different nitrocellulose particles 
(NCPs) prepared (nitrocellulose paper will be called Ntcp). Negative 
controls were either prepared with irrelevant antigens blotted or 
spotted on Ntcp and will be called Neg (Ag) -NCP where Ag refers 
to the antigen used. A second type of negative control - more 
frequently used in this report - was prepared by spotting or blotting 
buffer alone on Ntcp and these negative controls NCP will be named 
MOCK-NCP. The corresponding buffer for these latter NCP was 
chosen in relation to the experiment performed and will be described 
for each experiment. The negative control for the blotting 
experiment was prepared with denaturing buffer alone blotted on 
Ntcp. In general the negative control for an experiment was 
prepared in parallel on the same SDS-PAGE gel as the antigens to be 
tested. This was prepared from a track where electrophoresis buffer 
alone was run and then blotted on Ntcp as the antigen (see Figure 
MM 12-6 pg 121 for an example).
a/ Influenza virus antigens (gift Mr A. Douglas, NIMR)
First influenza antigens were used but did not induce a proliferation 
in either a normal T cell assay or the 'NTP T cell' assay. Figure R6- 
la shows the SDS PAGE of the virus preparation and Figure R6-lb 
shows the blot which was used for preparing the NCP related to this 
antigen preparation. Two major bands are visible on the SDS PAGE 
gel as well as minor bands, the top major band, FI, corresponded to 
the viral proteins HA1, NP and NA and the lower band, F2, 
corresponds to HA2 [Murphy B.R. et al, 1990]. The negative control 
(Neg (Ag)-NCP ) used in this experiment was normal human serum 
blotted on Ntcp from which bands corresponding to the molecular 
weight region of heavy and light chain were cut out; another 
negative control used was MOCK-NCP. 192
1 2
Figure R6-la : SDS-PAGE of the purified influenza virus 
preparation (X 31 strain) used for preparing the FLU-NCP used for 
the standardisation of the 'NTP T cell' assay. The virus preparation 
was run on the right track number 2 (the corresponding viral 
proteins are discussed in the text). Track 1 (left) shows the 
molecular weight markers starting from the lower band 14 kd, 18kd, 
29 kd, 43 kd, 68 kd and 97 kd.
193
A B
Figure R6-lb (A): Blot used for the preparation of the FLU-NCP 
and the MOCK-NCP. The influenza preparation shown in figure 
R6-la was run on SDS PAGE using a single comb tooth and then 
transferred onto the blot shown above. The 2 edges of the blot were 
stained with naphthalene black and the 2 main bands of the virus 
preparation located. The central part of the blot, which was only 
washed with PBS and not stained, was cut in order to select only the 
2 viral bands (hatched area) for the purpose of the experiment FLU 1 
(middle band) and FLU2 (lower band)(the corresponding viral 
proteins are discussed in the text). An additional band was cut in the 
high molecular weight region (the top hatched band) to provide the 
negative control, MOCK-NCP.
Figure R6-lc(B): Second blot used for the preparation of new 
FLU-NCP using the same virus preparation as shown in figure R6- 
la. The negative control, MOCK-NCP, was prepared in parallel 
from a different blot where electrophoresis had been carried out in 
the absence of antigen. 194
Figure R6-2a shows the negative results of the proliferation assay; 
PHA mitogenic stimulation was satisfactory but none of the antigens- 
NCPs induced a significant stimulation index over the controls. This 
experiment was repeated with the same negative results (see Figure 
R6-2b) using the same system but with newly prepared influenza- 
NCP particles (see figure R6-lc) . The quantity of proteins (about 
0.05 |Ltg/ml) used in the T cell proliferation assay in the well 
corresponded to the quantity used in already published work 
[Palacios-Boix A.A., 1988] [Abou-Zeid C et al, 1987], At this point 
it was not known if the conditions of a T cell proliferation were 
right for the soluble viral protein or if the control was not immune 
to the strain (X 31) of influenza virus used to prepare the FLU- 
NCPs. One colleague (BCP) performed a haemagglutination assay 
using different strain of influenza virus and BES’ serum in order to 
evaluate the antibody response against different influenza virus. It 
was shown that BES had antibody against X 31. Antibodies to 
influenza strain X 31 positive at 1/128; antibodies to influenza strain 
AJAP1967 positive at > 1/64; antibodies to influenza strain C 
positive at < 1/64 and antibodies to influenza strain APR8 1944 (Hl 
negative) negative. Therefore no definitive conclusion could be 
drawn in relation to the 'NTP T cell' assay (later on, it was shown 
that soluble virus X 31 (control not included in experiment described 
in fig R6-2a and R6-2b) induced a proliferative response with BES' 
PBMCs. It was therefore decided to test a different antigen which 
was likely to be positive for inducing a proliferative response with 
the control's PBMCs.
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Figure R6-2a : Result of the T cell proliferation (d.p.m) with 
FLU 1-NCP, FLU2-NCP and MOCK-NCP prepared as shown in 
figure R6-lb. Proliferations of mononuclear cells incubated with 
medium alone and with PHA (1 Jig/ml) are also shown.
d.p.m
110000 :
medium alone 
PHA lmg/ml 
MOCK-NCP
0
FLU1-NCP 400 pg/ml E2 
FLU1-NCP 200 pg/ml □ 
FLU1-NCP 100 pg/ml ■ 
FLU1-NCP 50pg/ml ||
,0000
0
test samples
FLU2-NCP 400 mg/ml FI 
FLU2-NCP 200mg/ml Q 
FLU1-NCP 100 pg/ml □ 
FLU1-NCP 50pg/ml m
Figure R6-2b: The same experiment as that described in figure 
R6-2a was repeated with the different NCP prepared as described in 
figure R6-lc. 196
b) Purified protein derivative (PPD):
As the normal control (BES) had been vaccinated against
tuberculosis, purified protein derivative (PPD) was used as one of 
the antigens to be tested by this technique, and when it was received 
in the department (gift from Wellcome), it induced a proliferation 
with the control’s PBMCs. Figure R6-3 shows the result of the 
proliferative response with soluble PPD and with other antigens 
tested in the same experiment.
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Test samples
Figure R6-3: T cell proliferation (d.p.m.) with soluble PPD (50 
and 10 |4,g/ml) to assess that the PPD preparation induced a T cell 
proliferation with BES’ mononuclear cells. PHA 1 JLtg/ml was also 
included in the experiment.
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When the proliferative capacity of the PPD preparation was 
established, an attempt to prepare the PPD-NCPs was made but the 
PPD could not be transferred onto Ntcp by electroblotting. This 
phenomenon is not understood despite an experiment undertaken to 
explain it. The concentration of the PPD preparation was assessed by 
dot blot and was 1 mg/ml. As PPD has a low molecular weight of 
between 9.5 kd to 11 kd, the PPD preparation was run on a 20%
SDS PAGE gel and electroblotted onto Ntcp. In this experiment 2 
nitrocellulose sheets were placed on the anodic side of the system and 
one nitrocellulose sheet was placed on the cathodic side of the gel. 
The sheets were stained with naphthalene black after electroblotting 
(see Figure R6-4 c, d and e) and the SDS-PAGE gel, after transfer, 
was stained with coomassie blue (Figure R6-4 a). PPD did not 
appear on any of the nitrocellulose papers after staining although the 
PPD seemed to have been transferred properly. PPD was stained by 
naphthalene black when spotted on Ntcp or when stained on an SDS 
PAGE (Figure R6-4 b). In conclusion the inability to transfer PPD 
on Ntcp by electroblotting made any attempt to test this antigen in a 
'NTP T cell' assay impossible.
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Figure R6-4: Experiment designed to investigate the transfer of 
PPD on nitrocellulose paper. PPD was run on different tracks of an 
SDS-PAGE gel. From left to right:
A: track 1: molecular weight marker; Track 2 and 3: PPD stained 
with coomassie blue.
B: tracks 4 and 5 stained with naphthalene black. The other side of 
the SDS PAGE gel was transferred onto nitrocellulose paper.
C: gel stained with coomassie blue after transfer of the PPD.
D: first nitrocellulose paper on the cathodic side stained with 
naphthalene black after electrotransfer.
E: a second nitrocellulose paper was put in contact on the cathodic 
side of the previous one and also stained with naphthalene black after 
electrotransfer. Another nitrocellulose paper was also applied on the 
other side of the SDS PAGE (anodic side) and was also stained with 
naphthalene black but did not show any stained PPD (not shown). 199
In the meantime, although the conditions of the T cell assay were not 
changed and the same batches of T cell medium components used, 
high background was recorded in the proliferative response of the 
control's PBMCs alone. A synopsis of the background over time (5 
proliferation assays experiments were done between the 10/3/89 and 
16/6/89) using the PBMCs from the same person (BES) and the same 
conditions of culture (5 days) is recorded in Figure R6-5. It was 
found that the sole agent responsible for this high background was 
the foetal calf serum (FCS). However, 2 types of media which were 
available in the laboratory were also tested: RPMI 1640 liquid 
medium purchased directly from the GIB CO company and RPMI 
1640 prepared in the laboratory from the powder purchased from 
GIBCO company. The latter gave high background whereas the 
former did not (see Figure R6-6a). Secondly, the effect of 
mercaptoethanol was tested using mitogen stimulation and it was 
found that the stimulation indexes with mercaptoethanol included in 
the culture medium were much higher than when mercaptoethanol 
was omitted (see Figure R6-6c). Thereafter human AB serum was 
used in the T cell assays and mercaptoethanol was included in the 
culture medium.
H
□
□
10/3/89
30/3/89
17/5/89
3/6/89
16/6/89
Figure R6-5: Increase of the background proliferation count 
(c.p.m.) over time with BES' PBMCs cultured for a total of 5 days 
with medium alone . The medium used in all the experiments 
contained 10 % of foetal calf serum from GIBCO. 200
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Figure R6-6a: Effect of different sera and media on the
proliferation (d.p.m) [A] of BES’ PBMC which were cultured for a 
total of 5 days with medium alone and on the stimulation index with 
PHA (1 jig/ml) [B].
A.B.C: the T cell medium was made with RPMI 1640 purchased as 
a liquid form from GIBCO and p-mercaptoethanol was included in 
medium. A: 10% human AB+ (BTS).
B: 10% FCS (GIBCO).
C: 10% FCS (Sera Lab).
D: The T cell medium was made up with RPMI 1640 prepared in the 
laboratory from a stock powder purchased from GIBCO. The 
culture medium contained 10% FCS from Sera Lab and p- 
mercaptoethanol (PHA stimulation with this medium was not tested).
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with mercaptoethanol
Figure R6-6b: Effect of P-mercaptoethanol on the proliferation of 
BES' PBMC to different concentrations of PHA which were cultured 
for a total of 3 days . SI (mean d.p.m with PHA/mean d.p.m with 
medium alone) is shown for all the test samples.
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c) Mycobacterium (M.) tuberculosis (gift from Dr A. Colston
NIMR)
M. tuberculosis as soluble antigen induced high proliferative 
response of the control's PBMCs (see Figure R6-8c) This 
preparation was successfully transferred onto Ntcp by electroblotting 
but when used in the 'NTP T cell’ assay, it did not induce any 
proliferation of the control's mononuclear cells. These experiments 
are illustrated in Figure R6-8 a which shows the SDS-PAGE minigel 
of the mycobacterium preparation used in the experiment and Figure 
R6-8 b shows the Ntcp blot used for preparing the 7 different NCPs 
which spanned over the low and medium molecular weight regions 
which are likely to contain recall antigens in most individual 
vaccinated with BCG (Dr Palacios-Boix, personal communication). 
Figure R6-8c shows the result of the proliferation assay using the 
NCPs. A lot of effort was thus spent to pint point the stage (s) of the 
procedure which could explain the failure of the technique - the type 
of nitrocellulose paper (3 types were tested), the batch of DMSO, the 
carbonate buffer, the washing procedure, the disruption mixture 
used to dissolved the protein, the T cell medium - but to no avail : 
changing one of these factors did not help in achieving a 
proliferative response (data not shown).
Figure R6-8a: SDS-PAGE of the mycobacterium Tuberculosis 
preparation (used in the proliferation assay reported in figure R6-7) 
stained with coomassie blue - first track (left). The second track 
represents the molecular weight marker (right). 203
Figure R6-8b: Nitrocellulose blot of the MT preparation. The blot 
was used to prepare the 7 mycobacterium-NCPs as labelled on the 
picture. A different blot with electrophoresis buffer transferred was 
used to prepared the MOCK-NCPs.
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Figure R6-8c: proliferation (d.p.m.) of BES' PBMCs incubated 7 
days with mycobacterium tuberculosis and with the 7 different MT- 
NCPs prepared as shown in figure R6-6b.
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After all these negative results and attempts, the 'NTP T cell' assay 
was discussed with a research worker (Dr Steve Lee, Birmingham 
[Lee S et al, 1989]) familiar with this technique, and, his advice 
proved to be useful. Other people had been consulted since the start 
of the investigation into the 'NTP T cell' assay including Dr A Rees 
(Hammersmith hospital) and Dr Rook (Middlesex hospital) (see 
[Abou-Zeid C. et al, 1987]) - who also had great experience in this 
technique. Numerous possibilities which could explain these negative 
results were considered with Dr Lee and were then tested in the 
following experiments.
It was first thought that the NCPs which had been processed in 
DMSO could be toxic to the PBMCs. Mycobacterium tuberculosis 
was incubated with previously prepared NCPs to assess if the latter 
could inhibit the proliferative response induced by M. tuberculosis 
antigen. This was not the case (see Figure R6-9).
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Figure R6-9: lack of inhibition by the MOCK-NCPs, used in the 
experiment described in figure R6-8b, upon the T cell proliferation 
of BES' PBMC after 7 days incubation with mycobacterium 
tuberculosis. 205
The other possibility was that the antigens had lost their antigenicity 
during the preparation of the NCPs (e.g because of the DMSO 
treatment) or that the antigen-NCPs were not able to be processed by 
the antigen presenting cells present in the wells during the T cell 
proliferation assay. The latter alternative could have been explained 
by the possibility that too large a size of the NCPs were obtained. It 
was thus decided that the preparation of the NCPs - especially the 
reprecipitation step - had to be refined. Reprecipitation of the 
particles dissolved in DMSO was achieved, under control condition, 
by delivering the carbonate buffer at a constant speed of 0.8 ml/min 
using a peristaltic pump with the nitrocellulose dissolved in DMSO 
stirred on an electric stirrer, at constant and reproducible speed (see 
Material and Methods section MM12, figure MM12-4 pg 117). After 
precipitation, the particles washing was done in the cold. The 
precipitation of the particles was apparently much more efficient. 
This became evident when the suspension of the particles was 
monitored after precipitation: the NCPs stayed in suspension for a 
longer period of time instead of sedimenting quickly at the bottom of 
the Eppendorf tubes. The size of the NCPs was very small and they 
were visualised by scanning electron microscopy. They measured in 
average less than 1 gm (see Figure R6-10 a, b, c).
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Figure R6-10a: Scanning electronmicroscopy of an antigen 
presenting cell (BES') incubated with mycobacterium-NCP. Two 
lymphocytes can be seen on the cell and the mycobacterium-NCP 
(arrow); (white bar shown corresponds to 1 pm).
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Figure R6-10b: A different antigen presenting cell (APC) is 
photographed. The NCP are shown (arrow) and it is thought that 
platelets are also present on the APC (*); white bar =10 |im.
Figure R6-10 c: High magnification of mycobacterium- NCPs 
(arrow) on the APC (white bar shown corresponds to 1 pm). At 
least 4 lymphphocytes (L) can be seen .
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However, it was also realised that both, the amount of Ntcp in 
relation to the amount of DMSO, was critical for the optimal 
precipitation of the Ntcp. These two parameters were interdependent 
in producing an optimal curve of precipitation - the result of an 
experiment demonstrating this is shown in figure R6-11: 6mm x 2 
mm Ntcp and 6mm x 4 mm Ntcp were dissolved in different 
amounts of DMSO (150 pi, 250 pi, 500 pi) and then reprecipitated 
with carbonate buffer delivered with a peristaltic pump at 0.8 mis 
per minute. Precipitation was scored as degree of cloudiness and 
time of naturally occurred sedimendation of the NCPs was also 
registered. Then each aliquot was centrifuged on a minifuge to 
visualise the volume of the pellet obtained. The optimum quantity of 
DMSO for 6 mm x 2 mm Ntcp was 250 pi and the optimum 
concentration of DMSO for 6 mm x 4 mm Ntcp was 500 pi.
The spotting technique: (see Material and Methods, section MM12, 
page 112)
Following other workers' advice (Dr G.Rook and E. Filley 
[Abou-Zeid C. et al, 1987][Filley E. et al, 1989]), it was also 
realised that the spotting technique could give invaluable data on the 
standardisation of the T cell technique with less steps involved in the 
preparation of the NCP. Mycobacterium spotted onto Ntcp was 
tested successfully (see Figure R6-12, track A to F): ten pg of 
M.tuberculosis was spotted on 20 mm2 Ntcp and after treatment with 
DMSO and reprecipitation and washing the MT-NCP were 
resuspended in 1 ml of medium, aliquoted and stored at - 70°C. The 
optimum concentration/well was 10 pi (0.2 mm2,0.1 pg of this 
solution (see below).
As the next step, experiments were carried out to standardise 
the method further by analysing the different factors which could 
influence a proliferative response (see figure R6-12). These were 
tested at least twice to assert the reproducibility of the method. In 
particular, dose dilution effect of the NCP-antigen upon the T cell 
proliferation assay were studied (see also the blotting technique 
(below)). It was found that unlike a standard proliferation assay 
where only the concentration of soluble antigen (Ag) per well 
(usually 1-100 pg/ml) is critical, 2 factors have to be taken into 
consideration for the 'NTP T cell' assay - the quantity of 
antigen/mm2 of Ntcp and the quantity of Ag-NCPs that is incubated 
into each well during the T cell proliferation assay. From the result 209
of the present study, and, comparing with the literature [Abou-Zeid 
C. et al, 1987] [Lamb J.R. et al, 1988] [Lee S.P. et al, 1989], it was 
concluded that the optimum concentration of Ag and corresponding 
quantity of Ntcp per 200 jil well was 0.01-0.1 pg and 0.1 -0.4 mm2 
respectively. These parameters were calculated as a function of the 
concentration of Ag loaded or spotted at the beginning of the 
procedure and do not take into consideration the possible loss of 
antigen during the procedure e.g during the washing of the NCPs. 
These parameters can be further optimised when one considers the 
type of antigen used in the assay. For example, for a complex 
antigenic preparation like mycobacterium tuberculosis spotted on 
Ntcp, one should choose the higher range of the optimum 
concentration of antigen (0.1- 0.05 pg /well) whereas for an antigen 
which represents a single protein band (e.g 155 kd TT transferred 
on a blot) a much lower concentration of antigen is more 
appropriate (0.02-0.01 pg/well) (see figure R6-14).
Other factors related to the preparation of the NCPs were 
studied e.g the sonication of the particles prior to incubation for the 
T cell assay and the washing of the Ntcp prior to dissolution by 
DMSO. It was found that sonication of the particles did not improve 
the stimulation ( figure R6-12, tracks G) and that washing the Ntcp 
with detergent (after the spotting of protein) could induce loss of 
protein from the Ntcp (figure R6-12, tracks H to J). Thereafter 
another experiment was set up to determine the importance of 
washing of the Ntcp during the blotting technique and will be 
described below under the blotting technique section.
The time course of the T cell proliferation assay using NCP- 
antigen particles was also assessed (see figure R6-13) using soluble 
mycobacterium tuberculosis and mycobacterium tuberculosis-NCPs 
as antigens. PHA (1 pg/ml) was also tested for comparison with 
mitogenic T cell stimulation. It was found that the optimum culture 
time was 6 to 7 days for the 'NTP T cell assay' with unsatisfactory 
stimulation index at 5 days whereas it was 5 to 7 days with a classical 
T cell proliferation assay .
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Figure R6-11: Interrelationship between the quantity of DMSO 
and the surface of nitrocellulose paper on the precipitation of the 
NCP by the carbonate buffer. Two different sizes of NCP (6 mm x 2 
mm; 6 mm x 4 mm) were incubated with different quantities of 
DMSO (150, 250, 500 pis). The precipitation was graded by 3 
different methods: 1. visually: after precipitation the solution became 
uniformly cloudy ; however if there was no precipitation, the 
solution remained clear.
2. The time of the natural sedimentation of the nitrocellulose 
particles: the time registered was when the pellet began to appear at 
the bottom of the Eppendorfs.
3. The size of the pellet after sedimendation was graded visually.
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Figure R6-12 : T cell proliferation with different Mycobacterium 
tuberculosis (MT)-NCPs prepared by spotting the MT on Ntcp 
before DMSO treatment. The samples were incubated for 7 days.
A: medium alone
B: M.T. : 2 pg/ml.
C: NTP-Blank, control of E (2 mm2 of Ntcp/well)
D: NTP-Blank, control of F (0.2 mm2 of Ntcp/well)
E: M.T.-NCP (2 mm2 of Ntcp/well; 1 pg of M.T. /well)
F: M.T-NCP, 1/10 dilution of E.
G: sonicated M.T.- NCP (same concentration as F)
H: M.T.-NCP (the M.T. was boiled dissolved in electrophoresis 
loading buffer (disruption mixture) but the Ntcp was not washed 
before treatment with DMSO, same concentration as F/well.
I: NTP was processed in the same manner as H but the NTP was 
washed with PBS+ Np 40.
J: Same as I but the quantity of M.T. spotted on the Ntcp was twice 
as in the case of I.
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Figure R6-13: Time course of the T cell proliferative response 
with soluble mycobacterium tuberculosis (MT) (2 Jig/ml), MT-NCPs 
(0.2 mm2, o.l gg of MT/ well), and PHA (1 gg/ml).
The stimulation indices for each samples are shown:
Stimulation index of MT (d.p.m sample/ d.p.m medium alone) 
Stimulation index of PHA as above.
Stimulation index of MT-NCP (d.p.m MT-NCP/d.p.m NTP-Blank)
The numbers in bracket shows the corresponding d.p.m background 
for each sample
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The blotting technique (see Material and Methods section MM 12, pg 
119)
When the spotting technique was thought to be reproducible 
the blotting technique was tested with proteins electroblotted on 
Ntcp. To achieve this 2 types of system were used: 1. Tetanus Toxin 
(TT) electroblotted on Ntcp, 2. Adenovirus proteins electroblotted 
on Ntcp. The protocol of the blotting technique is basically the same 
as the protocol for the spotting technique. A home-made comb was 
devised in order to optimise the loading of the proteins on the SDS 
PAGE minigel. The representation of the measurement of the comb 
is shown in Figure MM-12 page 119 (Material and Methods section) 
and fitted a minigel apparatus. Figure MM12-6, page 121 (Material 
and Methods section) shows the blot prepared with purified Tetanus 
Toxin (gift from Dr Colin Watts, Dundee). This blot was used to 
prepare the 3 different TT-NCPs and the MOCK-NCPs. Denatured 
TT shows 3 bands (155 kd, 100 kd, 55 kd) as seen in figure MM12-6 
(and Dr C. Watts, Dundee, personal communication). Six pi (3 pg) 
of the stock TT solution (0.5 mg/ml) were loaded on a gel and half 
of the track was processed, thus 1.5 pg of TT. Bands of 6 mm x 2 
(12 mm2) were cut out for each protein band (155, 100 and 55 kd), 
thus the 155 kd band (roughly half of the total weight of TT as seen 
on the gel page 121) was processed at 0.75 pg / 12 mm2 and 
resuspended in 500 pi of T cell medium and stored aliquoted at - 
70°C. The final concentration of the 155 kd band-NCP was 8.33 pi 
/well (0.2 mm2 Ntcp,0.012 pg/ 200 pi well (x4, /ml)). Using this 
comb system, the system was well standardised when assessed on a 
'NTP T cell assay' (see Figure R6-14).
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Figure R6-14: Proliferative response of different TT-NCPs (TT= 
tetanus toxin). The samples were incubated for 7 days.
A: medium alone.
B: TT (1 gg/ml)
C: TT155 kd-NCPs (0.2mm2,0.012gg/weU)
D: TT 155 kd-NCPs (0.2mm2, 0.022gg/well)
E: TT 155 kd-NCPs 1/4 dilution of C.
F: TT 155 kd-NCPs 1/10 dilution of C.
G: TT 100 kd -NCPs (0.2mm2, 0.006 gg/well).
H: TT 55 kd-NCPs (0.2mm2, 0.006 gg/well).
I : NTP-MOCK, control of C D, G, H (0.2mm2 of Ntcp).
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The other system used was the adenovirus type 2 (Ad-2) (prepared 
in the laboratory by Ian Leith [Russell W.C. et al, 1967 and 1982]) 
and the nitrocellulose blot used to prepare the different adenovirus 
proteins-NCPs is shown in figure R6-15a.
Six main adenovirus proteins were visible on the blots (from high 
molecular to low molecular weights (H (hexon), P (penton), F 
(fibre), V, VI and VII) and NCPS were prepared for the 6 proteins. 
These Ad2 proteins-NCPs were tested in a T cell proliferation assay 
and H, F and VI induced a proliferation when incubated with BES' 
PBMC with F producing the most proliferation. However in this 
particular experiment the background counts were higher than in the 
previously T cell proliferation experiments (medium alone and 
MOCK-NCPs) (see figure R6-16).
AB C
Figure R6-15a: Blot used for the preparation of the Ad2 proteins- 
NCPs. Track A shows the transferred Ad2 proteins with their 
corresponding names. Track B: molecular weight marker. Track C: 
Ad2-proteins blotted, the width of the track was originally 12 mm 
(same as track A but a 6 mm lane was cut out in the middle in order 
to prepare the Ad2 proteins-NCPs corresponding to H, P, F, V, VI 
and VII. 216
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Figure R6-15b: T cell proliferation (d.p.m) experiment using the 
Ad2 proteins-NCPs prepared as shown in figure R6-15. The T cell 
assay was done over 7 days.
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Some experiments were then undertaken in order to standardise and 
to assess the blotting and the spotting technique further. One 
experiment established that the storage of the Ag-NCPs does not 
alter their antigenic potential. This was demonstrated with TT 
155kd-NCPs stored 2 months at - 70°C. These particles were 
compared with newly prepared TT 155kd-NCPs which had only 
been stored 24 hours at - 70°C. Both NCPs induced comparable T 
cell proliferation of BES’ PBMC (see figure R6-17)
medium alone 
gg PHA 1 (ig/ml 
H TT lpg/ml
□ MOCK-NCP
□ TT 155-NCP(new)
_ TT 155-NCP (2 months)
Antigens tested
Figure R6-17: T cell proliferation (d.p.m) experiment in order to 
assess the influence of the storage of NCPs at -70°C for a period of 
2 months. The T cell proliferation induced by TT 155 -NCPs freshly 
prepared (new) was compared with the T cell proliferation induced 
by TT 155-NCPs which had been prepared 2 months previously and 
stored at - 70°C until the T cell proliferation assay.
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One other experiment assessed the influence of the washing of Ntcp 
after electrotransfer (see in Figure R6-18), just before the treatment 
of the Ntcp with DMSO during the preparation of the NCPs. 
Doubling dilutions of a bovine serum albumin (BSA) solution 
(lmg/dl) was either run on a SDS-PAGE and electrotransferred ,or, 
after the electrotransfer spotted on the same Ntcp. A third technique 
[Randall RE et al, 1985] was also analysed: Aliquots of BSA solution 
were double diluted in the wells of a Terasaki plate and then put into 
contact for 1 hour with a nitrocellulose paper which was sandwiched 
between 2 plates (the top Terasaki plates contained the BSA 
dilutions). The nitrocellulose paper which had been in contact with 
the different dilutions of BSA was then either not washed, washed in 
PBS, washed with 0.3% tween 20 in PBS and then with PBS alone or 
washed with 0.05 % Np 40 in PBS and then in PBS alone. It was 
found that BSA directly spotted on Ntcp as well as BSA spotted on 
Ntcp by the immunodotblot method were washed away if detergent 
(Np 40 or Tween 20) was included in the washing buffer. However, 
when the BSA was electroblotted, it was not significantly washed 
away with detergent although it appears that there was some loss of 
proteins when compared to the washing without detergent. It was 
therefore decided, for the 'NTP T cell' assay that the proteins 
spotted- or electroblotted-Ntcp should be washed briefly in PBS 
without detergent before treatment with DMSO (spotting and 
electroblotting could therefore be compared).
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Figure R6-18: Effect of the washing on the retention of proteins 
electroblotted or spotted on Ntcp (see text for description of the 
experiment). In the central part of the photo, the nitrocellulose paper 
used for the electrotransfer of the double dilutions of BSA is shown 
(top part of each central nitrocellulose paper). On the same Ntcp, 
double dilutions of BSA were also spotted after transfer (lower part 
of each Ntcp). On the sides, double dilutions of BSA were 
transferred to a different Ntcp using the immunodotblot method with 
Terasaki plates.
The different Ntcps were subject to different washing procedures.
A. no washing .
B. washing with PBS .
C. washing with 0.3% Tween 20 in PBS .
D. washing with 0.05 % Np 40 in PBS .
The different Ntcps were then stained with naphthalene black and 
compared for the retention of proteins.
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CONCLUSION OF THE STANDARDISATION OF THE T 
CELL ASSAY AND INTRODUCTION TO THE CLINICAL 
STUDY.
The standardisation of the 'NTP T cell' assay has been achieved 
with 3 different antigenic systems: mycobacterium tuberculosis, tetanus 
toxin and adenovirus 2. The critical factor for the success and 
reproducibility of the technique was the size of the antigen nitrocellulose 
particles. The particles had to be very small to be presented to 
lymphocytes in the T cell assay. This was achieved by resuspending the 
nitrocellulose paper particles, previously dissolved in DMSO, in a 
bicarbonate buffer at constant and slow speed using a peristaltic pump. 
When reproducibility was achieved it was found that the technique was 
sensitive in the well controlled systems investigated.
The next step of the project was to undertake the clinical study 
(the NTP T cell assay and western blotting assay) with the antigens 
previously purified (myelin and brain vessels) with patients suffering 
from multiple sclerosis compared with neurological controls and 
normal controls. These investigations are described in the last results 
sections.
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R7- CLINICAL STUDY USING THE T CELL
PROLIFERATION ASSAY.
The assay, as defined after these studies, was performed on 12 
patients (6 MS and 6 neurological controls) and 6 normal controls 
using human brain microvessels and myelin as antigens (Table R7-1 
summarises the characteristics of the patients).
The results of the T cell proliferation study are 
presented in figure R7-1 for those patients who showed some T cell 
proliferation against Ag (myelin or vessel)-NCPs over the 
background and table R7-2 summarises these results. Two lots of 
AB+ serum were used; the second (used for the last 4 patients) had a 
much higher background than the first. One MS patient in acute 
relapse showed significant stimulation against a 55-65 Kd myelin 
band. Another MS patient in chronic relapse showed stimulation 
against a 45 Kd vessel band. A patient with progressive MS showed 
some stimulation against a ~ 68 Kd protein from the brain vessels. 
The 3 remaining MS patient showed no stimulation or suppression 
with either myelin or vessels bands tested: these patients were in 
remission at the time of the testing. Two patients with epilepsy and 1 
with anoxic brain damage showed stimulation or suppression with 
either myelin or vessel band tested : these patients were in time of 
remission at the time of the testing. The remaining 3 neurological 
controls (2 epilepsy and 1 diabetic) did not show any stimulation or 
suppression with the bands tested.
The results using spotted whole antigen were consistent with 
the results of the separated NCP in 2 pairs. The remaining pair of 
patients showed stimulated antigens but not with spotted whole 
antigen.
The 6 normal controls did not show any significant stimulation 
against either the vessels or the myelin antigens-NCPs.
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Numbers in each group SEX AGE Clinical status
Multiple sclerosis : 6
MS 1
MS 2
MS 3
MS 4
MS 5
MS 6
5 female / 1 male 41(26-52) Relapsing-remitting
attack
attack
remission
remission
remission
remission
Neurological controls
Epilepsy : 4 
Diabetes : 1
Brain damage : 1
3 female / 3 male 34(17-57) non determined
Normal controls : 6 2 female / 4 male 34 (24-60)
Table R7-1: Characteristic of the patients and the controls 
recruited for the T cell proliferation study.
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EPILEPSY 2 : NO STIMULATION OR SUPPRESSION WITH 
MYELIN-NCPs OR VESSELS-NCPs.
2i
NS 2
hhilllill
J i • “ ! i i i • i
1 234567891011
MS 6 AND DIABETIC PATIENT: NO STIMULATION OR SUPPRESSION 
WITH MYELIN-NCPs OR VESSELS-NCPs.
Figure R7-la: Stimulation indices obtained from MS patients and 
their neurological controls with the 11 myelin-NCPs bands and the 
17 vessels-NCPs bands. The results are shown by pairs as they were 
tested (* = stimulation index > 2). 224
Brain damage : No stimulation or suppression with myelin-NCPs or 
vessels-NCPs
Epilepsy 4 : No stimulation or suppression with myelin-NCPS 
or vessels-NCPs
MS 5 : No stimulation or suppression 
or vessel-NCPs
Figure R7-lb: Stimulation indices obtained from MS patients and 
their neurological controls with the 11 myelin-NCPs bands and the 
17 vessels-NCPs bands. The results are shown by as they were tested 
(* = stimulation index > 2 ).
MS PATIENTS CLINI. MYELIN VESSELS
MS-1 Remis. 0 16*
MS-2 Attack 7 0
MS-3 Remis. 0 0
MS-4 Attack 4,5,6,9*. 10* 8
MS-5 Remis. 0 0
MS-6 Remis. 0 0
NEUROLOGICAL C.
EPILEPSY-1 nd 0 6*,7*.9*
EPILEPSY-2 nd 0 0
EPILEPSY-3 nd 0 2,[3,5,15,16]* -
EPILEPSY-4 nd 0 8
DIABETES nd 0 0
BRAIN DAMAGE nd 0 0
NORMAL CONTROLS
NC-1 0 0
NC-2 0 0
NC-3 0 0
NC-4 0 0
NC-5 0 0
NC-6 0 0
Table R7-2: Summary of the T cell proliferation results with 
the 6 MS patients, 6 neurological controls and the 6 normal 
controls.
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R8: THE WESTERN BLOTTING STUDY,
a) Autoantibodies against human brain vessels
The western blots of the brain vessels showed only few sera 
with autoantibodies: six out 45 MS patients (13%), 8 out of 47 
neurological controls (17%) and 1 out of 20 normal controls (5%) 
had auto-antibodies against vessel bands on western blotting. The 
diagnoses of the neurological controls with autoantibodies to brain 
vessels were as follows: prolapsed disc : 1, headache/migraine : 2 , 
vertigo: 1, epilepsy : 4. Most individuals with autoantibodies against 
human brain vessels show reactivity with more than one band.
Figure R8-1 shows the blots of the individuals with autoantibodies 
against brain vessels (Tracks 1-6: MS patients; tracks 7-14: 
neurological controls; track 15: normal control). There was no 
unspecific reactivity recorded against the human brain vessel 
preparation (track 16 and 17: individual with no antibodies, track 19 
and 20: negative controls, 'conjugate' alone) unlike the myelin 
preparation (see below). Table R8 -1 shows the pattern of reactivity 
by molecular weight.
There is no significant difference between MS and other 
neurological controls concerning the pattern of reactivity. 
Nevertheless, 2 MS patients have autoantibodies against human brain 
vessels against the 64 Kd and 2 other MS patients have autoantibodies 
against the 97 Kd proteins whereas none of the controls have 
autoantibodies against these 2 proteins. The other bands with 
autoantibodies against brain vessels proteins are distributed evenly 
between MS patients and controls (22, 26, 30, 43, 50, 110, 190, 250, 
300 Kd proteins). Although the intensity of the bands are difficult to 
compare between blots, there is no obvious difference between MS 
and neurological controls. A rabbit anti - bovine serum was available 
and reacted against 2 human vessel proteins of around 43kd and 22 
kd. The sera of some of the patients with autoantibodies reacted with 
these 2 proteins (see Table R8-1 and fig R8-1, track 18).
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[ MS ][ Neurol. Cont. ]N[ - ]R[ - ]
Figure R8-1 : Blots of the purified brain vessels incubated with the sera from 
the MS patients (1-6) [MS], the neurological controls (7-14) [Neurol. Cont.] and 
the normal control (15) [N] containing autoantibodies to the brain vessels. Strips 
incubated with one MS patient (16) and one neurological control (17) sera [-] 
without such autoantibodies are also included. Track 18 [R] shows the reaction 
with the rabbit anti- brain vessels prepared in the laboratory. Tracks 19 and 20 
[-] show the strips incubated with the conjugate alone, (anti-human antibody 
(track 19) and anti-rabbit antibody (track 20)).
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Table R8-1: Molecular weight (kd) of the bands recognised by 
autoantibodies in the sera of the 6 MS patients (MS1-MS6), the 8 
neurological controls (C1-C8), the normal individual (N) (in the 
same order as figure R8-1) and the rabbit anti-human brain vessels 
(R).
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b) Autoantibodies against myelin:
The reactivity against myelin was more difficult to interpret. 
Most MS and neurological controls showed reactivity in the 45 to 60 
Kd range with different intensity above the background pattern of 
reactivity (see figure R8-2, tracks 2 to 18). The intensity of the blot 
with the normal controls was however weak (track 14-17).
On the strip incubated with the ’negative control' (second 
antibody alone), a band around the 70 kd region was present which 
therefore was due to non specific staining, perhaps due to 
endogenous peroxidase activity linked to this band (see figure R8-2, 
track 17). The band corresponding to the non specific band was 
present on most of the blots tested incubated with the patients' and 
controls' sera although its intensity varied greatly between blots. One 
batch (a blot) did not show this non specific background after 
development although other bands were highlighted with the sera 
tested (see figure R2-8, track 1).
Two MS patients and 1 neurological control suffering from 
migraine showed reactivity with the region corresponding to myelin 
basic protein and this may be relevant to the disease process (see 
figure R8-2, track 4,5 and 10).
A group of patients (4 MS and 4 neurological controls) 
reacted against proteins of medium molecular weight region > 25 
kd and < 50 kd but the pattern was variable between patients (see 
figure R8-2, tracks 6, 11, 12 and 13).
Many patients and controls (80 %) showed reactivity against 
high molecular weight region (< 150 kd), often as a doublet (see 
figure R8-2, tracks 4 to 9, tracks 11-13 as well as track 18 
corresponding the rabbit anti myelin serum) corresponding to the 
molecular weight region between 150 and 200 kd and others showed 
reactivity with even a higher molecular region > 200 kd (5 %) (see 
figure R8-2, track 1, 2 and 11).
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MYELIN
Figure R8-2: Blots of the purified human myelin incubated with 
the sera from the MS patients. Tracks 1 to 13: MS and neurological 
controls. Tracks 14 to 16 normal controls. Track 18 shows the strip 
incubated with the rabbit myelin antisera and track 17 shows the 
strip incubated with the conjugate alone (anti human
immunoglobulin).
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DISCUSSION.
Pl: THE CSF STUDIES:
The sensitivity and the specificity of the three CSF techniques 
(imprint immuno-fixation, immunoblotting and immunoabsorption 
and silver staining) was analysed in these studies.
All three techniques have been used to detect the production 
of oligoclonal IgGs in the CSF of MS patients and of other 
neurologically impaired patients. Immunoabsorption is based on the 
detection of bands by silver staining. Imprint immuno-fixation and 
the immunoblotting method rely upon the ability of immuno­
globulins to transfer either to agarose gel or nitrocelullose paper 
respectively and then to be detected by an immunological reaction. 
The sensitivity of each technique differed markedly with the 
immunoblotting being the most sensitive. The specificities of the 
techniques were more difficult to assess. Reproducibility , to some 
extent, correlates to specificity. The silver staining detection of 
oligoclonal IgG was a reliable method when the concentration of 
immunoglobulin was high in the CSF. The band pattern was clear 
but some additional band(s) sometimes appeared with variation in the 
value of the electric current. These bands were artefacts and could 
be seen across the whole gel and between tracks. Normally, the 
method was reproducible if the same CSF was tested repeatedly.
Using another step for each of these CSF techniques, one can 
also assess the prevalence of viral specific immunoglobulins in a 
CSF. The sensitivity of each technique was the same as when used to 
detect the oligoclonal response. However, in the detection of viral 
specific immunoglobulins none of the methods were totally specific.
Oligoclonal IgGs produced in the CSF of MS patients are 
strikingly cathodic. Heterogeneity of charges among 
immunoglobulins has been known for quite a long time. It has been 
shown that charge properties of IgE antibodies inversely correlate, 
to some extend, with the charge of the corresponding antigens 
[Underdown B J. et al, 1970]. It has also been observed that charges 
of IgGs correlate in the same inverse way to the charge of the 
corresponding antigens [Levy D.E. et al, 1981]. It is therefore 
tempting to suggest that the antigens corresponding to the oligoclonal 
response in MS are mainly negatively charged.
Concerning the immunoabsorption technique, it was 
demonstrated that the relative cathodic oligoclonal immunoglobulin 232
G’s appeared to be sensitive to changes in phosphate ion
concentration and in pH. Therefore, it may be that some of the 
absorptions noted in the original series of experiments done by Dr 
K. Goswami were due to non specific immune reactions. It is 
therefore possible that depending on the particular viral preparation 
used, certain CSFs may have had their biological properties e.g their 
charges modified and were thus more prone to precipitate. However, 
this cannot explain all the findings reported and published in the 
article in Nature [Goswami K.K. et al, 1987]. For example one 
particular CSF had a very high level of antibodies to the viral 
protein HN (a protein which is known to be very specific for SV5 
and not to cross react with the HN protein of the related virus PF2). 
This CSF was not available for further study but it may be that a 
proportion of CSFs - much smaller than previously thought - may 
still possess a significant portion of their oligoclonal IgGs specific 
for SV5 [Russell W.C et al, 1989]. Only, an extensive study on a 
very large number of CSFs will answer this question. Brankin and 
colleagues [Brankin B. et al, 1989] tested SV5 antibodies by the 
ELISA technique in the CSF of MS patients. They found that 40 % 
of the patients tested (total number of patients tested: n=13) had 
specific antibodies to SV5. However they found that the elevation of 
SV5 antibodies correlated to some extent to the elevation of measles 
antibodies in these CSFs and concluded that the response specific to 
SV5 was part of the non specific anti viral response found in the 
CSFs of MS patients.
The specificity of the other 2 techniques (immunoblotting and 
imprint immuno-fixation) were also questionable. The immuno­
blotting technique gave results difficult to interpret when a defined 
antigenic system and corresponding monoclonal antibodies was used. 
Moreover, the results obtained with the human CSFs against 
different viral antigens were also difficult to interpret in some cases. 
In practice positive controls (usually mouse monoclonal antibodies) 
or specific controls are included in an analytical system when testing 
human CSFs but it is claimed that mixing conjugate antibodies of 
different allotypes may disturb the result of the test [B. McLean, 
personal communication]. Therefore no mouse monoclonal antibody 
specific to a particular virus is included when testing human 
antibodies specific to this virus in CSFs. In conclusion the 
immunoblotting technique is not a recommended method of detection 
of antigen specific IgG in the CSF. Nevertheless, as a diagnostic tool 233
for the detection of oligoclonal IgG in the CSF of neurological 
patients, this technique appears to be the most sensitive and as 
specific as the other two. Only a proper large scale clinical study 
would detect the proportion of false positive and negative results 
experienced with this technique. This will be difficult to achieve as 
there is no gold standard method in CSF characterisation.
The results obtained by Dr Vandvick and Professor Norrby 
with the imprint immuno-fixation method appeared quite specific 
and the correct controls were included in each experiment [Vandvik 
B. et al, 1989]. This discrepancy of specificity between the St 
Andrews' group with this technique and the Scandinavian group may 
be due to the lack of experience of the St Andrews' group with this 
technique. One of the factors which influenced the specificity of the 
technique was the time of overlay between the agarose gel (where 
the CSF have been electrofocused) and the antigen containing gel.
The other important point is that the technique is not very sensitive 
and the CSF must be concentrated before the electrophoresis. Some 
have suggested that critical IgG could be lost during concentration of 
the CSF e.g absorbing to a dialysis sac. Others have shown that the 
loss of protein during concentration is not restricted to particular 
proteins and thus there is no reason to believe that critical IgGs are 
preferentially lost during dialysis [Walsh M.J. et al, 1983] [Kaplan A. 
et al, 1966].
However, the preparation of the antigen in hot agarose may 
have been a source of loss of specificity in their otherwise well 
controlled experiment. In order to mix the antigen within the 
agarose, the agarose has to be molten at 56 0 C, and this temperature 
may potentially have altered some epitopes. It is possible that 
epitopes which are critical in MS patients can be destroyed by this 
process and this is especially relevant for the membrane glycoprotein 
HN of the SV5 virus as it appears that most of the epitopes on this 
glycoprotein are conformational [Goswami K.K. et al, 1987]. On the 
contrary, the epitopes of the internal proteins of the virus e.g NP 
and P are less sensitive to external treatment. This may explain why 
some cross reactivity was observed between PF-2 and SV5 with 
some MS CSFs as internal proteins of these 2 viruses cross react 
[Randall R.E. et al, 1988]. However, it is possible that the critical 
response to the HN glycoprotein was not detected because of thermal 
inactivation of virus antigens. From the previous work, HN has been
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described as the very protein which is recognised by the oligoclonal 
response in some MS patients [Goswami K.K. et al, 1987].
In conclusion, none of the 3 techniques was specific when 
examining antigen-specific IgGs in the CSF. The most sensitive 
method of detection of oligoclonal IgG is the immunoblotting 
method. New methods should be designed to study antigen specific 
immunoglobulins in the CSF.
D2: CULTURE OF ENDOTHELIAL CELLS
Although culture of rodent or bovine brain endothelial cells 
seems to be well established by some research groups [Bowman P.D. 
et al, 1983][Audus K.L. et al, 1986][Wilcox C.E. et al, 1989], there 
are few reports of culture of human brain endothelial cell lines 
[Gerhart D.Z. et al, 1988] [Vinters H.V.et al, 1987] and these have so 
far been limited to the description of the culture conditions.
The aim of this project was to grow human brain endothelial 
cells in culture principally because a source of human brain 
endothelial antigens would facilitate the use of clinical material. The 
brain endothelial cells could have been used as a source of antigens 
for immunisation in order to produce polyclonal and monoclonal 
human brain-specific antibodies. The cell line would have been also a 
good source of antigens for a monoclonal screening procedure. 
Moreover, the analysis of expression of adhesion molecules on 
human brain endothelia may have given some information relevant 
to the pathogenesis of multiple sclerosis (see the introduction section: 
the brain vessel in MS).
The culture of human brain endothelial cells appears very 
difficult to achieve from the work reported in this thesis. This is 
partly due to the lack of human fresh brain tissue for such 
experiments. Gerhartz and colleagues also used human brain tissue 
removed at surgery as a source of tissue for growing brain 
endothelial cells in culture [Gerhartz D.Z. et al, 1988]. However, 
Vinters and colleagues reported that they were able to grow 
endothelial cells in culture from brain tissue removed from post 
mortem material [Vinters H.V. et al, 1987]. In this present work, 
only culture of endothelial cells from surgical material was tried 
because it was felt that the chance of obtaining viable material was 
greater from this source. There are about 200 temporal lobectomies 235
performed a year in the U.K and 2 were done in Dundee during the 
time of this project on brain endothelial cell culture (it appears that 
the indication for temporal lobectomy varies slightly between 
surgical departments with some neurosurgeons more interventionist 
than others).
The first attempt of growing human brain endothelial cells in 
culture was unsuccessful. It was therefore decided to use brains from 
animals and as bovine brains had been used successfully by others 
for the preparation of the brain vessels [Audus K.L. et al, 1987] and 
some preliminary experiments were attempted using material 
obtained from the local slaughterhouse. However, at the time of the 
project bovine spongiform encephalopathy (BSE) was an almost 
everyday news headline and it was felt that it would be more prudent 
to use another source of animal brain. Since rat brains were 
available in the department from the neurochemistry group these 
were used as a source of rodent microvessels.
The principle of growing endothelial cells in culture is first to 
purify the brain vessels, then to partially disrupt the overall 
structure of the vessels with collagenase and then to culture these 
vessels in tissue culture flasks in order to let endothelial cells grow 
from the purified vessels. The main problem encountered was that 
the vessels after purification did not stick to the tissue culture flasks 
and were seen floating after 2 days in culture. The reasons for this 
inability to stick to the plates are not known but different 
possibilities were discussed and some were tested. The first 
possibility is that purified vessels need a long time (more than 2 
days) in order to stick to tissue culture plates. It is known that vessels 
purified from the omentum take a long time to seed on tissue culture 
plates (J Pearson, C.R.C Northwick Park, personal communication). 
However, it is is unlikely in the case of purified brain vessels as after 
more than 2 days in culture the purified vessels appeared completely 
disrupted and not viable. It is more likely that something which 
could have promoted seeding of the vessels was missing from the 
experiment. Some researchers have suggested that vessels should be 
incubated in the tissue culture flask in a minimal volume to promote 
adhesion (S. Kumar, Manchester, personal communication). Only 
once in the cited references was the problem of adhesion of purified 
vessels to culture dishes discussed by the authors. When Forrester 
and colleagues tried to grow endothelial cells from purified vessels 
of bovine retina on fibronectin-coated coverslips , they observed that 236
the vessels had a tendency to detach from the coverslips. They then 
used a highly viscous substance, sodium hyaluronate (Pharmacia) to 
cover the purified vessels on day 0 of culture. The sodium 
hyaluronate slowly dissolved in the culture medium and was only 
removed when the medium was changed. In this way, the adherence 
of the vessels was achieved on the coverslips [Roberts J.M. et al, 
1990][Hughes C.C.W. et al, 1986]..
Another factor which is thought to promote seeding is the 
preliminary treatment of the purified vessels by collagenase. 
Collagenase treatment disrupts the extracellular matrix of the vessels 
and is likely to disclose reactive groups which may promote seeding. 
Other factors which also may help the seeding are the attachment 
factors which may be used to coat the tissue culture flask: they all 
mimic an extracellular matrix [Russo R.G., 1986]. Only gelatin was 
used as an attachment factor in our experiments. Other attachments 
factors for the coating of the culture petri dishes may be more 
suitable. Some research groups have used commercial extracellular 
matrices like 'basement membrane Matrigel' (collaborative research) 
[Gerhart D.Z, 1988], extracellular Matrix -ECM-coated culture 
dishes (Eldan technologies) [Shivers R.R., 1988] or Falcon primaria 
culture plates [Lathey J.L. et al, 1990] . Other attachment factors, 
alone or in combination have been used e.g collagen [Hughes C.C.W. 
et al, 1986][Bowman P.D et al, 1980], collagen + fibronectin [Audus 
K.L. et al, 1987] or fibronectin alone [Bowman P.D., 1983]. 
Forrester and colleagues found that fibronectin and laminin provided 
excellent substrates for bovine retina endothelial cells in culture but 
in contrast plasmin and collagen were poor substrates [Roberts J.M. 
et al, 1990][McIntosh L.C. et al, 1988]. Others have prepared their 
own culture dishes plates coated with extracellular matrix by 
culturing cells producing extracellular matrix on the culture dishes 
and then disposing off the cells to obtain an extracellular matrix 
coated plate [Meresse S. et al, 1989] [Gospodarowicz D., 1984].
It is also possible that different media could promote the 
adhesion of vessels e.g the different ion content could modify the 
activities of certain proteases involved in the adhesion process or in 
the disruption of the extracellular matrix. In the same way, vessels 
may need to be purified in magnesium or calcium free medium - 
ions known to influence the activity of certain proteases. Different 
media have been utilised to grow brain endothelial cells e.g M 199, F 
12, Ham's media. 237
Other factors may influence the success of a culture of brain 
endothelial cell especially when the vessels have adhered and cells 
have begun to grow from them. Pericytes, which are not endothelial 
cells but are thought to be of smooth muscle lineage, may 
contaminate the culture. Some research groups have advocated the 
use of plasma derived serum (PDS) in place of normal serum [Audus 
K.L. et al, 1986]. It seems that PDS promotes the growth of 
endothelial cells and inhibits the growth of contaminating pericytes 
as PDS is characterised by the absence of some soluble factors 
[Vogel A. et al,1978], Others have used an anti-Thyl.l with 
complement to kill contaminant cells in order to grow rat brain 
endothelial cells [Risau W. et al, 1990].
The use of other types of sera have been advocated especially 
human serum for some endothelial cell culture and the proportion of 
serum in the culture may be critical e.g it appears that dermal 
microvascular endothelial cells require very high (40-50%) serum 
concentrations [Pearson J., 1990].
It has been demonstrated that tumors produce endothelial 
growth factors as they need blood supply when they increase in size 
[Folkman J. et al, 1980] and some research workers have used 
tumor-conditioned media to promote the long term growth of 
endothelial cells in vitro [Folkman J. et al, 1979]. Again there is no 
consensus on which tumors cells are good producers of endothelial 
cell growth factors and exactly what type of endothelial cell growth 
factor is produced. Different cells have been used e.g murine 
melanoma cells (K1735-M2) [Gerhart D.Z. et al, 1988] or sarcoma 
180 cell line [Folkman J. et al, 1979] .
In the same way, it is thought that glial cells and/or glial 
factors secreted by glial cells promote the brain specific properties 
of these endothelial cells [Goldstein G.W., 1988]. Thus it was 
decided that brain endothelial cells should be grown in glial- 
conditioned medium and to achieve this we decided to grow glial 
cells in culture from neural biopsies. This was done following the 
method described by Bama and colleagues which is based on the 
principle that adherent cells grown from primary culture of a brain 
biopsy of an astrocytoma are likely to be glial cells [Bama B.P. et 
al, 1985]. However, the cells obtained in our study did not express 
the specific glial marker -glial associated fibrillary protein. It has 
been well reported that glial cells can lose their glial-specific marker 238
(GFAP) when they are cultured and that the prevalence of GFAP- 
expressing cells can vary with cell density and differentiation [Frame 
M.C. et al, 1984]. It is thus possible that the cell lines grown in 
culture were in fact glial cells which did not express GFAP in 
culture because of their differentiation or because they had lost this 
marker in very early passages. Another explanation is that the 
method of purification followed [Bama B.P. et al, 1985] was not as 
stringent as the other published method of glial cell purification [e.g 
Selmaj K.W. et al, 1990] and that the cells obtained were not glial in 
origin but contaminant cells e.g fibroblastic in origin. It is however 
extremely difficult to be sure of the fibroblastic origin of cells by 
immunohistochemistry as there is no specific marker for fibroblast 
cells. Indeed the intermediate filaments expressed by fibroblast e.g 
vimentin are also expressed by other cells. Cheng-Mayer and 
colleagues used a monoclonal antibody thought to be specific for 
fibroblastic cells and which recognised procollagen III [Cheng- 
Mayer C. et al, 1987]. However this monoclonal antibody was not 
available in the U.K.
Therefore, as the home-grown 'glial cell lines' were not 
satisfactory, we assessed glial cell lines already characterised and 
available from colleagues. U 138, a glioma cell line, was given by 
Professor Weiss and CM-C-CM, also a glial cell line, was purchased 
from the European cell culture collection (Porton Down, Salisbury). 
They were tested for the expression of the marker GFAP - less than 
10 % of the cells of both cell line were positive for the marker. This 
is again in accord with previous reports which described the loss of 
the glial specific marker by glial cell grown in culture [Frame M.C. 
et al, 1984].
In conclusion, growing human brain endothelial cells in 
culture may be possible when all conditions are met (medium, 
attachment factor, optimum digestion of purified vessels, endothelial 
growth factors and glial growth factors). However both brain 
endothelial cells and glial cells (source of glial factors) may loose 
their specific markers in culture and therefore proof of the origin of 
a cell line may be difficult. In the same way, very little is known 
about the factors influencing the loss or gain of endothelial and glial 
cell markers in culture although some factors have been studied in 
relation to glial cells [Frame M.C. et al, 1984].
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D3: THE 'NITROCELLULOSE T CELL ASSAY*
The idea of separating proteins from a crude source of 
antigens on a SDS PAGE gel in order to facilitate the study of 
possible autoantigens is not new as it has been used in conjunction 
with the 'Western blotting’ technique to detect autoantibodies in a 
number of autoimmune conditions [Lynch D.M. et al, 1986][De 
Keyser F. et al, 1989] or in paraneoplastic syndrome which are 
thought to be autoimmune in origin [Babikian V.L. et al, 1985]. 
However, study of T cell reactivity tested by a T cell proliferation 
assay was based on the use of soluble antigen . The 'NTP T cell 
assay’ has been described recently and may allow researchers to 
study autoimmune T cell reactivity using antigens separated by 
molecular weight by SDS-PAGE gel electrophoresis. The principle 
of the technique was first described by Laurent and colleagues who 
demonstrated proliferation of T cells after stimulation by 
phytohemagglutinin (PHA) separated after SDS-PAGE 
electrophoresis and electroblotting transfer to nitrocellulose 
membranes [Laurent B. et al, 1985]. Lamb J. , Young D. and 
colleagues followed this idea by using different antigens particularly 
proteins from influenza virus, M. tuberculosis and allergens [Young 
et al, 1986] [Lamb J.R. et al, 1987, 1988]. They used the same 
principle as described by Laurent and colleagues and called the 
technique a 'solid-phase antigen T cell' assay. In their assay, the 
antigens separated on SDS-PAGE electrophoresis were blotted on 
nitrocellulose paper (Ntcp), the 'band' corresponding to the antigen 
of interest was cut out and the piece of Ntcp with the antigen directly 
incubated in a well of a microtiter plate in order to perform a 
classical T cell proliferation assay. Abou-Zeid and colleagues 
described an improvement of the technique. Instead of incubating the 
piece of Ntcp containing the antigen of interest in the well, they first 
dissolved the piece of Ntcp in DMSO and then reprecipitated it into a 
suspension of antigen-bearing particles by adding carbonate buffer 
[Abou-Zeid C. et al, 1987]. Serendipity played an important part in 
the discovery of the buffer : the buffer chosen for reprecipitation 
was that used in ELISA buffer assay protocols (G. Rook, personal 
communication). The antigen-bearing particles appeared to be taken 
up readily by antigen-presenting cells and induce a significant 
proliferation with very small amounts of antigen. With 
mycobacterium leprae as antigen, Abou-Zeid and colleagues found 240
that 0.1 jig of antigen-bearing NCP per well gave an optimal 
stimulation in a T cell proliferation assay whereas the same soluble 
antigen gave an optimum stimulation at 2 pg per well.
The ’NTP T cell* assay had to be assessed and standardised in 
our laboratory in order to be able to use this assay confidently for a 
clinical study.
a/ STANDARDISATION OF THE ’NTP T CELL' ASSAY.
When starting to use the ’NTP T cell assay’ there are 2 
potential problems - contamination and non stimulation by the 
antigen-bearing particles. Possible contamination of the T cell assay 
by the antigen (antigen-bearing NCPs) is indeed possible as it is 
processed in a non sterile fashion through a cycle of gel 
electrophoresis and electroblotting and prepared with a non sterile 
NTP. However, contamination with antigen-bearing NCPs has never 
been encountered during the work related to this thesis. 
Contamination is often detected in a T cell assay when the counts of a 
test-sample in triplicate are distorted for example with one well 
giving very high background whereas the other wells containing the 
same sample give low or intermediate counts. When the technique 
described in Material and Methods is followed, the antigen 
preparation goes through a DMSO step which it is thought to 
sterilise the antigen preparation. All the next stages of the technique 
are performed in a sterile fashion.
The second problem was experienced during the course of this 
thesis and is concerned with the non stimulation of potential antigen 
specific T lymphocytes when these T cells are apparently incubated 
with the appropriate antigen-bearing NCPs. Many factors which 
could influence this non stimulation were assessed (see the Results 
section) but only one was found to be critical and this was the size of 
the antigen - bearing particles. The optimum size can be assessed 
very easily after resuspension of the antigen-NCPs by carbonate 
buffer. The sedimentation of the particles can be seen and the time of 
sedimentation appears to correlate inversely with the capacity of 
inducing stimulation to antigen specific T cells. Optimum results 
were achieved when the reprecipitation was carried out under 
control conditions (when the carbonate buffer was delivered at a 
constant speed of 0.8 ml/min using a peristaltic pump with NTP 
dissolved on DMSO stirred on an electric magnetic stirrer, at 
constant and reproducible speed). It is thought that the small size of 241
the nitrocellulose particles obtained allowed them to be properly 
phagocytosed, processed and then presented by the antigen- 
presenting cells in the T cell proliferation assay.
One factor which was also thought to be critical was the 
possible contamination of the Ag-NCPs with DMSO - inducing 
inhibition of stimulation in a standard T cell assay. However 
washings performed and described in the Material and Methods 
section appeared to be adequate. They were also performed at 4 °C 
because it was thought that, as this washing procedure was lengthy (4 
washes of 10 minutes each), it would help preserve the optimal 
antigenicity of the Ag-bearing NCPs.
To achieve the standardisation of the ’NTP T cell assay’, the 
'spotting technique was used as it is a simple technique which allows 
the antigen, spotted directly on Ntcp, to be processed readily into 
Ag-NCPs without the electroblotting step. This reduced the time and 
efforts involved in the preparation of different Ag-bearing NCPs.
On the other hand it cannot provide data on proteins separated by 
molecular weight and thus, in itself, is a procedure with little 
advantage over a classical T cell proliferation assay with soluble 
antigen. However, the amount of antigen needed to induce a 
proliferative response as compared to a classical T cell proliferation 
assay (see results section) is less and, thus, an economy of antigen 
can be achieved with the same end result when one is testing a 
'precious' antigen in a T cell proliferation assay.
On the subject of optimal concentration of the antigen, it is 
likely that proteins are to some extend lost during the preparation of 
the NCPs (for example during the washing) and therefore the real 
concentration of protein into each well may be much lower that 
calculated. Radioactive labelled proteins processed into Ag -NCPs 
could give data on this question; these types of experiments were not 
done in this study. A series of experiments was performed in order 
to analyse the effect of washing on antigen blotted or spotted on Ntcp 
and interesting results were obtained which have implications not 
only for the 'NTP T cell assay" presently discussed but also for other 
techniques involving transfer of proteins to Ntcp e.g 'western 
blotting’ or immunodot-blot. From the results presented, it is 
apparent that proteins spotted on nitrocellulose paper do not behave 
like proteins electroblotted - presumably the latter are much more 
firmly bound to the nitrocellulose paper. This is important when 
using a washing buffer which contains detergent which may wash 242
away the proteins spotted on nitrocellulose paper and thus this factor 
has to be taken into consideration for any assay which uses spotted 
protein on nitrocellulose paper e.g immunodotblot.
After standardisation of the ’NTP T cell’ assay, it was noticed 
that the antigen concentration needed to induce a proliferation and 
the optimum time of incubation for this optimum proliferation 
differed between a classic T cell assay and a 'NTP T cell assay. 
Comparing with a classic T cell assay, the optimum concentration of 
antigen is much less in a ’NTP T cell' assay. However the optimum 
time is longer, about 5-7 days, compared to 4-6 days for a classic T 
cell proliferation assay. Data presented in the Results section also 
show that the optimum stimulation index is lower with antigen­
bearing nitrocellulose particles than with soluble antigen. The 
explanation for these phenomena is not known. The lower antigen 
concentration needed in a 'NTP T cell' assay has been reported by all 
the groups who have used the method [Abou-Zeid C. et al,
1987][Filley E. et al, 1989][Lee S.P. et al, 1989]. The particulate 
structure of the antigen (as antigen-bearing nitrocellulose particles) 
is likely to be critical and the antigen coated on a particulate matrix 
may help the antigen presenting cell (APC) to phagocytose the 
antigen more readily.
As already mentioned above, the optimum time of stimulation 
appears longer with antigen coated particles than with soluble 
antigen. This observation has been made by other groups.
Moreover, those who have used T cell clones in a 'NTP T cell' assay 
have also reported the same trend of a longer incubation time when 
compared to T cell clones in culture with soluble antigen. The 
optimum time concentration for the former is about 4 days whereas 
it is 3 days with the latter (Anne Rees, Hammersmith Hospital, 
personal communication). The fact that overall incubation time for T 
cell clones is shorter than for peripheral blood mononuclear cells 
may be explained by the fact that the effector T cells are monoclonal 
and therefore, proportionally, the frequency of antigen-specific T 
cells in the well is much higher than in a polyclonal system (e.g with 
peripheral blood mononuclear cells). However the fact that it takes 
more time to observe an optimum proliferation in a 'NTP T cell' 
assay compared to a classic T cell assay is difficult to explain. Taking 
into account the lower optimum concentration in a 'NTP T cell' 
assay compared to the classic assay and the lower stimulation index 
with the 'NTP T cell' assay, it appears that the antigen is more 243
efficiently captured and phagocytosed by the antigen presenting cells 
(less antigen needed) but it takes longer for the antigen to be 
processed (longer incubation time) and the proliferation is less 
intense (lower stimulation index), the latter suggesting that there is 
less antigen presented at the surface of the APC or that most of the 
antigen is presented by the wrong MHC class e.g class I MHC 
molecules instead of class II MHC molecules for a T cell 
proliferation assay. The lower stimulation index could also be 
explained by a negative effect of the nitrocellulose particles on the 
proliferation independent of the antigen specific effect. This is 
unlikely as it was demonstrated that nitrocellulose particles incubated 
with soluble antigen do not induce a negative effect on the T cell 
proliferation due to the soluble antigen (see Results section). In the 
same way, the possibility of stimulation by a superantigen which 
could be present on nitrocellulose is very unlikely as negative 
control nitrocellulose particles do not induce proliferation in the 
standardised system (superantigen stimulation is not mediated via the 
specific recognition of the antigen by the T cell receptor on a HLA 
restricted manner but by reaction of the antigen directly with the 
V p segment of the T cell receptor [Acha-Orbea H. et al, 1991]).
In conclusion, the ’NTP T cell’ assay was standardised and a 
number of points about the techniques have been shown to be 
critical. The ’NTP T cell’ assay is reproducible with characterised 
antigens and is a useful tool for studying T cell response to proteins 
separated by molecular weight. However, it is recommended that one 
should start with the spotting technique especially when 
standardisation of a previously unknown system is necessary. It is 
also recommended that an assessment, in a mock experiment with 
MOCK-NCPs, of the optimum precipitation of the NCPs with 
carbonate buffer while changing the volume of DMSO: the optimum 
quantity of DMSO depends on the volume of NCPs processed (see 
Results section).
b/THE CLINICAL STUDY USING THE T CELL ASSAY:
Autoreactive T cells are thought to be the main components of 
the proposed autoimmune reaction in multiple sclerosis (MS). 
Considerable attention has been focussed on myelin basic protein 
(MBP) since experimental allergic encephalomyelitis (EAE) can be 
induced by MBP. Surprisingly little work has been done to study the 
T cell response with other myelin proteins. As discussed in the 244
introduction section, the blood brain barrier may also be a target for 
a T cell response. The next part of the thesis therefore tested the 
possible T cell reactivity of MS patients against different antigens 
from both the myelin and the brain vessels using the ’NTP T cell' 
assay. It was decided to use the T cell proliferation assay which is 
mainly an indicator of the T helper cell response. Most of the T 
helper lymphocytes are CD4 positive cells and thus are restricted by 
MHC class II molecules (the CD4 antigen on the T cell making 
contact with the class II MHC molecule on the antigen presenting 
cell). The genetic association described with the MHC system in MS 
patients has been strongly linked to the MHC class II locus 
(especially DR 2 and DQwl). If T lymphocytes are involved in the 
MS process, class II restricted T cells are therefore likely to be the 
main culprits and it is thus more appropriate to utilise a T cell 
proliferation assay which analyses the T helper cell response in MS 
studies. Moreover, if class II restricted cytotoxic T cells (instead of 
T helper lymphocytes) are the main culprits in the MS process, it is 
likely that T helper lymphocytes related to these cytotoxic responses 
will be detectable; the cytotoxic T cell response is mainly T helper 
cell dependent as are the B cell response [Cantor H. et al, 1976]. A T 
helper cell first recognises the antigen and will produce soluble 
factors which will help to generate a cytotoxic response directed 
against this same antigen [Balkwill F.R. et al, 1989] [Hamblin A. et al, 
1988].
The source and the purity of the antigen incubated in the assay 
is also a limitation to many T cell proliferation assay. It is extremely 
difficult to completely solubilise proteins from purified brain 
vessels. It was also thought that if satisfactory solubilisation is 
achieved, it will be extremely difficult to separate different 
molecules from one another unless long purification procedures 
were used. Thus the only way to test the vessel molecules in a T cell 
assay would be to incubate the total solubilised proteins in each well. 
Two main limitations were discussed at the time in relation to this 
possibility. First, the concentration of each molecule would be 
difficult if not impossible to predict. T cell proliferation is 
dependent on the antigen concentration as the curve of stimulation is 
a bell shape curve. In a classic T cell assay normally 1 to 100 pg. of 
pure protein induce an optimum proliferation response. If one starts 
with a very heterogeneous preparation of antigens and if only one of 
the antigens is recognised by T cells as part of an autoimmune 245
response, it is very difficult to find this optimum concentration or at 
least a concentration of antigen which will induce a proliferation. 
Secondly, if one uses the whole solubilised brain vessels as antigens 
in a T cell proliferation it is likely that MHC class I and perhaps 
class II molecules will be present in the preparation as both classes of 
MHC molecules may be expressed on the brain endothelial cells, the 
class n molecules being expressed only if the brain endothelial cells 
are treated with certain cytokines e.g y - INF and IL2 (see BBB 
section in the introduction). It is thus possible that these MHC 
molecules will induce an alloreactivity in a T cell proliferation assay 
where the T cells are from a MS patient (or from a neurological 
control) who is likely to have a different HLA status from the 
postmortem patient whose brain vessels act as antigen in the T cell 
proliferation assay.
It was therefore decided to adapt the recently described 
'nitrocellulose T cell assay' for the study of autoantigens in 
autoimmune diseases. This technique had never been used in MS 
studies before or in any studies of autoimmune diseases. The 'NTP T 
cell’ assay may allow the HLA molecules bands to be eliminated after 
their localisation either by immunological method (for example by 
Western blotting technique' with an anti-HLA class I and/or class II 
molecules) or in relation to their molecular weights (MHC class I 
molecules have a molecular weight of around 43 kd whereas the both 
class II chains have a molecular weight of 28 kd). On the other hand, 
standardisation of the concentration for each antigen band is difficult 
to achieve even if the 'NTP T cell' assay may allow more flexibility 
than a classic T cell assay with a heterogenous antigen preparation 
e.g myelin or brain vessels. When proteins of brain vessels or 
myelin are stained with naphthalene black after electrotransfer, the 
quantity of each proteins is very heterogeneous. However, it may be 
possible to select a band of interest and load the appropriate antigen 
in amounts relating in function of this band of interest e.g if the 
protein is not very well represented on the original gel, it may be 
possible to "overload” the minigel and thus concentrate to some 
extent on the protein of interest whereas if the quantity of the 
protein of interest is high, it is possible to load less of the original 
concentration of the whole preparation. This possibility of this 
modulation was not explored in the thesis.
The results obtained with the MS patients and the neurological 
controls, using only peripheral blood lymphocytes, were not 246
definitive although some patients showed minor T cell proliferation 
against a number of components of the myelin or of the brain 
vessels. This reactivity tended to correlate with activity of the disease 
in the multiple sclerosis patients as only the 2 patients who were 
suffering from an attack, at the time of the assay, showed 
proliferations against myelin or vessels components. The other 4 
patients who were in remission at the time of the assay did not show 
any proliferation. Interestingly, among the neurological controls, 
some patients showed proliferation against components of the brain 
vessels and these patients suffered from epilepsy (although it is 
difficult to draw any statistical conclusions as the number of the 
neurological controls tested is low (n=6)). None of the normal 
controls showed any reactivity to either myelin- or vessel- NCP. The 
same trend was observed with the Western blotting study as 14 
patients (15%) showed reactivity towards some of the proteins of the 
the brain vessels whereas only one normal control (5%) did. The 
reactivities seen in both the T cell assay and the western blotting may 
be consequences of the disease as it may be that an immune response 
is triggered when there is release of brain components during the 
pathological process e.g in multiple sclerosis or in epilepsy. The 
results using spotted whole antigen were consistent with the results 
of the separated NCP in 2 pairs. The remaining pairs of patients 
showed stimulated antigens but not with spotted whole antigen. This 
is to be expected as whole spotted antigen has been shown to produce 
less stimulation than separated antigens in some cases e.g with the 
mycobacterium tuberculosis system [Lee S.P. et al, 1989].
Overall, the stimulation indexes observed were low. It is 
difficult to know if this was due to the overall lack of response to the 
antigens tested by the patients or to the technique used - the 'NTP T 
cell' assay. It has already been discussed that overall, stimulation 
indices obtained with the 'NTP T cell' assay are lower than those 
obtained with soluble antigens. In addition, in the clinical study 
described, only one concentration of antigens for each band was 
tested and therefore it is possible that for the various myelin and 
brain vessel proteins, the optimum concentrations were different 
even though the corresponding nitrocellulose particles prepared 
were done following standardisation of the assay. The
standardisation of the 'NTP T cell' assay was done with known 
protein systems, mainly M. tuberculosis, tetanus toxin and
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adenovirus type 2 proteins but brain vessel and myelin proteins may 
not ’behave’ in the same way at the defined optimum concentrations.
However, it is also possible that there was no ’high responders’ 
to myelin or brain vessels tested in the population tested. Johnson 
and colleagues tested the reactivity of peripheral blood mononuclear 
cells from MS patients and neurological controls against soluble 
purified MBP, PLP and MAG. Only about 15 % of the patients were 
high responders (mainly against MAG and MBP) whereas the rest 
did not produce stimulation indexes above 2 with the proteins tested 
[Johnson D. et al, 1986]. Consequently, the frequency of autoreactive 
T lymphocytes in the peripheral blood compartment may be too low 
in most of the MS patients and thus amplification techniques e.g T 
cell cloning may be useful to expand the population of autoreactive T 
lymphocytes in the compartment tested.
One important point on the clinical T cell assay study is that 
the human serum used in the T cell assay gave a high background. 
The background interferes with the proliferation in terms of 
stimulation index. If an antigen is incubated with antigen-specific T 
lymphocytes in a medium which gives low background, the 
stimulation index is much higher than when this antigen is incubated 
in a medium which gives high background (see Results section). 
Therefore some significant antigen-specific proliferation may have 
been missed in the clinical T cell study (no 'low background' serum 
was available at the time of the study - twenty mis of low 
background serum was obtained for the standardisation of the 'NTP 
T cell' assay (see Results section, figure R6-2a, page 199) but none 
was left for the clinical study). Retrospectively it would have been 
proper to use autologous sera for the clinical T cell assay because 
autologous serum usually induces low background count (Dr Luis 
Carlo-Branco, C.D.U, St Georges Hospital, personal
communication). However at the time of the study it was thought that 
a unique batch of AB serum would keep the conditions of culture 
standardised between the different patients tested.
The other possibility to explain the low stimulation index is 
that multiple sclerosis is not an autoimmune disease and that the T 
lymphocytes in the lesions do not react with autoantigens. Some may 
be specific for viral (or bacterial) antigens and there is very little or 
even no reaction against brain autoantigens (see introduction Viruses 
and MS section). This appears to be the case in some viral
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demyelinating diseases where most of the myelin damage appears to 
be mediated by soluble factors as a bystander effect.
Nevertheless, the author still considers the ’NTP T cell' assay 
as a potentially useful assay for the study of autoimmune disease and 
particularly multiple sclerosis. Similar studies using peripheral blood 
lymphocytes, 'low background' serum and fewer antigens 
(increasing the possibility of testing different doses for each antigen) 
have to be performed with more multiple sclerosis patients. In 
addition, this technique could be very useful for testing the 
specificity of T cell clones derived from the CSF or even from the 
brain of post mortem patients. The peripheral blood is indeed only a 
'window' on the lymphoid system and blood lymphocytes are 
released from and migrate into disease tissue [Westermann J. et al,
1990]. Other than the peripheral blood the different sources of T 
cells available for studying the T cell response in MS are the CSF, 
the target organ itself e.g the MS lesions and possibly the lymph 
nodes related to the brain. It is likely that possible autoreactive T 
cells will be concentrated at the site of the lesions and it is thought 
that the CSF may reflect more closely the T cell population of the 
brain than the peripheral blood [Calder V. et al, 1989] [Hafler D.A et 
al, 1989]. However, there is still much debate about the compartment 
in which the autoreactive T cells may be found - blood versus brain 
[Calder V. et al, 1989][Hafler D.A. et al, 1989].
There are two ways of raising T cell clones/lines [Fathman G. 
et al, 1989]. Commonly, this is done in an antigen specific fashion by 
raising T cell clones with IL2 in the presence of the antigen thus 
promoting only the T cells specific for the antigen of choice e.g see 
[Richert J.R. et al, 1986][Sredni B., 1982]. However, the other 
technique which is less commonly used is to raise T cell clones in the 
absence of antigen, using only IL2 and a mitogen [Moretta A. et al,
1983 a and b] , therefore, theoretically only inducing the long-term 
culture of activated T lymphocytes present in the sample collected 
for the preparation of these T cell clones [Hafler D.A. et al, 1987, 
b]. This technique has been used to test T cell clones raised from the 
CSF of MS patients [Fleisher B. et al, 1984][Hafler D.A. et al, 1985]
[Hafler D.A. et al, 1987] and one report described the successful 
preparation of T cell clones from the lymphocytes collected from 
post mortem plaques from 2 MS patients. However, only MBP, PLP 
and myelin associated glycoprotein (MAG) antigens were tested in a 
classic T cell proliferation assay and no proliferation of these T cell 249
clones was measured with these antigens [Hafler D.A. et al, 1987]. 
The 'NTP T cell' assay could provide a mean of increasing the panel 
of antigens which can be tested provided that there are enough 
cloned T cells and antigen presenting cells to performed the test.
P ; -IHE„CLINICAL STUDY USING THE WESTERN
BLOTTING TECHNIQUE..
There are many advantages of the Western blotting procedure 
(SDS PAGE followed by Western blotting) [Towbin H. et al, 1984]. 
The preparation used as a source of antigen can be crude e.g a piece 
of tissue or cells grown in tissue culture or partially purified 
components from a tissue. Secondly, the 'Western blotting' technique 
is to some extend analytical as the proteins are separated by 
molecular weight but it may also be used as a screening procedure as 
many sera can be tested in parallel against a unique antigen. 
Sensitivity of the technique cannot be considered alone but only 
when also considering specificity. These 2 factors depend on each 
system studied principally on the definition of the negative controls. 
When the question of negative and positive control has been 
overcome, the sensitivity of the technique is satisfactory and depends 
on the visualisation system used e.g peroxidase or radioactive probe.
The main disadvantages of the method is the preparation of the 
samples which involves denaturation of the proteins before the SDS- 
PAGE gel electrophoresis: the samples are disrupted in SDS with or 
without mercaptoethanol (reduced or unreduced mixture 
respectively). This procedure can destroyed critical epitopes on the 
antigen of interest especially if these epitopes are conformational 
[Horsfall A.C. et al, 1991]. In die same way, the conditions of 
transfer of the antigens from the SDS PAGE gel onto nitrocellulose 
may also alter certain epitopes for example due to heat or to the 
buffer used during the transfer procedure [Towbin H. et al, 1984]. 
Also, it has been shown, in some system, that blocking solutions 
influence the antigenicity of the proteins transferred on 
nitrocellulose paper [Hauri H.P. et al, 1986] [Petit C. et al, 1982].
On the other hand, the antigen preparation used in this study 
was considered to be adequate as the purified vessels expressed von 
Willebrand factor and y glutamyl transpeptidase. Moreover, the 
vessels were prepared from a post-mortem brain less than 36 hours 250
after death and Choi et al showed no difference in the protein pattern 
and functional integrity between rabbit brain capillaries isolated 
either at 0 or 42 hours post mortem [Choi T.B. et al, 1986].
When considering possible autoantigens recognised by 
autoantibodies on Western blotting, one has also to ask if these 
autoantibodies are relevant for the disease process. Indeed, some 
have suggested that some autoantibodies are ’physiological' and are 
part of the normal equilibrium of the immunological network, this 
network being part of a bigger system which has been called milieu 
interieur . For example, it has been suggested that some 
'autoantibodies may have a role in disposing of the product of 
metabolism and catabolism [Grabar P., 1983]. This may be 
particularly relevant to some autoantibodies detected by Western 
blotting after disruption of the antigen. Some may not be 'harmful 
autoantibodies' but autoantibodies involved in the clearance of 
denatured antigens as these antigens, when a cell is dead, may be 
exposed to the recognition of the immune system. Some researchers 
have shown that some autoantibodies occurs in normal individual, 
most of them being against cytoskeleton proteins [Guilbert B. et al, 
1982] [Stefansson K. et al, 1985]. In the same way, Babikian and 
colleagues described the detection of autoantibodies 'bands' on 
'western blots' after incubation of sera from normal individuals with 
spinal cord extracts [Babikian V.L. et al, 1985]. In neurological 
diseases, proteins may be released in the circulation because of the 
disease process and these proteins could induce an humoral immune 
response.
However, the denaturation of the antigen before the SDS 
PAGE electrophoresis and electrotransfer may be an advantage as it 
may expose antigens which will be hidden otherwise. In the case of 
human brain vessels, antigens exposed on the intraluminal surface of 
the vessels are inaccessible on undisrupted purified vessels. These are 
the very antigens which are likely to be involved with a possible 
autoimmune reaction in MS. Therefore and despite its drawbacks, 
the 'western blotting technique was the only technique worth 
utilising to study possible autoantigens on brain vessels mainly 
because human brain endothelial cells in culture were lacking, 
otherwise, other techniques which may be more powerful - when 
well controlled - could have been used e.g the radioimmune 
precipitation technique. The same applies, to some extend, to myelin
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as most of the myelin proteins in the myelin are hidden within the 
myelin sheath [Norton W.T. , 1984].
a/ Discussion of the result of the western blotting assay with the 
purified vessels as antigens.
Only one group has reported that MS patients and patients 
suffering from HTLV1- associated myelopathy have autoantibodies 
to endothelial cells [Tsakuda N. et al, 1989] [Tanaka Y. et al, 1987]. 
However these particular observations were based on ELISA tests 
using rat endothelial cells as antigen and with low dilution (1/10) of 
the tested sera. Thus these observations needed to be complemented 
by other approaches and we decided to use the Western blotting 
technique to investigate the prevalence of autoantibodies to human 
brain antigens taking into account the limits of both methods.
Taking into account the limitation of the 'western blotting' 
technique discussed above, there was nevertheless no strong evidence 
in the present study that patients suffering from MS are more prone 
to develop autoantibodies against the BBB than other neurological 
controls. There is however a small proportion of individuals (MS 
and neurological controls) who possess autoantibodies against either 
myelin or vessels which can be visualised by the 'western blotting' 
technique. The significance and relevance of these autoantibodies are 
still unknown. The reaction seen in some individuals may in fact be a 
consequence of a neurological disease rather than a cause of the 
disease. It appears that the proportion of individuals showing 
autoantibodies against brain vessels (or myelin) is much higher in the 
patients groups (MS or neurological controls) than in the normal 
group. This difference could also be explained by the younger age of 
the normal group in comparison with the age of the patients groups. 
It has been reported that autoantibodies are more prevalent in the 
older population. However, the only normal individual who showed 
autoantibody against the brain vessels was only 25 years of age and 
there was no correlation with age among the neurological patients 
(MS and others) who showed autoantibodies against the brain vessels: 
the mean age was 45.5 years - range: 29-67 (n= 14).
Although the numbers are very small, it appears that the 
number of neurological patients suffering from epilepsy or 
migraine/headache and with autoantibodies to brain vessels detected 
on 'western blotting' was increased: epilepsy (20 %), 
migraine/headache (40%). Some have suggested that disruption of 252
the blood-brain barrier occurs in epilepsy [Bolwig T.G. et al, 
1988][Comford E.M et al, 1986]. Further studies on the prevalence 
on autoantibodies to brain vessels in patients suffering from epilepsy 
and in patients suffering from migraine/headache are necessary.
Unlike the myelin, background reactivity against human brain 
vessels was not observed with human sera and thus the reactivity 
observed in some individuals (patients and controls) seems genuine. 
However, a reliable human brain vessel-antiserum was lacking in this 
study which may have made these results more interesting as a 
positive control could have been used in each experiments. An 
attempt to immunise rabbits with whole human brain vessels resulted 
in an antisera with little reactivity. The antisera recognised two 
protein one of 22 kd and one of 43 kd protein. This may be due to 
the immunisation procedure that we adopted as we immunised the 
rabbits with whole purified human brain vessels in complete 
Freund’s adjuvant. Critical antigens may have been hidden or the 
human brain vessel antigens may not have been 'foreign’ enough for 
the immune system of the rabbits.
On the other hand, these autoantibodies directed to brain 
vessels in some neurological patients may be related to vessels 
specific components. Although little is known about the molecular 
structure of the BBB, some interesting features have already been 
uncovered and some proteins related to the BBB partially 
characterised. The exact location of the proteins detected by 
autoantibodies on ’western blotting’ is not known. It has been shown 
that the protein composition of the luminal membrane is different 
from that of the antiluminal membrane of the brain vessels [Lidinsky 
W.A. et al, 1983]. If autoantibodies to brain vessels are important in 
the aetiopathogenesis of MS, it is likely (but not necessary) that they 
will recognise antigens situated at the luminal side of the brain 
vessels. W. M. Pardridge and colleagues raised an antisera against a 
46 Kd protein which seemed to be specific for bovine brain 
capillaries [Pardridge W.M. et al, 1986]. In the same molecular 
weight region, a inducible BBB specific molecule called HT7 of 
around 45-52 Kd has been characterised in chick brain microvessels 
[Seulberger H. et al, 1990]. Stemberger N.H. and Stemberger raised 
a monoclonal antibody named anti-endothelial-barrier-antigen 
(EBA) which appeared to be specific for brain vessels including 
optic nerve, spinal cord and retina. The monoclonal reacted also 
with some vessels in the spleen and some cells in the epidermis of the 253
skin and recognised a 30/25/23.5 Kd triplet [Stemberger N. et al,
1987] . Other proteins have been located on the brain vessels e.g 
transferrin receptor (a 95 kd dimer) [Jefferies W.A. et al, 1984], 
insulin receptor (127 kd protein) [Pardridge W.M. et al, 1985], P- 
glycoprotein [Gordon-Cardo C. et al, 1989] and proteins involved in 
glucose transport and other transport systems [Kalaria R.N. et al,
1988] [Pardridge W.M. et al, 1986]. Pardridge and colleagues have 
shown that low molecular weight proteins (14, 16, 17, 18 Kd) in 
isolated brain capillaries are histones [Pardridge W.M. et al, 1989]. 
Tsakuda and colleagues using the ELISA assay showed that sera 
from MS patients had antibodies directed to even lower molecular 
weight proteins (8, 11, 12.3 Kd) [Tsakuda N. et al, 1989]. However 
this observation needs to be confirmed. Some of the proteins 
detected by autoantibodies in our study (see table 1) may correspond 
to these characterised brain vessels proteins. They may also 
correspond to more common proteins like actin of molecular weight 
of 43 Kd.
Detection of autoantibodies to brain vessels in patients 
suffering from neurological diseases especially MS has been difficult 
because of the limitations of the assays used (immunofluorescence 
assay [Fillit H.M. et al, 1986], ELISA assay [Tsakuda N. et al, 1989], 
’western blotting' technique). The histopathology of MS suggests that 
the MS lesions could be in part due to an immune response to brain 
vessels as part of an autoimmune reaction or because of a viral 
infection of the brain vessels. In epilepsy, autoantibodies to brain 
vessels may be associated with the disease and their aetiopathogenesis 
relevance needs to be examined. In another neurological disease 
namely senile dementia of Alzheimer’s type, autoantibodies to brain 
vessels have been reported in the patients suffering from this disease 
[Fillit H.M. et al, 1986]. There is a need of further studies looking at 
the prevalence of autoantibodies to brain vessels in patients with 
neurological diseases and new assays should be devised to approach 
this question.
b/ Results with the myelin:
The results with the myelin as antigens were more difficult to 
interpret. Firstly there was an unspecific reaction when the myelin 
was only incubated with the second antibody (the anti-human IgG 
serum). This unspecific reaction was always observed around 95 254
kd. This nonspecific reaction was not seen when the antigen was the 
human brain vessels. The reason for this unspecific reaction is not 
known; it may be that the region of the myelin concerned with this 
reaction has an endogenous peroxidase activity. Secondly, the pattern 
of reactivity - above the background - was more complex as most of 
the sera reacting with at least one or two proteins of the myelin 
preparation. This was observed also by Newcombe and colleagues 
who tested human sera by western blotting against CNS particulate 
fractions. Sera from normal individuals and sera from neurological 
patients reacted against a number of bands from the CNS particulate 
preparation [Newcombe J.I.A. et al, 1984]. In the case of the 
myelin, a positive antisera was available (kindly provided by Dr Eric 
Blair, Leeds). This antisera, raised against rat myelin, reacted 
against most of the human myelin proteins.
The occurrence of antibodies reacting to myelin in normal 
individuals is puzzling. They may be physiological as discussed 
above . The other possibility is that these antibodies are in fact low 
affinity antibodies which cross react with myelin but are of no 
physiological relevance.
255
REFERENCES:
Abou-Zeid C., Filley E., Steele J., Rook G.A.W. (1987) : A simple new 
method for using antigens separated by polyacrylamide gel 
electrophoresis to stimulate lymphocytes in vitro after converting 
bands cut from Western blots into antigen-bearing particles. J.
Immunol. Meth. 98; 5-10.
Abramsky O., Lisak R.P., Silberberg D.H., Pleasure D.E. (1977) :
Antibodies to oligodendria in patients with multiple sclerosis. 
N.Eng.J.Med. 297;1277-81.
Acha-Orbea H., Mitchell D.J., Timmerman L., Wraith D.C., Tausch G.S., 
Waldor M.K., Zamvil S.S., McDevitt H.O., Steinman L. (1988) : Limited 
heterogeneity of T cell receptors from lymphocytes mediating 
autoimmune encephalomyelitis allows specific immune interventions. 
Cell 54;263-273.
Acha-Orbea H., Palmer E. (1991): Mis- a retrovirus exploits the immune 
system. Immunol. Today 12; 356-361.
Acheson E.D. (1985) : The epidemiology of multiple sclerosis. In 
Matthews W.B., Acheson E.D., Batchelor J.R., Weller R.O. eds. McAlpine's 
multiple sclerosis. Churchill Livingstone, Edinburgh.
Adams J.M., Imagawa D.T. (1962) : Measles antibodies in multiple 
sclerosis. Proc. Soc. Exp. Biol. Med. 3; 562-566.
Adams C.W.M. (1977) : Pathology of multiple sclerosis: progression of 
the lesion. Br. Med. Bull. 33; 15-20.
Adams C.W.M. (1983) : The general pathology of multiple sclerosis: 
morphological and chemical aspects of the lesions. In Hallpike J.F., 
Adams C.W.M., Tourtelotte W.W. eds. Multiple sclerosis. Chapman and 
Hall, London.
Adams C.W.M., Poston R.N., Buk S.J., Sidhu Y.S., Vipond H. (1985) : 
Inflammatory vasculitis in multiple sclerosis. J. Neurol. Sci. 69; 269­
283.
Adams C.W.M., Abdulla Y.H., Torres E.M., Poston R.N. (1987) :
Periventricular lesions in multiple sclerosis, their perivenous origin 
and relationship to granular ependymitis. Neuropath. Appl. Neurobiol. 13; 
141-152.
256
Adams C.W.M. (1989) : A colour atlas of multiple sclerosis & other 
myelin disorders. In Adams C.W.M. ed. Wolfe medical publications Ltd, 
London.
Adams C.W.M., Poston R.H., Buk S.J. (1989) : Pathology, histochemistry 
and immunocytochemistry of lesions in acute multiple sclerosis. J. 
Neurol. Sci. 92;291-306.
Aharoni R., Teitelbaum D., Arnon R., Puri J. (1991) : Immunomodulation 
of experimental allergic encephalomyelitis by antibodies to the 
antigen-la complex. Nature 351 ;147-150.
Aksamit A.J., Mourrain P., Sever J.L. Major E.O. (1985) : Progressive 
multifocal leukoencephalopathy investigation of three cases using in 
situ hybridization with JC virus biotinylated DNA probe. Ann. Neurol. 
18;490- 496.
Albeldo S.M., Oliver P.D., Romer L.H., Buck C.A. (1990): endoCAM: A novel 
endothelial cell-cell adhesion molecule. J. Cell. Biol. 110; 1227­
12337.
Allen I. (1981) : The pathology of multiple sclerosis. Neuropath. Appl. 
Neurobiol. 7; 169-182.
Alter M., Kahana E., Loewenson R. (1978) : Migration and risk of multiple 
sclerosis. Neurology 28; 1089-1093.
Alvord E.C. (1984) : Species-restricted encephalitogenic determinants. 
In experimental allergic encephalomyelitis: a useful model for multiple 
sclerosis. Alan R. Liss, New York.
Alvord E.C., Jahnke U., Fisher E.H., Kies M.W., Driscoll B.F., Compston 
D.A.S. (1987) : The multiple causes of multiple sclerosis: the 
importance of age of infections in childhood. J. Child. Neurol. 2;313- 
321.
Ammitzboll T., Clausen J. (1972) : Measles antibody in serum of 
multiple sclerosis patients, their children, siblings and parents. Acta 
Neurol. Scand. 48; 47-56.
Antel J.P., Arnason G.G.W., Medof M.E. (1978) : Suppressor cell function 
in multiple sclerosis, correlation with clinical disease activity. Ann. 
Neurol. 5; 338-342.
257
Arnadottir T., Reunanen M., Meurman O., Salmi A, Panelius M., Halonen P. 
(1979) : Measles and rubella virus antibodies in patients with MS: A 
longitudinal study of serum and CSF specimens by radioimmunoassay. 
Arch. Neurol. 36; 261-265.
Arnadottir T. (1980) : Measles and canine distemper virus. Antibodies in 
patients with multiple sclerosis determined by radioimmune assay.
Acta Neurol. Scand. 62; 81-89.
Arthur F.E., Shivers R.R., Bowman P.D. (1987): Astrocyte-mediated 
induction of tight junctions in brain capillary endothelium: an efficient 
in vitro model. Brain Res 433; 155-159.
Asher D.M., Epstein L.G., Goudsmit J. (1987) : Human immunodeficiency 
virus in the central nervous system. Curr. Topics in AIDS 1; 225-246.
Atkins G.J., Sheahan B.J., Mooney D.A. (1990) : Pathogenecity of Semliki 
Forest virus for the rat CNS and primary rat neural cell cultures: 
possible implication for the pathogenesis of multiple sclerosis. 
Neuropath. Appl. Neurob. 16; 57-68.
Audus K.L., Borchardt R.T. (1986): Characterisation of an in vitro blood- 
brain barrier model system for studying drug transport and metabolism. 
Pharmaceut. Res. 3; 81-87.
Audus K.L., Borchardt R.T. (1987): Bovine brain microvessel endothelial 
cell monolayers as a model system for the blood-brain barrier. Ann. N. Y. 
Aca. Sciences 507; 9-18.
Auerbach R., A,by L., Grieves J., Joseph J., Lindgren C., Morrisey L.W., 
Sidky Y.A., Tu M., Watt S.L.(1982) : Monoclonal antibody against 
angiotensin-converting enzyme: its use as a marker for murine, bovine, 
and human endothelial cells. Proc. Natl. Acad. Sci. USA 79; 7891-7895.
Axthelm M.K., Kirakowka S. (1987) : Canine distemper virus, the early 
blood-brain barrier lesion. Acta neuropathologica 75; 27-33.
Babikian V.L., Stefansson K., Dieperink M.E., Arnason B.G.W., Marton L.S., 
Levy B.E. (1985): Paraneoplastic myelopathy: autoantibodies against 
protein in normal spinal cord and underlying neoplasm. Lancet ii: 49­
50.
258
Baig S., Olsson T., Yu-Ping J., Hojeberg B., Cruz M., Link H. (1991) : 
Multiple sclerosis: cells secreting antibodies against myelin- 
associated glycoprotein are present in cerebrospinal fluid. Scand. J. 
Immunol. 33; 73-9.
Balkwill F.R., Burke F. (1989): The cytokine network. Immunol. Tod. 10; 
299-304.
Bangham C., Nightingale S., Cruickshank J.K., Daenke S. (1989) : PCR 
analysis of DNA from multiple sclerosis patients for the presence of 
HTLV I. Science 246; 821.
Barbano R.L., Dal Canto M.C. (1984) : Serum and cells from Theiler’s 
virus infected mice fail to to injure myelination culture or to produce 
in vivo transfer of the disease. The pathogenesis of Theiler’s virus 
induced demyelination appears to differ from that of EAE. J. Neuro. Sci. 
66; 283-293.
Barfeld H., Atoynatan T. (1970): Lymphocyte transformation in multiple 
sclerosis. B.M.J. 2; 91-92.
Barna B.P., Chou S.M., Jacobs B., Ransohoff R.M., Hahn J.F., Bay J.W.
(1985): Enhanced DNA synthesis of human glial cells exposed to human 
leukocyte products. J. Neuroimmunol. 10; 155-158.
Batchelor J.R., Compston D.A.S., McDonald W.l. (1978) : HLA and multiple 
sclerosis. Brit. Med. Bull. 34; 279-284.
Bates D. (1986) : Neurology seminar : multiple sclerosis. Hosp. upd. Oct; 
771-788.
Baxevanis C.N., Reclos G.J., Sfagos C., Darfexis E, Papageorgiou R., 
Papamichail M. (1987): Multiple sclerosis I: monocyte stimulatory 
defective mixed lymphocyte reaction associated with clinical disease 
activity. Clin. Exp. Immunol. 67; 362-371.
Bellamy A.S., Calder V.L., Feldmann M., Davison A.N. (1985) : The 
distribution of interleukin-2 receptor bearing lymphocytes in multiple 
sclerosis: evidence for a key role of activated lymphocytes. Clin. Exp. 
Immunol. 61; 248-256.
Benczur M., Petranyi G.G., Palffy G., Varga M., Talas M., Kotsy B., Foldes 
I., Hollan S.R. (1980) : Dysfunction of natural killer cells in multiple 
sclerosis: a possible pathogenetic factor. Clin. Exp. Immunol. 39;657- 
662.
259
Benveniste E.N., Merrill J.E. (1986) : Stimulation of oligodendroglial 
proliferation and maturation by interleukin-2. Nature 321; 610-613
Ben-Nun A., Wekerle H., Cohen I.R. (1981) : Vaccination against 
encephalomyelitis using attenuated cells of a T lymphocyte line 
reactive against myelin basic protein. Nature 292; 60-61.
Bergstrom T., Anderson O., Vahlne A. (1989) : Isolation of herpes 
simplex virus type I during the first attack of multiple sclerosis. Ann. 
Neurol. 26; 283-285.
Birnbaum G., Aubitz S., Kotilinek L. (1988) : Search for autonomously 
proliferating spinal fluid lymphocytes in patients with multiple 
sclerosis. Neurology 38; 28-30.
Bogdanove L., Clark G. (1957) : The induction of exacerbations of 
allergic meningoencephalomyelitis. J. Neuropathol. Exp. Neurol 16; 57­
60.
Bollo E., Zurbriggen A., Vandevelde M., Faukhauser R. (1986) : Canine 
distemper virus clearance in chronic inflammatory demyelination . Acta 
Neuropathol. (Berlin) 72; 69-73.
Bolwig T.G. (1988): Blood-brain barrier studies with special reference to 
epilectic seizures. Acta Psychiatr. Scand. suppl. 345; 15-20.
Boos J., Esiri M.M., Tourtelotte W.W., Mason D.Y. (1983) :
Immunohistochemical analysis of T lymphocyte subsets in the central 
nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci. 
62; 219-232.
Bottazo G.F., Pujol-Borrel R., Hanafusa T., Feldmann M. (1983) : Role of 
aberrant HLA-DR expression and antigen presentation in induction of 
endocrine autoimmunity. Lancet 2; 1115-9.
Bottazo G.F., Todd I., Mirakian R., Belfiore A., Pujol-Borrel R. (1986) : 
Organ specific autoimmunity: a 1986 overview Immun. Rev. 94; 137­
169.
Bowman P.D., Betz L.A., Ar D., Wolinsky J.S., Penney J.B., Shivers R.R., 
Goldstein G.W. (1980): Primary culture of capillary endothelium from 
rat brain. In Vitro 17; 353-362.
Bowman P.D., Ennis S.R., Rarey K.E., Lorris Betz A., Goldstein G.W. (1983): 
Brain microvessel endothelial cells in tissue culture: a model for study 
of blood-brain barrier permeability. Ann. Neurol. 14; 396-402.
260
Brahic M., Stroop W.G., Baringer J.R (1981) : Theiler’s virus persists in 
glial cells during demyelinating disease. Cell 26; 123-128.
Brankin B., Wisdom G.B., Allen I.V., Hawkins S.A., Cosby S.L. (1989) : 
antibodies to simian virus 5 in patients with multiple sclerosis and 
other neurological diseases. J. Neurol. Sci. 89; 181-187.
Brendel K., Meezan E., Carlson E.C. (1974): Isolated brain microvessels: s 
purified, metabolically active preparation from bovine cerebral cortex. 
Sciences 185; 953-955.
Brockman R.W., Stiffey A.V. (1970): Multiple sclerosis: lymphocyte 
transformation by basic protein from bovine spinal cord. Experentia 
26; 413-4.
Brooks B.R., Walker D.L. (1984) : Progressive multifocal
leukoencephalopathy. Neurol. Clin. 2; 299-313.
Brown W.J. (1978) : The capillaries in acute and subacute multiple 
sclerosis sclerosis plaques: a morphometric analysis. Neurology 28;89 
92.
Burns J., Rosenzweig A., Zwieman B., Lisak R.P. (1983) : Isolation of 
myelin basic protein-reactive T-cell lines from normal human blood. 
Cellular Immunol. 81; 435-40.
Burns J, Krasner L.J., Rostami A., Pleasure D. (1986) : Isolation of P2 
protein-reactive T cell lines from human blood. Ann. Neurol. 11; 391-3.
Caldwell P.R.B., Segal B.C., Hsu K.C., Das M., Sofer R.L. (1976) ; 
Angiotensin- converting enzyme: vascular endothelial localization. 
Sciences 191; 1050-1051.
Campbell A.M.G., Daniel P., Porter R.J., Ritchie-Russell W., Smith H.V., 
Innes T.R.M. (1947) : Disease of the nervous system occurring among 
research workers on swayback in lambs. Brain 70; 50-58.
Cantor H., Boyse E.A. (1976): Regulation of cellular and humoral immune 
response by T-cell subclasses. Cold Spring Harbor Symp. Quant. Biol.
41; 23-32.
Carp R.I., Licursi P.C. Merz P.A., Merz G.S. (1972) : Decreased percentage 
of polymorphonuclear neutrophils in mouse peripheral blood after 
inoculation with material from multiple sclerosis patients J. Exp. Med 
136; 618-629.
261
Carrigan D.R., Johnson K.P. (1980) : Chronic relapsing myelitis in 
hamsters associated with experimental measles virus infection. 
P.N.A.S. 77; 4297-4300.
Carrigan D.R. (1987) : Chronic relapsing encephalomyelitis associated 
with experimental measles virus infection, J. Med. Virol. 21; 223-230. 
Chan W.W.C. (1977) : multiple sclerosis and dogs. Lancet i; 487-488.
Chan K-F.J., Stoner G.L., Hashim G.A., Huang K-P. (1986) : Substrate 
specificity of rat brain calcium-activated and phospholipid-dependent 
protein kinase. Biochem. Biophys. Res. Commun. 134; 1358-1364.
Chantry A., Glynn P. (1988) : Characterisation of a neural proteinase 
which may play a key role in demyelinating disease. Biochem. Soc. 
Trans. 16; 469-72.
Charcot J.M. (1868, a) : Histologie de la sclerose en plaques. Gaz. Hop. 
(Paris) 41; 554-555, 557-558, 566.
Charcot J.M. (1868, b) : Seance du 14 mars. C. R. Soc. Biol. (Paris) 20; 
13-14.
Cheng-Mayer C., Rutka J.T., Rosenblum M.L., McHugh T., Stites D.P., Levy 
J.A. (1987): Human immunodeficiency virus can productively infect 
cultured human glial cells. P.N.A.S. 84; 3526-3530.
Chiodi F., Sunqvist V.A., Link H., Norrby E. (1987) : Viral IgM antibodies 
in the serum and cerebrospinal fluid in patients with multiple sclerosis 
and controls. Acta. Neurol. Scand. 75; 201-208.
Chofflon M.M., Weiner H.L., Hafler D.A. (1988) : loss of functional 
suppression is linked to decreases in circulating suppressor inducer 
(CD4+ 2H4+) T cells in multiple sclerosis. Ann. Neurol. 24; 185-191.
Chofflon M.M., Weiner H.L., Morimoto C., Hafler D.A. (1989): Decrease of 
suppressor inducer (CD4+, 2H4+) T cells in multiple sclerosis 
cerebrospinal fluid. Ann. Neuroi. 25: 494-9.
Choi T.B., Pardridge W.M. (1986) : Phenylalanine transport at the human 
blood-brain barrier. J. Biol. Chem. 261; 6536-6541.
Chou C-H.J., Tourtelotte W.W., Kibler R.F. (1983) : Failure to detect 
antibodies to myelin basic protein or peptic fragments of myelin basic 
protein in CSF of patients with MS. Neurology 33; 24-8.
Clapham P.R, Weber J.N, Withby D., McIntosh K., Dalgleish A.G., Maddon 
P.J. Deen K.C., Sweet R.W, Weiss R. (1989): Soluble CD4 blocks the 
infectivity of diverse strains of HIV and SIV for T cells and monocytes 
but not for brain and muscle cells. Nature 337; 368-370.
Clark G., Bogdanove L. (1955) : The induction of the lesions of allergic 
meningoencephalomyelitis in a predetermined location. J. Neuropathol. 
Exp. Neurol. 14; 433-437.
Clatch R.J., Melvod R., Miller S.D., Lipton H.L. (1985) : Theiler’s murine 
encephalomyelitis virus (TMEV)-induced demyelinating disease in mice 
is influenced by the H-2D region. Correlation with TMEV-specific 
delayed-type hypersentivity. J. Immunol. 135; 1408-1414.
Clements J.E., Golwin S.L., Montelano R.C., Narajan O. (1988) : Antigenic 
variation in lentiviral diseases. Ann. Rev. Immunol. 6; 139-159.
Colby-Germinaro S.P., Sheremata W., Bain B., Eylar (1977, a) : Studies 
of cellular sensitization to myelin antigens in multiple sclerosis. J. 
Neurol. Sci. 33; 11-129.
Colby-Germinaro S.P., Sheremata W., Bain B., Eylar (1977, b) : Cellular 
hypersensitivity in attacks of multiple sclerosis. I. A comparative 
study of migration inhibitory factor production and lymphoblastic 
transformation in response to myelin basic protein in multiple 
sclerosis. Neurology 27; 132-139.
Compston D.A.S. (1986) : Genetic factors in the aetiology of multiple 
sclerosis. In McDonald W.I., Silberberg D.H. eds. Multiple sclerosis. 
Butterworth, Borough Green, Sevenoaks.
Compston D.A.S., Vakarelis B.N., Paul E., McDonald W.I., Batchelor J.R., 
Mims C.A. (1986) : Viral infections in patients with multiple sclerosis 
and HLA-DR matched controls. Brain 109; 325-344.
Compston D.A.S. (1988) : The 150th anniversary of the first depiction of 
the lesions of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 51; 
1249-1252.
Compston D.A.S., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas 
N.D., Jasani B. (1989) ; Immunocytochemical localization of the 
terminal complement complex in multiple sclerosis. Neuropath. Appl. 
Neurobiol. 15; 307-316.
263
Compston D.A.S. (1990) : The dissemination of multiple sclerosis, the 
Langdown-Brown lecture 1989. J. Roy. Coll. Phys. Lond. 24; 207-218.
Cook S.D., Dowling P.C. (1977) : A possible association between house 
pets and multiple sclerosis. Lancet i; 980-982.
Cook S.D., Dowling P.C., Russell W.C. (1978) : Multiple sclerosis and 
canine distemper. Lancet i; 605-606.
Cook S.D., Dowling P.C., Russell W.C. (1979) : Neutralising antibodies to 
canine distemper and measles virus in multiple sclerosis. J. Neurol. Sci. 
41; 61-70.
Cook S.D., Dowling P.C. (1980) : Multiple sclerosis and viruses: an 
overview. Neurology 30(2); 80-91.
Cook S.D., Gudmundsson G., Benedikz J., Dowling P.C. (1980, b) : Multiple 
sclerosis and distemper in Iceland 1966-1978. Acta. Neurol. Scand. 61; 
244-251.
Cook S.D., Blumberg B.M., Dowling P.C. (1985) : Epidemiological studies 
on multiple sclerosis. Neurology 35; 1528-1529.
Cook S.D., Blumberg B.M., Dowling P.C., Deans W., Cross R. (1987) :
Multiple sclerosis and canine distemper on Key West, Florida. Lancet i; 
1426-1427.
Cornford E.M., Oldendorf W.H. (1986): Epilepsy and the blood-brain 
barrier. Adv. Neurol. 44; 787-812.
Cosby S.L. Lyons C., Fitzgerald S.P., Martin S.J., Pressdee S., Alan I.V. 
(1981) : The isolation of large and small plaque canine distemper 
viruses which differ in their neurovirulence for hamsters. J. Gen. Virol. 
52; 345-353.
Cosby S.L., McQuaid S., Taylor M.J., Bailey M., Rima B.K., Martin S.J., Allen 
I.B. (1989) : Examination of eight cases of multiple sclerosis and fifty 
six neurological and non-neurological controls for genomic sequences 
to measles virus, canine distemper virus, simian virus 5 and rubella. J. 
Gen. Virol. 70; 2027-2036.
Critical digest (1896) : Abstracts of papers on the etiology and 
pathology of disseminated sclerosis. Brain XIX; 388-400.
264
Cross A.H., Cannello B., Brosman L.T. Raine C.S. (1991): Hypothesis: 
antigen specific T cells prime central nervous system endothelium for 
recruitment of non specific inflammatory cells to effect autoimmune 
demyelination. J. Neuroimmunol. 33; 237-44.
Cruickshank K., Rudge P., Dalgleish A.G., Newton M., McLean B.N., Barnard 
R.O., Kendall B.E., Miller D.H. (1989) : Tropical spastic paraparesis and 
HTLV-1 in the United Kingdom. Brain 112; 1057-1090.
Cruz T.F., Moscarello M.A. (1985) : Characterization of myelin fractions 
from human brain white matter. J. Neurochem. 44; 1411-1418.
Cruz M., Olsson T., Ernerudh J., Hojeberg B., Link H. (1987) : Immunoblot 
detection of oligoclonal anti-myelin basic protein IgG antibodies in 
cerebrospinal fluid in multiple sclerosis. Neurology 37; 1515-1519.
Cuzner M.L., Hayes G.M., Newcombe J., Woodroofe M.N. (1988) : The 
nature of the inflammatory components during demyelination in 
multiple sclerosis. J. Neuroimmunol. 20; 203-209.
Dale S., Fujinami R.S., Oldstone M.B.A. (1983): Infection with vaccinia 
favours the selection of hybridomas synthesizing autoantibodies 
against intermediate filaments, one of them cross-reacting with the 
virus hemagglutinin. J. Immunol. 131; 1546-1553.
Dalgleish A.G., et al. (1987) : Do human T-lymphotropic viruses (HTLVs) 
and other enveloped viruses induce autoimmunity in multiple sclerosis. 
Neuropath. Appl. Neurobiol. 13; 241-250.
Dalgleish A.G., Richardson J., Matutes E., Cruiskshank K., Newell A., 
Sinclair A., Thorpe R., Brasher M., Weber J., Catosky D et al (1988) : 
HTLV-1 infection in tropical spastic paraparesis: lymphocytes culture 
and enhanced serological response. Aids Hum. Retroviruses 4; 6; 475­
486.
Dalgleish A.G. (1991) : Viruses and cancer. Brit. Med. Bull. 47; 21-46.
Dalgleish A.G. (1992) : The pathogenesis of AIDS. Classical and 
alternative views. J. R. C. P. London Issue 26(2); 152-158.
Deacon W.E., Alexander L., Siedler H.D., Kurland L.T. (1959) : Multiple 
sclerosis in a small New England community. N. Eng. J. Med. 261; 1059­
1069.
265
Dean G., Kurtzke J.F. (1971) : On the risk of multiple sclerosis according 
to age at immigration to South Africa. B. Med. J. 3; 725-729.
Dean G., McDougall E.I., Elian M. (1985) : Multiple sclerosis in research 
workers studying swayback in lambs: an updated report. J. Neurol. 
Neurosurg. Psych iat. 48; 859-865
DeBault L.E., Cancilla P.A. (1980): y- Glutamyl transpeptidase in 
isolated brain endothelial cells: induction by glial cells in vitro. 
Sciences 207; 653-655.
DeCarli C., Menegus M.A., Rudick R.A. (1987) : Free light chains in 
multiple sclerosis and infections of the CNS. Neurology 37; 1334-1338
De Keyser F., Verbruggen G., Veys E.M. (1989): Identification of a new 
antinuclear antibody by immunoblotting. Lancet ii; 927.
Del Vecchio P.J., Smith J.R. (1981) : Expression of angiotensin­
converting emzyme activity in culture pulmonary artery endothelial 
cells. J. Cell. Physiol. 108; 337-345.
deRossi A., Gallo P., Tavolato B., Callegaro L., Chieco-Bianchi L. (1986) : 
Search of HTLV I and LAV/HTLV III antibodies in serum and CSF of MS 
patients. Acta Neurol. Scand. 74; 161-164.
Devereux J., Haeberli P., Smithies O. (1984): A comprehensive set of 
sequence analysis programs for the VAX. Nucleic Acids Res. 12; 387­
95.
Dhib-Jalbut S., McFarlin D.E., McFarland H.F. (1989) : Measles virus- 
polypeptide specificity of the cytotoxic T-lymphocyte response in 
multiple sclerosis. J. Neuroimmun. 21; 205-212.
Dinh Xuan A.T., Higenbottem T.W. (1989) : Non-prostanoid endothelium- 
derived vasoactive factors. J. Intern. Med. Res. 17; 305-315.
Drumond R.J., Dean G. (1980) : Comparison of 2'3'-cyclic nucleotide 3'- 
phosphodiesterase and the major component of Wolgram protein W1. J. 
Neurochem. 35; 1155-1165.
Eastman R., Sheridan J., Poskanzer D.C. (1973) : Multiple sclerosis 
clustering in a small Massachusetts community with possible common 
exposure 23 years before the onset. N. Eng. J. Med. 289; 793-794.
266
Ebers G.C., Farrel J.C., Kaufmann J.C. (1983) : Oligoclonal bands in MS- 
clinical pathological correlation. Neurology 33(suppl. 2); 141.
Ebers G.C. (1984) : Oligoclonal banding in multiple sclerosis. Ann. N. Y. 
Acad. Sciences 436; 206-212.
Ebers G.C., Bulman D.E., Sadovnick A.D., Paty D.W., Warren S., Hader W., 
Murray T.J., Seland T.P., Duquette P., Grey T., Nelson R., Nicolle M.,
Brunet D. (1986) : A population-based study of multiple sclerosis in 
twins. N. Eng. J. Med. 315; 1638-1642.
Ebina T., Tsukamoto T., Suzuki H., Takase S., Itahara K., Ishida N. (1979) 
Measles virus in jejunum of patients with multiple sclerosis. Lancet i; 
99.
Editorial a) (1981) : The aetiology of multiple sclerosis. Lancet i; 
1347-8.
Editorial b) (1981) : Multiple sclerosis in the Orkney and Shetland 
islands and in the north-east Scotland. B. Med. J. 282; 502-503.
Editorial (1988) : HTLV-1 comes of age. Lancet i; 217-219.
Ehrlich P. (1885) : Das Sauerstoff-Bedurfnis des Organismus: eine 
farbenanalytische studie. Hirschwald, Berlin.
Eisenlohr L.C., Yewdell J.W., Bennink J.R. (1992): Flanking sequences 
influence the presentation of an endogenously synthetized peptide by 
cytotoxic T lymphocyte. J. Exp. Med. 175; 481-487.
Elian M., Dean G. (1987) : Multiple sclerosis among the United Kingdom- 
born children of immigrants from the West Indies. J. Neurol. Neurosurg. 
Psychiat. 50; 327-332.
Erlich S.S., O'Fleming J., Stohlman S.A., Weiner L.P. (1987) :
Experimental neuropathology of chronic demyelination induced by JHM 
virus variant (DS). Arch. Neurol. 44; 839-842.
Eldridge R., Herndon C.N. (1987) : Multiple sclerosis in twins. N. Eng. J. 
Med. 317;50.
267
Endo T., Stewart S.S., Kurdu S.K., Osovitz S., Marcus D.M. (1984) : 
Antibodies to glycosphingolipids in patients with multiple sclerosis. 
Ann. N. Y. Acad. Sciences 436; 213-20.
Engell T., Huidberg A., Uhrenholdt A. (1984) ; Multiple sclerosis: 
periphlebitis retinalis and cerebro-spinalis. A correlation between 
periphlebitis retinalis and abnormal technetium brain scintigraphy.
Acta Neurol. Scand. 69; 293-7.
Engell T. (1986) : Neurological disease activity in multiple sclerosis 
patients with periphlebitis retinae. Acta Neurol. Scand. 73; 168-72.
Engell T., Kroogsaa B., Lund-Andersen H. (1986) : Breackdown of the 
blood-retinal barrier in multiple sclerosis measured by vitreous 
fluorophotometry. Acta Ophtalm. 64; 583-7.
Esiri M.M. (1977) : Immunoglobulin-containing cells in multiple 
sclerosis plaques. Lancet ii; 478.
Esiri M.M. (1980) : Multiple sclerosis: a quantitative and qualitative 
study of immunoglobulin-containing cells in the central nervous 
system. Neuropath. Appl. Neurobiol. 6; 9-21.
Esiri M.M., McGee J. O'D. (1986) : Monoclonal antibody to macrophages 
(EMB/11) labels macrophages and microglial cells in human brain.
J.CIin. Pathol. 39; 615-621.
Esiri M.M., Reading ML . (1987) : Macrophage populations associated with 
multiple sclerosis plaques. Neuropathol. Appl. Neurobiol. 13; 451-465.
Esiri M.M., Gay D. (1990) : Immunological and neurological significance 
of the Virchow-Robin space. J. Neurol. Sci. 100;3-8.
Etingin O.R., Silverstein R.L., Friedman H.M., Hajjar D.P. (1990) : Viral 
activation of the coagulation cascade: molecular interactions at the 
surface of infected cells. Cell 61; 657-662.
Fabry Z., Waldschmidt M.M., Moore S.A. Hart M.N. (1990) : Antigen 
presentation by brain microvessel smooth muscle and endothelium. J. 
Neuroimmunol. 28; 63-71.
Fathman G., Fitch F.W., Denis K.A., Witte O.N. (1989) : Long term culture 
of immunocompetent cells. In Fundamental Immunology, Second Edition, 
Paul W.E. ed. Raven Press Ltd, New York pg 803-813.
268
Fazakerley J.K, Amor S., Webb H.E. (1983) : Reconstitution of Semliki 
Forest virus infected mice induces immune mediated pathological 
changes in the CNS. Clin. Exp. Immunol. 52; 115-120.
Fazakerley J.K, Webb H.E. (1987,a) : Semliki Forest virus-induced , 
immune demyelination: the effect of radiation. Br. J. Exp. Path. 68; 
101-113.
Fazakerley J.K, Webb H.E. (1987,b) : Semliki Forest virus-induced , 
immune demyelination. Adoptive transfer studies and viral persistence 
in nude mice. J Gen. Virol. 67; 377-385.
Field E.J., Cowshall S., Narang H.K., Bell T.M. (1972) : Viruses in 
multiple sclerosis ? Lancet ii; 280-281.
Fillit HM, Kemeny E, Luine V, Weksler ME, Zabriskie JB. (1987): 
Antivascular antibodies in the sera of patients with senile dementia of 
the Alzheimer's type. J. Gerontol. 42; 180-4.
Filley E., Abou-Zied C., Waters M., Rook G. (1989) : The use of antigen­
bearing nitrocellulose particles derived from Western blots to study 
proliferative responses to 27 antigenic fractions from Mycobacterium 
leprae in patients and controls. Immunol. 67; 75-80.
Fisher A.G., Ensoli B., Looney D., Rose A., Gallo R.C., Saag M.S., Shaw G.M., 
Hahn B.H., Wong-Staal F. (1988) : Biologically diverse molecular 
variants within a single HIV-1 isolate. Nature 334; 444-447.
Fleischer B., Marquardt P., Poser S. et al, (1984) : Phenotypic markers 
and functional characteristics of T lymphocyte clones from 
cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 7; 151- 62.
Fog T. (1964) : Vessel plaque relations, and cerebrospinal fluid and 
brain tissue changes in multiple sclerosis. Acta. Neurol. Scand. 40; 
suppl 10; 9-15.
Fog T. (1965) : The topography of plaques in multiple sclerosis. Acta. 
Neurol. Scand. 41; suppl 15; 1-162.
Folkman J., Haudenschild C.C., Zetter B.R. (1979): Long term culture of 
capillary endothelial cells. Proc. Natl. Acad. Sci. USA 76; 5217-5221.
Folkman J., Haudenschild C.C. (1980): Angiogenesis in vitro. Nature 288; 
551-556.
269
Fontana A., Fierz W., Wekerle H. (1984) : Astrocytes present myelin 
basic protein to encephalitogenic T cell lines. Nature 307; 273-276.
Frame M.C., Freshney R.l, Vaughan P.F.T., Graham D.l. Shaw R. (1984): 
Interrelationship between differentiation and malignancy-associated 
properties in glioma. Br. J. Cancer 49; 269-280.
Francis D.A., Compston D.A., Batchelor J.R., McDonald W.l. (1987) : A 
reassessment of the risk of multiple sclerosis developing in patients 
with optic neuritis after extended follow up. J. Neurol. Neurosurg. 
Psychiatry 50(6); 758-65.
Fraser K.B., Haire M., Millar J.H.D. (1977) : Measles antigen in jejunal 
mucosa in multiple sclerosis. Lancet i; 1313-1314.
Fraser N.W., Lawrence W.L., Wroblewska Z., Gliden D.H., Koprowski H. 
(1981) : Herpes simplex type I DNA in human brain tissue P.N.A.S. 78; 
6461- 65.
Freedman M.S., Antel J.P. (1988) : Immunoregulatory circuits in multiple 
sclerosis: is there a "short” ?. Ann. Neurol. 24; 183-184.
Freund J., Stern E.R., Pisani T.M. (1947) : Isoallergic encephalomyelitis 
and radiculitis in guinea pigs after one injection of brain and 
mycobacteria in water oil emulsion. J. Immunol. 57; 179-94.
Friedman H.M., Macarak E.J., MacGregor R.R., Wolfe J., Kefalides N.A. 
(1981) : Virus infection of endothelial cells. J. Inf. Diseas. 143; 266­
273.
Friedman J., Buskirk D., Marino L.J., Zabriskie J.B. (1987) : The detection 
of brain antigens within the circulating immune complexes of patients 
with multiple sclerosis. J. Neuroimmunol. 14;1-17.
Fujinami R.S., Oldstone M.B.A., Wroblewska Z., Frankel M.E., Koprowski H., 
(1983 ): Molecular mimicry in virus infection. Cross-reaction of 
measles virus phosphoprotein or of herpes simplex virus protein with 
human intermediate filaments. P.N.A.S. USA, 80; 2346-2350.
Fujinami R.S., Norrby E., Oldstone M.B.A. (1984): Antigenic modulation 
induced by monoclonal antibodies: Antibodies to measles virus 
haemagglutinin alters expression of other viral polypeptides in infected 
cells. J. Immunol. 132; 2618-2621.
270
Fujinami R.S., Oldstone M.B.A. (1985): Amino acid homology between the 
encephalitogenic site of myelin basic protein and virus: mechanism for 
autoimmunity. Science 123; 1043-1045.
Fujinami R. (1988) : Virus-induced autoimmunity through molecular 
mimicry. Ann. N.Y. Acad. Sciences 540; 210-7.
Fultz P.N., McClure H.M., Swenson R.B., et al (1986) : Persistent infection 
of chimpanzees with human T-lymphotropic virus type 
lll/lymphadenopathy-associated virus: A potential model for acquired 
immunodeficiency syndrome. J. Virol. 58; 116-24.
Gallo R.C., Wong-Staal F. (1985) : Human T lymphotrophic retroviruses. 
Nature 317; 395-403.
Gallou M., Madigand M., Masse L., Morel G., Oger J., Sabouraud O. (1983) : 
Epidemiologie de la sclerose en plaques en Bretagne. Presse Med. 12; 
995-999. '
Gerhart D.Z., Zlonis M.S., Drewes L.R. (1986) : Light and electron 
microscopic localization of D-Galactosyl residues in capillary 
endothelial cells of the canine cerebral cortex. J. Histochem. Cytochem. 
34; 641-648.
Gerhart D.Z., Broderius M.A., Drewes L.R. (1988) : Cultured human and 
canine endothelial cells from brain microvessels. Brain Res. Bull. 21; 
785-793.
Gessain A., Barin F., Vernant J.C., Gout O., Maurs L., Calender A., de The 
G. (1985) : Antibodies to human T-lymphotropic virus type-1 in patients 
with tropical spastic paraparesis. Lancet 2; 407-410.
Gessain A., Abel L., de The G., Vernant J.C., Raverdy P., Guillard A.
(1986) : Lack of antibodies to HTLV I and HIV in patients with MS in 
France and French West Indies. Brit. Med. J. 293; 424-425.
Gillepsie C.S., Wilson R., Davidson A., Brophy P.J. (1989) :
Characterisation of a cytoskeletal matrix associated with myelin from 
rat brain. Biochem. J. 260; 689-696.
Golstein G.W. (1988) : Endothelial cell-astrocyte interactions: a cellular 
model of the blood-brain barrier. Ann. N.Y. Aca. Sci. 529; 31-39.
Gonsette R., Andre-Balisaux G., Delmotte P. (1966) : La permeabilite des 
vaissaux cerebraux. VI. Demyelinisation experimentals provoquee par 
des substances agissant sur la barriere hemato-encephalique. Acta 
Neurol. Belg. 66; 247-262.y 271
Gordon- Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed 
M.R. (1989) Multidrug- resistance gene (P-glycoprotein) is expressed by 
endothelial cells at the blood-brain barrier sites. P.N.A.S. : 86: 695-8.
Gospodarowicz D. (1984) : Preparation of extracellular matrices 
produced by cultured bovine corneal endothelial cells and PF HR-9 
endodermal cells, their use in cell culture, in Methods in Molecular and 
Cell Biology , vol 1; 275-293. Alan R. Liss, Inc., New York.
Goswami K.K.A., Cameron K.R., Russell W.C., Lange L.S., Mitchell D.N. 
(1984) : Evidence for the persistence of paramyxoviruses in human 
bone marrows. J. Gen. Virol. 65; 1881-1888.
Goswami K.K.A., Lange L.S., Mitchell D.N., Cameron K.R., Russell W.C., 
(1984, a) : Does simian virus 5 infect humans. J. Gen. Virol. 65; 1295­
303.
Goswami K.K.A., Morris R.J., Rastogi S.C., Cameron K.R., Russell W.C. 
(1985) : A neutralizing monoclonal antibody against a paramyxovirus 
reacts with a brain antigen . J. Neuroimmunol. 9; 99-108.
Goswami K.K.A., Randall R.E., Lange L.S., Russell W.C. (1987) : Antibodies 
against the paramyxovirus SV5 in the cerebrospinal fluids of some 
multiple sclerosis patients. Nature 327; 244-247.
Goswami K.K., Kaye S., Miller R., McAllister R., Tedder R. (1991) : 
Intrathecal IgG synthesis and specificity of oligoclonal IgG in patients 
infected with HIV-1 do not correlate with CNS disease. J. Med. Virol. 
33; 106-13.
Grabar P. (1983): Autoantibodies and the physiological role of 
immunoglobulins. Immunol. Today 4; 337-340.
Granieri E., Rosati G., Tola R., Pinna L., Carreras M., Manca M., Boldrini P. 
(1983) : The frequency of multiple sclerosis in Mediterranean Europe.
An incidence and prevalence study in Barbagia, Sardinia, insular Italy. 
Acta. Neurol. Scand. 68; 84-89.
Greenberg S.J., Ehrlich G.D., Abbott M.A., Hurwitz B.J., Waldmann T.A., 
Poiesz B.J. (1989) : Detection of sequence homologous to human 
retroviral DNA in multiple sclerosis by gene amplification. P.N.A.S. 86; 
2878-2882.
Gregson N.A. (1983) : The molecular biology of myelin. In Hallpike J.F., 
Adams C.W.M., Tourtelotte W.W. eds. Multiple sclerosis. Chapman and 
Hall, London.
272
Gudnadottir M., Helgadottir H., Bjarnason O. et al, (1964) : Virus isolated 
from the brain of a patient with multiple sclerosis.
Exp. Neurol. 9; 85-95.
Guilbert B, Dighiero G, Avrameas S. (1982): Naturally occurring 
antibodies against nine common antigens in human sera I. Detection, 
isolation, and characterisation. J. Immunol. 128; 2779-87.
Gyorkey F., Melnick J.L., Gyorkey P. (1987) : Human immunodeficiency 
virus in brain biopsies of patients with AIDS and progressive 
encephalopathy. J. Infect. Dis. 155; 870-876.
Haase A.T., Ventura P., Gibbs C.J. jr, Tourtelotte W.W. (1981) : Measles 
virus nucleotide sequence : detection by hybridisation in situ. Science 
212; 672-675.
Haase A.T., Stowring L., Ventura P., Burks J., Ebers G., Tourtelotte W.V\I., 
Warren K. (1984) : Detection by hybridization of viral infection of the 
CNS. Ann. N. Y. Acad. Sci. 436; 103-108.
Haase A.T. (1986) : Pathogenesis of lentivirus infections. Nature 322; 
130-136.
Hafler D.A, Buchsbaum M., Weiner H.L. (1985, a) : Decreased autologous 
mixed lymphocyte reaction in multiple sclerosis. J. Neuroimmunol. 9; 
339-347.
Hafler D.A, Fox D.A., Manning M.E., Schlossman S.F., Reinherz E.L., Weiner 
H.L. (1985, b) : In vivo activated T cells in the peripheral blood and 
cerebrospinal fluid of patients with multiple sclerosis. AZ. Eng. J. Med. 
312; 1405-1411.
Hafler D.A, Hemler M., Christenson L. , Williams J.M., Shapiro H.M., Strom 
T.B., Strominger J.L., Weiner H.L. (1985, c): Investigation of in vivo 
activated T cells in multiple sclerosis and inflammatory central 
nervous system diseases. Clin. Immunol. Immunopathol. 37; 163-171.
Hafler D.A., Buchsbaum M., Johnson D., Weiner H.L. (1985, d) : Phenotypic 
and functional analysis of T cell clones directly from the blood and 
cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol.
18; 451-458.
273
Hafler D.A. , Benjamin D.S., Burks J., Weiner H.L. (1987) : Myelin basic 
protein and proteolipid protein reactivity of brain and cerebrospinal 
fluid-derived T cell clones in multiple sclerosis and postinfectious 
encephalomyelitis. J. Immunol. 139; 68-72.
Hafler D.A., Weiner H.L. (1987, b) : T cells in multiple sclerosis and 
inflammatory central nervous system diseases. Immunol. Rev. 100; 
307-32.
Hafler D.A., Weiner H.L. (1989) : MS: a CNS and systemic autoimmune 
disease. Immunol. Today 10; 104-107.
Haire M. (1977) : Significance of virus antibodies. Br. Med. Bull. 33; 40­
44.
Halawa I., Lolli F., Link H. (1990) : Terminal complement C9 in CSF and 
plasma patients with MS and aseptic meningitis. Acta Neurol. Scand.
80; 130-135.
Hamblin A.S. (1988): Lymphokines IRL Press , Oxford.
Hammond S.R., English D., de Wytt C., Maxwell I.C., Millingen K.S., 
Stewart-Wynne E.G., McLeod J.G., McCall M.G. (1988) : The clinical 
profile of MS in Australia: a comparison between medium- and high- 
frequency prevalence zones. Neurology 38; 980-986.
Hanafusa T., Pujol-Borrell R., Chiovato L., Russell R.C., Doniach D., 
Botazzo G.F. (1983) : Aberrant expression of HLA-DR antigen in Graves' 
disease: relevance to autoimmunity. Lancet 2; 1111-5.
Harlow E., Lane D. (1988) : Antibodies: a laboratory manual. Cold Spring 
Harbor N.Y. Cold Spring Harbor Laboratory, pg 508.
Hart M.N., Tassell S.K., Sadewasser K.L., Schelper R.L., Moore S.A. (1985) 
: Autoimmune vasculitis resulting from in vitro immunization of 
lymphocytes to smooth muscles. Am. J. Pathol. 119; 448-455.
Hart M.N., Waldschmidt M.M., Hanley-Hyde J.H., Moore S.A., Kemp J.D., 
Schelper R.L. (1987) : Brain microvascular smooth muscle expresses 
class II antigens. J. Immunol. 138; 2960-2963.
Hauri H.P., Bucher K. (1986) : Immunoblotting with monoclonal 
antibodies: importance of the blocking solution. Analyt. Biochem. 159; 
386-389.
274
Hauser S.L., Bhan A.K., Gilles F., Kemp M., Kerr C., Weiner H.L (1986) : 
Immunohistological analysis of the cellular infiltrate in multiple 
sclerosis. Ann. Neurol. 19; 578-587.
Hauser S.L., Aubert C., Burks J.S., Kerr C., Lyon-Caen O., de The G., Brahic 
M. (1986, b) : Analysis of human T-lymphotropic virus sequences in 
multiple sclerosis tissue. Nature 322; 176-177.
Hawkins C.P., Munro P.M.G, MacKenzie F., Kesselring J. Tofts P.S., du 
Boulay E.P.G.H., Landon D.N., McDonald W.l. (1990) : Duration and 
selectivity of blood-brain barrier breakdown in chronic relapsing 
experimental allergic encephalomyelitis studied by gadolinium-DTPA 
and protein markers. Brain 113; 365-378.
Hayashi T., Morimoto C., Burks J.S., Kerr C., Hauser S.L. (1988) : Dual­
label immunocytochemistry of the active multiple sclerosis lesion; 
major histocompatibility complex and activation antigens. Ann. Neurol. 
24; 523-531.
Heard R.N.S, Cullen C., Middleton D., Hawkins S.A., Francis D.A., Hern 
J.E.C., McDonald W.I., Batchelor J.R., Lechler R.l. (1989) : An allelic 
cluster of DQa restriction fragment is associated with multiple 
sclerosis; evidence that a second haplotype may influence disease 
susceptibility. Hum. Immunol. 25; 111-123.
Henson T.E., Brody J.A., Sever J.L, Dyken M.L., Cannon J. (1970) : Measles 
antibody titers in multiple sclerosis patients, siblings and controls. 
JAMA 211; 1985-1988.
Herndon C.N., Jennings R.G. (1951) ; A twin-family study of
susceptibility to poliomyelitis. Am. J. Hum. Gen. 3; 17-46.
Hershey L.A., Trotter J.L. (1980) : The use and the abuse of the 
cerebrospinal fluid IgG profile in the adult: a practical evaluation. Ann. 
Neurol. 8; 426-434.
Hirsch R.L. (1986) : Defective autologous mixed lymphocyte reactivity 
in multiple sclerosis. Clin. Exp. Immunol. 64; 107-113.
Hoffman R.E., Zack MM., Davis L.E., Burchfiel C.M. (1981) : Increased 
incidence and prevalence of multiple sclerosis in Los Alamos County, 
New Mexico. Neurology 31; 1489-1492.
Hofman F.M., von Hanwehr R.I., Dinarello C.A., Nizel S.B., Hinton D., Merril 
J.E. (1986) : Immunoregulatory molecules and IL 2 receptors identified 
in multiple sclerosis brain. J. Immunol. 136; 3239-3245.
275
Hofman F.M., Hinton D.R., Johnson K., Merrill J.E. (1989) : Tumor necrosis 
factor identified in multiple sclerosis brain. J. Exp. Med. 170; 607-612.
Holthofer H., Virtanen I., Kariniemi A.L., Hormia M., Linder E., Miettinen 
A. (1982) : Ulex europaeus I lectin as a marker for vascular endothelium 
in human tissues. Lab. Invest. 47; 60-66.
Howell M.D., Winters S.T., Olee T., Powell H.C., Carlo D.J., Brostoff S.W. 
(1989) : Vaccination against experimental allergic encephalomyelitis 
with the T cell receptor peptides. Science 246; 668-670.
Horsfall A.C., Hay F.C., Soltys A.J., Jones M.G. (1991) : Epitope mapping. 
Immunol. Today 12; 211-213.
Hsiung G.D. (1972) : Parainfluenza-5 virus . Infection of man and 
animals. Prog. Med. Virol. 14; 241-274.
Hudson L., Hay F. (1989) : Practical immunology, 3 rd edition. Blackwell 
Scientific publication , Oxford, pg 468-469.
Hughes R., Gray I., Clifford-Jones R., Stern M. (1979) : Lymphocyte 
transformation in the presence of myelin basic protein in multiple 
sclerosis and control subjects. Acta Neurol. Scand. 60; 65-75.
Hughes R.C., Russell W.C., Froude J.R.L., Jarrett R.J. (1980) : Pet 
ownership, distemper antibodies and multiple sclerosis. J. Neurol. Sci. 
47; 429-432.
Hughes C.C.W., Lantos P.L. (1986) : Brain capillary endothelial cells in 
vitro lack surface IgG Fc receptors. Neurosciences letters 68; 100­
106.
Hughes C.C.W.,Male D.K., Lantos P.L. (1986) : Adhesion of lymphocytes to 
cerebral microvascular cells: effect of interferon y, tumour necrosis 
factor and interleukin 1. Immunol. 64; 677-81.
Ichioka T., Uobe K., Stokopf M., Kishimoto Y., Tennekoon G., Tourtelotte 
W.W. (1988) : Anti-galactocerebroside antibodies in human 
cerebrospinal fluids determined by enzyme-linked immunosorbent assay 
(ELISA) Neurochem. Res. 13; 203-207.
Imagawa D.T., Goret P., Adams J.M. (1960) : Immunological relationships 
of measles, distemper and rinderpest viruses. P.N.A.S. 46; 1119-1123.
276
Itoyama Y., Stemberger N. H., Webster H.deF., Quarles R.H., Cohen S.R., 
Richardson E.P. (1980) : Immunocytochemical observations on the 
distribution of myelin-associated glycoprotein and myelin basic protein 
in multiple sclerosis lesions. Ann. Neurol. 7; 167-177.
Jacobs L., Kinkel P.R., Kinkel W.R. (1986) : Silent brain lesions in 
patients with isolated optic neuritis. A clinical and nuclear magnetic 
resonance study. Arch. Neurol. 43; 452-455.
Jacobson S., Richert J.R., Biddison W.E., Satinsky A., Hartzman R.J., 
McFarland H.F. (1984) : Measles virus specific T4+ human cytotoxic T 
cell clones are restricted by class II HLA antigens. J. Immunol. 133; 
754-757.
Jacobson S., Sekaly R.P., Jacobson C.L., McFarland H.F., Long E.O. (1989) : 
HLA Class Il-restricted presentation of cytoplasmic measles virus 
antigens to cytotoxic T cells. J. Virol. 63; 1756-1762.
Jahnke U., Fisher E.H., Alvord E.C. (1985) : Sequence homology between 
certain viral proteins and proteins related to encephalomyelitis and 
neuritis. Nature 346; 283-284.
Janzer R.C., Raff M.C. (1987): Astrocytes induce blood-brain barrier 
properties in endothelial cells. Nature 325; 253-257.
James P.B. (1982): Evidence for subacute fat embolism as the cause of 
multiple sclerosis Lancet i; 380-386.
Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatters K.C., Mason 
D.Y. (1984): Transferrin receptor on endothelium of brain capillaries. 
Nature 312: 162-163.
Jerne NK. (1974): Toward a network theory of the immune system. Ann. 
Immunol. (Paris). 125(C); 373-89.
Jonhson D., Hafler D.A., Fallis R.J., Lees M.B., Brady R.O., Quarles R.H., 
Weiner H.L. (1986) : Cell-mediated immunity to myelin-associated 
glycoprotein, proteolipid protein, and myelin basic proteins in multiple 
sclerosis. J. Neuroimmunol. 13; 99-108.
Johnson P.M., Lyden T.W., Mwenda J.M. (1990) : Endogenous retroviral 
expression in the human placenta. Am. J. Reprod. Immunol. 23; 115­
120.
277
Johnson R.T. (1985) : Viral aspects of multiple sclerosis. In Handbook of 
clinical neurology, Koester J.C., Vinken P.J., Bruyn G.W., Klawans H.L. eds 
revised series 3 47; 319-336. Elsevier Sciences Publisher, Amsterdam.
Johnson R.T., Griffin D.E., Hirsch R.L. , Wolinsky J.S., Roedenbeck S.,
Lindo de Soriani I., Vaisberg A. (1984) : Measles encephalomyelitis- 
clinical and immunological studies. N. Eng. J. Med. 310; 137-141.
Kalaria R.N., Gravina S.A., Schmidley J.W., Perry G., Harik S.l. (1988)
The glucose transporter of the human brain and blood-brain barrier. Ann. 
Neurol. 24: 757-64.
Karn-Hansen S., Lu C.Z., Fredrikson S., Baig S. (1989) : Retroviruses in 
multiple sclerosis. Acta Neurol. Scand. 80; 467-471.
Kaplan A., Johnstone M. (1966) : Concentration of cerebrospinal fluid 
proteins and their fractionation by cellulose acetate electrophoresis. 
Clin. Chem. 12; 727-733.
Karpas A., Kampf U., Siden A., Koch M., Poser S. (1986) : Lack of 
involvement for known human retroviruses in MS. Nature 322; 177­
178.
Kastrukoff L., Lau A., Osborne D., Kim S.U. (1989) : Herpes simplex virus 
type 1 (HSV-1): a murine model of virus induced central nervous system 
demyelination. In Kim S.U. ed. Myelination and demyelination, 
implications for multiple sclerosis. Plenum Press, New York and 
London.
Kennedy P.G.E. (1989) : Human immunodeficiency virus infection of the 
nervous system. Curr. Opin. Neurol. Neurosurg. 2;191-4.
Kerman R.H., Wolinsky J.S., Nath A., Sears E.S. (1988): Serial immune 
evaluation of cyclosporin- and placebo- treated multiple sclerosis J. 
Neuroimmunol. 18; 325-331.
Kermode A.G., Thompson A.J., Tofts P., MacManus D.G., Kendall B.E., 
Kingsley D.P.E., Moseley I.F., Rudge P., McDonald W.l. (1990, a) :
Breakdown of the blood-brain barrier precedes symptoms and other MRI 
signs of new lesions in multiple sclerosis. Brain 113; 1477-1489.
Kermode A.G., Tofts P., Thompson A.J., MacManus D.G., Rudge P., Kendall 
B.E., Kingsley D.P.E., Moseley I.F., du Boulay E.P.G.H., McDonald W.l. (1990, 
b) : Heterogeneity of blood-brain barrier changes in multiple sclerosis. 
Neurology 40; 229-235.
278
Kingsbury D.W. (1991) : Paramyxoviridae and their replication. In 
Virology, second edition. Fields B.N., Knipe D.H. et al, Raven Press Ltd 
N.Y. pg 945-962.
Kingston D., Shiner M., Lange L.S., Mertin J., Meade C. (1977) : Measles 
antigens in jejunal mucosa in multiple sclerosis. Lancet i; 1313.
Kinnunen E. (1984) Multiple sclerosis in Finland: evidence of increasing 
frequency and uneven geographic distribution. Neurology 34; 457-461.
Kinnunen E., Konttinnen Y.T., Bergroth V., Kemppinen P. (1989) : 
Immunological studies on patients with optic neuritis without 
evidence of multiple sclerosis. J. Neurol. Sci. 90; 43-52.
Knobler R.L., Lampert P.W., Olstone M.B.A. (1982) : Virus persistence and 
recurring demyelination produced by a temperature-sensitive mutant of 
MHV-4. Nature 298; 279-280.
Koch M.J., Reed D., Stern R., Brody J.A. (1974) : Multiple sclerosis, a 
cluster in a small northwestern United States community. JAMA 228; 
1555-1557.
Fauci A.S. (1986) : Detection of AIDS virus in macrophages in brain 
tissue from AIDS patients with encephalopathy. Science 233; 1089­
1093.
Koprowski H., Warren K.G. (1979): Perspectives in Biology & Medicine 
22; 10-18.
Koprowski H., DeFreitas E.C., Harper M.E., Sandberg-Wollheim M., 
Sheremata W.A., Robert-Guroff M., Saxinger C.W., Feinberg M.A., Wong- 
Staal F., Gallo R.C. (1985) : Multiple sclerosis and human T- 
lymphotropic viruses. Nature 318; 154-160.
Kraal G., Duijvestijn A.M., Hendriks H.H. (1987) : The endothelium of high 
endothelial venule: a specialized endothelium with unique properties. 
Expl. Cell. Biol. 55; 1-10.
Kristensson K., Svenerholm B., Vahlne A., Nilheden E., Persson L., Lycke 
KE. (1982) : Virus-induced demyelination in herpes simplex virus- 
infected mice. J. Neurol. Sci. 53; 205-216.
279
Kurada Y., Shibasaki H., Sato H., Okochi K. (1987) : Incidence of antibody 
to HTLV I is not increased in Japanese MS patients. Neurology. 37; 
156-158.
Kurtzke J.F. (1970) : Neurologic impairment in multiple sclerosis and 
the disability status scale. Acta Neurol. Scand. 46; 493-512.
Kurtzke J.F. (1974) : Further features of the fennoscandinavian focus of 
multiple sclerosis. Acta. Neurol. Scand. 50; 478-502.
Kurtzke J.F., Hillested K. (1978) : Multiple sclerosis in the Faroe 
Islands: clinical and epidemiological features. Ann. Neurol. 5; 6-21.
Kurtzke J.F., Beebe G.W., Norman J.E. (1979) : Epidemiology of multiple 
sclerosis in US veterans 1. race, sex, and geographic distribution. 
Neurology 29; 1228-1235.
Kurtzke J.F. (1980) : Epidemiological contributions to multiple 
sclerosis: an overview. Neurology 30; 61-79.
Kurtzke J.F., Kjartan D.C., Gudmonsson R., Bergmann S. (1980) : Multiple 
sclerosis in Iceland: a postwar epidemic. Neurology 30; 437.
Kurtzke J.F. , Hillested K. (1986) : Multiple sclerosis in the Faroe 
Islands. II. Clinical update, transmission, and the nature of MS. 
Neurology 36; 307-328.
Lagenaur C.F. (1984) : Glial antigens in central nervous system 
development. In Behan P., Spreafico F. eds. Neuroimmunology. Raven 
Press, New York.
Lamb J.R., Young D.B. (1987): A novel approach to the identification of 
T-cell epitopes in Mycobacterium tuberculosis using human T- 
lymphocytes clones. Immunology 60; 1-5.
Lamb J.R., O'Hehir R.E., Young D.B. (1988): The use of nitrocellulose 
immunoblots for the analysis of antigen recognition by T lymphocytes. 
J. Immunol. Meth. 110; 1-10.
Larson D.M., Carson M.P., Haudenschild C.C. (1987) : Junctional transfer 
of small molecules in cultured bovine brain microvascular endothelial 
cells and pericytes. Microvasc. Res. 34(2); 184-99.
280
Larsson E., Kato H., Cohen M. (1989) : Human endogenous provirus. Curr. 
Top. Microb. Immunol. 148; 115-32.
Lathey J.L., Wiley C.A., Verity A., Nelson J.A. (1990): Cultured human 
brain capillary endothelial cells are permissive for infection by human 
cytomegalovirus. Virology 176; 266-273.
Laurent P., Beal B., Gaspar A., Guilloux L. (1985) : Blotting methods 
applied to investigations of the mitogenic activity of 
phytohemagglutinin (PHA). J. Immunol. Methods 82; 181-184.
Lee S.P., Stoker N.G., Grant K.A., Handzel Z.T., Hussain R., McAdam 
K.P.W.J., Dockrell H.M. (1989) : Cellular immune responses of leprosy 
contacts to fractionated Mycobacterium leprae antigens. Infect. 
Immunit. 57; 2475-2480.
Lee S.J., Wucherpfenning W, Brod S.A., Benjamin D., Weiner H.L., Hafler 
D.A. (1991) : Common T-cell receptor Vp usage in oligoclonal T 
lymphocytes derived from cerebrospinal fluid and blood of patients 
with multiple sclerosis. Ann. Neurol. 29; 33-40.
Leenstra S., Das P.K., Troost D., Bosch D.A., Claessen N., Becker A.E. 
(1990) : PAL-E. monoclonal antibody with immunoreactivity for 
endothelium specific to brain tumours. Lancet i; 671.
Leibowitz S., Hughes R.A.C. (1983) : Immunology of the nervous system. 
In Turk J. ed. Current topic in immunology. Edward Arnold, London.
Levy D.A., Horner A.A., Solomon A. (1981) ; Immunoglobulin-sulfated 
polysaccharide interactions, binding of agaropectin and heparin by 
human IgG proteins. J. Exp. Med. 153; 883-896.
Levy R.M., Bredesen D.E., Rosenblum M.L. (1985) : Neurological 
manifestations of the acquired immunodefiency syndrome (AIDS) : 
experience at UCSF and review of the literature. J. Neurosurg. 62; 475 
95.
Liebert U.G., ter Meulen V. (1987) : Virological aspects of measles 
induced encephalomyelitis in Lewis and BN rat. J. Gen. Virol. 68; 1715 
1 722.
Liebert U.G., Livington C., ter Meulen V. (1987, b) : Induction of 
autoimmune reactions to myelin basic protein in measles virus 
encephalitis in Lewis rats. J. Neuroimmunol. 17; 103-118. .
281
Liebert U.G., Hashim G.A., ter Meulen V. (1989) : Characterization of 
measles virus-induced cellular autoimmune reaction against myelin 
basic protein in Lewis rats. J. Neuroimmunol. 29; 139-47.
Lidinsky W.A., Drewes L.R. Characterisation of the blood-brain barrier: 
protein composition of the capillary endothelial cell membrane. J. 
Neurochem. 1983: 41: 1341-8.
Lightman S., McDonald W.I., Bird A.C., Francis D.A., Hoskins A, Batchelor 
J.R., Halliday A.M. (1987) : Retinal venous sheating in optic neuritis : its 
significance for the pathogenesis of multiple sclerosis. Brain 110; 
405-414.
Link H., Zettervall H. (1970) : Multiple sclerosis: disturbed
kappa/lambda chain ratio of immunoglobulin G in cerebrospinal fluid. 
Clin. Exp. Immunol. 6; 435-439.
Link H., Tibbling G. (1977) : Principles of albumin and IgG analyses in 
neurological disorders. II evaluation of IgG synthesis within the central 
nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 37; 
397-401.
Link H., Laurenzi M.A. (1979) : Immunoglobulin class and light chain type 
of oligoclonal bands in CSF in multiple sclerosis determined by agarose 
gel electrophoresis and immunofixation. Ann. Neurol. 6;107-110.
Lipton H.L. (1975) : Theiler’s virus infection in mice: an unusual biphasic 
disease leading to demyelination. Infect. Immun. 11; 1147-1155.
Lipton H.L., Melvod R. (1984) : Genetic susceptibility to Theiler’s mice 
induced demyelinating disease in mice. J. Immunol. 132; 1821-1825.
Lisak R.P., Behan P.O., Zweiman B., Shetty T. (1974) : Cell-mediated 
immunity to myelin basic protein in acute disseminated 
encephalomyelitis. Neurology 24; 560-564.
Lisak R.P., Zweiman B. (1977) : In vitro cell-mediated immunity of 
cerebrospinal fluid lymphocytes to myelin-basic protein in primary 
demyelinating diseases. N. Eng. J. Med. 297; 850-853.
282
Lisak R.P., Zweiman B., Waters D., Koprowski H., Pleasure D.E. (1978) : 
Cell-mediated immunity to measles, myelin basic protein and central 
nervous system extract in multiple sclerosis: A longitudinal study 
employing direct buffy coat migration assays. Neurology 28; 798-803.
Lisak R.P., Zweiman B., Burns J.B., Rostami A., Silberberg D.H. (1984) : 
Immune responses to myelin antigens in multiple sclerosis. Ann. N.Y. 
Acad. Sciences 436; 221-30.
Livrea P., Trojano M., Simone I.L., Zimatore G.B., Lamontanara G., Leante 
R. (1981) : Intrathecal IgG synthesis in multiple sclerosis. Comparison 
between isoelectric focusing and quantitative estimation of 
cerebrospinal fluid IgG. J. Neurol. 224; 159-169.
Londei M., Lamb J.R., Botazzo G.F., Feldmann M. (1984) : Epithelial cells 
expressing aberrant MHC class II determinants can present antigen to 
cloned human T cells. Nature 312; 639-41.
Lowenthal A., Vansande M., Karcher D. (1960) : The differential 
diagnosis of neurological disease by fractionating electrophoretically 
the CSF-globulins. J. Neurochem. 6; 51-60.
Lumsden C.E. (1970) ; The pathology of multiple sclerosis. In Vinken 
P.J., Bruyn G.W. eds. Handbook Clin. Neurol. 9; 217-309.
Lynch D.M., Howe S.E. (1986) : Antigenic determinants in idiopathic 
thrombocytopenic purpura. Br. J. Haematol. 63; 301-308.
Lyons M.J., Hall W.W., Petito C., Cam V., Zabriskie J.B. (1980) : Induction 
of chronic neurologic disease in mice with canine distemper virus. 
Neurology 30; 92-98.
MacKay R.P., Hirano A. (1967) : Forms of benign multiple sclerosis. 
Report of two clinically silent cases discovered at autopsy. Arch. 
Neurol. 17; 588-600.
Madden D.L., Wallen W.C., Hauff S.A., Shekarcki I.C., Reinikki P.O., 
Castellano G.A., Sever J.L. (1981) : Measles and canine distemper 
antibody. Presence in the sera from parents with multiple sclerosis and 
matched control subjects . Arch. Neurol. 38; 13-15.
Male D., Pryce G. (1988) : Kinetics of MHC gene expression and mRNA 
synthesis in brain endothelium. Immunol. 63; 37-42.
283
Margulis M.S., Soloviev V.D., Shubladze A.K. (1946) : Aetiology and 
pathogenesis of acute sporadic disseminated encephalomyelitis and 
multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 9; 63-74.
Martin J.R., Holt R.K., Webster H.D. (1988) : Herpes-simplex-related 
antigen in human demyelinating disease and encephalitis. Acta 
Neuropathol. (Berlin) 76; 325-37.
Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E-0., 
McFarlin D.E., McFarland H.F (1990) : Fine specificity and HLA 
restriction of myelin basic protein specific cytotoxic T cell lines from 
multiple sclerosis and healthy individuals. J. Immunol. 145; 540-548.
Martin R., Howell M.D., Jaraquemada D., Flerlage M., Richert J., Brostoff 
S., Long E.O., McFarlin D.E., McFarland H.F. (1991) : A myelin basic protein 
peptide is recognised by cytotoxic T cells in the context of four HLA-DR 
types associated with multiple sclerosis. J. Exp. Med. 173; 19-24.
Matthews W.B. (1985) : Demyelinating disease. In Weatherall D.J., 
Ledingham J.G.G., Warrell D.A. Oxford textbook of medicine. Oxford 
Medical publication , Oxford Pg 21-98 and 21-99.
Mattson D.H., Roos R.P., Arnason B.W. (1980) : Isoelectric focusing of IgG 
eluted from multiple sclerosis and subacute sclerosing panencephalitis 
brains. Nature 287; 335-337.
Mattson D.H., Roos R.P., Arnason B.G. (1982) : Oligoclonal IgG in multiple 
sclerosis and subacute sclerosing panencephalitis brains. J.
Neuroimmun. 2; 261-276.
McCallum K., Esiri M.M., Tourtelotte W.W., Boos J. (1987) : T cell subsets 
in multiple sclerosis: gradients at plaque borders and differences in 
nonplaque regions. Brain 110; 1297-1308.
McCarron R.M., Racke M., Spatz M. McFarlin D.E. (1991): Cerebral vascular 
endothelial cells are effective targets for in vitro lysis by 
encephalitogenic T lymphocytes. J. Immunol. 147; 503-508.
McDonald W.l. (1986): The mystery of the origin of multiple sclerosis. J. 
Neurol. Neurosurg. Psychiatry 49; 113-123.
McDonald W.L (1989) : Diagnosis of multiple sclerosis: remains 
essentially clinical though silent lesions can now be identified. B.Med.
J. 299; 635-637.
284
McFarlin D.E, McFarland H.F. (1982) : Multiple sclerosis (first of two 
parts). N. Eng. J. Med. 307; 1183-1188.
McFarlin D.E. (1983) : Treatment of multiple sclerosis. N. Eng. J. Med. 
308; 215-217.
McFarlin D.E., Lachmann P.J. (1989) : Hopeful genes and immunology 
(news). Nature 341; 693-694.
McIntosh I.C., Muckersie L, Forrester J.V. (1988): Retinal capillary 
endothelial cells prefer different substrates for growth and migration. 
Tissue Cell 20; 193-209.
McLean B.N., Thompson E.J. (1989) : Antibodies against the
paramyxovirus SV 5 are not specific for cerebrospinal fluid from 
multiple sclerosis. J. Neurol. 92; 261-266.
Melnick J.L., Seidel E., Inoue Y.K., Nishibe Y. (1982) : Isolation of virus 
from the spinal fluid of three patients with multiple sclerosis and one 
with amyotrophic lateral sclerosis. Lancet i; 830-833.
Meresse S., Dehouck M.P., Delorme P., Bensai'd M., Tauber J.P., Delbart C., 
Fruchart J.C., Cechelli R. (1989): Bovine brain endothelial cells express 
tight junctions and monoamine oxidase activity in long term culture. J. 
Neurochem. 53; 1363-1371.
Milligan N.M., Newcombe R., Compston D.A. (1987) : A double-blind 
controlled trial of high dose methylprednisoione in patients with 
multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 
50; 511-6.
Mitchell D.N., Porterfield J.S., Mitcheletti R., Lange L.S. Goswami K.K.A., 
Taylor P., Jacobs J.P., Hockley D.J., Salsbury A.J. (1978) : Isolation of an 
infectious agent from bone-marrows of patients with multiple 
sclerosis. Lancet ii; 387-391.
Mitchell D.N., Goswami K.K.A., Taylor P., Salsbury A.J., Porterfield J.S., 
Mitcheletti R., Lange L.S., Jacobs J.P., Hockley D.J., Taylor-Robinson D.A 
(1979) : Reply to 'failure to isolate a transmissible agent from the 
bone-marrow of patients with multiple sclerosis Lancet ii; 415-416.
Moller J.R., Yanagisawa K., Brady R.O., Tourtelotte W.W., Quarles R.H. 
(1987) : Myelin-associated glycoprotein in multiple sclerosis lesions: a 
quantitative and qualitative analysis. Ann. Neurol. 21; 135-141.
285
Moore S.A., Strauch A.R., Yoder E.T., Rubenstein P.A., Hart M.N. (1984) : 
Cerebral microvascular smooth muscle in tissue culture. In vitro 20; 
512-520.
Morariu M., Klutzow W.F. (1976) : Subclinal multiple sclerosis. J. Neurol. 
213; 71-6.
Moretta A., Pantaleo G., Moretta J., Cerottini J., Mingari M.C. (1983, a) : 
Direct demonstration of the clonogenic potential of every human 
peripheral blood T cell. J. Exp. Med. 157; 743-54 .
Moretta A., Pantaleo G., Moretta J., Mingari M.C., Cerottini J.(1983, b) : 
Quantitative assessment of the pool size and subset distribution of 
cytolytic T lymphocytes within human resting or alloactivated 
peripheral blood T cell population. J. Exp. Med. 158; 571-85.
Morgan B.P., Campbell A.K., Compston D.A.S. (1984) : Terminal component 
of complement (C9) in cerebrospinal fluid of patients with multiple 
sclerosis. Lancet ii; 251-255.
Morimoto C., Hafler D.A., Weiner H.L., Letvin N.L., Hagan M., Daley J., 
Schlossman S.F. (1987) : Selective loss of the suppressor/inducer T 
cell subset in progressive multiple sclerosis. AZ. Eng. J. Med. 316; 67­
72.
Moyle S., Keir G., Thompson E.J. (1984) : Viral immunoblotting: a 
sensitive method for detecting viral-specific oligoclonal bands in 
unconcentrated cerebrospinal fluid. Bioscience report 4; 505-510.
Murphy B.R., Webster R.G. (1990): Orthomyxoviruses. In Virology, second 
edition. Fields B.N., Knipe D.M. et al eds. Raven Press Ltd N.Y., chapter 
40; 1091-1152.
Murray T.J. (1976) : An unusual occurrence of multiple sclerosis in a 
small rural community. Can. J. Neurol. Sci. 3; 163-166.
Mutinelli F., Vandevelde M., Griot C., Richard A. (1989) : Astrocytes are 
infected by canine distemper virus. Acta neuropathologica 77; 333-335.
Narayan O., Griffin D.E., Chase J. (1977) : Antigenic drift of visna virus 
in persistently infected sheep. Science 197; 376-378.
Narayan O., Cork L.C. (1985): Lentiviral diseases of sheep and goat: 
chronic pneumonia, leukoencephalomyelitis and arthritis. Rev. Infect. 
Dis. 7; 89-98.
286
Navia B.A., Jordan B.D., Price R.W.. (1986, a) : The AIDS dementia 
complex: I clinical features. Ann. Neurol. 19; 517- 524.
Navia B.A., Cho E.S., Petito C.K., Price R.W. (1986, a) : The AIDS dementia 
complex: II. Neuropathology. Ann. Neurol. 19; 525-535.
Nepom J.T., Weiner J.L., Dichter M.A. et al (1982) : Identification of a 
haemagglutinin specific idiotypes associated with reovirus recognition 
shared by lymphoid and neural cell. J. Exp. Med. 155; 155-67.
Nigg E.A., Walter G., Singer S.J. (1982): On the nature of cross reactions 
observed with antibodies directed to defined epitopes. P.N.A.S. 79; 
5939-5943.
Nordal H.J., Vandvik B., Norrby. (1978): Demonstration of
electrophoretically restricted virus-specific antibodies in serum and 
cerebrospinal fluid by imprint electroimmunofixation. Scand. J. 
Immunol. 7; 381-388.
Noronha A., Richman D.P., Arnason B.G.W. (1980) : Detection of in vivo 
stimulated cerebrospinal fluid lymphocytes by flow cytometry in 
patients with multiple sclerosis. N. Eng. J. Med. 303; 713-717.
Norrby E., Link H., Olsson J.E. (1974) : Comparison of measles virus 
antibody titers in cerebrospinal fluids and serum from patients with 
multiple sclerosis and from controls. Arch. Neurol. 30; 285-292, 1974.
Norrby E. (1978) : Viral antibodies in multiple sclerosis. Prog. Med.
Virol. 24; 1-39. 1978.
Norton W.T. (1984) : Recent advances in myelin biochemistry. Ann. N. Y. 
Acad. Sciences 436; 5-10.
Offner H., Hashim G., Vandenbark A.A. (1991) : T cell receptor peptide 
therapy triggers autoregulation of experimental encephalomyelitis. 
Science 251; 430-432.
Oger J. Wolloghby E., Paty D.W. (1987) : Immune function in MS: 
correlation with disease activity as revealed by MR,. J. Neuroimmunol. 
16; 134.
Operskalski E.A., Visscher B.R., Malmgren R.M., Detels R. (1989) : A case- 
control study in multiple sclerosis. Neurology 39; 825-829.
287
Oppenheimer D. (1978) : The cervical cord in multiple sclerosis. 
Neuropathol. Appl. Neurobiol. 4; 151-162.
Oppenheimer D. (1982) : Oxygen for multiple sclerosis. Lancet ii; 632.
Oksenberg J.R., Sherrit M., Begovich A.B., Erlich H.A., Bernard C.C.A. 
Cavalli-Sforza L.L., Steinman L. (1989) : T cell receptor Va and Ca 
alleles associated with multiple sclerosis and myasthenia gravis. Proc. 
Natl. Acad. Sci. USA 86; 988-992.
Oksenberg J.R., Steinman L. (1990) : The role of the MHC and T cell 
receptor in susceptibility to multiple sclerosis. Curr. Opin. Immunol. 2; 
619-621.
Orlowski M., Sessa G., Green J.K. (1974) : y-glutamyl transpeptidase in 
the brain capillaries: possible site of a blood-brain barrier for amino 
acids. Sciences 184; 66-68.
Ormerod I.E.C., McDonald W.I., Du Boulay G.H., Kendall B.E., Moseley I.F., 
Halliday A.M., Kakiji R., Kriss A., Peringer E. (1986) : Disseminated 
lesions at presentation in patients with optic neuritis. J. Neurol. 
Neurosurg. Psychiatry 49; 124-7.
Ormerod I.E.C., Miller D.H., McDonald W.I., du Boulay E.P., Rudge P.,
Kendall B.E., Moseley I.F., Johnson G., Tofts P.S., Halliday A.M. (1987) : 
The role of NMR imaging in the assessment of multiple sclerosis and 
isolated neurological lesions: A qualitative study Brain 110; 1579­
1616.
Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto 
M., Tara M (1986) : HTLV-1 associated myelopathy, a new clinical 
entity. Lancet i; 1031- 1032.
Osame M, Matsumoto M., Usuku K., Izumo S., Igichi N., Anitani H., Tara M., 
Igata A. (1987) : Chronic progressive myelopathy associated with 
elevated antibodies to human T-lymphotropic virus type I and adult T 
cell leukemia-like cells. Ann. Neurol. 21; 117-122.
Osterland C.K., Miller E.J., Karakawa W.W.. Krause R.M. (1966) : 
Characteristics of streptococcal group-specific antibody isolated from 
hyperimmune rabbits. J. Exp. Med. 123; 599-614.
Ota K., Matsui M., Milford E., Mackin G.A., Weiner H.L., Hafler D.A. (1990): 
T cell recognition of an immunodominant myelin basic protein epitope 
in multiple sclerosis. Nature 346; 183-187.
288
Owen S.J., Watson C., Davison A.N. (1988) : Multiple sclerosis, a T cell 
disease? Lancet ii; 801.
Palacios-Boix A.A., Estrada I., Colston J.M. , Panayi G.S. (1988): HLA-DR4 
restricted lymphocyte proliferation to a mycobacterium tuberculosis 
extract in rheumatoid arthritis and healthy subjects. J. Immunol. 140; 
1844-1850.
Palade G.E. (1961) : Blood capillaries of the heart and other organs. 
Circulation. 24; 368-384.
Palsson P.A., Pallson H.I., Field E.J. (1965) : Transmission experiments 
with multiple sclerosis. Slow, latent and temperate viral infection 
(NINDB monograph 2). Gajdusek D.C., Gibbs C.J., Alpers M. Eds. Bethesda, 
Mar. dep. health educ.welfare pg: 49-54.
Pandey J.R., Goust J.M., Salier J.P. (1981) : Immunoglobulin G heavy chain 
(Gm) allotypes in multiple sclerosis. J. Clin. Inv. 67; 1797-1800.
Panelius, M., Salmi A., Halonen P.E., Kivalo E., Rinne U.K., Penttinen K. 
(1973) : Virus antibodies in serum specimens from patients with 
multiple sclerosis, from siblings and matched controls . A final report. 
Acta. Neurol. Scand. 49; 85-107.
Pardridge W.M., Yang J., Eisenberg J. (1985): Blood-brain barrier protein 
phosphorylation and dephosphorylation. J. Neurochem. 45; 1141-1147.
Pardridge W.M., Eisenberg J., Yang J. (1985) : Human blood-brain barrier 
insulin receptor. J. Neurochem. 44; 1771-1778.
Pardridge W.M., Yang J., Eisenberg J., Mietus L.J. (1986): Antibodies to 
blood-brain barrier bind selectively to brain capillary endothelial 
lateral membranes and to a 46 K protein. J. Cerebral Blood Flow 
Metabol. 6; 203-211.
Pardridge W.M., Oldendorf W.H., Cancilla P., Frank H.J.L. (1986,b) : Blood- 
brain barrier: interface between internal medicine and the brain. Ann.
Int. Med. 105; 82-95.
Pardridge W.M., Nowlin D.M., Calaycay J., Shively J.E. (1989):
Predominant low-molecular weight proteins in isolated brain 
capillaries are histones. J. Neurochem. 53; 1014-1018.
289
Padgett B.L. (1976) : JC papovavirus in progressive multifocal 
leukoencephalopathy. J. Infect. Dis. 133; 686-690.
Panelius M., Salmi A., Halonen P.E., Kivalo E., Rinne U.K., Pentinnen K. 
(1973) : Virus antibodies in serum specimens from patients with 
multiple sclerosis, from siblings, and matched controls. Acta 
Neurol.Scand. 49; 85-107.
Parham P. (1991) : The case of the wonky mouse. Nature 353; 503-505.
Pearson J.D. (1990): Isolation and culture of microvascular endothelium. 
In " The endothelium: an introduction to current research". Ed Warren J. 
Alan R. Liss Inc, New York.
Pearson W., Lipman D. (1988) : Improved tools for biological sequence 
comparison. Proc. Natl. Acad. Sci, USA 85; 2444-2448.
Perron H., Geny C., Laurent A., Mouriquand C., Pellat J., Perret J., 
Seigneurin J.M. (1989): Leptomingeal cell line from multiple sclerosis 
with reverse transcriptase activity and viral particles. Res. Virol, (inst. 
Pasteur) 140; 551-561.
Perron H., Lalande B., Gratacap B., Laurent A., Genoulaz O, Geny C.,
Mallaret M., Schuller E., Stoebner P., Seigneurin J.M. (1991) : Isolation of 
retrovirus from patients with multiple sclerosis. Lancet 337; 862­
863.
Perron H., Geny C., Genoulaz O., Pellat J., Perret J., Seigneurin J.M. 
(1991,b) : Antibodies to reverse transcriptase of human retroviruses in 
multiple sclerosis. Acta. Neurol. Scand. 84; 507-513.
Pertschuk L.P., Cook A.W., Gupta J.K. (1976) : Measles antigen in multiple 
sclerosis: identification in the jejunum by immunofluorescence Life 
Sci. 19; 1603-1608.
Petursson G., Nathanson N., Georgsson G., Panitch H., Palsson P.A. (1976)
: Pathogenesis of visna : I Sequential virologic, serological and 
pathologic studies. Lab. Invest. 35; 402-412.
Peters A., Vaughn J.E. (1970) : Morphology and development of the 
myelin sheath, in Davison A.N., Peters A. eds. Myelination. Charles C. 
Thomas, Sprinfield, Illinois.
290
Petit C., Sauron M.E., Gilbert M., These J. (1982): Direct detection of 
idiotypic determinants on blotted monoclonal antibodies. Ann. Immunol. 
(Inst. Pasteur) 133 D; 77-85.
Petito C.K., Navia B.A., Cho E.S., Jordan B.D., George D.S., Price R.W.
(1985) : Vacuolar myelopathy pathologically resembling subacute 
combined degeneration in patients with the acquired immunodeficiency 
syndrome. N. Eng. J. Med. (1985) : 312; 874- 879.
Phadke J.G., Downie A.W. (1987) : Epidemiology of multiple sclerosis in 
the north-east (Grampian Region) of Scotland - an update. J. Epidemiol. 
Commun. Health 41; 5-13.
Plotz P.H. (1983): Autoantibodies are anti-idiotype antibodies to 
antiviral antibodies. Lancet ii; 824-826.
Pober J.S. (1988) : Cytokine-mediated activation of vascular 
endothelium, physiology and pathology. Am. J. Pathol. 133; 426-433.
Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. 
(1980) : Detection and isolation of type-C retrovirus particles from 
fresh and cultured lymphocytes of a patient with cutaneous T-cell 
lymphoma. Proc. Nat. Acad. Sci. USA 77; 7415-7419.
Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., 
Johnson K.P., Sibley W.A., Silberberg D.H., Tourtelotte W.W. (1983) : New 
diagnostic criteria for multiple sclerosis: guidelines for research 
protocols. Ann. Neurol. 13; 227-231.
Poser C.M. (1986) : Pathogenesis of multiple sclerosis: a critical 
reappraisal. Acta Neuropathol. (Berl.) 71; 1-10.
Poser C.M. (1987) : Multiple sclerosis on islands. Lancet i; 1426.
Poser C.M., Hibberd P.L., Benedikz J., Gudmundsson G. (1988, a) : Analysis 
of the 'epidemic' of multiple sclerosis in the Faroe Islands. I. Clinical 
and epidemiological aspects. Neuroepidemiol. 7; 168-80
Poser C.M., Hibberd P.L. (1988, b) : Analysis of the 'epidemic' of multiple 
sclerosis in the Faroe Islands. II. Biostatistical aspects. 
Neuroepidemiol. 7; 181-9.
Poskanser D.C., Schapira K., Miller H. (1963) : Multiple sclerosis and 
poliomyelitis. Lancet ii; 917-921.
291
Poskanser D.C., Sever J.L, Sheridan J.L, Prenney L.B. (1980) : Multiple 
sclerosis in the Orkney and Shetland islands. IV: Viral antibody titres 
and viral infections. J. Epidemiol. Commun. Health 34; 258-264.
Poskanser D.C., Adams R.D. (1981) : Multiple sclerosis and other 
demyelinating diseases. In Isselbacher K.J, Adams R.D., Braunwald E., 
Petersdorf R.G., Wilson J.D eds. Harrison's principles of internal 
medicine, ninth edition. McGraw-Hill International Ltd, Tokyo.
Prasad I., Broome J.D., Pertschuk L.P., Gupta J., Cook A.W. (1977) : 
Recovery of paramyxovirus from the jejunum of patients with multiple 
sclerosis. Lancet i; 1117-119.
Price R.W., Brew B., Sidtis J., Rosenblum M., Scheck A.C., Cleary P.
(1988) : The brain in AIDS: central nervous system HIV-1 infection and 
AIDS dementia complex. Science 239; 586-592.
Prineas J.W, Raine C.S. (1976) : Electron microscopy and
immunoperoxidase studies of early multiple sclerosis lesions. 
Neurology 26(suppl.); 29-32.
Prineas J.W., Wright R.G. (1978) : Macrophages, lymphocytes and plasma 
cells in the perivascular compartment in chronic multiple sclerosis. 
Lab Invest. 38; 409-421.
Prineas J.W. (1979): Multiple sclerosis: presence of lymphatic 
capillaries and lymphoid tissue in the brain and spinal cord. Science 
203; 1123-1125.
Putman T.J. (1937) : Evidence of vascular occlusion in multiple 
sclerosis and "encephalomyelitis". Arch. Neurol. Psychiat.fChic.) 37; 
1298-1321.
Raff M.C., Mirsky R., Fields K.L, Lisak R.P., Dorfman S.H., Silverberg D.H., 
Gregson N.A., Liebowitz S., Kennedy M. (1978) : Galactocerebroside is a 
specific cell-surface antigenic marker for oligodendrocytes in culture. 
Nature 274; 813-816.
Raff M.C., Miller R.H., Noble M. (1983) : A glial cell precursor that 
develops in vitro into an astrocyte or an oligodendrocyte depending on 
the culture medium. Nature 303; 390-6.
Raine C.S. Scheinberg L.C., Waltz J.M. (1981) : Multiple sclerosis: 
oligodendrocyte survival and proliferation in an active, established 
lesion. Lab. Invest. 45; 534-546.
292
Raine C.S., Scheinberg L.C. (1988) : On the immunopathology of plaque 
development and repair in multiple sclerosis. J. Neuroimmunol. 20; 189­
201
Raine C.S., Lee S.C., Scheinberg L.C. (1990) : Adhesion molecules on 
endothelial cells in the central nervous system: an emerging area in 
neuroimmunology of multiple sclerosis. Clin. Immunol. Immunopathol. 
57; 173-187.
Raine C.S., Canella B., Duijvestiyn A.M., Cross A.N. (1990) : Homing to 
central nervous system vasculature by antigen-specific lymphocytes. II 
Lymphocytes, endothelial cell adhesion during the initial stages of 
autoimmune demyelination. Lab. Invest. 63; 476-489, 1990.
Randall R.E. , Newman C. , Honess R.W. (1984) : Isolation and
characterization of monoclonal antibodies to structural and 
nonstructural proteins of herpes virus saimiri proteins. J. Virol. 52; 
872-883.
Randall R.E., Young D.F., Goswami K.K.A., Russell W.C. (1987) :
Isolation and characterisation of monoclonal antibodies to simian virus 
5 and their use in revealing antigenic differences between human, 
canine and simian isolates. J. Gen. Virol. 68; 2769-2780.
Randall R.E., Young D.F. (1988, a) : Comparison between parainfluenza 
virus type 2 and simian virus: monoclonal antibodies reveal major 
antigenic difference. J. Gen. Virol. 69; 2051-2061.
Randall R.E., Young D.F., Southern J.A. (1988, b) : Immunization with 
solid matrix-antibody-antigen complexes containing surface or internal 
virus structural proteins protects mice from infections with the 
paramyxovirus, simian virus 5. J. Gen. Virol. 69; 2517-2526.
Randall R.E., Russell W.C.R. (1990): Paramyxovirus persistence, 
consequences for host and virus. In Kinepbury D.W. ed.
"paramyxoviruses". Plenum Publishing C., New York.
Randall R.E, Souberbielle B.E. (1990, b) : Presentation of virus antigens 
for the induction of protective immunity. In Dimmock N.J., Griffiths 
P.D., Madeley C.R. Control of virus diseases. Cambridge University Press, 
Cambridge.
Rastogi S.C., Clausen J., Offner H., Konat G., Fog T. (1979) : Partial 
purification of MS specific brain antigens. Acta. Neurol. Scand. 59; 
281-296.
293
Read D., Nassim D., Smith P., Patterson C., Warlow G. (1982) : Multiple 
sclerosis and dog ownership. A case control investigation. J. Neurol. 
Sci. 55; 359-367.
Reddy E.P., Sandberg-Wollheim M., Mettus R.V., Ray P.E., de Freitas E., 
Koprowski H. (1989) : Amplification and molecular cloning of HTLV-1 
sequences from DNA of multiple sclerosis patients. Science 243; 529­
533.
Reese T.S., Karnovsky M.J. (1967) : Fine structural localisation of a 
blood-brain barrier to exogenous peroxydase. J. Cell. Biol. 34; 207-217.
Rice G.P.A., Armstrong H.A., Bulman D.E., Paty D.W., Ebers G.C. (1986) : 
Absence of antibody to HTLV I and III in sera of Canadian patients with 
MS and chronic myelopathy. Ann. Neurol. 20; 533-534.
Richardson E.P. (1988) : Progressive multifocal leukoencephalopathy 30 
years later. N. Eng. J. Med. 318; 315-317.
Richardson J.H., Wucherpfennig K.W., Endo H., Rudge P., Dalgleish A.G., 
Hafler D.A. (1989): PCR analysis of DNA from multiple sclerosis 
patients for the presence of HTLV I. Science 246: 821-823.
Richardson J.H. , Edwards A.J., Cruickshank J.K., Rudge P., Dalgleish A.G. 
(1989, b) : In vivo cellular tropism of human T cell leukemia virus type- 
1. J. Virol. 64; 5682-7.
Richert J.R., Rose J.W., Reuben-Burniside C., Kearns M.C., Jacobson S., 
Mingioli E.S., Hatzman R.J., McFarland H.F., McFarlin D.E. (1986) : 
Polypeptide specificities of measles virus-reactive T cell lines and 
clones derived from a patient with multiple sclerosis. J. Immunol.
137; 2190-2194.
Richert J.R., Robinson E.D., Deibler G.E., Martenson R.E., Dragovic L.J.,
Kies M.W. (1989) : Evidence for multiple human T cell recognition sites 
on myelin basic protein. J. Neuroimmunol. 22; 55-66.
Riechert T., Hassler R., Mundinger F. (1975) : Pathologic-anatomical 
findings and cerebral localization in stereotactic treatment of 
extrapyramidal motor disturbances in multiple sclerosis. Confin.
Neurol. 37; 24-40.
Risau W., Engelhardt B., Wekerle H. (1990) : Immune function of the 
blood-brain barrier: incomplete presentation of protein (auto-) antigens 
by rat brain microvascular endothelium in vitro. J. Cell Biol. 110; 
1757-66. 294
Rivers T.M., Schwentker F.F. (1935) : Encephalomyelitis accompanied by 
myelin destruction experimentally produced in monkeys. J. Exp. Med. 61; 
689-702.
Roberts J.A. (1965) : A study of the antigenic relationship between 
human measles virus and canine distemper virus. J. Immunol. 94; 622­
628.
Roberts J.M., Forrester J.V. (1990): Factors affecting the migration and 
growth of endothelial cells from microvessels of bovine retina. Exp. Eye 
Res. 50; 165-172.
Rocklin R.E., Sheremata W.A., Feldman R.G., Kies M.W., David J.R. (1971) : 
The Guillain-Barre syndrome and multiple sclerosis: In vitro cellular 
responses to nervous tissue antigens N. Eng. J. Med. 284; 803-808.
Rodriguez M., Leibowitz J.L., Lampert P.W. (1983) : Persistent infection 
of oligodendrocytes in Theiler’s virus-induced encephalomyelitis. Ann. 
Neurol. 13; 426-433.
Rodriguez M., Leibowitz J.L. , David C.S. (1986) : Susceptibility to 
Theiler’s virus-induced demyelination. Mapping of the gene within the 
H-2D region. J. Exp. Med. 163; 620-631.
Roitt I.M. (1984): Essential immunology. 5 th edition. Roitt I.M. ed. 
Blackwell Scientific Publications, Oxford, pg 311-352.
Roizman B. (1990) : Multiplication of viruses, an overview. In Virology, 
second edition. Fields B.N., Knipe D.H. et al, Raven Press Ltd N.Y. pg 87­
94.
Roman C. G., Sheremata W.A. (1987) : Multiple sclerosis (not tropical 
spastic paraparesis on Key West, Florida. Lancet i; 1199.
Romano P., Federici A.B., Benaglia G., Croci S., Soligo D., Berti E. (1989) : 
Human umbilical vein endothelial cells (HUVEC) culture as a system to 
confirm reactivity with vessels. Tissue Antig. 33(2); 345.
Rorke L.B., Iwasaki Y. Koprowski H., et al, (1979) : Acute demyelinating 
disease in a chimpanzee three years after inoculation of brain cells 
from a patient with MS. Ann. Neurol. 5; 89-94.
295
Rose L.M., Ginsberg A., Rothstein T.L., Ledbetter J.A, Clark E.A. (1988) : 
Fluctuations of CD4+ T cell subsets in relapsing-remitting multiple 
sclerosis. Ann. Neurol. 24; 192-199.
Rosenbaum J., Pottinger B.E., Woo P., Black C.M., Loizou S., Byron M.A., 
Pearson J.D. (1988) : Measurement and characterisation of circulating 
anti-endothelial cell IgG in connective tissue disease. Clin. Exp. 
Immunol. 72; 450-456.
Rostami A.M., Burns J.B., Eccleston F.A., Manning M.C., Lisak R.P., 
Silberberg D.H. (1987) : Search for antibodies to galactocerebroside in 
the serum and the cerebrospinal fluid in human demyelinating disorders 
Ann. Neurol. 22; 381-383.
Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., 
Padula S.J., Clark R.B. (1990) : An antibody to lymphotoxin and tumor 
necrosis factor prevents transfer of experimental allergic 
encephalomyelitis. J. Exp. Med. 172; 1193-1200.
Rudensky A.Y., Preston-Hurbburt P., Hong S-C, Barlow A., Janeway Jr
C.A. (1991): Sequence analysis of peptides bound to MHC class II 
molecules. Nature 353; 622-627.
Rudge P. (1991): Does a retrovirally encoded superantigen cause 
multiple sclerosis? J. Neurol. Neurosurg. Psych. 54; 853-855.
Rudge P., Ali A., Cruickshank J.K. (1991): Multiple Sclerosis, tropical 
spastic paraparesis and HTLV-1 infection Afro-Caribbean patients in 
the United Kingdom. J. Neurol. Neurosurg. Psychiat. 54; 689-94.
Rupnick M.A., Carey A., Williams S.T. (1987) : Phenotypic diversity in 
cultured cerebral microvascular endothelial cells. In Vitro Cell. Dev. 
Biol. 24; 435-444.
Russell W.C.R., Hayashi K., Sanderson P.J., Pereira H.G. (1967): 
Adenovirus antigens - a study of their properties and sequential 
development in infection. J. Gen. Virol. 1; 495-507.
Russell W.C.R., Newman C., Williamson D.H. (1975) : A simple technique 
for demonstration of DNA in cells infected with mycoplasmas and 
viruses. Nature 253; 461-2.
Russell W.C.R., Precious B. (1982): Nucleic acid-binding properties of 
adenovirus structural polypeptides. J. Gen. Virol. 63; 69-79.
296
Russell W.C.R. (1983) : Paramyxovirus and morbillivirus infections and 
their relationship to neurological disease. Prog. Brain Res. 59; US- 
132.
Russell W.C.R., Randall R.E., Goswami K.K.A. (1989) : Paramyxovirus SV5 
and multiple sclerosis. Nature (scientific correspondence) 340; 140.
Russo R. G. (1986): Cell-substrate interactions in relation to 
metastasis. In Chadwick C.M. ed. Receptors in tumour biology. Cambridge 
University Press, Cambridge.
Saag M.S., Hahn B.H., Gibbons J., Li Y., Parks E.S., Parks W.P., Shaw G.M. 
(1988) : Extensive variation in human immunodeficiency virus type-1 in 
vivo. Nature 334; 440-444.
Salmi A.A., Norrby E., Panelius M. (1972) : Identification of different 
measles virus-specific antibodies in the serum and cerebrospinal fluid 
from patients with subacute sclerosing panencephalitis and multiple 
sclerosis and multiple sclerosis. Infect. Immun. 6; 248-254.
Salmi A., Reunanen M., Ilonen J., Panelius M. (1983) : Intrathecal 
synthesis to virus antigens in multiple sclerosis. Clin. Exp. Immunol.
52, 241-249.
Salzer J.L., Holmes W.P., Colman D.R. (1987): The amino acid sequences 
of the myelin-associated glycoproteins: Homology to the 
immunoglobulin gene superfamily. J. Cell Biol. 104; 957-65.
Sandberg-Wolheim M., Alumets J., Biorblud A.A., Gay R., Gay S. (1988) : 
Bone marrow derived cells express human T cell lymphotropic virus 
type I (HTLV I) related antigens in patients with multiple sclerosis. 
Scand. J. Immunol. 28; 801-806.
Schipper H.I., Kruse H., Reiber H. (1984): Silver-staining of oligoclonal 
IgG subtractions in the cerebral fluid after isoelectric focusing in thin- 
layer polyacrylamide gels. Science Tools 31; 5-6.
Schlingemann R.O., Oingjan G.M., Erneis J.J., Blok J., Warnaar S.O., Rviter
D.J. (1985) : Monoclonal antibody PAL-E specific for endothelium. 
Laborat. Invest. 52; 71-76.
Schlingemann R.O., Rietveld F.J.R., de Waal R.M.W., Bradley N.J., Skene 
A.I., Davies A.J.S., Greaves M.F., Denekamp J., Ruiter D.J. (1990): 
Leukocyte antigen CD 34 is expressed by a subset of cultured 
endothelial cells and on endothelial ablumina, microprocesses in the 
tumour stroma. Lab. Inv. 62; 690-6.
297
Schlingemann R.O., Rietveld F.J.R., Kwaspen F., van de Kerkhof P.C.M., de 
Waal R.M.W., Ruiter D.J. (1991): Differential expression of markers for 
endothelial cells. Pericytes, and basal lamina in the microvasculature 
of tumours and granulation tissue. Am. J. Pathol. 138; 1335-1347.
Schmid D.S. (1988) : The human MHC-restricted cellular response to 
herpes simplex type 1 is mediated by CD4+, CD8- T cells and is 
restricted to the DR region of the MHC complex. J. Immunol. 140;
3610- 3616.
Schuller E., Delasnerie N., Lebon P. (1978) : DNA and RNA antibodies in 
serum and CSF of multiple sclerosis and subacute sclerosing 
panencephalitis patients. J. Neurol. Sci. 37; 31-6.
Scolding N.J., Morgan B.P., Houston W.A., Campbell A.K., Compston D.A. 
(1989) : Reversible injury of cultured rat oligodendrocytes by 
complement. Immunol. 67; 441-6.
Scolding N.J., Morgan B.P., Houston W.A., Linington C., Campbell A.K., 
Compston D.A.S. (1989) : Vesicular removal by oligodendrocytes of 
membrane attack complexes formed by activated complement. Nature 
339; 620-622.
Seboun E., Robinson M.A., Doolittle T.H., Ciulla T.A., Kindt T.J., Hauser S.L. 
(1989) : A susceptibility locus for multiple sclerosis is linked to the T 
cell receptor p chain complex. Cell 57; 1095-1100.
Seil F.J., Leiman A.L., Kelly J. 3rd. (1976) : Neuroelectric blocking 
factors in multiple sclerosis and normal sera. Arch. Neurol. 33; 418­
22.
Selmaj K.W., Farooq M., Norton W.T., Raine C.S., Brosnan C.F. (1990) : 
Proliferation of astrocytes in vitro in response to cytokines: A primary 
role for tumor necrosis factor. J. Immunol. 144; 129-135.
Selmaj K.W., Raine C.S., Cannela B., Brosnan C.F. (1991) : Identification 
of lymphotoxin and TNF in multiple sclerosis lesion. J. Clin. Inv. 87; 
949-954.
Seulberger H., Lottspeich F., Risau W. The inducible blood-brain barrier 
specific HT7 is a novel immunoglobulin-like cell surface glycoprotein.
E.M.B.O. J. 1990: 9: 2151-2158
298
Shaw S.Y., Laursen R.A., Lees M.B. (1986) : Analogous amino acid 
sequences in myelin proteolipid and viral proteins. FEBS let. 207; 266­
270.
Shepherd D.l. (1980) : Multiple sclerosis in north-east of Scotland. In 
Rose F.C. ed. Clinical Neuroepidemiology. Pitman Medical, London.
Sheremata W.A., Poskanzer D.C., Withum D.G., MacLeod C.L., Whiteside 
M.E. (1985) : Unusual occurence on a tropical island of multiple 
sclerosis. Lancet ii; 618.
Shivers R.R, Arthur F.E., Bowman P.D. (1988): Induction of gap junctions 
and brain endothelium-like tight junctions in cultured bovine 
endothelial cells: local control of cell specialization. J. Submicrosc. 
Cytol. Pathol. 20; 1-14.
Shubin R.A., Weiner L.P. (1989) : Viruses and demyelination. In Kim S.U. 
ed. Myelination and demyelination, implications for multiple sclerosis. 
Plenum Press, New York and London.
Sibley W.A., Bamford C.R., Clark K. (1985) : Clinical viral infection in 
multiple sclerosis. Lancet i; 1313-1315.
Siden A. (1980) : Abnormal CSF immunoglobulin components detected by 
isoelectric focusing. J. Neurol. 224; 133-144.
Simionescu N., Simionescu M. (1990): The cardiovascular system. In 
Weiss L. ed. A textbook of histology, sixth edition. Urban & 
Schwarzenberg, Baltimore-Munich.
Skegg D.C.G., Corwin P.A., Craven R.S., Malloch J.A., Pollock M. (1987) : 
Occurence of multiple sclerosis in the north and the south of New 
Zealand. J. Neurol. Neurosurg. Psych it. 50; 134-139.
Small J.A., Scangos G.A., Cork L., Jay G., Khoury G. (1986) : The early 
region of human papovirus: JC induces dysmyelination in transgenic 
mice. Cell 46; 13-18.
Smilek D.E., Wraith D.C., Hodgkinson S., Dwivedy S., Steinman L.,
McDevitt H.O. (1991): A single amino acid change in a myelin basic 
protein peptide confers the capacity to prevent rather than induce 
experimental autoimmune encephalomyelitis. P.N.A.S. 88; 9633-9637.
299
Sobel R.A., Hafler D.A., Castro E.E., Morimoto C., Weiner H.L. (1988) : The 
2H4 (CD45R) antigen is selectively decreased in multiple sclerosis. J. 
Immunol. 140; 2210-2214.
Sommer N., Harcourt G.C., Wilcox H., Beeson D., Newson-Davis J. (1991) : 
Acetylcholine receptor-reactive T lymphocytes from healthy subjects 
and myasthenia gravis patients. Neurology 41; 1270-1276.
Souberbielle B.E., Martin-Mondiere C., O'Brien M.E., Carydakis C., Cesaro 
P., Degos J.D. (1990) : A case-control epidemiological study of MS in the 
Paris area with particular reference to past disease history and 
profession. Acta Neurol. Scand. 82; 303-310.
Souberbielle B.E., Kemp G., Russell W.C. (1991) : Molecular mimicry 
between viral protein and myelin. Immunol. Tod. 12; 464-465.
Springer T.A (1990): Adhesion receptors of the immune system. Nature 
346; 425-434.
Sredni B. (1982): Methods for long term growth and cloning of T cells 
reactive with soluble antigens. J. Immunol. Meth. 49; 1-10.
Srinivasappa J., Saegusa J., Prabhakar B.S., Gentry M.K., Buchmeier M.J., 
Wiktor T. J., Koprowski H., Oldstone M.B.A., Notkins A.L. (1986):
Molecular mimicry: frequency of reactivity of monoclonal antiviral 
antibodies with normal tissues. J. Virol. 57; 397-401.
Stefansson K, Marton L, Dieperink M, Molnar G, Schlaepfer W, Hegalson C 
(1985) : Circulating autoantibodies to the 200,000 daltons protein of 
neurofilaments in the serum of healthy individuals. Sciences 228; 
1117-9.
Stephen H., Thompson G., Staines N.A. (1990) : Could specific oral 
tolerance be a therapy for autoimmune disease ? Immunol. Tod. 11; 
396-399.
Stemberger N.H., Stemberger L.A. (1987) : Blood-brain barrier protein 
recognized by monoclonal antibody. Proc. Natl. Acad. Sci. USA. 84; 8169­
73.
Stohlman S.A., Weiner L.P. (1981) : Chronic central nervous system 
demyelination in mice after JHM virus infection. Neurology 31; 38­
44.
300
Stoner G.L., Rysschkewitsch C.F., Walker D.L., Webster H de F. (1986, a) : 
JC papovirus large tumor (T)- antigen expression in brain tissue of 
acquired immunodeficiency syndrome (AIDS) and non-AIDS patients 
with progressive multifocal leukoencephalopathy. Proc. Natl. Acad. Sci. 
83; 2271-2275.
Stoner G.L., Ryschkewitsch C.F., Walker D.L., Softer D., Webster H de F. 
(1986,b) : Immunocytochemical search for JC papovirus large T-antigen 
in multiple sclerosis brain tissue. Acta Neuropath. 70; 345-347.
Sullivan C.B., Visscher B.R., Detels R. (1984) : Multiple sclerosis and age 
at exposure to childhood diseases and animal: cases and their friends. 
Neurology 34; 1144-1148.
Summers B.A., Greisen H.A., Apel M.J. G. (1983) : Does virus persist in 
the uvea in multiple sclerosis, as in canine distemper 
encephalomyelitis. Lancet ii; 372-375.
Swingler R.J., Hughes P.B., Munro J.A., Compston D.A.S. (1987) : Human T- 
cell lymphotrophic viruses in patients with multiple sclerosis. J. 
Neurol. 234; 234.
Swingler R.J., Compston D.A.S. (1988) : The distribution of multiple 
sclerosis in the United Kingdom. J. Neurol. Neurosur. Psychiatr. 49; 
1115-24.
Swinscow T.D.V. (1976): Statistics at square one. British Medical 
Association, London.
Tanaka R., Iwasaki Y., Koprowski H. (1976) : Intracisternal virus-like 
particles in the brain of multiple sclerosis patients. J. Neurol. Sci. 28; 
121-126.
Tanaka Y.,Tsakuda N., Koh C.S., Yanagisawa N. (1987) : Anti-endothelial 
cell antibodies and circulating immune complexes in the sera of 
patients with multiple sclerosis. J. Neuroimmunol. 17; 49-59.
Tao-Cheng J.H., Nagy Z., Brightman M.W. (1987) : Tight junctions of brain 
endothelium in vitro are enhanced by astroglia. J. Neurosci. 7; 3293-9.
ter Meulen V., Koprowski H., Iwasaki Y., Kackell Y.M., Muller D.(1972) : 
Fusion of cultured multiple sclerosis brain cells with indicator cells: 
presence of nucleocapsids and virions and isolation of parainfluenza- 
type virus. Lancet ii; 1-5.
301
ter Meulen V.T. (1988) : Autoimmune reactions against myelin basic 
protein induced by corona and measles virus. Ann. N. Y. Aca. Sci. 540; 
202-209.
Thompson A.J., Kermode A.G., MacManus D.G., Kingsley D.P.E., Kendall B.E. 
Moseley I.F., McDonald W.l. (1989) : Pathogenesis of progressive 
multiple sclerosis. Lancet i: 1322-3.
Tournier-Lasserve E., Gout O., Gessain A., Iba-Zizen M.T., Lyon-Caen O., 
Lhermitte F., De-The G. (1987) : HTLV-1, brain abnormalities on 
magnetic resonance imaging, and relation with multiple sclerosis. 
Lancet ii; 49-50.
Tourtelotte W.W. (1970) : Cerebrospinal fluid in multiple sclerosis. In 
Vinken P.J., Bruyn G.W. eds. Handbook of clinical neurology. North- 
Holland Publishing Company. Amsterdam, pg 324-383.
Tourtelotte W.W., Ma B.L (1978) : The blood-brain barrier and the 
measurement of de novo central nervous system IgG synthesis. 
Neurology 28; 76-83.
Towbin H., Gordon J. (1984): Immunoblotting and dot immunobinding - 
current status and outlook. J. Immunol. Methods 72; 313-340.
Townsend J.J., Baringer J.R. (1979) : Morphology of the central nervous 
system disease in immunosuppressed mice after peripheral herpes 
simplex virus inoculation. Lab. Invest. 40; 178-182.
Townsend J.J. (1983) : Schwann cell remyelination in experimental 
herpes simplex encephalitis at the trigeminal root entry zone. J. 
Neuropath. Exp. Neur. 42; 529-538.
Traugott U., Snyder D.S, Raine C.S. (1979) : Oligodendrocyte staining by 
multiple sclerosis serum is non- specific. Ann. Neurol. 6; 13-20.
Traugott U., Reinherz E.L., Raine C.S. (1983) : Multiple sclerosis 
distribution of T cell subsets within active chronic lesions. Science 
219; 308-310.
Traugott U., Scheinberg L.C., Raine C.S. (1985) : On the presence of la- 
positive endothelial cells and astrocytes in multiple sclerosis lesions 
and its relevance to antigen presentation. Neuroimmunol. 8; 1-14.
302
Tsakuda N., Koh C.S., Yanagisawa N., Okano A., Behan W.M.H., Behan P.O. 
(1987) : A new model for multiple sclerosis: Chronic experimental 
allergic encephalomyelitis induced by immunization. Acta. Neuropathol 
(Berl). 73; 259-266.
Tsakuda N., Koh C.S., Yanagisawa N., Okano A., Taketomi T. (1988) : 
Autoimmune encephalomyelitis in rhesus monkeys induced by 
immunization with cerebral endothelial cell membrane. Acta. 
Neuropathol (Berl). 77; 39-46.
Tsakuda N., Tanaka Y., Yanagisawa N. (1989,a) : Autoantibodies to brain 
endothelial cells in the sera of patients with human T-lymphotropic 
virus type I associated myelopathy and other demyelinating disorders. 
J. Neurol. Sciences. 90; 33-42.
Tsukada N.,Tanaka Y., Miyagi K., Yanagisawa N., Okano A. (1989,b) : 
Autoantibodies to each protein fraction extracted from cerebral 
endothelial cell membrane in the sera of patients with multiple 
sclerosis. J. Neuroimmunol. 24; 41-46.
Urban J.L., Kumar V., Kono D.H., Gomez C., Horvath S.J., Clayton J., Ando 
D.G., Sercarz E.E., Hood L. (1988) : Restricted use of T cell receptor V 
genes in murine autoimmune encephalomyelitis raises
possibilities for antibody therapy. Cell 54; 577-592.
Underdown B.J., Goodfriend L. (1970) : Correlation of charge properties 
of human reaginic antibodies with charge of the corresponding 
allergens. J. Immunol. 104; 530-533.
Vass K., Lassman Mann H., Wisniewski H.M., Igbal K. (1984) : 
Ultrachemical distribution of myelin basic protein after injection into 
cerebral spinal fluid : evidence for transport through the blood-brain 
barrier and binding to the luminal surface of cerebral veins. J. Neurol. 
Sci. 63; 423- 33.
Vanderbark A.A., Hashim G., Offner H. (1989) : Immunisation with a 
synthetic T-cell receptor V-region peptide protects against 
autoimmune encephalomyelitis. Nature 341; 541-544. .
Vandvik B, Degre M. (1975) : Measles virus antibodies in serum and 
cerebrospinal fluids in patients with multiple sclerosis and other 
neurological disorders with special reference to measles antibody 
synthesis within the central nervous system. J. Neurol. Sci. 24; 201­
219.
303
Vandvik B., Norrby E., Nordal H.J., Degre M. (1976) : Oligoclonal measles 
virus-specific antibodies isolated from the cerebral fluids, brain 
extracts, and sera from patients with subacute sclerosing 
panencephalitis and multiple sclerosis. Scand. J. Immunol. 5; 979-992.
Vandvik B., Natvig J.B., Wiger D. (1976) : lgG1 subclass restriction of 
oligoclonal IgG from cerebrospinal fluids and brain extracts in patients 
with multiple sclerosis. Scand. J. Immunol. 5; 427-436.
Vandvik B., Mellbye J., Norrby E. (1977) : Local synthesis of oligoclonal 
measles antibodies and smooth muscles antibodies in a case of atypical 
rheumatoid arthritis. Ann. Rheum. Dis. 36; 302-310.
Vandvik B., Norrby E. (1989) : Paramyxovirus SV5 and multiple 
sclerosis. Nature 338;769-771.
Vane J.R, Anggard E.E., Botting R.M. (1990) : Regulatory functions of the 
vascular endothelium. AZ. Eng. J. Med. 323; 27-36.
Vartdal F., Vandvik B., Norrby E. (1979): Viral and bacterial antibody 
responses in multiple sclerosis. Ann. Neurol. 8; 248-255.
Vartdal F., Vandvik B. (1982) : Multiple slcerosis: electrofocused 
"bands" of oligoclonal CSF IgG do not carry antibody activity against 
measles, varicella-zoster or rotaviruses. J. Neurol. Sci. 54; 99-107.
Vartdal F., Solid L.M., Vandvik B., Markussen G., Thorsby E. (1989) : 
Patients with MS carry DQB1 genes which encode shared polymorphic 
amino acid sequences. Hum. Immunol. 25; 103-110.
Vernant J.C., Maurs L., Gessain A., Barin F., Gout O., Delaporte J.M., 
Sanhadjis K., Buisson G., de The G. (1987) : Endemic tropical paraparesis 
associated with human T-lymphotropic virus type. A clinical and 
seroepidemiological study of 25 cases. Ann. Neurol. 21; 123- 130.
Vinters H.V., Reave S., Costello P., Girvin J.P., Moore S.A. (1987) : 
Isolation and culture of cells derived from human cerebral 
microvessels. Cell Tissue Res. 249; 657-67.
Vismara A., Meroni P.L., Tincani A., Harris E.N., Barcellini W. Brucato A., 
Khamashta M., Hughes G.R.V., Zanussi C., Balestrieri G. (1988) : 
Relationship between anti-cardiolipin and anti-endothelial cell 
antibodies in systemic lupus erythematosus. Clin. Exp. Immunol. 74; 
247-253.
304
Vogel S.N., Weedon L.L., Oppenheim J.J., Rosenstreich D.L (1978): 
Coordinate control of 3T3 cell proliferation by platelet-derived growth 
factor and plasma components. P.N.A.S. 75; 2810-2814.
Voyta J.C., Via D.P., Butterfield C.E. et al. (1984) : Identification and 
isolation of endothelial cells based on their increased uptake of 
acetylated-low density lipoprotein. J. Cell. Biol. 99; 2034-2040.
Walsh M.J., Tourtelotte W.W., Potvin A.R., Potvin J.H. (1983) : The 
cerebrospinal fluid in multiple sclerosis. In Hallpike J.F., Adams C.W.M., 
Tourtelotte W.W. eds. Multiple sclerosis. Chapman and Hall, London.
Waksman B.H., Reynolds W.E. (1984) : Multiple sclerosis as a disease of 
immune regulation. Proc. Soc. exp. Biol. Med. 175; 282-294.
Wanatabe M., Ringler D.J., Fultz P. et al. (1991): Chimpanzee passaged 
isolate is cytopathic for chimpanzee cells but does not induce disease. 
J. Virol. 65; 3344-8.
Wagner D.D., Olmsted J.B., Marder V.J. (1982): Immunolocalisation of von 
Willebrand protein in Weibel-Palade bodies of human endothelial cells.
J. Cell Biol. 95; 355-360.
Williams A.C., Mingoli E.S., McFarland H.F., Tourtelotte W.W., McFarlin 
D.E. (1978) : Increased CSF IgM in the cerebrospinal fluid of neurological 
patients. Neurology 28; 996-998.
Watanabe R., Wege H., ter Meulen V. (1983) : Adoptive transfer of EAE- 
like lesions from rat with coronavirus- induced demyelinating 
encephalomyelitis. Nature 305; 150-153.
Webb H.E., Fazakerley J.K. (1984) : Can viral envelope glycolipids 
produce auto-immunity, with reference to the CNS and multiple 
sclerosis ? Neuropath. Appl. Neurobiol. 10; 1-10.
Wechezak H.R., Hollbrook K.A., Way S.A., Mansfield P.B. (1979) : Platelet 
adherence in endothelial cell cultures. Blood Vessels 16; 35-42.
Wege H., Wanatabe R., ter Meulen V. (1984) : Relapsing subacute 
demyelinating encephalomyelitis in rats during the course of 
coronavirus JHM infection. Nature 6; 325-336.
Weibel E.R., Palade G.E. (1964): New cytoplasmic components in arterial 
endothelia. J. Cell Biol. 23; 101-112.
305
Weiner L.P., Herndon R.M., Narayan O. (1972) : Isolation of virus related 
to SV 40 from patients with progressive multiple leukoencephalopathy. 
N. Eng. J. Med. 286; 385-390.
Weiner L.P. (1973) : Pathogenesis of demyelination induced by mouse 
hepatitis virus (JHM virus). Arch. Neurol. 28; 298-303.
Weinshenker B., Rice G.P.A. (1989) : Retroviral disease of the nervous 
system. In Kim S.U. ed. Myelination and demyelination, implications for 
multiple sclerosis. Plenum Press, New York and London.
Weinshenker B., Rice G.P.A. (1989) : Retroviral disease of the nervous 
system. In Kim S.U. ed. Myelination and demyelination, implications for 
multiple sclerosis. Plenum Press, New York and London.
Weise M.J., Carnegie P.R. (1988): An approach to searching protein 
sequences for superfamily relationships or chance similarities relevant 
to the molecular mimicry hypothesis: application to the basic proteins 
of myelin. J. Neuroch. 51; 1267-1273.
Westermann J., Pabst R. (1990) : Lymphocyte subsets in the blood: a 
diagnostic window on the lymphoid system? Immunol. Today 11; 406­
410.
Wilcox C.E., Healey D.G., Baker D., Willoughby D.A., Turk J.L. (1989): 
Presentation of myelin basic protein by normal guinea-pig brain 
endothelial cells and its relevance to experimental allergic 
encephalomyelitis. Immunology 67; 435-440.
Wiles C.M., Clarke C.R.A, Irwin H.P., Edgar E.F., Swan A.V. (1986) : 
Hyperbaric oxygen in multiple sclerosis: a double blind trial. B. Med. J. 
292; 367-371.
Wiley C.A., Schrier R.D., Nelson J.A., Lampert P.W., Oldstone M.B.A.
(1986) : Cellular localization of human immunodeficiency virus 
infection within the brains of acquired immune deficiency syndrome 
patients. P.N.A.S. 83; 7089-7093.
Woodroofe M.N., Bellamy A.S., Feldmann M., Davison A.N., Cuzner M.L. 
(1986) : Immunocytochemical characterisation of the immune reaction 
in the central nervous system in multiple sclerosis. J. Neurol. Sci. 74; 
135-152.
306
Woyciechowska J.L., Madden D.L., Sever J.L (1977) ; Absence of 
measles-virus antigen in the jejunum of multiple sclerosis patients. 
Lancet ii; 1046-1049.
Wraith D.C., Smilek D.E., Mitchell D.J., Steinman L., McDevitt H.O. (1989) : 
Antigen recognition in autoimmune encephalomyelitis and the potential 
for peptide-mediated immunotherapy. Cell 59; 247-255.
Wray W.T., Boulikas T., Wray V., Hancock R. (1981) : Silver staining of 
proteins in polyacrylamide gels. Anal. Biochem. 118; 197-201.
Wren D.R., Noble M. (1989) : Oligodendrocytes and adult specific O-2A 
progenitor cells are uniquely susceptible to the lytic effects of 
complement in the absence of complement P.N.A.S. 86; 9025-9.
Wucherpfennig K.W., Ota K., Endo N., Siedman J.G., Rosenzweig A., Weiner 
H.L., Hafler D.A. (1990): Shared human T cell receptor Vb usage to 
immunodominant regions of myelin basic protein. Science 248; 1016­
19.
Yamada M., Zurbriggen A., Fujinami R.S. (1990) : Monoclonal antibody to 
Theiler’s murine encephalomyelitis virus defines a determinant on 
myelin and oligodendrocytes and augments demyelination in 
experimental allergic encephalomyelitis. J. Exp. Med. 171; 1893-1907.
Yamada M., Zurbriggen A., Fujinami R.S. (1991) : Pathogenesis of 
Theiler’s murine encephalomyelitis virus. Adv. Virus Res. 39; 291-320.
Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin 
N. (1992): Prevention of experimental autoimmune encephalomyelitis by 
antibodies against a4|31 integrin. Nature 356; 63-66.
Yoshida M., Miyoshi I., Hinuma Y. (1982) : Isolation and characterization 
of retrovirus from cell lines of human T cell leukemia and its 
implication in the disease. P.N.A.S. 79; 2031-35.
Young D.B., Lamb J.R. (1986) : T lymphocytes respond to solid-phase 
antigen: a novel approach to the molecular analysis of cellular 
immunity. Immunology 59; 167-171.
Zanetta J.P., Warter J.M., Kuchler S., Marschal P., Rumbach L., Lehmann 
S., Tranchant C., Reeber A., Vincendon G. (1990) : Antibodies to 
cerebellar soluble lectin CSL in multiple sclerosis. Lancet i; 1482­
1484.
307
Zetter B.R. (1981) : The endothelial cells of large and small blood 
vessels. Diabetes 30 suppl. 2; 24-28.
Zetter B.R. (1988) : Endothelial heterogeneity: influence of vessel size, 
organ localization, and species specificity on the properties of cultured 
endothelial cells. In Ryan U.S. ed. Endothelial cells. Boca Raton: CRC 
Press II; 63-79.
Zu Rhein G.M. (1967) : Polyoma-like virions in a human demyelinating 
disease. Acta Neuropathol. 8; 57-68.
Zurbrigger A., Vandevelde M., Dumas A., Griot G., Bollot I. (1987) : 
Oligodendroglial pathology in canine distemper virus infection in vitro. 
Acta neuropathologica 74; 366-73.
Zurbrigger A., Fujinami R.S. (1987) : Theiler’s virus infection in nude 
mice with viral mRNA in vascular endothelial. J. Virol. 62; 3589-96.
308
